ZA200603598B - Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties - Google Patents
Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties Download PDFInfo
- Publication number
- ZA200603598B ZA200603598B ZA200603598A ZA200603598A ZA200603598B ZA 200603598 B ZA200603598 B ZA 200603598B ZA 200603598 A ZA200603598 A ZA 200603598A ZA 200603598 A ZA200603598 A ZA 200603598A ZA 200603598 B ZA200603598 B ZA 200603598B
- Authority
- ZA
- South Africa
- Prior art keywords
- groups
- substituted
- unsubstituted
- alkyl
- aryl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims description 199
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title description 904
- 230000001976 improved effect Effects 0.000 title description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 229
- 125000003118 aryl group Chemical group 0.000 claims description 187
- 150000001875 compounds Chemical class 0.000 claims description 187
- 125000000623 heterocyclic group Chemical group 0.000 claims description 177
- -1 guanidinyl groups Chemical group 0.000 claims description 176
- 238000000034 method Methods 0.000 claims description 112
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 102
- 239000000203 mixture Substances 0.000 claims description 96
- 150000003893 lactate salts Chemical class 0.000 claims description 94
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 91
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 56
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 44
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 38
- 125000005128 aryl amino alkyl group Chemical group 0.000 claims description 37
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 36
- 239000002904 solvent Substances 0.000 claims description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 33
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 28
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 27
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 27
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 26
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 25
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 20
- 229910052731 fluorine Inorganic materials 0.000 claims description 20
- 239000003112 inhibitor Substances 0.000 claims description 20
- 229910052740 iodine Inorganic materials 0.000 claims description 20
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 18
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 17
- 239000013078 crystal Substances 0.000 claims description 16
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 16
- 125000003277 amino group Chemical group 0.000 claims description 14
- 125000004104 aryloxy group Chemical group 0.000 claims description 14
- 229910052801 chlorine Inorganic materials 0.000 claims description 14
- 229910052794 bromium Inorganic materials 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 239000004310 lactic acid Substances 0.000 claims description 12
- 235000014655 lactic acid Nutrition 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 10
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- 125000003418 alkyl amino alkoxy group Chemical group 0.000 claims description 8
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 8
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000004986 diarylamino group Chemical group 0.000 claims description 6
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 claims description 6
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 4
- 125000001769 aryl amino group Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003586 protic polar solvent Substances 0.000 claims description 3
- 229920000180 alkyd Polymers 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 235
- 210000004027 cell Anatomy 0.000 description 183
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 description 109
- 238000006243 chemical reaction Methods 0.000 description 92
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 90
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 90
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 89
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 68
- 206010035226 Plasma cell myeloma Diseases 0.000 description 66
- 229910052799 carbon Inorganic materials 0.000 description 52
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 48
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 45
- 239000000243 solution Substances 0.000 description 42
- 201000000050 myeloid neoplasm Diseases 0.000 description 39
- 229930185107 quinolinone Natural products 0.000 description 39
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 38
- 230000000694 effects Effects 0.000 description 37
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 37
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 34
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 34
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 33
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 31
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 30
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 30
- 230000026731 phosphorylation Effects 0.000 description 30
- 238000006366 phosphorylation reaction Methods 0.000 description 30
- 239000007787 solid Substances 0.000 description 30
- 239000002253 acid Substances 0.000 description 28
- 208000034578 Multiple myelomas Diseases 0.000 description 27
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 27
- 230000035755 proliferation Effects 0.000 description 27
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 26
- 229910052757 nitrogen Inorganic materials 0.000 description 26
- 206010028980 Neoplasm Diseases 0.000 description 24
- 229940049920 malate Drugs 0.000 description 24
- 230000035772 mutation Effects 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 23
- 239000001257 hydrogen Substances 0.000 description 22
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 150000001412 amines Chemical class 0.000 description 20
- 230000006907 apoptotic process Effects 0.000 description 20
- 238000003556 assay Methods 0.000 description 20
- 238000004128 high performance liquid chromatography Methods 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
- 102000004889 Interleukin-6 Human genes 0.000 description 18
- 108090001005 Interleukin-6 Proteins 0.000 description 18
- 229940100601 interleukin-6 Drugs 0.000 description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 18
- 125000000547 substituted alkyl group Chemical group 0.000 description 18
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 17
- 239000012458 free base Substances 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- 108091000080 Phosphotransferase Proteins 0.000 description 16
- 102000020233 phosphotransferase Human genes 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 15
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 15
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 15
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 15
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 230000022131 cell cycle Effects 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 230000003213 activating effect Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000012091 fetal bovine serum Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 12
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 125000004434 sulfur atom Chemical group 0.000 description 12
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 11
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- 238000004821 distillation Methods 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 238000000634 powder X-ray diffraction Methods 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- WQKHERPPDYPMNX-UHFFFAOYSA-N 6-chloro-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(Cl)=CC=C21 WQKHERPPDYPMNX-UHFFFAOYSA-N 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 10
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000008186 active pharmaceutical agent Substances 0.000 description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 229940088679 drug related substance Drugs 0.000 description 10
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 229940095064 tartrate Drugs 0.000 description 10
- BBAPINQUGISEPY-UHFFFAOYSA-N 1,3-dimethoxyquinolin-2-one Chemical compound C1=CC=C2N(OC)C(=O)C(OC)=CC2=C1 BBAPINQUGISEPY-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 230000005945 translocation Effects 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 8
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 8
- 125000003710 aryl alkyl group Chemical group 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 125000004093 cyano group Chemical group *C#N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 7
- MWLBMGPQZJDFKZ-UHFFFAOYSA-N 23491-48-7 Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(N)=C1 MWLBMGPQZJDFKZ-UHFFFAOYSA-N 0.000 description 7
- FNLQDVXHDNFXIY-UHFFFAOYSA-N 3h-benzimidazole-5-carboxamide Chemical compound NC(=O)C1=CC=C2NC=NC2=C1 FNLQDVXHDNFXIY-UHFFFAOYSA-N 0.000 description 7
- ZCWXYZBQDNFULS-UHFFFAOYSA-N 5-chloro-2-nitroaniline Chemical compound NC1=CC(Cl)=CC=C1[N+]([O-])=O ZCWXYZBQDNFULS-UHFFFAOYSA-N 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 108090000672 Annexin A5 Proteins 0.000 description 7
- 102000004121 Annexin A5 Human genes 0.000 description 7
- 206010065687 Bone loss Diseases 0.000 description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 7
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 7
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 241000508269 Psidium Species 0.000 description 7
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 7
- 230000033115 angiogenesis Effects 0.000 description 7
- 150000007942 carboxylates Chemical class 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 230000000010 osteolytic effect Effects 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 125000003107 substituted aryl group Chemical group 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- ANQVKHGDALCPFZ-UHFFFAOYSA-N ethyl 2-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]acetate Chemical compound C1=C2NC(CC(=O)OCC)=NC2=CC=C1N1CCN(C)CC1 ANQVKHGDALCPFZ-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 229940001447 lactate Drugs 0.000 description 6
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 210000000066 myeloid cell Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102200143295 rs78311289 Human genes 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 150000003892 tartrate salts Chemical class 0.000 description 6
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 5
- UONUOBRIMYZYRS-UHFFFAOYSA-N 1-chloroquinolin-2-one Chemical compound C1=CC=C2C=CC(=O)N(Cl)C2=C1 UONUOBRIMYZYRS-UHFFFAOYSA-N 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 5
- DANLZOIRUUHIIX-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]indazol-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(C1=CC=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F DANLZOIRUUHIIX-UHFFFAOYSA-N 0.000 description 5
- WUWLDOZFKQIIQW-UHFFFAOYSA-N 5-fluoro-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=CC=C2F WUWLDOZFKQIIQW-UHFFFAOYSA-N 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 206010061728 Bone lesion Diseases 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 5
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 5
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 5
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 5
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 5
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 150000001491 aromatic compounds Chemical group 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000000021 kinase assay Methods 0.000 description 5
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 5
- 108010014186 ras Proteins Proteins 0.000 description 5
- 102000016914 ras Proteins Human genes 0.000 description 5
- 238000013207 serial dilution Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 150000003894 D-lactate salts Chemical class 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 4
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 4
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 4
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 4
- 102100039788 GTPase NRas Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 231100000002 MTT assay Toxicity 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 239000001630 malic acid Substances 0.000 description 4
- 235000011090 malic acid Nutrition 0.000 description 4
- 229940098779 methanesulfonic acid Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000011975 tartaric acid Substances 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- QYEMNJMSULGQRD-UHFFFAOYSA-N 1-methyl-2-quinolone Chemical compound C1=CC=C2C=CC(=O)N(C)C2=C1 QYEMNJMSULGQRD-UHFFFAOYSA-N 0.000 description 3
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 3
- IQUNZGOZUJITBJ-UHFFFAOYSA-N 2-amino-6-fluorobenzonitrile Chemical compound NC1=CC=CC(F)=C1C#N IQUNZGOZUJITBJ-UHFFFAOYSA-N 0.000 description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 3
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 3
- PEDMFCHWOVJDNW-UHFFFAOYSA-N 5-fluoro-2-nitroaniline Chemical compound NC1=CC(F)=CC=C1[N+]([O-])=O PEDMFCHWOVJDNW-UHFFFAOYSA-N 0.000 description 3
- YCIOUNSWHDKEBM-UHFFFAOYSA-N 6,7-dimethoxy-1h-quinolin-2-one Chemical compound C1=CC(=O)NC2=C1C=C(OC)C(OC)=C2 YCIOUNSWHDKEBM-UHFFFAOYSA-N 0.000 description 3
- OJEBWFGRUPIVSD-UHFFFAOYSA-N 6-chloro-1h-quinolin-2-one Chemical compound C1=C(Cl)C=CC2=NC(O)=CC=C21 OJEBWFGRUPIVSD-UHFFFAOYSA-N 0.000 description 3
- 102000000412 Annexin Human genes 0.000 description 3
- 108050008874 Annexin Proteins 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010055196 EphA2 Receptor Proteins 0.000 description 3
- 229910052693 Europium Inorganic materials 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 3
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 3
- 101710113436 GTPase KRas Proteins 0.000 description 3
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 3
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 3
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 3
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 3
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 3
- 150000003895 L-lactate salts Chemical class 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 101150038994 PDGFRA gene Proteins 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940022663 acetate Drugs 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000003973 alkyl amines Chemical group 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000012054 celltiter-glo Methods 0.000 description 3
- 238000005056 compaction Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 125000005265 dialkylamine group Chemical group 0.000 description 3
- 230000007783 downstream signaling Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- HYMXUYQKXCHWDC-UHFFFAOYSA-N ethyl 3-ethoxy-3-iminopropanoate;hydrochloride Chemical compound Cl.CCOC(=N)CC(=O)OCC HYMXUYQKXCHWDC-UHFFFAOYSA-N 0.000 description 3
- NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 3
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229940063718 lodine Drugs 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 125000002560 nitrile group Chemical group 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 102200143271 rs121913485 Human genes 0.000 description 3
- 102200032899 rs796065052 Human genes 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 125000003944 tolyl group Chemical group 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 238000012447 xenograft mouse model Methods 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical class NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- PAITUUNNJZYNFY-UHFFFAOYSA-N 1-(2-methylpropylamino)quinolin-2-one Chemical compound C1=CC=C2C=CC(=O)N(NCC(C)C)C2=C1 PAITUUNNJZYNFY-UHFFFAOYSA-N 0.000 description 2
- IGDKEGPXDLZYFG-UHFFFAOYSA-N 1-(methylamino)quinolin-2-one Chemical compound C1=CC=C2C=CC(=O)N(NC)C2=C1 IGDKEGPXDLZYFG-UHFFFAOYSA-N 0.000 description 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
- LSNPHHKHXUPAIC-UHFFFAOYSA-N 1-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C(N(N)C4=CC=CC(F)=C4C=3)=O)C2=C1 LSNPHHKHXUPAIC-UHFFFAOYSA-N 0.000 description 2
- NPYZNNYWBUXNRC-UHFFFAOYSA-N 1-bromoquinolin-2-one Chemical compound C1=CC=C2C=CC(=O)N(Br)C2=C1 NPYZNNYWBUXNRC-UHFFFAOYSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- NCSGPOWDKZUREZ-UHFFFAOYSA-N 1-methoxyquinolin-2-one Chemical compound C1=CC=C2C=CC(=O)N(OC)C2=C1 NCSGPOWDKZUREZ-UHFFFAOYSA-N 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- HLCPWBZNUKCSBN-UHFFFAOYSA-N 2-aminobenzonitrile Chemical class NC1=CC=CC=C1C#N HLCPWBZNUKCSBN-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- CRMACCRNCSJWTO-UHFFFAOYSA-N 2h-pyridine-1,2-diamine Chemical class NC1C=CC=CN1N CRMACCRNCSJWTO-UHFFFAOYSA-N 0.000 description 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- IQXUIDYRTHQTET-UHFFFAOYSA-N 4-amino-3-nitrophenol Chemical compound NC1=CC=C(O)C=C1[N+]([O-])=O IQXUIDYRTHQTET-UHFFFAOYSA-N 0.000 description 2
- YLAFBGATSQRSTB-UHFFFAOYSA-N 6-bromo-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=CC(Br)=CC=C21 YLAFBGATSQRSTB-UHFFFAOYSA-N 0.000 description 2
- IQTAMWMUCVXMFU-UHFFFAOYSA-N 6-fluoro-7-(3-hydroxypiperidin-1-yl)-1h-quinolin-2-one Chemical compound C1C(O)CCCN1C(C(=C1)F)=CC2=C1C=CC(=O)N2 IQTAMWMUCVXMFU-UHFFFAOYSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101150003532 CSH gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100033299 Glia-derived nexin Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101100066427 Homo sapiens FCGR1A gene Proteins 0.000 description 2
- 101000997803 Homo sapiens Glia-derived nexin Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 2
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000002431 aminoalkoxy group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 2
- 150000004982 aromatic amines Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 2
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000007402 cytotoxic response Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- 125000005266 diarylamine group Chemical group 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 150000002012 dioxanes Chemical class 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 230000005014 ectopic expression Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- JTVPWPDLKUQDAU-UHFFFAOYSA-N ethyl 2-(1h-benzimidazol-2-yl)acetate Chemical class C1=CC=C2NC(CC(=O)OCC)=NC2=C1 JTVPWPDLKUQDAU-UHFFFAOYSA-N 0.000 description 2
- MBJLVQKGFDSQGA-UHFFFAOYSA-N ethyl 2-(1h-imidazo[4,5-b]pyridin-2-yl)acetate Chemical class C1=CC=C2NC(CC(=O)OCC)=NC2=N1 MBJLVQKGFDSQGA-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 235000011167 hydrochloric acid Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 150000003949 imides Chemical group 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000026045 iodination Effects 0.000 description 2
- 238000006192 iodination reaction Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000004701 malic acid derivatives Chemical class 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- XJLSEXAGTJCILF-UHFFFAOYSA-N nipecotic acid Chemical compound OC(=O)C1CCCNC1 XJLSEXAGTJCILF-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical group 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- CXWQAPHDSYDHBR-UHFFFAOYSA-N piperidine-4-carboxamide Chemical compound NC(=O)C1CCNCC1.NC(=O)C1CCNCC1 CXWQAPHDSYDHBR-UHFFFAOYSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- KONTUBJJPNBLSG-UHFFFAOYSA-N (3,5-dimethylphenyl)urea Chemical compound CC1=CC(C)=CC(NC(N)=O)=C1 KONTUBJJPNBLSG-UHFFFAOYSA-N 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- PSOYRBSNMNQPTL-UHFFFAOYSA-N 1,2-dihydroquinoline-6-carboxamide Chemical compound N1CC=CC2=CC(C(=O)N)=CC=C21 PSOYRBSNMNQPTL-UHFFFAOYSA-N 0.000 description 1
- LPYDODDZWQESTQ-UHFFFAOYSA-N 1,2-dimethylbenzimidazole-5-sulfonamide Chemical compound NS(=O)(=O)C1=CC=C2N(C)C(C)=NC2=C1 LPYDODDZWQESTQ-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- SSNCMIDZGFCTST-UHFFFAOYSA-N 1,3-difluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=C(F)C=CC=C1F SSNCMIDZGFCTST-UHFFFAOYSA-N 0.000 description 1
- JBYHSSAVUBIJMK-UHFFFAOYSA-N 1,4-oxathiane Chemical compound C1CSCCO1 JBYHSSAVUBIJMK-UHFFFAOYSA-N 0.000 description 1
- XQVCBEAUUNDAKR-UHFFFAOYSA-N 1-(1,3-thiazol-2-ylmethylamino)quinolin-2-one Chemical compound O=C1C=CC2=CC=CC=C2N1NCC1=NC=CS1 XQVCBEAUUNDAKR-UHFFFAOYSA-N 0.000 description 1
- RMYBWYQRUGXUBK-UHFFFAOYSA-N 1-(1-methylpiperidin-4-yl)benzimidazole-5-carboxamide Chemical compound C1CN(C)CCC1N1C2=CC=C(C(N)=O)C=C2N=C1 RMYBWYQRUGXUBK-UHFFFAOYSA-N 0.000 description 1
- OSBJHPSSVKHNBK-UHFFFAOYSA-N 1-(1h-benzimidazol-2-yl)quinolin-2-one Chemical compound C1=CC=C2NC(N3C4=CC=CC=C4C=CC3=O)=NC2=C1 OSBJHPSSVKHNBK-UHFFFAOYSA-N 0.000 description 1
- IHZSEYLWFHXAFK-UHFFFAOYSA-N 1-(cyclohexylmethylamino)quinolin-2-one Chemical compound O=C1C=CC2=CC=CC=C2N1NCC1CCCCC1 IHZSEYLWFHXAFK-UHFFFAOYSA-N 0.000 description 1
- OIRFCOOSSXHQPN-UHFFFAOYSA-N 1-(dimethylamino)quinolin-2-one Chemical compound C1=CC=C2C=CC(=O)N(N(C)C)C2=C1 OIRFCOOSSXHQPN-UHFFFAOYSA-N 0.000 description 1
- AUSQZRNIINDROH-UHFFFAOYSA-N 1-(piperidin-3-ylamino)quinolin-2-one Chemical compound O=C1C=CC2=CC=CC=C2N1NC1CCCNC1 AUSQZRNIINDROH-UHFFFAOYSA-N 0.000 description 1
- PUINRCFXNUECTH-UHFFFAOYSA-N 1-(piperidin-4-ylamino)quinolin-2-one Chemical compound O=C1C=CC2=CC=CC=C2N1NC1CCNCC1 PUINRCFXNUECTH-UHFFFAOYSA-N 0.000 description 1
- ZCRJPDWKBVWPHL-UHFFFAOYSA-N 1-(piperidin-4-ylmethylamino)quinolin-2-one Chemical compound O=C1C=CC2=CC=CC=C2N1NCC1CCNCC1 ZCRJPDWKBVWPHL-UHFFFAOYSA-N 0.000 description 1
- OAAMDGZGSAOBRQ-UHFFFAOYSA-N 1-(pyrazin-2-ylmethylamino)quinolin-2-one Chemical compound O=C1C=CC2=CC=CC=C2N1NCC1=CN=CC=N1 OAAMDGZGSAOBRQ-UHFFFAOYSA-N 0.000 description 1
- IMMNKPZCHHOYML-UHFFFAOYSA-N 1-(pyrrolidin-2-ylmethylamino)quinolin-2-one Chemical compound O=C1C=CC2=CC=CC=C2N1NCC1CCCN1 IMMNKPZCHHOYML-UHFFFAOYSA-N 0.000 description 1
- JONXZAAXKUTPMG-UHFFFAOYSA-N 1-(pyrrolidin-3-ylamino)quinolin-2-one Chemical compound O=C1C=CC2=CC=CC=C2N1NC1CCNC1 JONXZAAXKUTPMG-UHFFFAOYSA-N 0.000 description 1
- DWOFPTOMAPPICU-UHFFFAOYSA-N 1-(trifluoromethyl)quinolin-2-one Chemical compound C1=CC=C2C=CC(=O)N(C(F)(F)F)C2=C1 DWOFPTOMAPPICU-UHFFFAOYSA-N 0.000 description 1
- IMMNKPZCHHOYML-LBPRGKRZSA-N 1-[[(2s)-pyrrolidin-2-yl]methylamino]quinolin-2-one Chemical compound O=C1C=CC2=CC=CC=C2N1NC[C@@H]1CCCN1 IMMNKPZCHHOYML-LBPRGKRZSA-N 0.000 description 1
- JONXZAAXKUTPMG-NSHDSACASA-N 1-[[(3s)-pyrrolidin-3-yl]amino]quinolin-2-one Chemical compound O=C1C=CC2=CC=CC=C2N1N[C@H]1CCNC1 JONXZAAXKUTPMG-NSHDSACASA-N 0.000 description 1
- PPJVXZVTPWQOQS-UHFFFAOYSA-N 1-ethoxy-1-(1-ethoxyethoxy)ethane Chemical compound CCOC(C)OC(C)OCC PPJVXZVTPWQOQS-UHFFFAOYSA-N 0.000 description 1
- ONETWPUKNIHTGZ-UHFFFAOYSA-N 1-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C(N(F)C4=CC=CC=C4C=3)=O)C2=C1 ONETWPUKNIHTGZ-UHFFFAOYSA-N 0.000 description 1
- VQKOVWJIZYGLNG-UHFFFAOYSA-N 1-fluoro-7-(piperidin-3-ylmethylamino)quinolin-2-one Chemical compound C=1C=C2C=CC(=O)N(F)C2=CC=1NCC1CCCNC1 VQKOVWJIZYGLNG-UHFFFAOYSA-N 0.000 description 1
- XVKURBZSARQAMW-UHFFFAOYSA-N 1-fluoro-7-(pyrrolidin-3-ylamino)quinolin-2-one Chemical compound C=1C=C2C=CC(=O)N(F)C2=CC=1NC1CCNC1 XVKURBZSARQAMW-UHFFFAOYSA-N 0.000 description 1
- GPAAEZIXSQCCES-UHFFFAOYSA-N 1-methoxy-2-(2-methoxyethoxymethoxymethoxy)ethane Chemical compound COCCOCOCOCCOC GPAAEZIXSQCCES-UHFFFAOYSA-N 0.000 description 1
- AYNIVHXEPJAQNN-UHFFFAOYSA-N 1-morpholin-4-ylquinolin-2-one Chemical compound O=C1C=CC2=CC=CC=C2N1N1CCOCC1 AYNIVHXEPJAQNN-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XTMDFKSYHRPNQF-UHFFFAOYSA-N 1-propylquinolin-2-one Chemical compound C1=CC=C2C=CC(=O)N(CCC)C2=C1 XTMDFKSYHRPNQF-UHFFFAOYSA-N 0.000 description 1
- 102000004899 14-3-3 Proteins Human genes 0.000 description 1
- 101710112812 14-3-3 protein Proteins 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- DIPGYZSCGXBTEU-UHFFFAOYSA-N 2,3-difluoro-6-nitroaniline Chemical compound NC1=C(F)C(F)=CC=C1[N+]([O-])=O DIPGYZSCGXBTEU-UHFFFAOYSA-N 0.000 description 1
- RJXOVESYJFXCGI-UHFFFAOYSA-N 2,4-difluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1F RJXOVESYJFXCGI-UHFFFAOYSA-N 0.000 description 1
- GFTPLFVZKMIYAP-UHFFFAOYSA-N 2-(1h-benzimidazol-1-ium-2-yl)acetate Chemical compound C1=CC=C2NC(CC(=O)O)=NC2=C1 GFTPLFVZKMIYAP-UHFFFAOYSA-N 0.000 description 1
- NFQTXNZDURSTFY-UHFFFAOYSA-N 2-(1h-imidazo[4,5-b]pyridin-2-yl)acetonitrile Chemical class C1=CC=C2NC(CC#N)=NC2=N1 NFQTXNZDURSTFY-UHFFFAOYSA-N 0.000 description 1
- OZZQHCBFUVFZGT-UHFFFAOYSA-N 2-(2-hydroxypropanoyloxy)propanoic acid Chemical compound CC(O)C(=O)OC(C)C(O)=O OZZQHCBFUVFZGT-UHFFFAOYSA-N 0.000 description 1
- ULXWTCABPJZGLC-UHFFFAOYSA-N 2-(4-amino-2-oxo-1H-quinolin-3-yl)-3H-benzimidazole-5-carboxylic acid Chemical compound O=C1NC2=CC=CC=C2C(N)=C1C1=NC2=CC=C(C(O)=O)C=C2N1 ULXWTCABPJZGLC-UHFFFAOYSA-N 0.000 description 1
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 description 1
- JEBQLPWDWZIMSY-UHFFFAOYSA-N 2-(dimethylamino)-n-methylacetamide Chemical compound CNC(=O)CN(C)C JEBQLPWDWZIMSY-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- HTPCDVLWYUXWQR-UHFFFAOYSA-N 2-aminopyridine-3-carboxamide Chemical class NC(=O)C1=CC=CN=C1N HTPCDVLWYUXWQR-UHFFFAOYSA-N 0.000 description 1
- MLIREBYILWEBDM-UHFFFAOYSA-M 2-cyanoacetate Chemical compound [O-]C(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-M 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- QCFAKTACICNQGT-UHFFFAOYSA-N 2-methyl-2-[(2-methylpropan-2-yl)oxymethoxymethoxy]propane Chemical compound CC(C)(C)OCOCOC(C)(C)C QCFAKTACICNQGT-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- PZFRBYNHQICAJS-UHFFFAOYSA-N 2-nitro-4-(3-pyrrolidin-1-ylpropoxy)aniline Chemical compound C1=C([N+]([O-])=O)C(N)=CC=C1OCCCN1CCCC1 PZFRBYNHQICAJS-UHFFFAOYSA-N 0.000 description 1
- WXORYMJWFSZLIB-UHFFFAOYSA-N 2-oxo-1h-quinoline-6-carbonitrile Chemical compound N#CC1=CC=C2NC(=O)C=CC2=C1 WXORYMJWFSZLIB-UHFFFAOYSA-N 0.000 description 1
- ZEGJLQZSCUPAPR-UHFFFAOYSA-N 2-oxo-1h-quinoline-6-carboxylic acid Chemical compound N1C(=O)C=CC2=CC(C(=O)O)=CC=C21 ZEGJLQZSCUPAPR-UHFFFAOYSA-N 0.000 description 1
- SDNUSNYVSDILFK-UHFFFAOYSA-N 3,4-difluoro-1h-quinolin-2-one Chemical compound C1=CC=C2C(F)=C(F)C(=O)NC2=C1 SDNUSNYVSDILFK-UHFFFAOYSA-N 0.000 description 1
- CEZFISYLOPAGKV-UHFFFAOYSA-N 3-(1-methylpiperidin-4-yl)benzimidazole-5-carboxamide Chemical compound C1CN(C)CCC1N1C2=CC(C(N)=O)=CC=C2N=C1 CEZFISYLOPAGKV-UHFFFAOYSA-N 0.000 description 1
- TWKLYDJRVDQGLS-UHFFFAOYSA-N 3-(1-methylpyrrolidin-3-yl)benzimidazole-5-carboxamide Chemical compound C1N(C)CCC1N1C2=CC(C(N)=O)=CC=C2N=C1 TWKLYDJRVDQGLS-UHFFFAOYSA-N 0.000 description 1
- HDBOHJJRWWZZQP-UHFFFAOYSA-N 3-(1H-benzimidazol-2-yl)-4-pyrrolidin-1-yl-1H-quinolin-2-one Chemical compound N=1C2=CC=CC=C2NC=1C=1C(=O)NC2=CC=CC=C2C=1N1CCCC1 HDBOHJJRWWZZQP-UHFFFAOYSA-N 0.000 description 1
- ZXJIVOHMGHTMPF-UHFFFAOYSA-N 3-(1H-benzimidazol-2-yl)-6-fluoro-1H-quinolin-2-one Chemical compound C1=CC=C2NC(C=3C(=O)NC4=CC=C(C=C4C=3)F)=NC2=C1 ZXJIVOHMGHTMPF-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- LSSDQFGDRREDLN-UHFFFAOYSA-N 3-ethoxy-3-iminopropanoic acid Chemical compound CCOC(=N)CC(O)=O LSSDQFGDRREDLN-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- XMKCHQVJPWPSPQ-UHFFFAOYSA-N 3h-benzimidazole-5-carbohydrazide Chemical compound NNC(=O)C1=CC=C2N=CNC2=C1 XMKCHQVJPWPSPQ-UHFFFAOYSA-N 0.000 description 1
- COYPLDIXZODDDL-UHFFFAOYSA-N 3h-benzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CNC2=C1 COYPLDIXZODDDL-UHFFFAOYSA-N 0.000 description 1
- LIWIJSLICFXSEB-UHFFFAOYSA-N 4-(2-morpholin-4-ylethoxy)-2-nitroaniline Chemical compound C1=C([N+]([O-])=O)C(N)=CC=C1OCCN1CCOCC1 LIWIJSLICFXSEB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- WZQHCLHSUCBUKP-UHFFFAOYSA-N 4-amino-3-(1H-benzimidazol-2-yl)-6-chloro-1H-quinolin-2-one Chemical compound O=C1NC2=CC=C(Cl)C=C2C(N)=C1C1=NC2=CC=CC=C2N1 WZQHCLHSUCBUKP-UHFFFAOYSA-N 0.000 description 1
- ATHSAZHVGBCVGV-UHFFFAOYSA-N 4-amino-3-(1H-benzimidazol-2-yl)-6-nitro-1H-quinolin-2-one Chemical compound O=C1NC2=CC=C([N+]([O-])=O)C=C2C(N)=C1C1=NC2=CC=CC=C2N1 ATHSAZHVGBCVGV-UHFFFAOYSA-N 0.000 description 1
- KWOYACWBFMRONS-UHFFFAOYSA-N 4-amino-3-(1h-benzimidazol-2-yl)-1-methylquinolin-2-one Chemical compound C1=CC=C2NC(C3=C(N)C4=CC=CC=C4N(C3=O)C)=NC2=C1 KWOYACWBFMRONS-UHFFFAOYSA-N 0.000 description 1
- KPHOIEKHGSLXJY-UHFFFAOYSA-N 4-amino-3-(1h-benzimidazol-2-yl)-7-thiophen-2-yl-1h-quinolin-2-one Chemical compound C=1C=C2C(N)=C(C=3NC4=CC=CC=C4N=3)C(=O)NC2=CC=1C1=CC=CS1 KPHOIEKHGSLXJY-UHFFFAOYSA-N 0.000 description 1
- ZWOOLLZFQPQSSM-UHFFFAOYSA-N 4-amino-3-(1h-benzimidazol-2-yl)-7-thiophen-3-yl-1h-quinolin-2-one Chemical compound C=1C=C2C(N)=C(C=3NC4=CC=CC=C4N=3)C(=O)NC2=CC=1C=1C=CSC=1 ZWOOLLZFQPQSSM-UHFFFAOYSA-N 0.000 description 1
- LMVXWGVIORMRJK-UHFFFAOYSA-N 4-amino-3-(4-methyl-1h-benzimidazol-2-yl)-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)C(C=3NC=4C=CC=C(C=4N=3)C)=C(N)C2=C1 LMVXWGVIORMRJK-UHFFFAOYSA-N 0.000 description 1
- WUXRPYRNRSPTBP-UHFFFAOYSA-N 4-amino-3-(5,6-dichloro-1H-benzimidazol-2-yl)-1H-quinolin-2-one Chemical compound O=C1NC2=CC=CC=C2C(N)=C1C1=NC2=CC(Cl)=C(Cl)C=C2N1 WUXRPYRNRSPTBP-UHFFFAOYSA-N 0.000 description 1
- HATYZRHPCBUAKM-UHFFFAOYSA-N 4-amino-3-(6-ethoxy-1H-benzimidazol-2-yl)-1H-quinolin-2-one Chemical compound C1=CC=C2NC(=O)C(C3=NC4=CC=C(C=C4N3)OCC)=C(N)C2=C1 HATYZRHPCBUAKM-UHFFFAOYSA-N 0.000 description 1
- DAFMABDREMKTCY-UHFFFAOYSA-N 4-amino-3-(6-tert-butyl-1H-benzimidazol-2-yl)-1H-quinolin-2-one Chemical compound C1=CC=C2NC(=O)C(C3=NC4=CC=C(C=C4N3)C(C)(C)C)=C(N)C2=C1 DAFMABDREMKTCY-UHFFFAOYSA-N 0.000 description 1
- YAJOUNMDAGJXGI-UHFFFAOYSA-N 4-amino-3-(6-thiophen-3-yl-1H-benzimidazol-2-yl)-1H-quinolin-2-one Chemical compound O=C1NC2=CC=CC=C2C(N)=C1C(NC1=CC=2)=NC1=CC=2C=1C=CSC=1 YAJOUNMDAGJXGI-UHFFFAOYSA-N 0.000 description 1
- OTZGZDFNJWVIOF-UHFFFAOYSA-N 4-anilino-3-(1H-benzimidazol-2-yl)-6-chloro-1H-quinolin-2-one Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C=2NC3=CC=CC=C3N=2)=C1NC1=CC=CC=C1 OTZGZDFNJWVIOF-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- PJQNCNSQIBZTQY-UHFFFAOYSA-N 6,7-dichloro-1h-quinolin-2-one Chemical compound C1=CC(=O)NC2=C1C=C(Cl)C(Cl)=C2 PJQNCNSQIBZTQY-UHFFFAOYSA-N 0.000 description 1
- XFKXRLSCKJFLFQ-UHFFFAOYSA-N 6,7-difluoro-1h-quinolin-2-one Chemical compound C1=CC(=O)NC2=C1C=C(F)C(F)=C2 XFKXRLSCKJFLFQ-UHFFFAOYSA-N 0.000 description 1
- ODVFANKOECUNCN-UHFFFAOYSA-N 6,7-dihydroxy-1h-quinolin-2-one Chemical compound C1=CC(=O)NC2=C1C=C(O)C(O)=C2 ODVFANKOECUNCN-UHFFFAOYSA-N 0.000 description 1
- XZUCGWFQXJFKRF-UHFFFAOYSA-N 6,8-dimethyl-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=CC(C)=CC(C)=C21 XZUCGWFQXJFKRF-UHFFFAOYSA-N 0.000 description 1
- UDLZCYPKCUTYLI-UHFFFAOYSA-N 6-(2-hydroxyphenyl)-1h-quinolin-2-one Chemical compound OC1=CC=CC=C1C1=CC=C(NC(=O)C=C2)C2=C1 UDLZCYPKCUTYLI-UHFFFAOYSA-N 0.000 description 1
- MUBOKDUNDGXVDZ-UHFFFAOYSA-N 6-(3-hydroxyphenyl)-1h-quinolin-2-one Chemical compound OC1=CC=CC(C=2C=C3C=CC(=O)NC3=CC=2)=C1 MUBOKDUNDGXVDZ-UHFFFAOYSA-N 0.000 description 1
- PWJAZUTZMWJFEC-UHFFFAOYSA-N 6-(dimethylamino)-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=CC(N(C)C)=CC=C21 PWJAZUTZMWJFEC-UHFFFAOYSA-N 0.000 description 1
- XMDZSHQFXITHFO-UHFFFAOYSA-N 6-[2-(trifluoromethyl)phenyl]-1h-quinolin-2-one Chemical compound FC(F)(F)C1=CC=CC=C1C1=CC=C(NC(=O)C=C2)C2=C1 XMDZSHQFXITHFO-UHFFFAOYSA-N 0.000 description 1
- JRKAOSGYIYTAHW-UHFFFAOYSA-N 6-[3-(trifluoromethyl)phenyl]-1h-quinolin-2-one Chemical compound FC(F)(F)C1=CC=CC(C=2C=C3C=CC(=O)NC3=CC=2)=C1 JRKAOSGYIYTAHW-UHFFFAOYSA-N 0.000 description 1
- WERABQRUGJIMKQ-UHFFFAOYSA-N 6-chloro-3-nitropyridin-2-amine Chemical compound NC1=NC(Cl)=CC=C1[N+]([O-])=O WERABQRUGJIMKQ-UHFFFAOYSA-N 0.000 description 1
- DWKSJMWYHYPKKJ-UHFFFAOYSA-N 6-fluoro-7-(2-hydroxyethylamino)-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=C(NCCO)C(F)=C2 DWKSJMWYHYPKKJ-UHFFFAOYSA-N 0.000 description 1
- XZDVEYRJRLHNGH-UHFFFAOYSA-N 6-fluoro-7-(2-methoxyethylamino)-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=C(NCCOC)C(F)=C2 XZDVEYRJRLHNGH-UHFFFAOYSA-N 0.000 description 1
- ISUGPQPYGAWRKK-UHFFFAOYSA-N 6-fluoro-7-(2-methylimidazol-1-yl)-1h-quinolin-2-one Chemical compound CC1=NC=CN1C(C(=C1)F)=CC2=C1C=CC(=O)N2 ISUGPQPYGAWRKK-UHFFFAOYSA-N 0.000 description 1
- WTRDSPYDWFKWGP-UHFFFAOYSA-N 6-fluoro-7-(2-pyrrolidin-1-ylethylamino)-1h-quinolin-2-one Chemical compound FC1=CC=2C=CC(=O)NC=2C=C1NCCN1CCCC1 WTRDSPYDWFKWGP-UHFFFAOYSA-N 0.000 description 1
- PMHHRXYFTNWZHL-UHFFFAOYSA-N 6-fluoro-7-(3-methoxypropylamino)-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=C(NCCCOC)C(F)=C2 PMHHRXYFTNWZHL-UHFFFAOYSA-N 0.000 description 1
- CESBQXFELSCKRL-UHFFFAOYSA-N 6-fluoro-7-methoxy-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=C(OC)C(F)=C2 CESBQXFELSCKRL-UHFFFAOYSA-N 0.000 description 1
- HRQARRHZNIORQE-UHFFFAOYSA-N 6-iodo-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=CC(I)=CC=C21 HRQARRHZNIORQE-UHFFFAOYSA-N 0.000 description 1
- LOUXUHOSYWFSHV-UHFFFAOYSA-N 6-methyl-1h-quinolin-2-one Chemical compound N1=C(O)C=CC2=CC(C)=CC=C21 LOUXUHOSYWFSHV-UHFFFAOYSA-N 0.000 description 1
- OYLJUJGLDPDXHP-UHFFFAOYSA-N 6-nitro-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=CC([N+](=O)[O-])=CC=C21 OYLJUJGLDPDXHP-UHFFFAOYSA-N 0.000 description 1
- WGNYOCAOLVBRDL-UHFFFAOYSA-N 6-pyridin-2-yl-1h-quinolin-2-one Chemical compound C=1C=C2NC(=O)C=CC2=CC=1C1=CC=CC=N1 WGNYOCAOLVBRDL-UHFFFAOYSA-N 0.000 description 1
- KCOOTKBLYMFIMO-UHFFFAOYSA-N 6-pyridin-4-yl-1h-quinolin-2-one Chemical compound C=1C=C2NC(=O)C=CC2=CC=1C1=CC=NC=C1 KCOOTKBLYMFIMO-UHFFFAOYSA-N 0.000 description 1
- YTOAITGAGBCQPY-UHFFFAOYSA-N 6-thiophen-2-yl-1h-quinolin-2-one Chemical compound C=1C=C2NC(=O)C=CC2=CC=1C1=CC=CS1 YTOAITGAGBCQPY-UHFFFAOYSA-N 0.000 description 1
- LVEYAXYMUMTUHX-UHFFFAOYSA-N 6-thiophen-3-yl-1h-quinolin-2-one Chemical compound C=1C=C2NC(=O)C=CC2=CC=1C=1C=CSC=1 LVEYAXYMUMTUHX-UHFFFAOYSA-N 0.000 description 1
- KYPFKBQYDGZODD-UHFFFAOYSA-N 7-(diethylamino)-6-fluoro-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=C(N(CC)CC)C(F)=C2 KYPFKBQYDGZODD-UHFFFAOYSA-N 0.000 description 1
- QOFKBVYWLUKWLL-UHFFFAOYSA-N 7-bromo-1h-quinolin-2-one Chemical compound C1=CC(=O)NC2=CC(Br)=CC=C21 QOFKBVYWLUKWLL-UHFFFAOYSA-N 0.000 description 1
- SDRJFDTZVULXDE-UHFFFAOYSA-N 7-chloro-1h-quinolin-2-one Chemical compound C1=CC(Cl)=CC2=NC(O)=CC=C21 SDRJFDTZVULXDE-UHFFFAOYSA-N 0.000 description 1
- BHYARWJZFOVNCF-UHFFFAOYSA-N 7-chloro-6-iodo-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=C(Cl)C(I)=C2 BHYARWJZFOVNCF-UHFFFAOYSA-N 0.000 description 1
- IPFWGOPYTUCFDC-UHFFFAOYSA-N 7-fluoro-1h-quinolin-2-one Chemical compound C1=CC(=O)NC2=CC(F)=CC=C21 IPFWGOPYTUCFDC-UHFFFAOYSA-N 0.000 description 1
- UFDPMSOJTUGSEU-UHFFFAOYSA-N 7-fluoro-6-(2-methylphenyl)-1h-quinolin-2-one Chemical compound CC1=CC=CC=C1C(C(=C1)F)=CC2=C1NC(=O)C=C2 UFDPMSOJTUGSEU-UHFFFAOYSA-N 0.000 description 1
- IRWUCCUEZDORIJ-UHFFFAOYSA-N 7-fluoro-6-iodo-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=C(F)C(I)=C2 IRWUCCUEZDORIJ-UHFFFAOYSA-N 0.000 description 1
- AUHADULCABPIFC-UHFFFAOYSA-N 7-methoxy-1h-quinolin-2-one Chemical compound C1=CC(=O)NC2=CC(OC)=CC=C21 AUHADULCABPIFC-UHFFFAOYSA-N 0.000 description 1
- QLVPBCMPYVAWEW-UHFFFAOYSA-N 7-methyl-1h-quinolin-2-one Chemical compound C1=CC(O)=NC2=CC(C)=CC=C21 QLVPBCMPYVAWEW-UHFFFAOYSA-N 0.000 description 1
- XXPVCQMOIBCSDT-UHFFFAOYSA-N 8-methylquinolin-2(1H)-one Chemical compound C1=CC(=O)NC2=C1C=CC=C2C XXPVCQMOIBCSDT-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101100000858 Caenorhabditis elegans act-3 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 101710137199 Class II receptor tyrosine kinase Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 101000827763 Drosophila melanogaster Fibroblast growth factor receptor homolog 1 Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000050554 Eph Family Receptors Human genes 0.000 description 1
- 108091008815 Eph receptors Proteins 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 101150081880 FGF1 gene Proteins 0.000 description 1
- 229940125832 FGFR3 inhibitor Drugs 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 101710182387 Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 230000037057 G1 phase arrest Effects 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108091008603 HGF receptors Proteins 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
- 101150026109 INSR gene Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 101150105382 MET gene Proteins 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 150000001204 N-oxides Chemical group 0.000 description 1
- 229910017974 NH40H Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- DXCUKNQANPLTEJ-UHFFFAOYSA-N PD173074 Chemical compound CC(C)(C)NC(=O)NC1=NC2=NC(NCCCCN(CC)CC)=NC=C2C=C1C1=CC(OC)=CC(OC)=C1 DXCUKNQANPLTEJ-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000005450 TIE receptors Human genes 0.000 description 1
- 108010006830 TIE receptors Proteins 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- AYPPNZWCLQAJPT-UHFFFAOYSA-N acetic acid;1h-benzimidazole Chemical class CC(O)=O.C1=CC=C2NC=NC2=C1 AYPPNZWCLQAJPT-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005107 alkyl diaryl silyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- KHBQMWCZKVMBLN-IDEBNGHGSA-N benzenesulfonamide Chemical compound NS(=O)(=O)[13C]1=[13CH][13CH]=[13CH][13CH]=[13CH]1 KHBQMWCZKVMBLN-IDEBNGHGSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- TZSMWSKOPZEMAJ-UHFFFAOYSA-N bis[(2-methoxyphenyl)methyl] carbonate Chemical compound COC1=CC=CC=C1COC(=O)OCC1=CC=CC=C1OC TZSMWSKOPZEMAJ-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- YXCWBNCDJZEBKY-UHFFFAOYSA-N chembl377345 Chemical compound O=C1NC2=CC=CC=C2C(O)=C1C1=NC2=CC=CC=C2N1 YXCWBNCDJZEBKY-UHFFFAOYSA-N 0.000 description 1
- SQUBJXXBYMPOFW-UHFFFAOYSA-N chembl383417 Chemical compound O=C1NC2=CC=CC=C2C(N)=C1C1=NC2=CC=CC=C2N1 SQUBJXXBYMPOFW-UHFFFAOYSA-N 0.000 description 1
- BAWMPMUMXKTITQ-UHFFFAOYSA-N chembl498205 Chemical compound C1=CC=C2NC(=O)C(C3=NC4=CC=C(C=C4N3)C)=C(N)C2=C1 BAWMPMUMXKTITQ-UHFFFAOYSA-N 0.000 description 1
- RKESDYSOJBSAAE-UHFFFAOYSA-N chembl498206 Chemical compound C1=CC=C2NC(=O)C(C3=NC=4C=C(C(=CC=4N3)C)C)=C(N)C2=C1 RKESDYSOJBSAAE-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 125000000259 cinnolinyl group Chemical class N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 150000001893 coumarin derivatives Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007819 coupling partner Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- GCUVBACNBHGZRS-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopenta-2,4-dien-1-yl(diphenyl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.c1cc[c-](c1)P(c1ccccc1)c1ccccc1 GCUVBACNBHGZRS-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000007822 cytometric assay Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000006710 cytostatic response Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005105 dialkylarylsilyl group Chemical group 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical group [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002081 enamines Chemical group 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940127022 high-dose drug Drugs 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 150000007857 hydrazones Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- VYFOAVADNIHPTR-UHFFFAOYSA-N isatoic anhydride Chemical compound NC1=CC=CC=C1CO VYFOAVADNIHPTR-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 1
- UTBCRHAMJFMIIR-UHFFFAOYSA-N methyl 3-chloro-3-oxopropanoate Chemical compound COC(=O)CC(Cl)=O UTBCRHAMJFMIIR-UHFFFAOYSA-N 0.000 description 1
- FXNHJALUCDRYOR-SANMLTNESA-N methyl 4-[4-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]amino]-3-(1h-benzimidazol-2-yl)-7-chloro-2-oxo-1h-quinolin-6-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(C(=C1)Cl)=CC2=C1NC(=O)C(C=1NC3=CC=CC=C3N=1)=C2N[C@@H]1C(CC2)CCN2C1 FXNHJALUCDRYOR-SANMLTNESA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- UBGWYKSEGWKKFU-UHFFFAOYSA-N n-methyl-2-morpholin-4-ylacetamide Chemical compound CNC(=O)CN1CCOCC1 UBGWYKSEGWKKFU-UHFFFAOYSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical group 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical compound OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 description 1
- TYZYRCHEVXXLSJ-UHFFFAOYSA-N phenylmethoxymethoxymethoxymethylbenzene Chemical compound C=1C=CC=CC=1COCOCOCC1=CC=CC=C1 TYZYRCHEVXXLSJ-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 102200143278 rs17881656 Human genes 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 101150114085 soc-2 gene Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- OKODKVMXHLUQSW-JITBQSAISA-M sodium;(e)-4-hydroxy-4-oxobut-2-enoate;octadecanoic acid Chemical compound [Na+].OC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCC(O)=O OKODKVMXHLUQSW-JITBQSAISA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000004354 sulfur functional group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- ISXOBTBCNRIIQO-UHFFFAOYSA-N tetrahydrothiophene 1-oxide Chemical compound O=S1CCCC1 ISXOBTBCNRIIQO-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000005106 triarylsilyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE
COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES
[0001] This invention pertains generally to the preparation of pharmaceutically acceptable salts of specific protein kinase inhibiting quinolinone compounds having improved aqueous solubility and other desirable physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility). The quinolinone compounds are useful in treating diseases characterized by angiogenesis including cancer. More specifically, the invention described herein pertains to pharmaceutically acceptable salts of specific protein kinase inhibiting quinolinone compounds which have improved aqueous solubility and desirable drug substance properties. The present invention provides these salts which are inhibitors of vascular endothelial growth factor receptor tyrosine kinase and can be used in methods of treating patients wherein inhibition of vascular endothelial growth factor receptor tyrosine kinase is indicated.
[0002] Changing a drug substance form from its free base or acid to a salt form is one technique that may be employed to improve its pharmacokinetics or physicochemical properties such as absorption, bioavailability, aqueous solubility, stability, hygroscopicity, crystallinity, and processability (Handbook of
Pharmaceutical Salts Properties, Selection, and Use; P. H. Stahl, C.G. Wermuth (Eds.): Chapter 5 Biological effects of the drug salt form; F. Pfannkuch, H. Rettig,
P.H. Stahl. Preservation of Pharmaceutical Products to Salt Forms of Drugs and
Absorption, Encyclopedia of Pharmaceutical Technology; J. Swarbick, J.C. Boylan;
Vol. 13, p. 453-476). To date however, there is no reliable method to predict exactly what effect changing the salt would have on its physicochemical or pharmacokinetic properties. There is also no reliable way to predict which salt-forming agent or counterion will produce the most desirable pharmaceutical properties in a drug compound or substance. Depending on the dose required, aqueous solubilities in the range of 0.1-1.0 mg/mL are typical for oral dosage formulations. Parenteral formulation may require higher solubilities, such as 10 mg/mL or greater (Handbook of Pharmaceutical Salts Properties, Selection, and Use; P. H. Stahl, C.G. Wermuth (Eds.): Chapter 7. A Procedure for Salt Selection and Optimization; M. J. Bowker).
[0003] Generally, a salt may be manufactured by mixing an acid and a base in a suitable media (solution or resin). Typical approaches to induce the salt to crystallize from the medium include cooling, evaporation, pH shift, and addition of anti-solvent among others. For example, a salt of a basic compound may be prepared by reacting this compound with an inorganic acid, an organic acid, an acidic amino acid. Salts formed by adding inorganic bases and organic bases, such as amine cation, ammonium, and quaternary ammonium compounds to a drug substance are also included in the definition of "pharmaceutically acceptable salts."
[0004] The selected salt ion can significantly influence the pharmacokinetics of a drug, especially the absorption or membrane-transfer process. The salt form of a drug substance is known to influence the factors that affect bioavailability. Salts differ in their solubility profiles and dissolution rates which affects the rate of absorption of the drug and its bioavailability.
[0005] The solubility of a drug substance can be improved by converting the free base or acid into a salt form. The solubility of a drug substance affects the pharmacokinetic profile, chemical stability, and final formulation of the ultimate dosage composition. The solubility of a compound depends upon the physical and chemical properties of the drug substance and other factors such as temperature, pressure and solvent properties (such as pH). The physical and chemical properties can vary from one salt form to another. )
[0006] The particular salt form of a drug substance can affect its stability which can significantly affect the choice of the dosage form, the manufacturing process, packaging, and the ultimate therapeutic benefit of the finished drug product.
Factors that influence stability include hygroscopicity and crystallinity. Non hygroscopic salts as well as crystalline, non-amorphous salts are generally preferred for developing formulations with optimal storage, handling, and processing properties.
[0007] Processability (i.e., crystal morphology and compactibility) is another characteristic to consider when selecting a salt form. Generally, plate-shaped crystals are preferred over needle-shaped crystals because of their better bulk powder flow properties. Compactibility is defined as the ability of the powdered material to be . compressed into a tablet of specified tensile strength and is of particular importance in a high dose drug.
[0008] The ability to form a salt from the free acid or base of a drug substance provides a means for altering ‘the chemical, physical, and/or biological characteristics of a drug product without modifying its chemical formula. Such changes allow _ formulations to be developed which have increased solubility, stability, processability, and bioavailability over the parent drug substance.
[0009] Capillaries reach into almost all tissues of the human body and supply tissues with oxygen and nutrients as well as removing waste products. Under typical conditions, the endothelial cells lining the capillaries do not divide, and capillaries, therefore, do not normally increase in number or size in a human adult. Under certain normal conditions, however, such as when a tissue is damaged, or during certain parts of the menstrual cycle, the capillaries begin to proliferate rapidly. This process of iy forming new capillaries from pre-existing blood vessels is known as angiogenesis or neovascularization. See Folkman, J. Scientific American 275, 150-154 (1996).
Angiogenesis during wound healing is an example of pathophysiological neovascularization during adult life. During wound healing, the additional capillaries provide a supply of oxygen and nutrients, promote granulation tissue, and aid in waste removal. After termination of the healing process, the capillaries normally regress.
Lymboussaki, A. “Vascular Endothelial Growth Factors and their Receptors in
Embryos, Adults, and in Tumors” Academic Dissertation, University of Helsinki,
Molecular/Cancer Biology Laboratory and Department of Pathology, Haartman
Institute, (1999).
[0010] Angiogenesis also plays an important role in the growth of cancer cells. Tt is known that once a nest of cancer cells reaches a certain size, roughly 1t02 mm in diameter, the cancer cells must develop a blood supply in order for the tumor to grow larger as diffusion will not be sufficient to supply the cancer cells with enough oxygen and nutrients. Thus, inhibition of angiogenesis is expected to halt the growth of cancer cells. foo11] Receptor tyrosine kinases (RTKS) are transmembrane polypeptides that regulate developmental cell growth and differentiation, remodeling and regeneration of adult tissues. Mustonen, T. et al., J. Cell Biology 129, 895-898 (1995); van der
Geer, P. ef al. Ann Rev. Cell Biol. 10, 251-337 (1994). Polypeptide ligands known as growth factors or cytokines, are known to activate RTKs. Signaling RTKs involves ligand binding and a shift in conformation in the external domain of the receptor resulting in its dimerization. Lymboussaki, A. “Vascular Endothelial Growth Factors and their Receptors in Embryos, Adults, and in Tumors” Academic Dissertation,
University of Helsinki, Molecular/Cancer Biology Laboratory and Department of
Pathology, Haartman Institute, (1999); Ullrich, A. et al., Cell 61, 203-212 (1990).
Binding of the ligand to the RTK results in receptor trans-phosphorylation at specific tyrosine residues and subsequent activation of the catalytic domains for the phosphorylation of cytoplasmic substrates. Id.
[0012] FLT-3 is a receptor tyrosine kinase belonging to the PDGF Receptor family expressed on acute myelogenous leukemia (AML) cells in a majority of patients and can be present in wildtype form or have activating mutations that result in constitutively active kinase function. An internal tandem repeat (ITD) mutation is expressed in about 25% of AML patients and has been associated with poor prognosis in AML patients. Levis, M. et al., Blood 99, 11; 2002.
[0013] " ¢-Kit is another receptor tyrosine kinase belonging to the PDGF
Receptor family and is normally expressed in hematopoietic progenitor, mast and germ cells. C-kit expression has been implicated in a number of cancers including mast cell leukemia, germ cell tumors, small-cell lung carcinoma, gastroinstestinal stromal tumors, acute myelogenous leukemia (AML), neuroblastoma, melanoma,
ovarian carcinoma, breast carcinoma. Heinrich, M. C.etal., J. Clin. Onc. 20, 6 1692- 1703, 2002 (review article); Smolich, B. D. et al., Blood, 97, 5; 1413-1421.
[0014] c-ABL is a tyrosine kinase that was originally identified as an oncogene product from the genome of the Abelson murine leukemia virus. About 90% of chronic myelogenous leukemia (CML), 20-30% of acute lymphoblastic leukemia (ALL) and about 1% of acute myeloblastic leukemia (AML) have a reciprocal translocation between chromosome 9 and 22. The translocation results in the 'Philadelphia’ chromosome and is the reason for the expression of a chimeric
BCR/ABL transcript.
[0015] FGFR3 is a tyrosine kinase associated with various cancers. Fibroblast growth factor receptor 3 (FGFR3) is a class IV receptor tyrosine kinase. FGFR3 is deregulated due to a (4,14) translocation in about 15-20% of multiple myeloma patients. This translocation causes the expression of a functional FGFR3 that can respond to FGF 1 in e.g., the bone microenvironment. In some cases, activating ; mutations that make FGFR3 ligand independent have been identified. These activating FGFR3 mutations have been found to cause Ras-like tumor progression and evidence exists that similar signaling pathways are utilized (Chesi, et al., Blood 2001 97 729-736.) {0016] CSF-1 (colony-stimulating factor-1) and its receptor Macrophage
CSFR-1 (Fms) are required for macrophage proliferation and differentiation as well as placental development. It is expressed during pregnancy and lactation in the mammary gland. Abnormal expression of CSFR1 has been correlated with advanced stage and poor prognosis in breast cancer patients.
[0017] C-Met is a receptor tyrosine kinase that binds HGF (hepatocyte growth factor). C-Met is implicated in tumorigenesis, tumor progression and metastasis of multiple tumors including colon cancer, multiple myeloma, small and non small cell lung cancer and renal cell carcinoma. C-Met has been found mutated, amplified, and overexpressed in multiple cancers.
[0018] Two subfamilies of RTKs are specific to the vascular endothelium.
These include the vascular endothelial growth factor (VEGF) subfamily and the Tie receptor subfamily. Class V RTKs include VEGFR-1, VEGFR-2, and VEGFR-3.
Shibuya, M. et al., Oncogene 5, 519-525 (1990); Terman, B. ef al., Oncogene 6, 1677-1683 (1991); Aprelikova, O. et al., Cancer Res. 52, 746-748 (1992).
[0019] Members of the VEGF subfamily have been described as being able to induce vascular permeability and endothelial cell proliferation and further identified as a major inducer of angiogenesis and vasculogenesis. Ferrara, N. ef al., Endocrinol.
Rev. 18, 4-25 (1997). VEGF is known to specifically bind to RTKs including
VEGFR-1 and VEGFR-2. DeVries, C. et al., Science 255, 989-991 (1992); Quinn, T. et al., Proc. Natl. Acad. Sci. 90, 7533-7537 (1993). VEGF stimulates the migration and proliferation of endothelial cells and induces angiogenesis both in vitro and in vivo. Connolly, D. et al., J. Biol. Chem. 264, 20017-20024 (1989); Connolly, D. et al., J. Clin. Invest. 84, 1470-1478 (1989); Ferrara, N. ef al., Endocrino. Rew. 18, 4-25 (1997); Leung, D. et al., Science 246, 1306-1309 (1989); Plouet, J. et al., EMBO J 8, 3801-3806 (1989).
[0020] Because angiogenesis is known to be critical to the growth of cancer and to be controlled by VEGF and VEGF-RTK, substantial efforts have been undertaken to develop therapeutics that are antagonists of VEGF-RTK to thereby inhibit or retard angiogenesis, and, hopefully, interfere or stop tumor proliferation.
[0021] Class ITI RTKSs are characterized by an extracellular region composed of five immunoglobulin-like domains and by a split tyrosine kinase domain. Some of : the Class III RTKs which are inhibited by the compounds of Formula I include, but are not limited to, KIT, FMS, FLT3, PDGFRa, and PDGFR§.
[0022] Class IV RTKs contain three immunoglobulin-like domains in their extracellular regions. For example, FGFR is a class IV RTK which is inhibited by the compounds of Formula I.
[0023] Examples of Class V RTKSs that are inhibited by the compound of
Formula I include, but are not limited to, VEGFR-1, VEGFR-2, and VEGFR-3.
[0024] A wide variety of chemical compounds and compositions have been reported as having activity against one of more the VEGF-RTKs. Examples include quinoline derivatives such as described in WO 98/13350, aminonicotinamide derivatives (see, e.g., WO 01/55114), antisense compounds (see, e.g., WO 01/52904), peptidomimetics (see, e.g., WO 01/52875), quinazoline derivatives (see, ¢.g., U.S.
Patent No. 6,258,951) monoclonal antibodies (see, e.g., EP 1 086 705 Al), various 5,10,15,20-tetraaryl-porphyrins and 5,10,15-triaryl-corroles (see, e.g, WO 00/27379), heterocyclic alkanesulfonic and alkane carboxylic acid derivatives (see, e.g.
DE19841985), oxindolylquinazoline derivatives (see, e.g., WO 99/10349), 1,4- diazaanthracine derivatives (see, e.g., U.S. Patent No. 5,763,441), and cinnoline derivatives (see, e.g, WO 97/34876), and various indazole compounds (see, e.g, wO 01/02369 and WO 01/53268).
[0025] Various indolyl substituted compounds have recently been disclosed in
WO 01/29025, WO 01/62251, and WO 01/62252, and various benzimidazolyl compounds have recently been disclosed in WO 01/28993. These compounds are reportedly capable of inhibiting, modulating, and/or regulating signal transduction of both receptor-type and non-receptor tyrosine kinases. Some of the disclosed compounds contain a quinolone fragment bonded to the indolyl or benzimidazolyl group.
[0026] The synthesis of 4&-hydroxy quinolone and 4-hydroxy quincline : derivatives is disclosed in a number of references. For example, Ukrainets et al. have disclosed the synthesis of 3-(benzimidazol-2-yl)-4-hydroxy-2-oxo-1,2- dihydroquinoline. Ukrainets, I. et al., Tet. Lett. 42, 7747-7748 (1995); Ukrainets, I. et : al., Khimiya Geterotsiklicheskikh Soedinii, 2, 239-241(1992). Ukrainets has also disclosed the synthesis, anticonvulsive and antithyroid activity of other 4-hydroxy quinolones and thio analogs such as 1H-2-0x0-3-(2-benzimidazolyl)-4- hydroxyquinolinine. Ukrainets, I. ef al., Khimiya Geterotsiklicheskikh Soedinii, 1, 105-108 (1993); Ukrainets, I. ef al., Khimiya Geterotsiklicheskikh Soedinii, 8, 1105- 1108 (1993); Ukrainets, I. ef al., Chem. Heterocyclic Comp. 33, 600-604, (1997).
[0027] The synthesis of various quinoline derivatives is disclosed in WO 97/48694. These compounds are disclosed as capable of binding to nuclear hormone receptors and being useful for stimulating osteoblast proliferation and bone growth.
The compounds are also disclosed as being useful in the treatment or prevention of diseases associated with nuclear hormone receptor families.
[0028] Various quinoline derivatives in which the benzene ring of the quinolone is substituted with a sulfur group are disclosed in WO 92/18483. These compounds are disclosed as being useful in pharmaceutical formulations and as medicaments.
[0029] Quinolone and coumarin derivatives have been disclosed as having use in a variety of applications unrelated to medicine and pharmaceutical formulations.
References that describe the preparation of quinolone derivatives for use in photopolymerizable compositions or for luminescent properties include: U.S. Patent
No. 5,801,212 issued to Okamoto et al.; JP 8-29973; JP 7-43896; JP 6-9952; JP 63- 258903; EP 797376; and DE 23 63 459.
[0030] Quinolinone derivatives have been disclosed in U.S. Patent
Application Serial No. 09/951,265 published on August 8, 2002 as US 2002/0107392 and in a PCT Application published on March 21, 2002 as WO 02/22598A1, which : are useful as inhibitors of VEGF-RTK. Both of the foregoing references are hereby incorporated by reference in their entirety and for all purposes. However, a continuing need exists for improving the bioavailability, stability, solubility, and hygroscopicity of compounds that inhibit the proliferation of capillaries, inhibit the growth of tumors, and/or inhibit vascular endothelial growth factor receptor tyrosine kinase and pharmaceutical formulations that contain such compounds by conversion of the free bases and acids into their corresponding salt forms.
[0031] As a result of inhibition of various RTKs, other ligand-stimulated cellular functions are blocked, including activation of downstream signaling molecules, cellular proliferation and survival. Agents which act as inhibitors of specific RTKs are useful in the treatment of disseminated disease and leukemia, as well as solid tumors, outside of the agent’s antiangiogenic activity. That is, compounds such as those described in WO 01/60814, which have a broad range of activity at different RTKs and PTKs, are antiangiogenic agents as well as antitumor agents.
[0032] Multiple myeloma (MM), a disease of malignant B cells, is characterized by the accumulation of clonal plasma cells in the bone marrow (BM) and osteolytic bone lesions. Autologous stem cell transplant (ASCT) and advances in supportive care have had a significant impact on the disease and long-term survival.
Attal, M. et al., N. Engl. J. Med., 1996; 335:91-97; and Barlogie, B. et al., Blood, 1997; 89:789-793. However, patients invariably relapse, and MM remains a universal fatal disease. The identification of nonrandom chromosomal translocations in MM has resulted in the development of powerful prognostic tools and the identification of novel molecular targets. Nearly half of patients with MM overexpress a putative oncogene, dysregulated by one of five recurrent immunoglobulin heavy (IgH) translocations: 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (FGFR3 and MMSET), 1623 (c-maf) and 20q11 (mafB). Kuehl, W. M. et al., Nat Rev Cancer, 2002; 2:175- 187; and Avet-Loiseau, H. et al., Blood, 2002; 99:2185-2191. These translocations : likely represent an early and possibly seminal event in the development of MM.
More recently, it has become clear that these specific IgH translocations impart prognostic significance. Particularly, the t(4;14) translocation with occurs in approximately 20% of patients appears to confer a particularly poor prognosis for
MM, with no apparent therapeutic benefit to ASCT. Fonseca, R. et al., Blood, 2003; 101:4569-4575; Keats, 1. J. et al., Blood, 2003; 101:1520-1529; Moreau, P. et al.,
Blood, 2002; 100:1579-1583; and Chang, H. et al., Br. J. Haematol., 2004; 125:64-68.
Clearly, novel treatment approaches are required for these patients. : [0033] The t(4;14) translocation is unusual in that it appears to dysregulate two potential oncogenes, MMSET on der(4) and FGFR3 on der(14). Chesi, M. ef al.,
Nat. Genet., 1997; 16:260-265; and Chesi, M. et al., Blood, 1998; 92:3025-3034.
Whether dysregulation of either or both of these genes is critical for MM pathogenesis is not known, however several lines of evidence support a role for FGFR3 in tumor initiation and progression. Activation of WT FGFR3, a RTK, promotes proliferation and survival in myeloma cells and is weakly transforming in a hematopoetic mouse model. Plowright, E. E. et al., Blood, 2000; 95:992-998; Chesi, M. et al., Blood, 2001; 97:729-736; and Pollett, J. B. ez al., Blood, 2002; 100:3819-3821. Subsequent acquisition of activating mutations of FGFR3 in some MM are associated with progression to late stage myeloma and are strongly transforming in several experimental models. Chesi, M. et al., Blood, 2001; 97:729-736; and Li, Z. et al.,
Blood, 2001; 97:2413-2419. In vitro studies suggest that FGFR3 can impart chemoresistance, an observation supported by clinical data that demonstrate poor responses to conventional chemotherapy and shortened median survival of #(4;14)
MM patients. Fonseca, R. et al., Blood, 2003; 101:4569-4575; Keats, J.1 etal,
Blood, 2003; 101:1520-1529; Moreau, P. et al., Blood, 2002; 100:1579-1583; and
Chang, H. et al., Br. J. Haematol., 2004; 125:64-68. These findings suggest that ectopic expression of FGFR3 may play a significant, albeit not a singular, role in myeloma oncogenesis thus making this RTK a target for molecular based therapy.
[0034] Inhibition of FGFR3 in t(4;14) MM cell lines induces cytotoxic responses demonstrating that these cells remain dependent on FGFR3 signaling despite the complexity of genetic alterations in these cells derived from end stage patients. Trude, S. et al., Blood, 2004; 103:3521-3528; Paterson, J.L.etal., Br. J.
Haematol., 2004; 124:595-603; and Grand .E. K. ef al., Leukemia, 2004; 18:962-966.
These observations are congruent with the results of receptor tyrosine inactivation in a range of human malignancies where clinical successes have been documented and encourage the clinical development of FGFR3 inhibitors for the treatment of these poor-prognosis patients. Druker, B. J. ef al.,N. Engl. J. Med., 2001; 344:1031-1037;
Demetri, G. D. et al., N. Engl. J. Med., 2002; 347:472-480; Slamon, D. J. et al., N.
Engl. J. Med. 2001; 344:783-792; and Smith, B. D. ef al., Blood, 2004; 103:3669-
[0035] The invention provides pharmaceutically acceptable salts of various compounds, methods for making such salts, pharmaceutical formulations and medicaments that include such salts, uses of the salts in preparing medicaments and pharmaceutical formulations for use in treating various conditions, and methods of treating that use the pharmaceutically acceptable salt or pharmaceutical formulations of the invention.
[0036] Therefore, in one aspect the invention provides a lactate salt of a compound of Formula I or a tautomer of the compound. The lactate may be present in various molar ratios such that in some embodiments, molar ratio of acid to free base includes any fractional ratio between 0.5-4.5. In some such embodiments, the salt includes mono-lactate or bis-lactate salts. Compounds of Formula I have the following structure:
RE
RS
R12 R13 R’
LT Ar
R2 Re xX N \
RY
# : R4 ks 1 wherein, :
R!, R?, R®, and R* may be the same or different and are independently selected from the group consisting of H, Cl, Br, F, I, -CN, -NO,, -OH, -OR"* groups, -NR'’R"? groups, substituted and unsubstituted amidinyl groups, substituted and unsubstituted guanidinyl groups, substituted and unsubstituted primary, secondary, and tertiary alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted alkynyl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, and -C(=O)R'® groups;
RS, RS, R’, and R® may be the same or different and are independently selected from the group consisting of H, Cl, Br, F, I, -NO2, -OH, -OR"® groups, -NR¥R? groups, _SH, -SR? groups, -S(=0)R?* groups, -S(=0);R** groups, -CN, substituted and unsubstituted amidinyl groups, substituted and unsubstituted guanidinyl groups, substituted and unsubstituted primary, secondary, and tertiary alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted alkynyl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalky] groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyelylalkyl groups, -C(=0)R* groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups;
R’isH;
R™ is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, and substituted and unsubstituted heterocyclyl groups; :
RY is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, OH, alkoxy groups, aryloxy groups, -NH>, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted alkylamino groups, substituted and unsubstituted arylamino groups, substituted and unsubstituted dialkylamino groups, substituted and unsubstituted diarylamino groups, substituted and unsubstituted (alkyl)(aryl)amino groups, -C(=O)H, -C(=0)-alkyl groups, -C(=0)-aryl groups, -C(=0)O-alkyl groups, -C(=0)0-aryl groups, -C(=0)NHj, -C(=0)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alky), groups, -C(=0)N(aryl), groups, -C(=0)N(alkyl)(aryl) groups, -C(=0)-heterocyclyl groups, ~C(=0)-O-heterocyclyl groups, -C(=0)NH(heterocyclyl) groups, -C(=0)-N(heterocyclyl); groups, —C(=0)-N(alkyl)(heterocyclyl) groups, -C(=0)-N(aryl)(beterocyclyl) groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups;
R“isH;
RY and R may be the same or different and are independently selected from the - group consisting of substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heterocyclylalkyl groups, -C(=0)H, -C(=0)-alkyl groups, -C(=0)-aryl groups, -C(=0)NHz, -C(=O)NH (alkyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alkyl), groups, -C(=0)N(aryl), groups, ~C(=O)N(alkyl)(aryl) groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl, substituted and unsubstituted diheterocyclylaminoalkyl, substituted and unsubstituted (heterocyclyl)(alkyl)aminoalkyl, substituted and unsubstituted
(heterocyclyl)(aryl)aminoalkyl, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups;
R'¢ and R? may be the same or different and are independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, and substituted and unsubstituted heterocyclyl groups;
RY and R*! may be the same or different and are independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, ] -C(=0)H, -C(=0)-alkyl groups, ~C(=0)-aryl groups,-C(=O)NH, -C(=0)NH(alkyl) "groups, -C(=O)NH(aryl) groups, -C(=0)N(alkyl), groups, -C(=0)N(aryl), groups, -C(=0)N(alkyl)(aryl) groups, -C(=0)O-alkyl groups, -C(=0)O-ary groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, -C(=0)-heterocyclyl groups, -C(=0)-O-heterocyclyl groups, -C(=O)NH(heterocyclyl) groups, -C(=0)-N(heterocyclyl), groups, -C(=0)-N(alkyl)(heterocyclyl) groups, -C(=0)-N(aryl)(heterocyclyl) groups, substituted and unsubstituted heterocyclylaminoalky! groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups;
RR, R*, and R* may be the same or different and are independently selected from the group consisting of H, -NH,, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl), groups, -N(aryl), groups, -N(alkyl)(aryl) groups, -NH (heterocyclyl) groups, -N(heterocyclyl)(alkyl) groups, -N(heterocyclyl) (aryl) groups, -Ni(heterocyclyl), groups, substituted and unsubstituted alkyl groups, substituted and _ unsubstituted aryl groups, -OH, substituted and unsubstituted alkoxy groups, . substituted and unsubstituted aryloxy groups, substituted and unsubstituted heterocyclyl groups, -NHOH, -N(alkyl)OH groups, -N(aryl)OH groups, -N(alkyl)O-alkyl groups, -N(aryl)O-alkyl groups, -N(alkyl)O-aryl groups, and -N(aryl)O-aryl groups; and
R* is selected from the group consisting of substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, and substituted and unsubstituted heterocyclyl groups.
[0037] In some embodiments of the lactate salt of compounds of Formula I or tautomers thereof, at least one of R®, R®, R, or R® is selected from the group consisting of substituted and unsubstituted amidinyl groups, substituted and unsubstituted guanidiny] groups, substituted and unsubstituted saturated heterocyclyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalky! groups, substituted and _ unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; —OR'® groups wherein
RY is selected from the group consisting of substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heterocyclylalkyl groups, -C(=0)H, —-C(=0)-aryl groups, -C(=0)NHj, -C(=O)NH(alkyl) groups, -C(=0)NH(aryl) groups, -C(=O)N(alkyl), groups, -C(=O)N(aryl), groups, -C(=O)N(alkyl)(aryl) groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted diheterocyclylaminoalkyl groups, substituted and unsubstituted (heterocyclyl)(alkyl)aminoalkyl groups, substituted and unsubstituted (heterocyclyl)(aryl)aminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; ~NR?’R?! groups wherein R?’ is selected from the group consisting of substituted and unsubstituted heterocyclyl groups; ~“NR¥R? groups wherein R2! is selected from the group consisting of substituted and unsubstituted heterocyclyl groups, -C(=O)H, -C(=0)-aryl groups, -C(=0)NHz, -C(=0O)NH(alkyl) groups, -C(=0)NH(aryl) groups, -C(=O)N(alkyl), groups, -C(=0)N(aryl), groups, -C(=0)N(alkyl)(aryl) groups, -C(=0)O-alkyl groups, -C(=0)0-aryl groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; and -C(=0)R? groups wherein R? is selected from the group consisting of H, -NHj,, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl), groups, -N(aryl), groups, -N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyclyl) (alkyl) groups, ‘Niheterocyclyl)(aryl) groups, -N(heterocyclyl), groups, substituted and unsubstituted aryl groups, substituted and unsubstituted aryloxy groups, and substituted and unsubstituted heterocyclyl groups.
[0038] In one embodiment, the lactate salt of the compound of Formula I or the tautomer thereof has a water solubility at 22°C of from about 5 mg/mL to about 400 mg/mL. In some embodiments, the salt of the compound of Formula I or the tautomer thereof has a water solubility from about 100 mg/mL to about 400 mg/mL.
In other embodiments, the salt of the compound of Formula I or the tautomer thereof has a water solubility from about 200 mg/mL to about 400 mg/mL. In some embodiments, the salt of the compound of Formula I or the tautomer thereof has a water solubility of greater than 30 mg/mL. In other embodiments, the salt of the compound of Formula I or the tautomer thereof has a water solubility from about 150 mg/mL to about 250 mg/mL. In another embodiment, the salt of the compound of
Formula I or the tautomer thereof is capable of dissolution in an aqueous medium below about pH 7, such as from pH 1-7, from pH 3-7, or from pH 4-7. In some embodiments, the lactate salt is crystalline and in some such embodiments comprises plate-shaped crystals. :
[0039] In some embodiments the lactate salt of the compound of Formula I or the tautomer thereof is a DL-lactate salt. In other embodiments the salt of the compound of Formula I is an L-lactate salt. In still other embodiments the salt of the compound of Formula I is a D-lactate salt. In still other embodiments, the salt of the : compound of Formula I is a mixture of the D-lactate salt and the L-lactate salts. The salts can be present in more than one form. According to the present invention, the racemate or a specific enantiomer can be used to prepare the inventive salts.
[0040] In some embodiments the lactate salt of the compound of Formula I is a salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- : yl]quinolin-2(1H)-one or a tautomer thereof. In some such embodiments, the salt is a mono-lactate or bis-lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)- 1H-benzimidazol-2-yljquinolin-2(1H)-one or a tautomer thereof. In more preferred embodiments, the salt is a DL-lactate salt of 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-ylJquinolin-2(1H)-one or a tautomer thereof. In other such embodiments, the saii is an L-iaciaie sali of 4-amino-5-fluoro- 3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl] quinolin-2(1H)-one ora tautomer thereof. In still other embodiments, the salt is a D-lactate salt of 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one or a tautomer thereof,
[0041] In some embodiments of the lactate salt of the compound of Formula I,
R'? and R" are both H.
[0042] In some embodiments of the lactate salt of the compound of Formula I,
R! is selected from the group consisting of F, Cl, substituted and unsubstituted alkoxy groups, substituted and unsubstituted heterocyclylalkoxy groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted alkylaminoalkoxy * groups, substituted and unsubstituted arylaminoalkoxy groups, substituted and unsubstituted dialkylaminoalkoxy groups, substituted and unsubstituted diarylaminoalkoxy groups, and substituted and unsubstituted (alkyl)(aryl)aminoalkoxy groups. :
[0043] In some embodiments of the lactate salt of the compound of Formula I,
R! is selected from the group consisting of H and F. In some such embodiments, R'is * F. In some embodiments, R? is H.
[0044] In some embodiments of the lactate salt of the compound of Formula I, at least one R®, R®, R7, and R® is a substituted or unsubstituted heterocyclyl group. In some such embodiments, at least one of RS or R’ is a substituted or unsubstituted heterocyclyl group. In other such embodiments, at least one of R3 RR", andR%isa substituted or unsubstituted heterocyclyl group comprising at least one O or N atom.
In some such embodiments, at least one of R® or R’ is a substituted or unsubstituted heterocyclyl group comprising at least one O or N atom. In some such embodiments, the substituted or unsubstituted heterocyclyl group or the heterocyclyl group is oo selected from morpholine, piperazine, piperidine, pyrrolidine, thiomorpholine, homopiperazine, tetrahydrothiophene, tetrahydrofuran, or tetrahydropyran. In other such embodiments, at least one of R>, R%, R7, or R?, and in some such embodiments one of R® or R is selected from substituted or unsubstituted morpholine groups, or "substituted and unsubstituted piperazine groups.
[0045] In some embodiments of the lactate salt of the compound of Formula I, at least one of R® or R” is selected from substituted or unsubstituted morpholine groups, or substituted or unsubstituted piperazine groups. In some such embodiments,
R'is F. In some such embodiments, R? is H. In some such embodiments, R'? and R!? are both H. In other such embodiments, R’ is H and R® is H. In other such embodiments, R’ is H, and R* is H.
[0046] In some embodiments of the lactate salt of the compound of Formula I,
R® and R® are both H.
[0047] In some embodiments of the lactate salt of the compound of Formula I, at least one of R® or R” is selected from the group consisting of “NR*R* groups wherein RZ is selected from the group consisting of substituted and unsubstituted heterocyclyl groups; and -NR?*R?' groups wherein R*' is selected from the group consisting of substituted and unsubstituted heterocyclyl groups, groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups. In some such embodiments, R! is selected from the group consisting of H and F. In some such embodiments, R? is H. In some such embodiments, R'2 and R® are both H. In some such embodiments, R® is H and R®is H. In some such embodiments, R® is H and R*is
H.
[0048] The invention also provides lactate salts of a compound having
Formula II or a tautomer of the compound. In some such embodiments, the salt includes the mono-lactate or bis-lactate salt. Compounds of Formula IT have the following formula:
R%
ST
R28 N N (LX W—R2 i ~ J) 4, i Is NY N
SF N o
II wherein:
L is a covalent bond, -(CHy)m-, -CHR¥-, or NR?
XisCHorN;
Wis CH, O, or N;
R is selected from the group consisting of substituted or unsubstituted alkyl groups, substituted or unsubstituted alkylamino groups, substituted or unsubstituted dialkylamino, -OH, substituted or unsubstituted alkoxy groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted beterocyclylalkyl groups; provided that when W is O, R? is absent,
R? is absent or selected from the group consisting of -NO,, -OH, F, Cl, Br, I, -NHy, substituted or unsubstituted alkyl groups, substituted or unsubstituted alkylamino groups, substituted or unsubstituted dialkylamino groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, and substituted or unsubstituted alkoxy groups;
R28 is selected from the group consisting of F, Cl, Br, I, -OH, -NH, and substituted or unsubstituted alkyl groups;
R%?, R%, and R* are independently selected from the group consisting of H, F, Cl, Br, 1, substituted and unsubstituted alkyl groups, -OH, alkoxy groups, substituted and unsubstituted aryloxy groups, -NHa, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted alkylamino groups, substituted and unsubstituted dialkylamino groups, substituted and unsubstituted diarylamino groups, substituted and unsubstituted (alkyl)(aryl)amino groups, -C(=0)H, -C(=0)-alky! groups, -C(=0)-aryl groups, -C(=0)O-alkyl groups,
-C(=0)O-aryl groups, -C(=0)NH,, -C(=0)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alkyl), groups, -C(=O)N(aryl), groups, -C(=0)N(alkyl)(aryl) groups, -C(=O)-heterocyclyl groups, -C(=0)-O-heterocyclyl groups, -C(=0)NH(heterocyclyl) groups, -C(=0)-N(heterocyclyl), groups, -C(=0)-N(alkyD (heterocyclyl) groups, -C(=0)-N(aryl)(heterocyclyl) groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and ‘unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; nis 0, 1,or2; and . misl,2, 3, or4.
[0049] In one embodiment, the lactate salt of the compound of Formula II or the tautomer thereof has a water solubility at 22°C of from about 5 mg/mL to about 400 mg/mL. In some embodiments, the salt of the compound of Formula II or the tautomer thereof has a water solubility from about 100 mg/mL to about 400 mg/mL.
In other embodiments, the salt of the compound of Formula II or the tautomer has a water solubility from about 200 mg/mL to about 400 mg/mL. In some embodiments, the salt of the compound of Formula II or the tautomer thereof has a water solubility of greater than 30 mg/mL. In other embodiments, the salt of the compound of
Formula II or the tautomer thereof has a water solubility from about 150 mg/mL to about 250 mg/mL. In another embodiment, the salt of the compound of Formula II or the tautomer thereof is capable of dissolution in an aqueous medium below about pH 7, such as from pH 1-7, from pH 3-7, or from pH 4-7.
[0050] In some embodiments, the lactate salt of the compound of Formula II or the tautomer thereof is a DL-lactate salt. In other embodiments, the lactate salt of the compound of Formula IT is an L-lactate salt. In still other embodiments, the lactate salt of the compound of Formula II is a D-lactate salt.
[0051] In some embodiments of the lactate salt of the compound of Formula
II, R® is F and R? is H. In some such embodiments, n is 1.
[0052] In some embodiments of the lactate salt of the compound of Formula
Innis 1.
[0053] In some embodiments, the invention provides a method for preparing 2 lactate salt of a compound or tautomer of the compound of Formula I or the compound of Formula II. Such methods typically include: (a) suspending the free base of the compound of Formula I or Formula II or the tautomers thereof in a solvent or a mixture of solvents; (b) contacting lactic acid, acetic with the compound of Formula I or
Formula II or the tautomers thereof to provide a mixture; - ©) heating the mixture; (d) cooling the mixture; (¢) and isolating the salt. = [0054] In some methods for preparing a lactate salt of the compound of
Formula I or Formula II or the tautomers thereof, the mixture is cooled and the salt is precipitated out of the solution,
[0055] In some methods for preparing a lactate salt of the compound of
Formula I or Formula II, the mixture is heated and refluxed prior to cooling.
[0056] In some methods for preparing a lactate salt of the compound of
Formula I or Formula II, the solvent is a protic solvent.
[0057] In some embodiments of the method for preparing a lactate salt of the compound of Formula I or Formula II, the solvent is selected from methanol, ethanol, propanol, isopropanol, butanol, 2-butanol, acetone, butanone, dioxanes, water, tetrahydrofuran, or combinations of these.
[0058] In a preferred embodiment of the method for preparing a lactate salt of a compound or tautomer of the compound of Formula I or the compound of Formula
II, the isolating step includes filtering the mixture.
[0059] The invention further provides a composition comprising a tablet of the lactate salt of the compound of Formula I or the tautomer thereof or of the compound of Formula II or the tautomer thereof.
[0060] The invention further provides pharmaceutical formulations and medicaments. Such formulations and medicaments include the lactate salt of Formula
I or Formula II in combination with a pharmaceutically acceptable carrier.
[0061] The invention also provides methods of treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase. Such methods include administering an effective amount of a lactate salt or a pharmaceutical formulation or medicament that includes the lactate salt to a patient in need thereof. } [0062] Further objects, features and advantages of the invention will be apparent from the following detailed description.
[0063] FIG. 1 is a graph showing that 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one inhibits proliferation of multiple myeloma cell lines including KMS11, OPM-2, and H929.
[0064] FIG. 2 is a western blot showing that 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one inhibits FGFR3 phosphorylation at 0.5 pM in KMS11 cells.
[0065] FIGS. 3A, 3B, and 3C are western blots showing that 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one inhibits ERK phosphorylation at 0.5 pM in KMS11 cells (FIG. 3A), at 0.1 uM in : OPM-2 cells (FIG. 3B), and has no effect on ERK phosphorylation up to 5 pM in
H929 cells (FIG. 3C).
[0066] FIG. 4 is a graph showing apoptosis of KMS11 cells, as measured by
AnnexinVPE staining, when such cells were incubated with 4-amino-5-fluoro-3-[6-
(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one at various concentrations.
[0067] FIG. 5 is a graph showing that 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, at various contentrations, has minor effects on the cell cycle of KMS11 cells when it is incubated with the cell for 72 hours but induces apoptosis.
[0068] FIG. 6 is a graph showing apoptosis of OPM-2 cells, as measured by
AnnexinVPE staining, when such cells were incubated with 4-amino-5-fluoro-3-[6- (4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl] quinolin-2(1H)-one at various concentrations.
[0069] FIG. 7 is a graph showing that 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl] quinolin-2(1H)-one, at various concentrations, has minor effects on the cell cycle of OPM-2 cells when it is incubated with the cells for 72 hours but induces apoptosis.
[0070] FIG. 8 is a graph showing that 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl] quinolin-2(1H)-one, at various concentrations, has minor to no effect on the cell cycle of H929 cells when it is incubated with the cells. h
[0071] FIG. 9 is a graph showing that M-CSF mediated proliferation ofa mouse myeloblastic cell line M-NFS-60 was inhibited when the cells were incubated with 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl}quinolin- 2(1H)-one (ECsp of 220 nM). -
[0072] FIG. 10 is a graph showing that 4-amino-5-fluoro-3-[6-(4-
Co methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one inhibits the viability of FGFR3 expressing B9 cells, but not parental interleukin-6 (IL6) stimulated cells.
The values represent the mean +/- the standard deviation of four independent experiments.
[0073] FIG. 11 is a graph showing apoptosis in various human myeloma cell lines as assessed with a flow cytometric assay of annexin V binding and propidium jodide exclusion. KMS11, KMS18, OPM2, H929, and 8226 cells were incubated with vehicle (unshaded bar); with 100 nM (shaded bar) 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl] quinolin-2(1H)-one; and with 500 nM (hatched bar) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one. The values represent the mean +/- the standard deviation of four independent experiments.
[0074] FIGS 12A-12D are graphs showing that 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one inhibits FGF- mediated ERK 1/2 phosphorylation and induces cytotoxicity in FGFR3 expressing "primary multiple myeloma cells. FIG. 12A shows a graph obtained using flow cytometry of cells stained with FGFR3 antibody (open) or rabbit pre-immune serum (filled) and then stained with goat anti-rabbit FITC. Myeloma cells were identified by
CD138 labeling. FIG. 12B shows a graph obtained using flow cytometry of primary myeloma cells incubated in the absence (filled) or presence of aFGF (- -) or pre- incubated with 500 nM 4-amino-5-fluoro-3-[6~(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one for 2 hours and then stimulated with aFGF. - ERK1/2 phosphorylation was assessed using flow cytometry. FIGS. 12C and 12D are graphs obtained using flow cytometry of primary myeloma cells cultured in growth medium in the presence of DMSO (FIG. 12C) or 500 nM 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one (FIG. 12D). Cells were harvested after 7 days and stained with annexin V-FITC and analyzed by flow cytometry. Myeloma cells were identified by CD3 87/CD45" labeling. The total : percentage of CD3 87/CD45 /annexin V* cells is shown in upper right quadrant.
[0075] FIGS. 13A and 13B are graphs showing that 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one inhibits the viability of KMS11 cells in the presence of interleukin-6 (IL6), insulin growth factor (IGF-1), and bone marrow stroma cells (BMSCs). FIG 13A is a graph in which KMS11 cells were cultured with DMSO (unshaded bar); with 100 nM (shaded bar) 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; and with 500 nM (hatched bar) 4-amino-S-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one in the presence Or absence of 50 ng/mL IL6 or 50 ng/mL IGF-1. Cell viability was assessed by MTT assay after 48 hours. FIG. 13B is a graph in which BMSCs alone or together with KMS11 were cultured with DMSO (unshaded bar); with 100 nM (shaded bar) 4-amino-5-fluoro-3-[6-(4-methylpiperazin- 1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; and with 500 nM (hatched bar) 4- amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yllquinolin-2(1H)- one. Viability was assessed after 96 hours by MTT assay. The data represent means of quadruplicate cultures +/- standard deviations.
[0076] FIG. 14 is a graph showing that 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1 -yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one inhibits proliferation of M-NFS-60, a M-CSF growth driven mouse myeloblastic cell line with an ECsp of 220 nM. M-NSF-60 cells were incubated with serial dilutions of 4-amino- 5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-yl]quinolin-2(1H)-one in the presence of M-CSF and without GM-CSF. The number of viable cells was assessed after 72 hours using the Cell Titer-Glo™ assay.
[0077] FIG. 15 is a graph showing that 4-amino-5-fluoro-3-[6-(4- oo methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one inhibits FGFR3 phosphorylation and demonstrates anti-tumor effects in vivo. When tumor size reached 200 mm’, mice were randomly assigned (8-10/group) to receive vehicle alone or varying doses of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1 H)-one by oral gavage for 21 days. The graph shows tumor volume (mean +/- standard deviation) as a function of the days of treatment.
[0078] The present invention provides novel pharmaceutical salts of quinolinone compounds of Formula I and Formula II that act as antagonists of receptor tyrosine kinases, and, more particularly, as inhibitors of FGFR1 and FGFR3,
PDGFRa and PDGFRB, macrophage CSFR-1, FLT-3, ¢-KIT and/or VEGF-RTK function. Such kinases may also include IGFR1, EphA2, FGFR2, and FGFR4. The salts provided herein can be formulated into pharmaceutical formulations that are useful in treating patients with a need for an inhibitor of VEGF-RTK, especially, in particular embodiments, to provide compositions and methods for reducing capillary proliferation and in the treatment of cancer.
[0079] Pharmaceutically acceptable salts include a salt with an inorganic acid, an organic acid, a basic amino acid, or an acidic amino acid. As salts of inorganic acids, the instant invention includes, for example, hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid. As salts of organic acids, the instant invention includes, for example, lactic acid, formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.
Acidic amino acids include, for example, glycine, aspartic acid and glutamic acid.
[0080] Certain salts are preferred among the list above because of the properties that they impart to the compounds of Formula (I). Therefore, in some - embodiments the salts are tartrate, malate, lactate, bishydrochloride, citrate, acetate, bismesylate, bis-acetate, and mesylate salts. Some of the improved properties that these salts impart include solubility, hygroscopicity, crystallinity, compactibility, and morphology.
[0081] The following abbreviations and definitions are used throughout this application: “bFGF” is an abbreviation that stands for basic fibroblast growth factor; “bFGFR”, also referred to as FGFR1, is an abbreviation that stands for a receptor tyrosine kinase that interacts with the fibroblast growth factor FGF;
“C-MET”, also referred to as ‘HGF receptor”, is an abbreviation that stands for cellular product of the met gene or Hepatocyte growth factor receptor; a receptor tyrosine kinase that interacts with the Hepatocyte growth factor (HGF) also referred to as Scatter factor; “CSF-1” is an abbreviation that stands for colony stimulating factor-1 and its receptor. Macrophage CSFR-1 (Fms) is a receptor for CSF-1; “EGFR1” is an abbreviation that stands for Epidermal growth factor receptor 1 and binds Epidermal growth factor “EGF”; “EphA2” is an abbreviation that stands for Ephrin receptor A2, also referred to as epithelial cell receptor protein-tyrosine kinase or ECK; “ERK” is an abbreviation that stands for extracellular regulated kinase; “FACS” is an abbreviation that stands for fluorescence activated cell sorting; “FBS” is an abbreviation that stands for fetal bovine serum; “Flk-1” is an abbreviation that stands for fetal liver tyrosine kinase 1, also known as kinase-insert domain tyrosine kinase or KDR (human), also known as vascular endothelial growth factor receptor-2 or VEGFR2 (KDR (human), Flk-1 (mouse)); “FLT-1” is an abbreviation that stands for fms-like tyrosine kinase-1, also. known as vascular endothelial growth factor receptor-1 or VEGFR1; “FL T-3” is an abbreviation that stands for fms-like tyrosine kinase-3, also known as stem cell tyrosine kinase I (STK I); “FLT-4” is an abbreviation that stands for fms-like tyrosine kinase-4, also known as VEGFR3; “FGFR2” and “FGFR4” are abbreviations that stands for Fibroblast Growth
Factor Receptor 2 and Fibroblast Growth Factor Receptor 4, respectively. FGFR2 and FGFR4 are Class IV receptor tyrosine kinases;
“FGFR3” is an abbreviation that stands for the tyrosine kinase fibroblast growth factor receptor 3 that is expressed in 15-20% of multiple myeloma-type cancers; “G3,” is an abbreviation that stands for a phase of the standard eukaryotic cell cycle. In the standard cell cycle, G; phase is the gap before S phase and after M phase and G, is the gap after S phase and before M phase; “GM-CSF” is an abbreviation that stands for granulocyte macrophage colony stimulating factor; “[GFR1” is an abbreviation that stands for Insulin-like Growth Factor
Receptor-1. IFGR1 is a Class II receptor tyrosine kinase; “HER?2” is an abbreviation that stands for human epidermal growth factor receptor 2; \ “T1,6” is an abbreviation that stands for interleukin 6; “KDR?” is an abbreviation that stands for kinase- insert domain- containing receptor, also known as vascular endothelial growth factor receptor-2 or “VEGFR2”; “MAPK? is an abbreviation that stands for mitogen activated protein kinase; “M-CSF” is an abbreviation that stands for macrophage colony stimulating factor; “PDGF” is an abbreviation that stands for platelet derived growth factor.
PDGF interacts with tyrosine kinases PDGFRa and PDGFRB; “RTK? is an abbreviation that stands for receptor tyrosine kinase; “Tie-2” is an abbreviation that stands for tyrosine kinase with Ig and EGF ’ homology domains; “VEGF” is an abbreviation that stands for vascular endothelial growth factor; “VEGF-RTK? is an abbreviation that stands for vascular endothelial growth factor receptor tyrosine kinase.
[0082] Generally, reference to a certain element such as hydrogen or H is meant to include all isotopes of that element. For example, if an R group is defined to include hydrogen or H, it also includes deuterium and tritium.
[0083] The phrase “unsubstituted alkyl” refers to alkyl groups that do not contain heteroatoms. Thus the phrase includes straight chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl and the like. The phrase also includes branched chain isomers of straight chain alkyl groups, including but not limited to, the following which are provided by way of example: -CH(CHj),, -CH(CH3)(CH,CHj), -CH(CH,CH3),, -C(CHa)s, -C(CH,CHj)3, -CH,CH(CHs),, -CHCH(CH;)(CH2CHs), -CH,CH(CH,CHj3),, -CH,C(CHj)s, -CH,C(CH,CHi)s, -CH(CH3)CH(CH3)(CH>CH), -CH,CH,CH(CH3),, -CH,CH,CH(CH;)(CH,CHj), -CH,CH,CH(CH,CHj);, -CH;CH2C(CHa)s, -CH,CH,C(CH;CH3)s, -CH(CH;)CH,CH(CH3),, -CH(CH;)CH(CH3)CH(CHs),, © ~CH(CH,CH;)CH(CH;)CH(CH;)(CH,CHy), and others. The phrase also includes cyclic alkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl and such rings substituted with straight and branched chain alkyl groups as defined above. The phrase also includes polycyclic alkyl groups such as, but not limited to, adamantyl norbomyl, and bicyclo[2.2.2]octyl and such rings substituted with straight and branched chain alkyl groups as defined above.
Thus, the phrase unsubstituted alkyl groups includes primary alkyl groups, secondary alkyl groups, and tertiary alkyl groups. Unsubstituted alkyl groups may be bonded to one or more carbon atom(s), oxygen atom(s), nitrogen atom(s), and/or sulfur atom(s) in the parent compound. Preferred unsubstituted alkyl groups include straight and . branched chain alkyl groups and cyclic alkyl groups having 1 to 20 carbon atoms.
More preferred such unsubstituted alkyl groups have, from 1 to 10 carbon atoms while even more preferred such groups have from 1 to 5 or 1 to 6 carbon atoms. Most preferred unsubstituted alkyl groups include straight and branched chain alkyl groups having from 1 to 3 carbon atoms and include methyl, ethyl, propyl, and -CH(CH;),.
[0084] The phrase “substituted alkyl” refers to an unsubstituted alkyl group as defined above in which one or more bonds to a carbon(s) or hydrogen(s) are replaced by a bond to non-hydrogen and non-carbon atoms such as, but not limited to, a halogen atom in halides such as F, Cl, Br, and I; and oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, and ester groups; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfone groups, sulfonyl : groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as in trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups. Substituted alkyl groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom is replaced by a bond to a heteroatom such as oxygen in carbonyl, carboxyl, and ester groups; nitrogen in groups such as imines, oximes, hydrazones, and nitriles. Preferred substituted alkyl groups include, among others, alkyl groups in which one or more bonds to a carbon or hydrogen atom is/are replaced by one or more bonds to fluorine atoms, One example of a substituted alkyl group is the trifluoromethyl group and other alkyl groups that contain the trifluoromethyl group. Other alkyl groups include those in which one or more bonds to a carbon or hydrogen atom is replaced by a bond to an oxygen atom + such that the substituted alkyl group contains a hydroxyl, alkoxy, aryloxy group, or heterocyclyloxy group. Still other alkyl groups include alkyl groups that have an amine, alkylamine, dialkylamine, arylamine, (alkyl)(aryl)amine, diarylamine, heterocyclylamine, (alkyl)(heterocyclyl)amine, (aryl)(heterocyclyl)amine, or diheterocyclylamine group.
[0085] The phrase “unsubstituted aryl” refers to aryl groups that do not ' contain heteroatoms. Thus the phrase includes, but is not limited to, groups such as phenyl, biphenyl, anthracenyl, naphthenyl by way of example. Although the phrase “unsubstituted aryl” includes groups containing condensed rings such as naphthalene, it does not include aryl groups that have other groups such as alkyl or halo groups bonded to one of the ring members, as aryl groups such as tolyl are considered herein to be substituted aryl groups as described below. In some embodiments, aryl groups have from 6 to 14 carbon atoms. A preferred unsubstituted aryl group is phenyl.
Unsubstituted aryl groups may be bonded to one or more carbon atom(s), oxygen atom(s), nitrogen atom(s), and/or sulfur atom(s) in the parent compound, however,
Co WO 2005/046589 PCT/US2004/036941
[0086] The phrase “substituted aryl group” has the same meaning with respect to unsubstituted aryl groups that substituted alkyl groups had with respect to unsubstituted alkyl groups. However, a substituted aryl group also includes aryl groups in which one of the aromatic carbons is bonded to one of the non-carbon or * non-hydrogen atoms described above and also includes aryl groups in which one or more aromatic carbons of the aryl group is bonded to a substituted and/or : unsubstituted alkyl, alkenyl, or alkynyl group as defined herein. This includes bonding arrangements in which two carbon atoms of an aryl group are bonded to two atoms of an alkyl, alkenyl, or alkynyl group to define a fused ring system (e.g, dihydronaphthyl or tetrahydronaphthyl). Thus, the phrase “substituted aryl” includes, but is not limited to tolyl, and hydroxyphenyl among others.
[0087] The phrase “unsubstituted alkenyl” refers to straight and branched chain and cyclic groups such as those described with respect to unsubstituted alkyl groups as defined above, except that at least one double bond exists between two carbon atoms. Examples include, but are not limited to vinyl, -CH=C(H)(CHs), -CH=C(CHj3),, -C(CH3)=C(H), -C(CH3)=C(H)(CH}), -C(CH,CH3)=CH,, cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl among others. In some embodiments, alkenyl groups have from 2 to 8 carbon atoms.
[0088] The phrase “substituied aikenyi” has the same meaning witli respect to © unsubstituted alkenyl groups that substituted alkyl groups had with respect to unsubstituted alkyl groups. A substituted alkenyl group includes alkenyl groups in which a non-carbon or non-hydrogen atom is bonded to a carbon double bonded to another carbon and those in which one of the non-carbon or non-hydrogen atoms is bonded to a carbon not involved in a double bond to another carbon.
[0089] The phrase “unsubstituted alkynyl” refers to straight and branched chain groups such as those described with respect to unsubstituted alkyl groups as defined above, except that at least one triple bond exists between two carbon atoms.
Examples include, but are not limited to —~C=C(}), -C=C(CHs), -C=C(CH,CHs),
-C(H,)C=C(H), -C(H),C=C(CHjs), and -C(H),C=C(CH,CHj;) among others. In some embodiments, alkynyl groups have from 2 to 8 carbon atoms.
[0090] The phrase “substituted alkynyl” has the same meaning with respect to unsubstituted alkynyl groups that substituted alkyl groups had with respect to unsubstituted alkyl groups. A substituted alkynyl group includes alkynyl groups in which a non-carbon or non-hydrogen atom is bonded to a carbon triple bonded to another carbon and those in which a non-carbon or non-hydrogen atom is bonded to 2 carbon not involved in a triple bond to another carbon.
[0091] The phrase “unsubstituted aralkyl” refers to unsubstituted alkyl groups "as defined above in which a hydrogen or carbon bond of the unsubstituted alkyl group is replaced with a bond to an aryl group as defined above. For example, methyl -
CHa) is an unsubstituted alkyl group. If a hydrogen atom of the methyl group is replaced by a bond to a phenyl group, such as if the carbon of the methyl were bonded to a carbon of benzene, then the compound is an unsubstituted aralkyl group (i.e., a benzyl group). Thus the phrase includes, but is not limited to, groups such as benzyl, diphenylmethyl, and 1-phenylethyl (-CH(CsHs)(CHs)) among others. : [0092] The phrase “substituted aralkyl” has the same meaning with respect to unsubstituted aralkyl groups that substituted aryl groups had with respect to : unsubstituted aryl groups. However, a substituted aralkyl group also includes groups in which a carbon or hydrogen bond of the alkyl part of the group is replaced by a bond to a non-carbon or a non-hydrogen atom. Examples of substituted aralkyl groups include, but are not limited to, -CH,C(=0)(CsHs), and -CH;(2-methylphenyl) among others.
[0093] The phrase “unsubstituted heterocyclyl” refers to both aromatic and
N nonaromatic ring compounds including monocyelic, bicyclic, and polycyclic ring compounds such as, but not limited to, quinuclidyl, containing 3 or more ring members of which one or more is a heteroatom such as, but not limited to, N, O, and
Ss. Although the phrase “unsubstituted heterocyclyl” includes condensed heterocyclic rings such as benzimidazolyl, it does not include heterocyclyl groups that have other groups such as alkyl or halo groups bonded to one of the ring members as compounds such as 2-methylbenzimidazolyl are substituted heterocyclyl groups. Examples of heterocyclyl groups include, but are not limited to: unsaturated 3 to 8 membered rings containing 1 to 4 nitrogen atoms such as, but not limited to pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl etc.), tetrazolyl, (e.g., |H-tetrazolyl, 2H tetrazolyl, etc.); saturated 3 to 8 membered rings containing 1 to 4 nitrogen atoms such as, but not limited to, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl; condensed unsaturated heterocyclic groups containing 1 to 4 nitrogen atoms such as, but not limited to, indolyl, isoindolyl, oo indolinyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl; unsaturated 3 to 8 membered rings containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms such as, but not limited to, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.); saturated 3 to 8 membered rings containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms such as, . but not limited to, morpholinyl; unsaturated condensed heterocyclic groups containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, benzoxazolyl, benzoxadiazolyl, benzoxazinyl (e.g., 2H-1,4-benzoxazinyl, etc.); unsaturated 3t08 membered rings containing 1 to 3 sulfur atoms and 1 to 3 nitrogen atoms such as, but not limited to, thiazolyl, isothiazolyl, thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4- thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazoly], ete.); saturated 3 to & membered rings containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms such as, but not limited to, thiazolodinyl; saturated and unsaturated 3 to 8 membered rings containing 1 to 2 sulfur atoms such as, but not limited to, thienyl, dihydrodithiinyl, dihydrodithionyl,
So tetrahydrothiophene, tetrahydrothiopyran; unsaturated condensed heterocyclic rings containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms such as, but not limited to, benzothiazolyl, benzothiadiazolyl, benzothiazinyl (e.g., 2H-1,4-benzothiazinyl, etc.), dihydrobenzothiazinyl (e.g., 2H-3,4-dihydrobenzothiazinyl, etc.), unsaturated 3 to8 membered rings containing oxygen atoms such as, but not limited to furyl; unsaturated condensed heterocyclic rings containing 1 to 2 oxygen atoms such as benzodioxolyl (e.g., 1,3-benzodioxoyl, etc.); unsaturated 3 to 8 membered rings containing an oxygen atom and 1 to 2 sulfur atoms such as, but not limited to,
oo dihydrooxathiinyl; saturated 3 to 8 membered rings containing 1 to 2 oxygen atoms and 1 to 2 sulfur atoms such as 1,4-oxathiane; unsaturated condensed rings containing 1 to 2 sulfur atoms such as benzothienyl, benzodithiinyl; and unsaturated condensed heterocyclic rings containing an oxygen atom and 1 to 2 oxygen atoms such as benzoxathiinyl. Heterocyclyl group also include those described above in which one or more S atoms in the ring is double-bonded to one or two oxygen atoms (sulfoxides and sulfones). For example, heterocyclyl groups include tetrahydrothiophene, tetrahydrothiophene oxide, and tetrahydrothiophene 1,1-dioxide. Preferred heterocyclyl groups contain 5 or 6 ring members. More preferred heterocyclyl groups include morpholine, piperazine, piperidine, pyrrolidine, imidazole, pyrazole, 1,2,3- triazole, 1,2,4-triazole, tetrazole, thiomorpholine, thiomorpholine in which the S atom of the thiomorpholine is bonded to one or more O atoms, pyrrole, homopiperazine, oxazolidin-2-one, pyrrolidin-2-one, oxazole, quinuclidine, thiazole, isoxazole, furan, and tetrahydrofuran.
[0094] The phrase “substituted heterocyclyl” refers to an unsubstituted iE heterocyclyl group as defined above in which one of the ring members is bonded to a non-hydrogen atom such as described above with respect to substituted alkyl groups and substituted aryl groups. Examples, include, but are not limited to, 2- methylbenzimidazolyl, 5-methylbenzimidazolyl, 5-chlorobenzthiazolyl, 1-methyl piperazinyl, and 2-chloropyridyl among others.
[0095] The phrase “unsubstituted heterocyclylalkyl” refers to unsubstituted alkyl groups as defined above in which a hydrogen or carbon bond of the unsubstituted alkyl group is replaced with a bond to a heterocyclyl group as defined above. For example, methyl (-CHj) is an unsubstituted alkyl group. If a hydrogen atom of the methyl group is replaced by a bond to a heterocyclyl group, such as if the carbon of the methyl were bonded to carbon 2 of pyridine (one of the carbons bonded to the N of the pyridine) or carbons 3 or 4 of the pyridine, then the compound is an unsubstituted heterocyclylalkyl group.
[0096] The phrase “substituted heterocyclylalkyl” has the same meaning with respect to unsubstituted heterocyclylalkyl groups that substituted aralkyl groups had with respect to unsubstituted aralkyl groups. However, a substituted heterocyclylalkyl group also includes groups in which a non-hydrogen atom is bonded to a heteroatom in the heterocyclyl group of the heterocyclylalkyl group such as, but not limited to, a nitrogen atom in the piperidine ring of a piperidinylalkyl group.
[0097] The phrase “unsubstituted alkylaminoalkyl” refers to an unsubstituted alkyl group as defined above in which a carbon or hydrogen bond is replaced by a bond to a nitrogen atom that is bonded to a hydrogen atom and an unsubstituted alkyl group as defined above. For example, methyl (-CHs) is an unsubstituted alkyl group.
If a hydrogen atom of the methyl group is replaced by a bond to a nitrogen atom that is bonded to a hydrogen atom and an ethyl group, then the resulting compound is -CH,-N(H)(CH,CH3) which is an unsubstituted alkylaminoalkyl group.
[0098] The phrase “substituted alkylaminoalkyl” refers to an unsubstituted alkylaminoalkyl group as defined above except where one or more bonds to a carbon or hydrogen atom in one or both of the alkyl groups is replaced by a bond to a non- carbon or non-hydrogen atom as described above with respect to substituted alkyl groups except that the bond to the nitrogen atom in all alkylaminoalkyl groups does not by itself qualify all alkylaminoalkyl groups as being substituted. However, substituted alkylaminoalkyl groups does include groups in which the hydrogen bonded to the nitrogen atom of the group is replaced with a non-carbon and non- hydrogen atom. | :
[0099] The phrase “unsubstituted dialkylaminoalkyl” refers to an unsubstituted alkyl group as defined above in which a carbon bond or hydrogen bond is replaced by a bond to a nitrogen atom which is bonded to two other similar or different unsubstituted alkyl groups as defined above.
[0100] The phrase “substituted dialkylaminoalkyl” refers to an unsubstituted dialkylaminoalkyl group as defined above in which one or more bonds to a carbon or hydrogen atom in one or more of the alkyl groups is replaced by a bond to a non- carbon and non-hydrogen atom as described with respect to substituted alkyl groups.
The bond to the nitrogen atom in all dialkylaminoalkyl groups does not by itself qualify all dialkylaminoalkyl groups as being substituted.
[0101] The phrase “unsubstituted heterocyclyloxyalkyl” refers to an unsubstituted alkyl group as defined above in which a carbon bond or hydrogen bond is replaced by a bond to an oxygen atom which is bonded to an unsubstituted heterocyclyl group as defined above.
[0102] The phrase “substituted heterocyclyloxyalkyl” refers to an unsubstituted heterocyclyloxyalkyl group as defined above in which a bond to a carbon or hydrogen group of the alkyl group of the heterocyclyloxyalkyl group is bonded to a non-carbon and non-hydrogen atom as described above with respect to substituted alkyl groups or in which the heterocyclyl group of the heterocyclyloxyalkyl group is a substituted heterocyclyl group as defined above.
[0103] The phrase “unsubstituted arylaminoalkyl” refers to an unsubstituted alkyl group as defined above in which a carbon bond or hydrogen bond is replaced by a bond to a nitrogen atom which is bonded to at least one unsubstituted aryl group as defined above.
[0104] The phrase “substituted arylaminoalkyl” refers to an unsubstituted arylaminoalkyl group as defined above except where either the alkyl group of the arylaminoalkyl group is a substituted alkyl group as defined above or the aryl group of the arylaminoalkyl group is a substituted aryl group except that the bonds to the nitrogen atom in all arylaminoalkyl groups does not by itself qualify all arylaminoalkyl groups as being substituted. However, substituted arylaminoalkyl groups does include groups in which the hydrogen bonded to the nitrogen atom of the group is replaced with a non-carbon and non-hydrogen atom.
[0105] The phrase “unsubstituted heterocyclylaminoalky!” refers to an unsubstituted alkyl group as defined above in which a carbon or hydrogen bond is replaced by a bond to a nitrogen atom which is bonded to at least one unsubstituted heterocyclyl group as defined above.
[0106] The phrase “substituted heterocyclylaminoalkyl” refers to unsubstituted heterocyclylaminoalkyl groups as defined above in which the heterocyclyl group is a substituted heterocyclyl group as defined above and/or the alkyl group is a substituted alkyl group as defined above. The bonds to the nitrogen atom in all heterocyclylaminoalkyl groups does not by itself qualify all heterocyclylaminoalkyl groups as being substituted. However, substituted heterocyclylaminoalkyl groups do include groups in which the hydrogen bonded to the nitrogen atom of the group is replaced with a non-carbon and non-hydrogen atom.
[0107] The phrase “unsubstituted alkylaminoalkoxy” refers to an unsubstituted alkyl group as defined above in which a carbon or hydrogen bond is replaced by a bond to an oxygen atom which is bonded to the parent compound and in which another carbon or hydrogen bond of the unsubstituted alkyl group is bonded to a nitrogen atom which is bonded to a hydrogen atom and an unsubstituted alkyl group as defined above.
[0108] The phrase “substituted alkylaminoalkoxy” refers to unsubstituted: alkylaminoalkoxy groups as defined above in which a bond to a carbon or hydrogen atom of the alkyl group bonded to the oxygen atom which is bonded to the parent compound is replaced by one or more bonds to a non-carbon and non-hydrogen ators as discussed above with respect to substituted alkyl groups and/or if the hydrogen bonded to the amino group is bonded to a non-carbon and non-hydrogen atom and/or if the alkyl group bonded to the nitrogen of the amine is bonded to a non-carbon and non-hydrogen atom as described above with respect to substituted alkyl groups. The presence of the amine and alkoxy functionality in all alkylaminoalkoxy groups does not by itself qualify all such groups as substituted alkylaminoalkoxy groups.
[0109] The phrase “unsubstituted dialkylaminoalkoxy” refers to an unsubstituted alkyl group as defined above in which a carbon or hydrogen bond is : replaced by a bond to an oxygen atom which is bonded to the parent compound and in which another carbon or hydrogen bond of the unsubstituted alkyl group is bonded to a nitrogen atom which is bonded to two other similar or different unsubstituted alkyl groups as defined above.
[0110] The phrase “substituted dialkylaminoalkoxy™ refers to an unsubstituted dialkylaminoalkoxy group as defined above in which a bond to a carbon or hydrogen atom of the alkyl group bonded to the oxygen atom which is bonded to the parent compound is replaced by one or more bonds to a non-carbon and non-hydrogen atoms as discussed above with respect to substituted alkyl groups and/or if one or more of the alkyl groups bonded to the nitrogen of the amine is bonded to a non-carbon and non-hydrogen atom as described above with respect to substituted alkyl groups. The presence of the amine and alkoxy functionality in all dialkylaminoalkoxy groups does not by itself qualify all such groups as substituted dialkylaminoalkoxy groups.
[0111] The phrase “unsubstituted heterocyclyloxy” refers to a hydroxyl group (-OH) in which the bond to the hydrogen atom is replaced by a bond to a ring atom of an otherwise unsubstituted heterocyclyl group as defined above.
[0112] The phrase “substituted heterocyclyloxy” refers to a hydroxyl group (-
OH) in which the bond to the hydrogen atom is replaced by a bond to a ring atom of an otherwise substituted heterocyclyl group as defined above.
[0113] "The term “protected” with respect to hydroxyl groups, amine groups, and sulfhydryl groups refers to forms of these functionalities which are protected from undesirable reaction with a protecting group known to those skilled in the art such as those set forth in Protective Groups in Organic Synthesis, Greene, T.W.; Wuts, P. G.
M., John Wiley & Sons, New York, NY, (3rd Edition, 1999) which can be added or removed using the procedures set forth therein. Examples of protected hydroxyl groups include, but are not limited to, silyl ethers such as those obtained by reaction - of a hydroxyl group with a reagent such as, but not limited to, t-butyldimethyl- chlorosilane, trimethylchlorosilane, triisopropylchlorosilane, triethylchlorosilane; substituted methyl and ethyl ethers such as, but not limited to methoxymethyl ether, methythiomethyl ether, benzyloxymethyl ether, t-butoxymethyl ether, 2- methoxyethoxymethyl ether, tetrahydropyranyl ethers, 1-ethoxyethyl ether, allyl ether, benzyl ether; esters such as, but not limited to, benzoylformate, formate, acetate, trichloroacetate, and trifluoracetate. Examples of protected amine groups include, but are not limited to, amides such as, formamide, acetamide,
trifluoroacetamide, and benzamide; imides, such as phthalimide, and dithiosuccinimide; and others. Examples of protected sulfhydryl groups include, but ,are not limited to, thioethers such as S-benzyl thioether, and S-4-picolyl thioether; substituted S-methyl derivatives such as hemithio, dithio and aminothio acetals; and others.
[0114] The salts of compounds of Formula I and Formula II with lactic acid, acetic acid, tartaric acid, malic acid, methanesulfonic acid, hydrochloric acid, and citric acid can be prepared by dissolving a base of a compound of Formula I or
Formula TI in a suitable organic solvent or a mixture of solvents together with one, two, or more equivalents, of lactic acid, acetic acid, tartaric acid, malic acid, citric acid, hydrochloric acid, or methanesulfonic acid. The mixture is heated, usually refluxed, and then cooled. The formed salt is typically recovered by filtering or by evaporating to dryness. Suitable organic solvents include, but are not limited to, lower alcohols and ethers, preferably methanol, ethanol, diethyl ether, and combinations of these. The salts can be formulated into any one of a number of known dosage forms or delivery systems by means known in the art e.g., for oral, parenteral, transdermal or topical use. In some embodiments, the salt is crystalline and in some embodiments, the crystals are plate-shaped or needles. The salts may be compressed to form tablets. Preferably, the salts of the invention are used for nreparing aqueous formulations of the compounds of Formula I or Formula II. The salts of the invention have generally improved water solubility over the free base or acid of the compounds of Formula I or Formula II. For example, the solubility of the lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazo}-2- yl]-1H-quinolin-2-one in distilled water is about 330 mg/mL.
[0115] The present invention is directed to a pharmaceutically acceptable salt of a compound having Formula I or a tautomer of the compound. In some such embodiments, the salt is selected from lactate, malate, mesylate, acetate, tartrate, phosphate, sulfate, nitrate, HC, citrate, or maleate. In some such embodiments, the salt is selected from lactate, malate, mesylate, acetate, or tartrate salts. In some such embodiments, the salt is selected from lactate, bis-lactate, malate, mesylate, bis- mesylate, bis-acetate, or tartrate salts. In other embodiments the salt is selected from lactate, malate, or mesylate salts. Compounds of Formula I have the following formula:
RS
RS
" RG boo
RZ § | y RS : Vee
R3 N o]
R4 bs
I wherein,
R!, R?, R’, and R* may be the same or different and are independently selected from the group consisting of H, Cl, Br, F, I, -CN, -NO,, -OH, -ORP groups, NR!RY groups, substituted and unsubstituted amidinyl groups, substituted and unsubstituted guanidinyl groups, substituted and unsubstituted primary, secondary, and tertiary alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted alkynyl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, and -C(=O)R"® groups;
R® RS, R7, and R® may be the same or different and are independently selected from the group consisting of H, Cl, Br, F, 1, -NO,, -OH, -OR" groups, NR¥R?! groups, -SH, -SR? groups, -S(=0)R* groups, -S(=0),R* groups, -CN, substituted and unsubstituted amidinyl groups, substituted and unsubstituted guanidinyl groups, substituted and unsubstituted primary, secondary, and tertiary alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted alkynyl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalky! groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, -C(=0)R% groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups;
ROGsH;,
R'2 is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl, groups, and substituted and : unsubstituted heterocyclyl groups;
RY is selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, -OH, alkoxy groups, aryloxy groups, -NH;, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted alkylamino groups, substituted and unsubstituted arylamino groups, substituted and unsubstituted dialkylamino groups, substituted and unsubstituted diarylamino groups, substituted and unsubstituted (alkyl)(aryl)amino groups, -C(=0)H, -C(=0)-alkyl groups, -C(=0)-aryl groups, -C(=0)0-alkyl groups, -C(=0)O-aryl groups, -C(=0)NHa,, -C(=0)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=0)N(alkyl), groups, -C(=0)N(aryl), groups, -C(=0)N(alkyl)(aryl) groups, -C(=0O)-heterocyclyl groups, -C(=0)-0-heterocyclyl groups, -C(=O)NH(heterocyclyl) groups, -C(=0)-N(heterocyclyl), groups, -C(=0)-N(alkyl)(heterocyclyl) groups, -C(=0)-
N(aryl)(heterocyclyl) groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups;
RM*isH;
R'® and R" may be the same or different and are independently selected from the group consisting of substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heterocyclylalkyl groups, -C(=O)H, -C(=0)-alkyl groups, -C(=0)-aryl groups, -C(=0)NH,, -C(=0)NH(alkyl) groups, -C(=0)NH(ary!) groups, -C(=0)N(alkyl), groups, -C(=0)N(ary1), groups, ~C(=0)N(alkyl)(aryl) groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalky! groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl, substituted and unsubstituted diheterocyclylaminoalkyl, substituted and unsubstituted (heterocyclyl)(alkyl)aminoalkyl, substituted and unsubstituted (heterocyclyl)(aryl)aminoalkyl, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups;
R!6 and R?® may be the same or different and are independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, and substituted and unsubstituted heterocyclyl groups; -
R' and R* may be the same or different and are independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, -C(=O)H, -C(=0)-alkyl groups, ~C(=0)-aryl groups,-C(=0)NHz, -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=0)N(alkyl), groups, -C(=O)N(aryl), groups,
-C(=0)N(alkyl)(aryl) groups, -C(=0)0-alkyl groups, -C(=0)0-aryl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, -C(=0)-heterocyclyl groups, -C(=0)-0-heterocyclyl groups, -C(=0)NH(heterocyclyl) groups, -C(=0)-N(heterocyclyl), groups, -C(=0)-N(alkyl)(heterocyclyl) groups, -C(=0)-N(aryl)(heterocyclyl) groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted : aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups;
R'%, R%, R?, and R? may be the same or different and are independently selected from the group consisting of H, -NHa, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl), groups, -N(aryl); groups, -N(alkyl)(aryl) groups, -NH (heterocyclyl) groups, -N(heterocyclyl)(alkyl) groups, -N(heterocyclyl)(aryl) groups, -N(heterocyclyl), groups, substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, -OH, substituted and unsubstituted alkoxy groups, substituted and unsubstituted aryloxy groups, substituted and unsubstituted heterocyclyl groups, -NHOH, -N(alkyl)OH groups, -N(aryl)OH groups,
N(alkyl)O-alkyl groups, -N(aryl)O-alkyl groups, -N(alkyl)O-aryl groups, and -N(aryl)O-aryl groups; and
R? is selected from the group consisting of substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, and substituted and unsubstituted heterocyclyl groups.
[0116] In some embodiments of the pharmaceutically acceptable salts of the compounds or the tautomers of the compounds of Formula I, at least one of RRS,
R’, or R® is selected from the group consisting of substituted and unsubstituted amidinyl groups, substituted and unsubstituted guanidiny! groups, substituted and unsubstituted saturated heterocyclyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; ~OR" groups wherein RY is selected from the group consisting of substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heterocyclylalkyl groups, -C(=0O)H, ~C(=0)-aryl groups, -C(=O)NH,, -C(=O)NH(alkyl) groups, -C(=0)NH(aryl) groups,
-C(=0)N(alkyl), groups, -C(=O)N(aryl), groups, -C(=0)N(alkyl)(aryl) groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted * alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted diheterocyclylaminoalkyl groups, substituted and unsubstituted : (heterocyclyl)(alkyl)aminoalkyl groups, substituted and unsubstituted (heterocyclyl) (ary])aminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalky! groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; ~NR*R? groups wherein R?’ is selected from the group consisting of substituted and unsubstituted heterocyclyl groups; ~NR*R? groups wherein R?! is selected from the group consisting of substituted and unsubstituted heterocyclyl groups, -C(=0)H, —C(=0)-aryl groups, -C(=0)NH,, -C(=O)NH(alkyl) groups, -C(=0)NH(aryl) groups, -C(=0)N(alkyl), groups, -C(=0)N(aryl), groups, -C(=O)N(alkyl)(aryl) groups, -C(=0)0-alkyl groups, -C(=0)O-aryl groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted - alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; and -C(=0)R?® groups wherein Ris selected from the group consisting of H, -NHS,, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl), groups, -N(aryl); groups, “N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, “N(heterocyclyl)(alkyl) groups, -N(heterocyclyl)(aryl) groups, -N(heterocyelyl), groups, substituted and unsubstituted aryl groups, substituted and unsubstituted aryloxy groups, and substituted and unsubstituted heterocyclyl groups.
[0117] Tn one embodiment, the invention relates to a pharmaceutically acceptable salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol- 2-yl]quinolin-2(1H)-one. In some such embodiments, the salt is selected from tartrate, malate, lactate, acetate, bis-acetate, citrate, mesylate, bismesylate and bishydrochloride. In some such embodiments, the salt is selected from the group consisting of tartrate, malate, lactate, bis-lactate, bis-acetate, citrate, mesylate, bis- mesylate and bishydrochloride.
[0118] In some specific embodiments, the compound of structure I is a lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one or a tautomer thereof.
[0119] In a some embodiments of the compounds or the tautomers of the compounds of Formula I, R! is selected from the group consisting of F, Cl, substituted and unsubstituted alkoxy groups, substituted and unsubstituted heterocyclylalkoxy groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted alkylaminoalkoxy groups, substituted and unsubstituted arylaminoalkoxy groups, substituted and unsubstituted dialkylaminoalkoxy groups, substituted and unsubstituted diarylaminoalkoxy groups, and substituted and unsubstituted (alkyl)(aryl)aminoalkoxy groups.
[0120] In some other embodiments of the compounds or the tautomers of the compounds of Formula I, at least one of R35, RS, R7, and R® is a substituted or unsubstituted heterocyclyl group.
[0121] In still other embodiments of the compounds or the tautomers of the compounds of Formula I, at least one of R35, RS, R7, and R® is a substituted or unsubstituted heterocyclyl group comprising at least one O or N atom.
[0122] In yet other embodiments of the compounds or the tautomers of the compounds of Formula I, at least one of R’, RS, R’, and R® is a substituted or unsubstituted heterocyclyl group and the heterocyclyl group is selected from the group consisting of morpholine, piperazine, piperidine, pyrrolidine, thiomorpholine, homopiperazine, tetrahydrothiophene, tetrahydrofuran, and tetrahydropyran.
[0123] In yet other embodiments of the compounds or the tautomers of the compounds of Formula I, at least one of RS or R is a substituted or unsubstituted heterocyclyl group.
[0124] In yet other embodiments of the compounds or the tautomers of the compounds of Formula I, at least one of RS or R’ is a substituted or unsubstituted heterocyclyl group comprising at least one O or N atom.
[0125] In vet other embodiments of the compounds or the tautomers of the compounds of Formula I, one of R® or R” is a substituted or unsubstituted heterocyclyl group and the heterocyclyl group is selected from the group consisting of morpholine, piperazine, piperidine, pyrrolidine, thiomorpholine, homopiperazine, tetrahydrothiophene, tetrahydrofuran, and tetrahydropyran.
[0126] In still other particular embodiments of the compounds or the tautomers of the compounds of Formula I, one of R or R” is selected from the group consisting of substituted and unsubstituted morpholine groups, and substituted and unsubstituted piperazine groups.
[0127] In yet other embodiments of the compounds or the tautomers of the compounds of Formula I, at least one of and in some embodiments one of R® or R’ is selected from the group consisting of -NR**R>! groups wherein R® is selected from the group consisting of substituted and unsubstituted heterocyclyl groups; and
NR¥R?! groups wherein R* is selected from the group consisting of substituted and unsubstituted heterocyclyl groups, groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl . groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalky] groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups.
[0128] In yet another embodiments of the compounds or the tautomers of the compounds of Formula I, R! is selected from the group consisting of Hand F. In ' some such embodiments, R! is F, In some such embodiments, R?isH.
[0129] In one embodiment, the pharmaceutically acceptable salt of the compound of Formula I or the tautomer thereof has a water solubility at 22°C of from about 5 mg/mL to about 400 mg/mL. In some embodiments, the salt has a water solubility from about 100 mg/mL to about 400 mg/mL. In other embodiments, the salt has a water solubility from about 200 mg/mL to about 400 mg/mL. In some embodiments, the salt of the compound of Formula I or the tautomer thereof has a water solubility of greater than 30 mg/mL. In other embodiments, the salt of the compound of Formula I or the tautomer thereof has a water solubility from about 150 ‘mg/mL to about 250 mg/mL. In another embodiment, the pharmaceutically acceptable salt of the compound of Formula I or the tautomer thereof is capable of dissolution in an aqueous medium below about pH 7, such as from pH 1-7, from pH 3-7, or from pH 4-7.
[0130] The invention also provides pharmaceutically acceptable salts of a compound having Formula II or a tautomer of the compound. In some such embodiments, the salt is selected from lactate, malate, mesylate, acetate, tartrate,
phosphate, sulfate, nitrate, HC], citrate, or maleate. In some such embodiments, the salt is selected from lactate, malate, mesylate, acetate, or tartrate salts. In other embodiments the salt is selected from lactate, malate, or mesylate salts. Compounds of Formula II have the following formula:
R%7 28 ol J
R NH, N
Nth
XTX N
R# H
ZN o) : H
Jif wherein:
L is a covalent bond, -(CHa)m-, -CHR3’-, or -NR?')-;
XisCHorN;
Wis CH, O,orN;
R is selected from the group consisting of substituted or unsubstituted alkyl groups, substituted or unsubstituted alkylamino groups, subsiituted or unsubstituted dialkylamino, -OH, substituted or unsubstituted alkoxy groups, substituted or unsubstituted alkylaminoalky] groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted t heterocyclylalkyl groups; provided that when W is O, R% is absent;
R? is absent or selected from the group consisting of -NO,, -OH, F, Cl, Br, I, -NH,, substituted or unsubstituted alkyl groups, substituted or unsubstituted alkylamino groups, substituted or unsubstituted dialkylamino groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, and substituted or unsubstituted alkoxy groups;
R28 is selected from the group consisting of H, F, Cl, Br, I, -OH, -NHz, and substituted ~~. or unsubstituted alkyl groups;
R?, R*, and R*! are independently selected from the group consisting of H, F, Cl, Br, 1, substituted and unsubstituted alkyl groups, -OH, alkoxy groups, substituted and unsubstituted aryloxy groups, -NH,, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heteroaryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted alkylamino groups, substituted and unsubstituted dialkylamino groups, substituted and unsubstituted diarylamino groups, substituted and unsubstituted (alkyl)(aryl)amino groups, -C(=O)H, -C(=0)-alky! groups, -C(=0)-aryl groups, -C(=0)O-alkyl groups, -C(=0)0-aryl groups, -C(=0)NH,, -C(=0)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=0)N(alkyl), groups, -C(=0)N(aryl), groups, -C(=0)N(alkyl)(aryl) groups, -C(=0)-heterocyclyl groups, -C(=0)-O-heterocyclyl groups, -C(=O)NHi(heterocyclyl) groups, -C(=0)-N(heterocyclyl); groups, -C(=0)-N(alkyl)(heterocyclyl) groups, -C(=0)-N(aryl)(heterocyclyl) groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; nis 0, 1, or 2; and Toe misl,2,3, or 4,
[0131] In some embodiments of the pharmaceutically acceptable salt of the compound of Formula II, the salt is selected from lactate, malate, mesylate, acetate, tartrate, phosphate, sulfate, nitrate, HCI, citrate, or maleate. In some such embodiments, the salt is selected from lactate, malate, mesylate, acetate, or tartrate salts. In some such embodiments, the salt is selected from lactate, malate, mesylate, bis-acetate, or tartrate salts. In some embodiments of the pharmaceutically acceptable salt of the compound of Formula II, the salt is provided as the lactate salt. In other embodiments, the salt is provided as the tartrate salt. In other embodiments, the salt is provided as the malate salt. In other embodiments, the salt is provided as the bis- acetate salt. In other embodiments, the salt is provided as the tartrate, mesylate, bishydrochloride, citrate or bismesylate salt.
[0132] In some embodiments of the pharmaceutically acceptable salt of the compound of Formula II, R%2 is Fand R¥ is H. In some such embodiments, n is 1.
[0133] In some embodiments of the pharmaceutically acceptable salt of the compound of Formula II, nis 1.
[0134] In one embodiment, the pharmaceutically acceptable salt of the compound of Formula II or the tautomer theteof has a water solubility from about 20 mg/mL to about 100 mg/mL. In some embodiments, the salt of the compound of
Formula II or the tautomer thereof has a water solubility of greater than 30 mg/mL.
In other embodiments, the salt of the compound of Formula I or the tautomer thereof has a water solubility from about 150 mg/mL to about 250 mg/mL. In a more preferred embodiment the pharmaceutically acceptable salt of the compound of
Formula II or the tautomer thereof is capable of dissolution in an aqueous medium below about pH 7.
[0135] The invention further provides pharmaceutical formulations and medicaments. Such formulations and medicaments include the pharmaceutically acceptable salt of Formula I or Formula II in combination with a pharmaceutically acceptable carrier.
[0136] The invention also provides methods of treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase. Such methods include administering an effective amount of a pharmaceutically acceptable salt or a pharmaceutical formulation or medicament that includes the pharmaceutically acceptable salt to a patient in need thereof.
[0137] The invention also relates to a method of preparing a pharmaceutically acceptable salt of a compound of Formula I or Formula II. The method includes: (a) suspending the free base of the compound of Formula I or Formula IT or the tautomers thereof in a solvent or mixture of solvents; ®) contacting an acid selected from tartaric acid, malic acid, lactic acid, acetic acid, citric acid, hydrochloric acid, or methanesulfonic acid with the compound of Formula 1 or Formula I or the tautomers thereof to provide a mixture; (c) heating the mixture; (d cooling the mixture; (e) and isolating the salt.
[0138] In some methods for preparing a pharmaceutically acceptable salt of the compound of Formula I or Formula II, the mixture is cooled and the salt is precipitated out of the solution.
[0139] In some methods for preparing a pharmaceutically acceptable salt of the compound of Formula I or Formula II, the mixture is heated and refluxed prior to cooling.
[0140] In some embodiments of the method of preparing a pharmaceutically acceptable salt of a compound of Formula I or Formula IL, the isolating step includes filtering the mixture.
[0141] In some embodiments, the acid is lactic acid and may be a mixture of the D and L forms of lactic acid or may be the D lactic acid or the L lactic acid.
[0142] In some embodiments, the solvent used in the method of preparing the salt is a protic solvent.
[0143] In other embodiments of the invention, the solvent used in the method of preparing the salt is selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol, 2-butanol, acetone, butanone, dioxanes, water, tetrahydrofuran, and combinations of these.
[0144] Compounds of Formula I and Formula II are readily synthesized from simple starting molecules as shown in the following Examples. Compounds of
Formula I and Formula II may generally be prepared using benzene substituted with nitrile or carboxylic acid groups in addition to other optional groups. }
[0145] Compounds of Formula I and Formula II and analogs of such compounds may be synthesized from simple starting molecules as shown in Schemes 1-4 and exemplified in the Examples. As shown in Scheme 1, 4-hydroxy analogs of compounds of Formula I and Formula II may generally be prepared using aromatic compounds substituted with amines and carboxylic acid groups.
Scheme 1.
R
NX CO,H
Re x C02H 0 Oo [ X
LX fame TT TH
NH, oP -CO:Me
HaN e) — Rr
OH N-\ /
ZZ R 7 heat yy No
H
[0146] As shown in Scheme 1, a substituted aromatic compound such as a substituted or unsubstituted 2-aminobenzoic acid may be reacted with an acyl halide such as methyl 2-(chlorocarbonyl)acetate to produce an amide that will react with a substituted or unsubstituted 1,2-diaminobenzene. The resulting product is a 4- hydroxy-substituted analog of a compound of Formula I or Formula II. One skilled in the art will recognize that the procedure set forth in Scheme 1 may be modified to produce various compounds.
[0147] A method for preparing 4-amino substituted compounds of Formula I and Formula II is shown in Scheme 2. As shown in Scheme 2, aromatic compounds substituted with amine and nitrile groups may be used to synthesize 4-amino substituted compounds of Formula I or Formula II. A compound such as ethyl 2-
cyanoacetate may be reacted with ethanol to produce ethyl 3-ethoxy-3- iminopropanoate hydrochloride. Subsequent reaction with a substituted or unsubstituted 1,2-phenylenediamine provides substituted or unsubstituted ethyl 2- benzimidazol-2-ylacetate. Reaction ofa substituted or unsubstituted ethyl 2- benzimidazol-2-ylacetate with an aromatic compound having an amine and nitrile group such as substituted or unsubstituted 2-aminobenzonitrile with a base such as lithium bis(trimethylsilyl)amide or a Lewis acid such as tin tetrachloride provides the substituted or unsubstituted 4-amino substituted compound of Formula I and Formula
IL
Scheme 2. “5
Q 0 NH eHCl HN Ny fio” ~N . sooo rem od $I"
Rea ON
NH, NH, oY
LIHMDS NX SN
SnCly H
[0148] Scheme 3 illustrates a general synthetic route that allows for the ' synthesis of 4-dialkylamino and 4-alkylamino compounds of Formula I and Formula
I. An inspection of Scheme 3 shows that 4-hydroxy substituted analogs of compounds of Formula I or Formula II may be converted into the 4-chloro derivative by reaction with phosphorous oxychloride or thionyl chloride. The 4-chloro derivative may then be reacted with an alkylamine or dialkylamine to produce the corresponding 4-alkylamino or 4-dialkylamino derivative. Deprotection affords the final 4-alkylamino or 4-dialkylamino compounds of Formula I or Formula II. Other groups that may be reacted with the 4-chloro derivative in this manner include, but are not limited to, ROH, RSH, and CuCN.
Scheme 3. “9
ZZ
9 EtOH Q NH eHCI HN a T= 10” ON HC codon heat cod) Z
R
) x = R' =) R ’ & BS R ™ oY R \ oY
N ; NOS POC aa N R'NH,
LIHMDS; heat # or | o (P = protecting B soc 2 group) " =-R' —\_R'
RR oY . prey 7
DOCH deprotect SOC
Z No ” PP yo
[0149] As shown in Scheme 4, the synthesis of analogs of compounds of
Formula I or Formula II having a H, alkyl group, aryl group, or heterocyclyl group in the 4-position may be accomplished using a substituted or unsubstituted 2- ' benzimidazol-2-ylacetate prepared as shown in Schemes 2 and 3.
Scheme 4. or = gr
R" N
N x ZZ NH R | \ 7 . : ~~ 1 gr 2 ANN ON
Et0.C NF — H
H pipeEiivins NA No
HOAc H
R" =H, alkyl aryl, heterocyclyl
[0150] Heteroaromatic diamines may be used as precursors to produce heterocyclic analogs compounds of Formula I and Formula II. The synthesis of such analog compounds of Formula I and Formula II where NR'?R' = NH, is depicted in
Scheme 5.
Scheme 5.
R R
R: =X =x 0 Saat oa +S [ HCI. EtOH o Ss fi cN + | —_— —_— | N
IN CX, No A Wo co A eon 0 EtOH [0] HHCI Sa NH2 —_—
NS i 0, = R oF Jk 9 N \ _N LiHMDS NNN
FU mmm
EIO h) RS # 9 a, N
[0151] A compound such as ethyl cyanoacetate may be condensed with a substituted or unsubstituted heterocycle containing two ortho amino groups such as substituted or unsubstituted 1,2-diaminopyridine to obtain a substituted or unsubstituted 2-imidazolo[5,4-b]pyridin-2-ylethanenitrile, which may subsequently be hydrolyzed in acidic medium to provide a substituted or unsubstituted ethyl 2- imidazolo[5,4-b]pyridin-2-ylacetate. As an alternate route, a substituted or unsubstituted ethyl 2-imidazolo[5,4-b]pyridin-2-ylacetate may be obtained from a compound such as the hydrochloride salt of 3-ethoxy-3-iminopropanoate and a substituted or unsubstituted 1,2-diaminopyridine. Reaction of a substituted or unsubstituted ethyl 2-imidazolo{5,4-b]pyridin-2-ylacetates with an aromatic compound having an amine and nitrile group such as substituted or unsubstituted 2- aminobenzonitrile with a base such as lithium bis(trimethylsilyl)amide provides the substituted or unsubstituted analog of compounds of Formula I and Formula II.
[0152] The instant invention also provides for compositions which may be prepared by mixing one or more salts of the compounds of Formula I or Formula II, with pharmaceutically acceptable carriers, excipients, binders, diluents or the like, to treat or ameliorate a variety of disorders related to the activity of VEGF-RTK, more particularly angiogenesis associated with cancer.
[0153] Excipients, diluents, binders, carriers and the like include, but are not limited to, microcrystalline cellulose, lactose, dibasic calcium phosphate, tribasic calcium phosphate, sodium starch glycolate (NaSG), crospovidone, crosscarmellose (CC) , sodium lauryl sulfate (SLS), Tween, polyethylene glycol (PEG), povidone, hydroxypropyl cellulose (HPMC), Mg stearate, Ca stearate, stearic acid, sodium stearate fumarate, and silicon dioxide.
[0154] A therapeutically effective dose further refers to that amount of one or more salts of the compounds of Formula I and/or Formula II sufficient to result in amelioration of symptoms of the disorder. The pharmaceutical compositions of the instant invention can be manufactured by methods well known in the art such as conventional granulating, mixing, dissolving, encapsulating, lyophilizing, emulsifying or levigating processes, among others. The compositions can be in the form of, for example, granules, powders tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions. The instant compositions can be formulated for various routes of administration, for example, by oral administration, by . transmucosal administration, by rectal administration, or subcutaneous administration as well as intrathecal, intravenous, intramuscular, intraperitoneal, intranasal, intraocular or intraventricular injection. The salts of the compound or compounds of Formula I and
Formula II can also be administered in a local rather than a systemic fashion, such as injection as a sustained release formulation. The following dosage forms are given by way of example and should not be construed as limiting the instant invention.
[0155] In order to determine the amount of compound in a patient foliowing administration, certain manipulative steps can be taken. Such a method is described in the U.S. Provisional Application Serial No. 60/517,915, titled, “Methods of Treating
Cancer and Related Methods” filed on November 7, 2003, by Vora et al. incorporated by reference in its entirety herein.
[0156] Oral, buccal, and sublingual administration, powders, suspensions, granules, tablets, pills, capsules, gelcaps, and caplets are acceptable as solid dosage forms. These can be prepared, for example, by mixing one or more salts of the compounds of Formula I and/or Formula II, with at least one additive or excipient such as a starch or other additive. Suitable additives or excipients are sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, sorbitol, starch, agar, alginates, chitins,
chitosans, pectins, tragacanth gum, gum arabic, gelatins, collagens, casein, albumin, synthetic or semi-synthetic polymers or glycerides, methyl cellulose, hydroxypropylmethyl-cellulose, and/or polyvinylpyrrolidone . Optionally, oral dosage forms can contain other ingredients to aid in administration, such as an inactive diluent, or lubricants such as magnesium stearate, or preservatives such as paraben or sorbic acid, or anti-oxidants such as ascorbic acid, tocopherol or cysteine, a disintegrating agent, or chelating agents such as EDTA, binders, thickeners, buffers, sweeteners, flavoring agents or perfuming agents. Additionally, dyestuffs or pigments may be added for identification. Tablets and pills may be further treated with suitable coating materials known in the art, such as moisture protective, enteric, or sustained release coatings.
[0157] Liquid dosage forms for oral administration may be in the form of pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, slurries and : solutions, which may contain an inactive diluent, such as water. Pharmaceutical formulations may be prepared as liquid suspensions or solutions using a sterile liquid, such as, but not limited to, an oil, water, an alcohol, and combinations of these.
Pharmaceutically suitable surfactants, suspending agents, emulsifying agents, sweeteners, flavoring agents, chelating agents, preservatives, antioxidants, solubilizers such as propylene glycol and glycerin and sorbitol may be added for oral or parenteral administration. i0158] As noted above, suspensions may include oils. Such oil include, but are not limited to, peanut oil, sesame oil, cottonseed oil, corn oil and olive oil.
Suspension preparation may also contain esters of fatty acids such as ethyl oleate, isopropyl myristate, fatty acid glycerides and acetylated fatty acid glycerides.
Suspension formulations may include alcohols, such as, but not limited to, ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol and propylene glycol. Ethers, such as but not limited to, poly(ethyleneglycol), petroleum hydrocarbons such as mineral oil - and petrolatum; and water may also be used in suspension formulations. Furthermore suspension formulations may also include stabilizers, preservatives, antioxidants, surfactants, dyes, sweeteners, flavoring agents, solubilizers, thickeners, and emulsifying agents.
[0159] For nasal administration, the pharmaceutical formulations may be a spray or aerosol containing and appropriate solvents and optionally other compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH modifiers, surfactants, bioavailability modifiers and combinations of these. A propellant for an aerosol formulation may include compressed air, nitrogen, carbon dioxide, or a hydrocarbon based low boiling solvent. The salts of the compound or compounds of Formula I and/or Formula II are conveniently delivered in the form of an aerosol spray presentation from a nebulizer or the like.
[0160] Injectable dosage forms generally include aqueous suspensions or oil suspensions which may be prepared using a suitable dispersant or wetting agent and a suspending agent. Injectable forms may be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils may be employed as solvents or suspending agents. Preferably, the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.
[0161] For injection, the pharmaceutical formulation may be a powder suitable for reconstitution with an appropriate solution as described above. Examples of these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates. For injection, the formulations may optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these. The salts of the compounds of
Formula I and Formula II may be formulated for parenteral administration by injection such as by bolus injection or continuous infusion. A unit dosage form for injection may be in ampoules or in multi-dose containers.
[0162] For rectal administration, the pharmaceutical formulations may be in the form of a suppository, an ointment, an enema, a tablet or a cream for release of compound in the intestines, sigmoid flexure and/or rectum. Rectal suppositories are prepared by mixing one or more salts of the compounds of Formula I or Formula II, with acceptable vehicles, for example, cocoa butter or polyethylene glycol, which is present in a solid phase at normal storing temperatures, and present in a liquid phase at those temperatures suitable to release a drug inside the body, such as in the rectum. Oils may also be employed in the preparation of formulations of the soft gelatin type and suppositories. Water, saline, aqueous dextrose and related sugar solutions, and glycerols may be employed in the preparation of suspension formulations which may also contain suspending agents such as pectins, carbomers, methyl cellulose, hydroxypropyl cellulose or carboxymethyl cellulose, as well as buffers and preservatives.
[0163] In some embodiment, the salt is supplied in a powder form in a storage container such as a vial In some embodiments, the vial is closed and in other embodiments the vial can be evacuated with an inert gas and stoppered.
[0164] Besides those representative dosage forms described above, pharmaceutically acceptable excipients and carriers are generally known to those skilled in the art and are thus included in the instant invention. Such excipients and carriers are described, for example, in “Remingtons Pharmaceutical Sciences” Mack
Pub. Co., New Jersey (1991), which is incorporated herein by reference.
[0165] The formulations of the invention may be designed for to be short- acting, fast-releasing, long-acting, and sustained-releasing as described below. Thus, i the pharmaceutical formulations may also be formulated for controlled release or for slow release.
[0166] The instant compositions may also comprise, for example, micelles or liposomes, or some other encapsulated form, or may be administered in an extended release form to provide a prolonged storage and/or delivery effect. Therefore, the pharmaceutical formulations may be compressed into pellets or cylinders and implanted intramuscularly or subcutaneously as depot injections or as implants such as stents. Such implants may employ known inert materials such as silicones and biodegradable polymers.
[0167] Specific dosages may be adjusted depending on conditions of disease, the age, body weight, general health conditions, sex, and diet of the subject, dose 60 i intervals, administration routes, excretion rate, and combinations of drugs. Any of the above dosage forms containing effective amounts are well within the bounds of routine experimentation and therefore, well within the scope of the instant invention.
[0168] A therapeutically effective dose may vary depending upon the route of administration and dosage form. The preferred salts of compound or compounds of
Formula I or Formula II are in a formulation that exhibits a high therapeutic index.
The therapeutic index is the dose ratio between toxic and therapeutic effects which can be expressed as the ratio between LDso and EDso. The LDs is the dose lethal to 50% of the population and the EDs; is the dose therapeutically effective in 50% of the population. The LDsp and EDs are determined by standard pharmaceutical procedures in animal cell cultures or experimental animals.
[0169] “Treating” within the context of the instant invention, means an alleviation of symptoms associated with a disorder or disease, or halt of further progression or worsening of those symptoms, or prevention or prophylaxis of the disease or disorder. For example, within the context of treating patients in need of an inhibitor of VEGF-RTK, successful treatment may include a reduction in the proliferation of capillaries feeding a tumor or diseased tissue, an alleviation of symptoms related to a cancerous growth or tumor, proliferation of capillaries, or diseased tissue, a halting in capillary proliferation, or a halting in the progression of a disease such as cancer or in the growth of cancerous ceils. Treatment may aiso inciude administering the pharmaceutical formulations of the present invention in combination with other therapies. For example, the compounds and pharmaceutical formulations of the present invention may be administered before, during, or after surgical procedure and/or radiation therapy. The compounds of the invention can also be administered in conjunction with other anti-cancer drugs including those used in antisense and gene therapy.
[0170] In one embodiment of the invention is a method of treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase includes administering an effective amount of a pharmaceutical formulation according to the invention to a patient in need thereof.
[0171] Tn one embodiment of the invention is a method for inhibiting tumor growth in a patient includes administering an effective amount of a salt of the compound Formula I or Formula II to a patient having a tumor.
[0172] In one embodiment of the invention is a method for inhibiting the proliferation of capillaries in a patient includes administering an effective amount of a salt of the compound of Formula I or Formula II according to a patient in need.
[0173] In one embodiment of the invention is a method of preparing pharmaceutical formulations includes mixing any of the above-described salts of the compounds of Formula I or Formula II with a pharmaceutically acceptable carrier and water or an aqueous solution.
[0174] The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of : illustration and are not intended to be limiting of the present invention.
[0175] The following abbreviations are used in the Examples:
ATP: Adenosine triphosphate
BSA: Bovine Serum Albumin
DMA: N,N-Dimethylacetamide
DMF: N,N-Dimethylformamide dppf: 1,1°(diphenylphosphino)ferrocene
DTT: DL-Dithiothreitol
EDTA: Ethylene diamine tetraacetic acid
EtOAc: Ethyl acetate
EtOH: Ethanol
HBTU: O-Benzotriazol-1-y1-N,N,N’,N’ -tetramethyluronium hexafluorophosphate
ICsp value: The concentration of an inhibitor that causes a 50% reduction in a measured activity.
LiHMDS: Lithium bis(trimethylsilyl)amide
MeOH: Methanol
NMP: N-methylpyrrolidone
THF: Tetrahydrofuran
[0176] The compounds were named using Nomenclator (v. 3.0 & v. 5.0) from
CmemInovation Software, Inc. and ACD/Name v. 4.53.
SYNTHETIC METHODOLOGY
[0177] The various aryl diamine starting materials used to synthesize benzimidazole acetates may be obtained from commercial sources, prepared by methods know to one of skill in the art, or prepared by the following general Methods 1-15.
Method 1 oo
F NH, jon oo
F R'RN
[0178] 2,4-Difluoronitrobenzene (1.0 equivalent) was placed in a dry round- bottomed flask equipped with a dry ice condenser charged with acetone and dry ice.
Ammonia was condensed into the flask and the resulting solution was stirred at reflux for 7 hours. A yellow precipitate formed within 1 hour. After 7 hours, the condenser was removed and the liquid ammonia was allowed to evaporate over several hours.
The crude product was purified by flash chromatography on silica gel (85:15 hexanes:ethyl acetate, product at R= 0.32, contaminant at R¢= 0.51); GC/MS m/z 156.1 (M+), R; 11.16 minutes.
[0179] The resulting 5-fluoro-2-nitrophenylamine (1.0 equivalent) and an amine (1.1 equivalents) e.g., N-methyl piperazine, were dissolved in NMP and triethylamine (2.0 equivalents) was added. The reaction mixture was heated at 100°C for 3 hours. The solution was then cooled to room temperature and diluted with water. The resulting precipitate was filtered and dried under vacuum to provide the 2- nitro-diamino product. Alternatively, the same product may be obtained from commercially available 5-chloro-2-nitrophenylamine under identical conditions except heating at 130°C for 1-2 days. In some examples, the displacement on either 5-fluoro-2-nitrophenylamine or S-chloro-2-nitrophenylamine can be conducted in neat amine (5 equivalents) at 100°C or 130 °C, respectively. The product is isolated in an identical manner. LC/MS m/z 237.1 (MH+), R, 1.304 minutes.
[0180] The nitroamine (1.0 equivalent) and 10% Pd/C (0.1 equivalents) was suspended in anhydrous ethanol at room temperature. The reaction flask was evacuated and subsequently filled with Hy. The resulting mixture was then stirred under a hydrogen atmosphere overnight. The resulting solution was filtered through
Celite and concentrated under vacuum to provide the crude product which was used without further purification.
Method 2
NO, NH;
NH, NH,
JE
F F
F NRR'
[0181] A round-bottom flask was charged with 2,3-difluoro-6- nitrophenylamine (1 equivalent) and enough NMP to make a viscous slurry. An amine (5 equivalents), e.g., N-methyl piperazine, was added and the solution was heated at 100°C. After 2 hours, the solution was cooled and poured into water. A bright yellow solid formed which was filtered and dried. The nitroamine was reduced as in Method 1 to provide the crude product which was used without further purification. LC/MS m/z 225.1 (MH+), R,0.335 minutes.
Method 3
Or F R'RN 101 NH,
[0182] To a 0.1 M DMF solution of 1,3-difluoro-2-nitrobenzene was added
Et3N (2 equivalents) followed by an amine (1 equivalent), e.g., morpholine. The mixture was stirred for 18 hours and then diluted with water and extracted with ethyl acetate. LC/MS m/z 227.2 (MH+), R,2.522 minutes. The combined organic layers were dried over MgSOs, filtered, and concentrated. Ammonia was condensed into a bomb containing the crude product. The bomb was sealed and heated to 100°C (over 400 psi). After 72 hours the bomb was allowed to cool and the ammonia was evaporated to provide a reddish solid. The nitroamine was reduced as in Method 1 to provide the crude product which was used without further purification. LC/MS m/z 194.1 (MH), R, 1.199 minutes.
Method 4
NH NH;
Sos oo"
F RO
[0183] To a stirred NMP solution containing NaH (1.3 equivalents) was added an alcohol (1.0 equivalent), e.g., 2-methyloxyethanol. The resulting mixture was then stirred for 30 minutes. A slurry of 5-fluoro-2-nitrophenylamine in NMP was then added slowly. The mixture was then heated to 100°C. After 2 hours, the reaction mixture was cooled and water was added. The mixture was then filtered and the captured solid was washed with water and purified by silica gel chromatography (1:1 ethyl acetate:hexane). LC/MS m/z 213.2 (MH+), R,2.24 minutes. The nitroamine was reduced as in Method 1 to provide the crude product which was used without further purification. LC/MS m/z 183.1 (MH), R,0.984 minutes.
Method 5
NH, NH,
Vv HO RO
[0184] Diisopropyl azodicarboxylate (1.1 equivalents) was added dropwise to a stirred solution of 4-amino-3-nitrophenol (1.0 equivalent), triphenylphosphine (1.1 equivalents), and an alcohol, e.g., N-(2-hydroxyethyl)morpholine (1.0 equivalent), in tetrahydrofuran at 0°C. The mixture was allowed to warm to room temperature and stirred for 18 hours. The solvent was evaporated, and the product was purified by silica gel chromatography (98:2 CH,Cly:methanol) to yield 4-(2-morpholin-4- ylethoxy)-2-nitrophenylamine as a dark reddish-brown oil. LC/MS m/z 268.0 (MH),
R,1.01 minutes. The nitroamine was reduced as in Method 1 to give the crude product which was used without further purification. LC/MS m/z 238.3 (MHH),R;, 0.295 minutes.
Method 6
NH, NH; NH; NH go" or" r= or
OH a : O¢NRR OM NRR
[0185] To a flask charged with 4-amino-3-nitrophenol (1 equivalent), K2CO; (2 equivalents), and 2-butanone was added an alkyl dibromide, e.g., 1,3- dibromopropane (1.5 equivalents). The resulting mixture was then heated at 80°C for 18 hours. After cooling, the mixture was filtered, concentrated, and diluted with water. The solution was then extracted with CH,Cl; (3 x) and the combined organic layers were concentrated to give a solid that was then washed with pentane. LCMS m/z 275.1 (MH), R,2.74 minutes.
[0186] An acetonitrile solution of the bromide prepared above, an amine, e.g., pyrrolidine (5 equivalents), Cs2COs (2 eq) and BugNI (0.1 equivalents) was heated at 70°C for 48 hours. The reaction mixture was cooled, filtered, and concentrated. The residue was dissolved in CH,Cl,, washed with water, and concentrated to give the desired nitroamine, 2-nitro-4-(3-pyrrolidin-1-ylpropoxy)phenylamine. LCMS m/z 266.2 (MH+), R, 1.51 minutes. The nitroamine was reduced as in Method 1 to provide the crude product which was used without further purification.
Method 7
NH, NH» . cl ~F NRR™ 7
[0187] To a suspension of 6-chloro-3-nitropyridin-2-amine (1 equivalent) in acetonitrile was added an amine, e.g., morpholine (4 equivalent). The resulting reaction mixture was stirred at 70°C for 5 hours. The solvent was evaporated under reduced pressure, and the residue triturated with ether to provide the desired compound as a bright yellow powder. LC/MS m/z 225.0 (MH), R, 1.79 minutes.
The nitroamine was reduced as in Method 1 to provide the crude product which was used without further purification.
Method 8 aro + cl” ® “NH, KoCOg Arg NH,
[0188] A phenol (1 equivalent) and 5-chloro-2-nitro aniline (1 equivalent) were dissolved in DMF, and solid K2COj; (2 equivalents) was added in one portion.
The reaction mixture was heated at 120°C overnight. The reaction mixture was cooled to room temperature, most of the DMF was distilled off, and water was added to the residue to obtain a precipitate. The solid was dried and purified by chromatography on silicagel (2-10% MeOH/CH, Cl) to afford the desired product.
The nitroamine was reduced as in method 1 to give the crude product that was used without further purification.
Method 9 0 0]
NH; roa" 1. KOH NH Ra. x —N 2. R4R,NH x NN sec Joed
N™ ~O N~ 0
H H
[0189] The introduction of substituents on the benzimidazole ring need not be limited to the early stages of the synthesis and may arise after formation of the quinolinone ring. For example, the crude methyl ester shown in the figure above was dissolved in a 1:1 mixture of EtOH and 30% aqueous KOH and stirred overnight at 70°C. The reaction mixture was then cooled and acidified with IN HCl to give a - precipitate. The solid was filtered, washed with water and dried to obtain 2-(4-amino- 2-0x0~1,2-dihydroguinolin-3-y1)-1 H-benzimidazole-6-carboxylic acid 2-(4-amino-2-~ o0x0-3-hydroquinolyl)benzimidazole-6-carboxylic acid as a brown solid. LC/MS m/z: 321.1 (MH+), R, 2.26 minutes.
[0190] A mixture of 2-(4-amino-2-oxo-1,2-dihydroquinolin-3-yl)-1H- benzimidazole-6-carboxylic acid (1 equivalent) the amine (1 equivalent), EDC (1-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 1.2 equivalents), HOAT (1-hydroxy-7-azabenzotriazole, 1.2 eq) and triethylamine (2.5 equivalents) in DMF, was stirred at 23 °C for 20 hours. The reaction mixture was partitioned between water and ethyl acetate. The combined organic layers were dried (Na;SO4) and concentrated. Water was added and the precipitate thus formed was filtered off and dried to afford the desired product.
[0191] The various 2-amino benzoic acid starting materials used to synthesize isatoic anhydrides may be obtained from commercial sources, prepared by methods known to one of skill in the art, or prepared by the following general Methods 10-11,
General isatoic anhydride synthesis methods are described in J. Med. Chem. 1981, 24 (6), 735 and J. Heterocycl. Chem. 1975, 12(3), 565.
Method 10 oc 1. NaNO, jos H2S04 ocr — ————ee————
MeO No, 2CUWCN peo Nop, HO MeO NO, 1 2 3 10% Pd/C or Bn(Me)sNBr3 Yr — —_—
NH40H, 50C MeO NH, CaCO3, DCM, MeO NH2
MeOH 4 5
[0192] Compounds 1-3 were made using similar procedures as found in U.S.
Patent No. 4,287,341. Compound 3 was reduced using standard hydrogenation conditions of 10% Pd/C in NH,OH at 50°C over 48 hours. The product was precipitated by neutralizing with glacial acetic acid, filtering, and washing with water and ether. Yields were about 50%. Compound 5 was prepared in a manner similar to that disclosed in U.S. Patent No. 5,716,993.
Method 11 1. lodine,
Ag,SO0y, ore oan 4 - S oo
Ee
Cl NH 2. NaOH 3N cl NH 2 3 aq. HCI 2
E 1. lodine,
Ag;SOy, £
S ooue EtOH IN $ oo . —_—
NH 2. NaOH 3N 2 3.aq.HCl NH 1. lodine,
AgzSOq,
CO,Me EtOH [ CO,H
LL, meena JX
F NH 2. NaOH 3N 2 3 aq. HCI F NH;
[0193] Iodination of aniline containing compounds was accomplished using various procedures. Iodination was accomplished using a procedure similar to that described in J. Med. Chem. 2001, 44, 6, 917-922. The anthranilic ester in EtOH was added to a mixture of silver sulfate (1 equivalent) and I; (1 equivalent). The reaction was typically done after 3 hours at room temperature. The reaction was filtered through celite and concentrated. The residue was taken up in EtOAc and washed with aqueous saturated NaHCO (3x), water (3x), brine (1x), dried (MgSO), filtered, and concentrated. The crude product (~5 g) was dissolved in MeOH (60-100 mL), NaOH 6N (25 mL), and water (250 mL). The reactions were typically done after heating at 70-80°C for 4 hours. The reaction mixture was extracted with EtOAc (2x), neutralized with aqueous HC], filtered to collect the solids, and the solid products were washed with water. The products were dried in vacuo.
[0194] In various instances, substitutions on the quinolinone ring may also be introduced after coupling as shown in the general methods 12-15.
Method 12
De pe
X NN Pd,Cul,CO HOC An
H _— . H
N° NO
X =1, Br, TfO
[0195] . Conversion of the C-6 or C-7 halides to an acid group was accomplished using procedures in the following references: Koga, H. et al., Tet. Let., 1995, 36, 1, 87-90; and Fukuyama, T. et al., J. Am. Chem. Soc., 1994, 116, 31235- 3126. ‘Method 13
NHR a NHR —) “Or Pd, KCN or NaCN HOR:
NO Cul, THF No
H
X=1, Br, TfO
[0196] Conversion of the C-6 or C-7 halides to a cyano group was accomplished using procedures in the following reference. Anderson, B.A.etal.,l. . Org. Chem., 1998, 63, 8224-828.
Method 14
NHR N 4 ) Pd(dppfClz/Cl.CH, OF NHR N
X VS N _— x | {
N © Wa No
X =1, Br, TO Y = B(OH), or Sn(nBu)a
[0197] Conversion of the C-6 or C-7 halides to an aryl group was accomplished using standard Suzuki or Stille procedures such as described below.
[0198] Suzuki Method: To a 1 dram (4 mL) vial was added sequentially the quinolone (1 equivalent), boronic acid (1.2-1.5 equivalents), Pd(dppf)Cl, C1.CH; (0.2 equivalents), DMF (0.5 - 1 mL) and TEA (4 equivalents). The reaction was flushed with argon, capped and heated at 85°C for 12 hours. Once done, the reaction was cooled to room temperature, and filtered with a syringe filter disk. The clear solution was then neutralized with TFA (a couple of drops) and injected directly onto a preparative HPLC. The products were lyophilized to dryness.
[0199] Stille Method: Toa 1 dram (4 mL) vial was added sequentially the quinolone (1 equivalent), tin reagent (1.8 equivalent), Pd(dppf)Cl, . CL,.CH, (0.2 equivalents), and DMF (0.5 - 1 mL). The reaction was flushed with argon, capped and heated at 60-85°C for 4 hours. Once done, the reaction was cooled to room temperature, and filtered with a syringe filter disk. The clear solution was then neutralized with TFA (a couple of drops) and injected directly onto a preparative
HPLC. The products were lyophilized to dryness.
Method 15
NHR a R-YH NHR n)
X EN N > X = N
H NMP y | No H xX N 0 - ) ome 1
R
X, X=FCl,I
Y =NH,O, S
[0200] A dihaloquinolone such as a difluoroquinolone (12-15 mg) was placed in a 1 dram (2 mL) vial. NMP (dry and pre-purged with argon for 5 minutes) was added to the vial (0.5 mL). The amine reagent (40-50 mg) was added next. If the amine was an HCl salt, the reaction was neutralized with TEA (~1.2-1.5 equivalents).
The reaction was purged again with argon for about 5 seconds, and immediately capped. The reaction was typically heated in a heating block at 90-95°C for 18 hours.
The reaction was followed by HPLC or LCMS. After taking samples for HPLC, the vial was purged with argon again and capped. Some coupling partners took 24 or 48 hours to reach completion. Less nucleophilic amines like pyrrole required the addition of a strong base to reach completion. In these cases, cesium carbonate (2 equivalents based on the amine used) was added to the reaction. Once done, the reaction was cooled to room temperature, and filtered with a syringe filter disk. The clear solution was then neutralized with TFA (a couple of drops) and injected directly onto a preparative HPLC. The producis were iyophilized io dryness.
Method 16
General synthesis of compounds of Formula I and Formula II such as 4-amino-S- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one
F NH; ava N—- 504
N 0]
H
A. Synthesis of 5-(4-Methyl-piperazin-1-yl)-2-nitroaniline :
Procedure A ’ OoN HN N= ON = 1 er ————————— .
HaN cl HN YY
GP
[0201] 5-Chloro-2-nitroaniline (500 g, 2.898 mol) and 1-methyl piperazine (871 g, 8.693 mol) were placed in a 2000 mL flask fitted with a condenser and purged with N,. The flask was placed in an oil bath at 100°C and heated until the 5-chloro-2- nitroaniline was completely reacted (typically overnight) as determined by HPLC.
After HPLC confirmed the disappearance of the 5-chloro-2-nitroaniline, the reaction mixture was poured directly (still warm) into 2500 mL of room temperature water with mechanical stirring. The resulting mixture was stirred until it reached room temperature and then it was filtered. The yellow solid thus obtained was added to 1000 mL of water and stirred for 30 minutes. The resulting mixture was filtered, and the resulting solid was washed with TBME (500 mL, 2X) and then was dried under vacuum for one hour using a rubber dam. The resulting solid was transferred to a drying tray and dried in a vacuum oven at 50°C to a constant weight to yield 670 g (97.2%) of the title compound as a yellow powder. :
Procedure B
[0202] 5-Chloro-2-nitroaniline (308.2 g, 1.79 mol) was added to a 4-neck 5000 mL round bottom flask fitted with an overhead stirrer, condenser, gas inlet, addition funnel, and thermometer probe. The flask was then purged with N,. 1-
Methylpiperazine (758.1 g, 840 mL, 7.57 mol) and 200 proof ethanol (508 mL) were added to the reaction flask with stirring. The flask was again purged with Nj, and the reaction was maintained under Na. The flask was heated in a heating mantle to an internal temperature of 97°C (+/- 5°C) and maintained at that temperature until the reaction was complete (typically about 40 hours) as determined by HPLC. After the reaction was complete, heating was discontinued and the reaction was cooled to an internal temperature of about 20°C to 25°C with stirring, and the reaction was stirred for 2 to 3 hours. Seed crystals (0.20 g, 0.85 mmol) of 5-(4-methyl-piperazin-1-y1)-2- nitroaniline were added to the reaction mixture unless precipitation had already occurred. Water (2,450 mL) was added to the stirred reaction mixture over a period of about one hour while the internal temperature was maintained at a temperature ranging from about 20°C to 30°C. After the addition of water was complete, the resulting mixture was stirred for about one hour at a temperature of 20°C to 30°C.
The resulting mixture was then filtered, and the flask and filter cake were washed with water (3 x 2.56 L). The golden yellow solid product was dried to a constant weight of 416 g (98.6% yield) under vacuum at about 50°C in a vacuum oven.
Procedure C
[0203] 5-Chloro-2-nitroaniline (401 g, 2.32 mol) was added to a 4.neck 12 L round bottom flask fitted with an overhead stirrer, condenser, gas inlet, addition funnel, and thermometer probe. The flask was then purged with Np. 1-
Methylpiperazine (977 g, 1.08 L, 9.75 mol) and 100% ethanol (650 mL) were added to the reaction flask with stirring. The flask was again purged with N, and the reaction was maintained under N,. The flask was heated ina heating mantle to an internal temperature of 97°C (+/- 5°C) and maintained at that temperature until the reaction was complete (typically about 40 hours) as determined by HPLC. After the g reaction was complete, heating was discontinued and the reaction was cooled to an internal temperature of about 80°C with stirring, and water (3.15 L) was added to the mixture via an addition funnel over the period of 1 hour while the internal temperature was maintained at 82°C (+/- 3°C). After water addition was complete, heating was discontinued and the reaction mixture was allowed to cool over a period of no less than 4 hours to an internal temperature of 20-25°C. The reaction mixture was then stirred for an additional hour at an internal temperature of 20-30°C. The resulting mixture was then filtered, and the flask and filter cake were washed with water (1x 1
L), 50% ethanol (1 x 1L), and 95% ethanol (1 x 1L). The golden yellow solid product was placed in a drying pan and dried to a constant weight of 546 g (99% yield) under vacuum at about 50°C in a vacuum oven.
B. Synthesis of [6-(4-Methyl-piperazin-1-yl)-1H-benzimidazol-2-yl}-acetic acid ethyl ester
Procedure A
ON HaN
Ha, PU/C, EIOH
SO mm DOL
LN PN or HCI
EO Ot ~~ / BON . N N “N oo PN
[0204] A 5000 mL, 4-neck flask was fitted with a stirrer, thermometer, condenser, and gas inlet/outlet. The equipped flask was charged with 265.7 g (1.12 mol. 1.0 eq) of 5-(4-methyl-piperazin-1-yl)-2-nitroaniline and 2125 mL of 200 proof
EtOH. The resulting solution was purged with N; for 15 minutes. Next, 20.0 g of 5%
Pd/C (50% HO w/w) was added. The reaction was vigorously stirred at 40-50°C (internal temperature) while H, was bubbled through the mixture. The reaction was monitored hourly for the disappearance of 5-(4-methyl-piperazin-1-yl)-2-nitroaniline by HPLC. The typical reaction time was 6 hours.
[0205] After all the 5-(4-methyl-piperazin-1-yl)-2-nitroaniline had disappeared from the reaction, the solution was purged with N for 15 minutes. Next, 440.0 g (2.25 mol) of ethyl 3-ethoxy-3-iminopropanoate hydrochloride was added as a solid. The reaction was stirred at 40-50°C (internal temperature) until the reaction was complete. The reaction was monitored by following the disappearance of the diamino compound by HPLC, The typical reaction time was 1-2 hours. After the reaction was complete, it was cooled to room temperature and filtered through a pad of Celite filtering material. The Celite filtering material was washed with absolute
EtOH (2 x 250 mL), and the filtrate was concentrated under reduced pressure
EE providing a thick brown/orange oil. The resulting oil was taken up in 850 mL of a 0.37% HCl solution. Solid NaOH (25 g) was then added in one portion, and a precipitate formed. The resulting mixture was stirred for 1 hour and then filtered.
The solid was washed with HO (2 x 400 mL) and dried at 50°C in a vacuum oven providing 251.7 g (74.1%) of [6-(4-methyl-piperazin-1-yl)-1H-benzoimidazol-2-yl]- acetic acid ethyl ester as a pale yellow powder.
Procedure B
[0206] A 5000 mL, 4-neck jacketed flask was fitted with a mechanical stirrer, condenser, temperature probe, gas inlet, and oil bubbler. The equipped flask was charged with 300 g (1.27 mol) of 5-(4-methyl-piperazin-1-yl)-2-nitroaniline and 2400 mL of 200 proof EtOH (the reaction may be and has been conducted with 95% ethanol and it is not necessary to use 200 proof ethanol for this reaction). The resulting solution was stirred and purged with Nj for 15 minutes. Next, 22.7 g of 5%
Pd/C (50% H,O w/w) was added to the reaction flask. The reaction vessel was purged with N, for 15 minutes. After purging with Nj, the reaction vessel was purged with H, by maintaining a slow, but constant flow of Hj through the flask. The reaction was stirred at 45-55°C (internal temperature) while H, was bubbled through : the mixture until the 5-(4-methyl-piperazin-1-yl)-2-nitroaniline was completely consumed as determined by HPLC. The typical reaction time was 6 hours.
[0207] After all the 5-(4-methyl-piperazin-1-yl)-2-nitroaniline had disappeared from the reaction, the solution was purged with N for 15 minutes. The diamine intermediate is air sensitive so care was taken to avoid exposure to air. 500 g (2.56 mol) of ethyl 3-ethoxy-3-iminopropanoate hydrochloride was added to the reaction mixture over a period of about 30 minutes. The reaction was stirred at 45- 55°C (internal temperature) under Nj until the diamine was completely consumed as determined by HPLC. The typical reaction time was about 2 hours. After the reaction was complete, the reaction was filtered while warm through a pad of Celite.
The reaction flask and Celite were then washed with 200 proof EtOH (3 x 285 mL).
The filtrates were combined in a 5000 mL flask, and about 3300 mL of ethanol was removed under vacuum producing an orange oil. Water (530 mL) and then IM HCL
(350 mL) were added to the resulting oil, and the resulting mixture was stirred. The resulting solution was vigorously stirred while 30% NaOH (200 mL) was added over a period of about 20 minutes maintaining the internal temperature at about 25-30°C while the pH was brought to between 9 and 10. The resulting suspension was stirred for about 4 hours while maintaining the internal temperature at about 20-25°C. The resulting mixture was filtered, and the filter cake was washed with HO (3 x 300 mL).
The collected solid was dried to a constant weight at 50°C under vacuum in a vacuum oven providing 345.9 g (90.1%) of [6-(4-methyl-piperazin-1-yl)-1H-benzoimidazol-2- yl]-acetic acid ethyl ester as a pale yellow powder. In an alternative work up procedure, the filtrates were combined and the ethanol was removed under vacuum until at least about 90% had been removed. Water at a neutral pH was then added to the resulting oil, and the solution was cooled to about 0°C. An aqueous 20% NaOH solution was then added slowly with rapid stirring to bring the pH up to 9.2 (read with pH meter). The resulting mixture was then filtered and dried as described above. The alternative work up procedure provided the light tan to light yellow product in yields as high as 97%.
Method for Reducing Water Content of [6-(4-Methyl-piperazin-1-yl)-1H- benzoimidazol-2-yl]-acetic acid ethyl ester
[0208] [6-(4-Methyl-piperazin-1-y])-1H-benzimidazol-2-yl]-acetic acid ethyl ester {120.7 grams) that had been previously worked up and dried to a water content of about 8-9% H,O was placed in a 2000 mL round bottom flask and dissolved in absolute ethanol (500 mL). The amber solution was concentrated to a thick oil using a rotary evaporator with heating until all solvent was removed. The procedure was repeated two more times. The thick oil thus obtained was left in the flask and placed in a vacuum oven heated at 50°C overnight. Karl Fisher analysis results indicated a water content of 5.25%. The lowered water content obtained by this method provided increased yields in the procedure of the following Example. ‘Other solvents such as toluene and THF may be used in place of the ethanol for this drying process.
C. Synthesis of 4-Amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1H- benzimidazol-2-yl]-1H-quinolin-2-one
Procedure A
F
F NHz N =
Ler pe § | \ \_/"
KHMDS, THF
AA EY
ON IS
[0209] [6-(4-Methyl-piperazin-1-yl)-1H-benzimidazol-2-yl]-acetic acid ethyl ester (250 g, 820 mmol) (dried with ethanol as described above) was dissolved in
THF (3800 mL) in a 5000 mL flask fitted with a condenser, mechanical stirrer, temperature probe, and purged with argon. 2-Amino-6-fluoro-benzonitrile (95.3 g, 700 mmol) was added to the solution, and the internal temperature was raised to 40°C.
When all the solids had dissolved and the solution temperature had reached 40°C, solid KHMDS (376.2 g, 1890 mmol) was added over a period of 5 minutes. When addition of the potassium base was complete, a heterogeneous yellow solution was obtained, and the internal temperature had risen to 62°C. After a period of 60 minutes, the internal temperature decreased back to 40°C, and the reaction was determined to be complete by HPLC (no starting material or uncyclized intermediate was present). The thick reaction mixture was then quenched by pouring it into H,0
Co (6000 mL) and stirring the resulting mixture until it had reached room temperature. "The mixture was then filtered, and the filter pad was washed with water (1000 mL 2X). The bright yellow solid was placed in a drying tray and dried in a vacuum oven at 50°C overnight providing 155.3 g (47.9%) of the desired 4-amino-5-fluoro-3-[6-(4- methyl-piperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one.
Procedure B
[0210] A 5000 mL 4-neck jacketed flask was equipped with a distillation apparatus, a temperature probe, a N; gas inlet, an addition funnel, and a mechanical stirrer. [6-(4-Methyl-piperazin-1-yl)-1H-benzimidazol-2-yl]-acetic acid ethyl ester (173.0 g, 570 mmol) was charged into the reactor, and the reactor was purged with N,
for 15 minutes. Dry THF (2600 mL) was then charged into the flask with stirring.
After all the solid had dissolved, solvent was removed by distillation (vacuum or atmospheric (the higher temperature helps to remove the water) using heat as necessary. After 1000 mL of solvent had been removed, distillation was stopped and the reaction was purged with N;. 1000 mL of dry THF was then added to the reaction vessel, and when all solid was dissolved, distillation (vacuum or atmospheric) was again conducted until another 1000 mL of solvent had been removed. This process of adding dry THF and solvent removal was repeated at least 4 times (on the 4% distillation, 60% of the solvent is removed instead of just 40% as in the first 3 distillations) after which a 1 mL sample was removed for Karl Fischer analysis to determine water content. If the analysis showed that the sample contained less than 0.20% water, then reaction was continued as described in the next paragraph.
However, if the analysis showed more than 0.20% water, then the drying process described above was continued until a water content of less than 0.20% was achieved.
[0211] After a water content of less than or about 0.20% was achieved using the procedure described in the previous paragraph, the distillation apparatus was replaced with a reflux condenser, and the reaction was charged with 2-amino-6- fluoro-benzonitrile (66.2 g, 470 mmol) ( in some procedures 0.95 equivalents is used).
The reaction was then heated to an internal temperature of 38-42°C. When the internal temperature had reached 38-42°C, KHMDS solution (1313 g, 1.32 mol, 20%
KHMDS in THF) was added to the reaction via the addition funnel over a period of 5 minutes maintaining the internal temperature at about 38-50°C during the addition.
When addition of the potassium base was complete, the reaction was stirred for 3.5 to 4.5 bours (in some examples it was stirred for 30 to 60 minutes and the reaction may be complete within that time) while maintaining the internal temperature at from 38- 42°C. A sample of the reaction was then removed and analyzed by HPLC. If the reaction was not complete, additional KHMDS solution was added to the flask over a period of 5 minutes and the reaction was stirred at 38-42°C for 45-60 minutes (the amount of KHMDS solution added was determined by the following: If the IPC ratio is <3.50, then 125 ml. was added; if 10.0 = IPC ratio > 3.50, then 56 ml, was added; if 20.0 > IPC ratio > 10, then 30 mL was added. The IPC ratio is equal to the area corresponding to 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1H-benzimidazol- 2-yl]-1H-quinolin-2-one) divided by the area corresponding to the uncyclized intermediate). Once the reaction was complete (IPC ratio > 20), the reactor was cooled to an internal temperature of 25-30°C, and water (350 mL) was charged into the reactor over a period of 15 minutes while maintaining the internal temperature at 25-35°C (in one alternative, the reaction is conducted at 40°C and water is added within 5 minutes. The quicker quench reduces the amount of impurity that forms over time). The reflux condenser was then replaced with a distillation apparatus and solvent was removed by distillation (vacuum or atmospheric) using heat as required.
After 1500 mL of solvent had been removed, distillation was discontinued and the reaction was purged with N,. Water (1660 mL) was then added to the reaction flask while maintaining the internal temperature at 20-30°C. The reaction mixture was then stirred at 20-30°C for 30 minutes before cooling it to an internal temperature of 5- 10°C and then stirring for 1 hour. The resulting suspension was filtered, and the flask and filter cake were washed with water (3 x 650 mL). The solid thus obtained was dried to a constant weight under vacuum at 50°C in a vacuum oven to provide 103.9 g (42.6% yield) of 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1 H-benzimidazol- 2-yl]-1H-quinolin-2-one as a yellow powder.
Procedure C
NC. / \
Ley RO ! YY Town i (JE ~~
[0212] [6-(4-Methyl-piperazin-1-y1)-1H-benzimidazol-2-yl]-acetic acid ethyl ester (608 g, 2.01 mol) (dried) and 2-amino-6-fluoro-benzonitrile (274 g, 2.01 mol) were charged into a 4-neck 12 L flask seated on a heating mantle and fitted with a condenser, mechanical stirrer, gas inlet, and temperature probe. The reaction vessel was purged with N;, and toluene (7.7 L) was charged into the reaction mixture while it was stirred. The reaction vessel was again purged with N, and maintained under
N,. The internal temperature of the mixture was raised until a temperature of 63°C (+/- 3°C) was achieved. The internal temperature of the mixture was maintained at 63°C (+/- 3°C) while approximately 2.6 L of toluene was distilled from the flask under reduced pressure (380 -+/- 10 torr, distilling head t = 40°C (+/- 10°C) (Karl
Fischer analysis was used to check the water content in the mixture. If the water content was greater than 0.03%, then another 2.6 L of toluene was added and distillation was repeated. This process was repeated until a water content of less than 0.03% was achieved). After a water content of less than 0.03% was reached, heating was discontinued, and the reaction was cooled under N to an internal temperature of 17-19°C. Potassium t-butoxide in THF (20% in THF; 3.39 kg, 6.04 moles potassium t-butoxide) was then added to the reaction under Nj at a rate such that the internal temperature of the reaction was kept below 20°C. After addition of the potassium t- butoxide was complete, the reaction was stirred at an internal temperature of less than 20°C for 30 minutes. The temperature was then raised to 25°C, and the reaction was stirred for at least 1 hour. The temperature was then raised to 30°C, and the reaction was stirred for at least 30 minutes. The reaction was then monitored for completion using HPLC to check for consumption of the starting materials (typically in 2-3 hours, both starting materials were consumed (less than 0.5% by area % HPLC)). If the reaction was not complete after 2 hours, another 0.05 equivalents of potassium t- butoxide was added at a time, and the process was completed until HPLC showed that the reaction was complete. After the reaction was complete, 650 mL of water was added to the stirred reaction mixture. The reaction was then warmed to an internal temperature of 50°C and the THF was distilled away (about 3 L by volume) under reduced pressure from the reaction mixture. Water (2.6 L) was then added dropwise to the reaction mixture using an addition funnel. The mixture was then cooled to - room temperature and stirred for at least 1 hour. The mixture was then filtered, and the filter cake was washed with water (1.2 L), with 70% ethanol (1.2 L), and with 95% ethanol (1.2 L). The bright yellow solid was placed in a drying tray and dried in a vacuum oven at 50°C until a constant weight was obtained providing 674 g (85.4%) of the desired 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1H-benzimidazol-2- yl}-1H-quinolin-2-one.
Purification of 4-Amino-S-fluoro-3-[6-(4-methyl-piperazin-1-yI)-1H- benzimidazol-2-yl]-1H-quinolin-2-one
[0213] A 3000 mL 4-neck flask equipped with a condenser, temperature probe, Na gas inlet, and mechanical stirrer was placed in a heating mantle. The flask was then charged with 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1H- benzimidazol-2-yl}-1H-quinolin-2-one (101.0 g, 0.26 mol), and the yellow solid was suspended in 95% ethanol (1000 mL) and stirred. In some cases an 8:1 solvent ratio is used The suspension was then heated to a gentle reflux (temperature of about 76°C) with stirring over a period of about 1 hour. The reaction was then stirred for 45-75 minutes while refluxed. At this point, the heat was removed from the flask and the suspension was allowed to cool to a temperature of 25-30°C. The suspension was then filtered, and the filter pad was washed with water (2 x 500 mL). The yellow solid was then placed in a drying tray and dried in a vacuum oven at 50°C until a constant weight was obtained (typically 16 hours) to obtain 97.2 g (96.2%) of the purified product as a yellow powder. :
D. Preparation of Lactic Acid Salt of 4-Amino-5-fluore-3-[6-(4-methyl- piperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one
F NH; { N—
PP N
(CLL!
HF A o
D,L-Lactic Acid
EtOH, H,0
E NH, WN A 0 [ \
NTN 0
OH yo"
[0214] = A 3000 mL 4-necked jacketed flask was fitted with a condenser, a temperature probe, a Na gas inlet, and a mechanical stirrer. The reaction vessel was purged with Nj, for at least 15 minutes and then charged with 4-amino-5-fluoro-3-[6- _ (4-methyl-piperazin-1-yl)-1H-benzimidazol-2-y1]-1H-quinolin-2-one (484g, 1.23 mol). A solution of D,L-Lactic acid (243.3 g, 1.72 mol of monomer-see the following paragraph), water (339 mL), and ethanol (1211 mL) was prepared and then charged to the reaction flask. Stirring was initiated at a medium rate, and the reaction was heated to an internal temperature of 68-72°C. The internal temperature of the reaction was maintained at 68-72°C for 15-45 minutes and then heating was discontinued. The resulting mixture was filtered through a 10-20 micron frit collecting the filtrate in a 12
L flask. The 12 L flask was equipped with an internal temperature probe, a reflux condenser, an addition funnel, a gas inlet an outlet, and an overhead stirrer. The filtrate was then stirred at a medium rate and heated to reflux (internal temperature of about 78°C). While maintaining a gentle reflux, ethanol (3,596 mL) was charged to the flask over a period of about 20 minutes. The reaction flask was then cooled to an internal temperature ranging from about 64-70°C within 15-25 minutes and this temperature was maintained for a period of about 30 minutes. The reactor was inspected for crystals. If no crystals were present, then crystals of the lactic acid salt of 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1H-benzimidazol-2-yl}-1H- quinolin-2-one (484 mg, 0.1 mole %) were added to the flask, and the reaction was stirred at 64-70°C for 30 minutes before again inspecting the flask for crystals. Once crystals were present, stirring was reduced to a low rate and the reaction was stirred at 64-70°C for an additional 90 minutes. The reaction was then cooled to about 0°C over a period of about 2 hours, and the resulting mixture was filtered through a 25-50 micron fritted filter. The reactor was washed with ethanol (484 mL) and stirred until the internal temperature was about 0°C. The cold ethanol was used to wash the filter cake, and this procedure was repeated 2 more times. The collected solid was dried to a constant weight at 50°C under vacuum in a vacuum oven yielding 510.7 g (85.7%) : of the crystalline yellow lactic acid salt of 4-amino-5-fluoro-3-[6-(4-methyl-piperazin- 1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one. A rubber dam or inert conditions oo were typically used during the filtration process. While the dry solid did not appear to be very hygroscopic, the wet filter cake tends to pick up water and become sticky.
Precautions were taken to avoid prolonged exposure of the wet filter cake to the atmosphere.
[0215] Commercial lactic acid generally contains about 8-12% w/w water, and contains dimers and trimers in addition to the monomeric lactic acid. The mole ratio of lactic acid dimer to monomer is generally about 1.0:4.7. Commercial grade lactic acid may be used in the process described in the preceding paragraph as the monolactate salt preferentially precipitates from the reaction mixture.
SCREENING PROCEDURE FOR SALT SELECTION
[0216] In order to determine the improvements in characteristics of a salt of a compound of Formula I, certain baseline criteria were set and observed. These include: 1. Aqueous solubility > 10 mg/mL 2. Highly crystalline material as determined by X-Ray Powder Diffraction (XRPD), i.e., more chemically stable, less hygroscopic, preference for mono-salt to bis-salt as determined by NMR or ion chromatography, and high chemical yield.
SCREENING TECHNIQUES
[0217] Physiochemical property screening techniques including equilibrium solubility, XRPD, hygroscopicity, compactibility, morphology, and solid-state stability were utilized to evaluate the free base and salts.
Solubility
[0218] The aqueous solubility of compounds of Formula I and Formula I and their salts was determined by equilibrating excess solid with 1 mL of water for 24 hours at 22°C. A 200 uL aliquot was centrifuged at 15,000 rpm for 15 minutes. The supernatant was analyzed by HPLC and the solubility is expressed as its free base equivalent (mg FB/mL). For example, salts of 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one were prepared and the solubility and solution pH was measured. A table comparing the aqueous solubility and pH at saturation for the various salts is shown below.
Table 1. Solubility of 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]-1H-quinolin-2-one Free Base and Salts
L pH at Solubility Crystallinity
Wows | ® | ew | me | wwower
Warorese | © | 9% | ds | owe
I I A I
Wore | € | 4% | 2 | owe
Wore | F | a@ | oso | owen
Wows | © | sw | ow | owen
Worowe |W | 4m | omm | ost
IC LI SC EL
Wore | J | SU 0 | ewan
Ea I EE EC and amorphous
Femme | UL [ee | oova | owe
Worowae |W | 4 | ow | owas
Worerame |W | se | eu | ows
Mono-malate 0 4.08 3.66 crystalline
I A I cL
Worokcle | | Ee | mz | owas
Worokcel | RG | we | ovate
I Ic I “Words | 7 | 4% | oA | omnes _
Worokoe |u| 6% | wo | oven
EEE
Free base 0.011 & amorphous
EEE
Lactate & amorphous nvime | © | on | ww
Bis-Lactate 304 (gelled) & amorphous . gs mixture of crystalline
Mesylate 5.77 , 223 & amorphous >475 (metaphasic | mixture of crystalline
Bis-mesylate liquid crystal gel) & amorphous
FE : mixture of crystalline
Phosphate 3.98 13.8 & amorphous mixture of crystalline
Sulfate 19.7 & amorphous ’ mixture of crystalline
L-Tartrate 103.4 & amorphous mixture of crystalline
Acetate 5.72 16.4 & amorphous
J mixture of crystalline
Bis-Acetate 31.9 & amorphous
Wee | RC am ew owe | wae | we | ow
Wess | 00 | zw | ome | @ mixture of crystalline
L-Malate & amorphous
ND = Not Determined
Crystallinity
[0219] XRPD analyses were carried out on a Shimadzu XRD-6000 X-ray powder diffractometer using Cu Ka radiation. The instrument is equipped with a fine focus X-ray tube. The tube voltage and amperage were set to 40 kV and 40 mA, respectively. The divergence and scattering slits were set at 1° and the receiving slit was set at 0.15 mm. Diffracted radiation was detected by a Nal scintillation detector.
A theta-two theta continuous scan at 3 °/minute (0.4 seconds/0.02° step) from 2.5 to 40 °C was used. For example, salts of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1- y1)-1H-benzimidazol-2-yl]-1H-quinolin-2-one were prepared and the degree of crystallinity observed. Several of the salt forms in the above table were found to exhibit a high degree of crystallinity and have distinct powder X-ray diffraction patterns.
Hygroscopicity
[0220] Moisture sorption/desorption data were collected on a VTI SGA-100 moisture balance system or equivalent. For sorption isotherms, a sorption range of 5 to 95% relative humidity (RH) and a desorption range of 95 to 5% RH in 10% RH increments at 25°C were used for each analysis. For example, salts of 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one were prepared and the moisture induced weight change was measured.
Table 2. Moisture Induced Weight Change in Salts of 4-Amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl}-1H-quinolin-2-one
Salt Form Moisture induced % weight change 55% RH 85% RH 95% RH
Malate-trial 1 0.64 1.49 2.71
Chemical Stability
[0221] Dry powder samples of free base and salts were maintained in open flasks under stress conditions at 30°C/60% relative humidity and 40°C/70% relative humidity. Solution samples of the free base and salts were stored in sealed vials under ambient temperature. Samples were pulled at pre-determined time-points and analyzed for chemical stability, Samples were pulled at pre-determined time-points and assayed by HPLC with UV-visible multiple wavelength detector Two tables comparing the solid state and solution state chemical stability of the various salts are given below.
Table 3. Solid State Stability/ HPLC Analysis of 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl}-1H-quinolin-2-one Free Base and
Salts
Area % at Area % at Storage condition
I = Pe El
Tow [oo | ss | armen nmi
Table 4. Solution State Stability/HPLC Analysis of 4-Amino-S-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl}-1H-quinolin-2-one Salts
Area % at Area % at Storage
I = =
Malate | 9870 | EEE 98.69 ECE sc
Compaction studies
[0222] 200 mg of powdered 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1 -yl)- 1H-benzimidazol-2-yl]-1H-quinolin-2-one salt was preweighed and filled into a 0.8 cm diameter dje and compressed at 5000 psi using a Carver Press (hold for 1 minute).
The resulting tensile strength and thickness of the compacts were measured using a :
VK 200 Tablet Hardness Tester and Mitutoyo thickness gauge. For example, the : lactate and mesylate salts of 4-amino-5 -fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]-1H-quinolin-2-one was prepared and compaction studies were performed. When compressed under the same applied pressure, lactate, malate, and mesylate salts form compacts; the lactate salt generally forms stronger compacts without a tendency to cap or chip.
Table 5. Compaction of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-ylj-1H-quinolin-2-one Salts
Salt Form Compact (200 mg at 5000 psi)
Forms Thickness Tensile strength (SC-Strong
Compact | mm) Cobh)
Mesylate-trial 2 Yes 2.87 17.9
Morphology
[0223] The crystal morphology of 4-amino-5-fluoro-3-[6-(4-methylpiperazin- 1-y1)-1H-benzimidazol-2-yl]-1H-quinolin-2-one salt was determined using a Nikon
Eclipse 6600 POL polarized light microscope at 10x and 40x magnification.
Table 6. Morphology of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]-1H-quinolin-2-one Salts
[0224] As described above various physicochemical property screening techniques including solubility, XRPD, hygroscopicity, compactibility, morphology, and solid-state stability were utilized to evaluate salt forms of 4-amino-5-fluoro-3-[6- (4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one.
[0225] In the case of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one, the salt forms of the compound which exhibited solubilities in water generally between about 20 mg/mL and 330 mg/mL yielding a final water pH approximately between pH 3 to 6 without gelling were acetate, tartrate, malate, lactate, bis-acetate, mesylate, citrate, and bismesylate. Thus, changing 4-amino-5-fluoro-3-{6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H- quinolin-2-one free base (aqueous solubility about 0.01 mg/mL) to a salt form can significantly increase its solubility and rate of dissolution.
[0226] The XRPD pattern of the L-tartrate, citrate, L-malate, DL-lactate, mesylate, and bis-mesylate salts of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)- 1H-benzimidazol-2-y1]-1H-quinolin-2-one (Lots A-U) display resolution of reflections, demonstrating that the samples are crystalline in nature. The XRPD pattern of acetate salt suggests that the sample is amorphous in nature.
[0227] The following salts of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)- 1H-benzimidazol-2-y1]-1H-quinolin-2-one were analyzed by XRPD, mono-mesylate, sulfate, phosphate, mono-DL-lactate, bis-mesylate, bis-lactate, L-tartrate, bis-acetate, bis-acetate, and L-malate (Lots BB-PP). The XRPD patterns of all the samples
(except bis-mesylate salt) display several broad reflections on an offset baseline, suggesting that the samples are composed of a mixture of crystalline and amorphous material or have a low degree of order (low crystallinity). The XRPD pattern of bis- mesylate salt displays resolution of reflections, demonstrating that the sample is crystalline in nature. 10228] Of the crystalline salts, the malate, lactate, mesylate, and bis-mesylate salts exhibited solubilities in water generally between about 50 mg/mL and 330 mg/mL yielding a final water pH near pH 4 to 6. The degree of crystallinity of the free base or salt form can significantly impact its solubility and rate of dissolution.
The following crystalline salts of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl}-1H-quinolin-2-one were analyzed for hygroscopicity. The affinity of water sorption at 85% RH in general were mesylate > lactate = malate.
The lactate and malate salts are considered non-hygroscopic. Stability data demonstrated that 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol- 2-y1]-1H-quinolin-2-one free base and selected salts exhibited adequate chemical stability.
[0229] The lactate salts have plate shape crystal morphology, whereas the mesylate varies from plate to needle, and the malate shows needle shape crystal morphology. Plates are preferred to needle shape crystals because of their better flow properties, which are criticai for efficient formulation biending, filling, and tableting.
[0230] When compressed under the same applied pressure, lactate, malate, and mesylate salts form compacts; the lactate salt generally forms stronger compacts without tendency to cap or chip. The data generated from this example indicates that the lactate, acetate, malate, tartrate, mesylate, and citrate salts have improved aqueous solubility over the corresponding free base form. The lactate, malate, tartrate, mesylate, and citrate, bis-mesylate salts are crystalline in nature.
[0231] The malate and lactate salts can be considered non-hygroscopic thus minimizing the risk of chemical instability. The lactate salt shows good processability characteristics and is suitable for the development of tablets.
Assay Procedures . In vitro kinase assays for receptor tyrosine kinases :
[0232] The kinase activity of various protein tyrosine kinases can be measured by providing ATP and a suitable peptide or protein tyrosine-containing substrate, and assaying the transfer of phosphate moiety to the tyrosine residue. Recombinant proteins corresponding to the cytoplasmic domains of the flt-1 (VEGFR1), KDR (VEGFR2), PDGF, and bFGF receptors were expressed in Sf9 insect cells using a
Baculovirus expression system (InVitrogen) and purified via Glu antibody interaction (for Glu-epitope tagged constructs) or by Metal Ion Chromatography (for Hise (SEQ
ID NO: 1) tagged constructs). For each assay, test compounds were serially diluted in DMSO then mixed with an appropriate kinase reaction buffer plus ATP. Kinase protein and an appropriate biotinylated peptide substrate were added to give a final volume of 100 pL, reactions were incubated for 1-2 hours at room temperature and stopped by the addition of 50 uL of 45 mM EDTA, 50 mM Hepes pH 7.5. Stopped reaction mix (75 pL) was transferred to a streptavidin coated microtiter plate (Boehringer Mannheim) and incubated for 1 hour. Phosphorylated peptide product was measured with the DELFIA time-resolved fluorescence system (Wallac), using a
Eu-labeled anti-phosphotyrosine antibody PT66 with the modification that the
DELFIA assay buffer was supplemented with 1 mM MgCl, for the antibody dilution.
Time resolved fluorescence was read on a Wallac 1232 DELFIA fluorometer. The concentration of each compound for 50% inhibition (ICsy) was calculated by non- linear regression using XL Fit data analysis software.
[0233] Flt-1, KDR, PDGF, ¢-KIT, FLT-3 and bFGFR kinases were assayed in 50 mM Hepes pH 7.0, 2 mM MgCl, 10 mM MnCl; 1 mM NaF, 1 mM DTT, 1 mg/mL BSA, 2 uM ATP, and 0.42 pM biotin-GGGGQDGKDYIVLPI-NH, (SEQ ID
NO: 2). Flt-1, KDR, and bFGFR kinases were added at 0.1 pg/mL, 0.05 pg/mL, or 0.1 pg/mL respectively,
Example 1-Inhibition of CSF-1 mediated growth by 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one
[0234] The antiproliferative activity of 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl}-1H-quinolin-2-one was shown to inhibit CSF-1 (Colony Stimulating Factor-1) mediated proliferation of M-NFS-60 cells (mouse myeloblast cell line) with an ECs of 300 nM. The assay was run by plating 5000 cells/well in 50 uL assay media (growth media without 67.1 ng/ml GM-
CSF: RPMI-1640+10% FBS+0.044 mM beta Mercaptoethanol+2 mM L-
Glut+Pen/Strep) in a 96 well plate. Serially-diluted 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-y1]-1H-quinolin-2-one in a DMSO stock solution starting at 20 uM was added to the plate in 50 pL assay media containing
CSF-1 to make a final concentration of 10 ng/ml and then incubated for 72 hours at 37°C and 5% CQ,. The final DMSO concentration was 0.2%. After 72 hours of incubation, 100 pL of Cell Titer Glo (Promega #G755B) was added to the plate and, after shaking and a 10 minute incubation time, the luminescence was measured. The
ECs was calculated using nonlinear regression.
[0235] Autophosphorylation of CSFR1 is inhibited by 4-amino-5-fluoro-3-[6- (4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one with concentrations < 1 uM. Treatment of M-NFS-60 cells with 4-amino-5-fluoro-3-{6-(4- methyipiperazin-i-yi)- iH-benzimidazoi-2-yi]j-1H-quinolin-2-oie and treatment of the cells with CSF-1 for 5 minutes at the end of the incubation time, resulted in inhibition of receptor tyrosine phosphorylation detected by immunoprecipitation of CSFR1 and western blotting with an anti-phosphotyrosine antibody.
Example 2-Inhibition of FGFR3 by 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1- yD-1H-benzimidazol-2-yl]-1H-quinolin-2-one
[0236] The t(4;14) translocation that occurs uniquely in a subset (15-20%) of multiple myeloma (MM) patients results in the ectopic expression of the receptor tyrosine kinase (RTK), FGFR3. The subsequent acquisition of FGFR3 activating mutations in some MM is associated with disease progression and is strongly transforming in experimental models.
[0237] 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- . yl]-1H-quinolin-2-one inhibited proliferation of OPM-2 cells that express constitutively activated FGFR3 due to a K650E mutation with an ECso of 100 nM.
The assay was run by plating 8000 cells/well in 50 pL assay media (RPMI- 1640+10%FBS+Pen/Strep) in a 96 well plate. Serially-diluted 4-amino-5-fluoro-3-[6- (4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one in 2 DMSO stock solution starting at 20 uM was added to the plate in 50 uL assay media and then incubated for 72 hours at 37C and 5% CO,. The final DMSO concentration was 0.2%. After 72 hours of incubation, 100 pL of Cell Titer Glo (Promega #G755B) was added to the plate and, after shaking and a 10 minute incubation time, the luminescence was read. The ECs was calculated using nonlinear regression. The
ECs, for 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H- quinolin-2-one in the H929 cell line (IMDM+10%FBS+Pen/Strep) that expresses WT
FGFR3 receptor was 0.63 pM. The ECs was determined as described above using assay media that contained 50 ng/ml aFGF, 10 pg/ml Heparin and 1% FBS). The
ECs was calculated using nonlinear regression from the ODs at 490 nm which were determined after adding MTS tetrazolium reagent (Promega) for 4 hous.
[0238] Significant apoptosis was seen after 6 days of treatment of OPM-2 cells with 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]- 1H-quinolin-2-one (>60% of the cells were AnnexinV positive using the protocol and instrument from Guava Technologies for detection of Annexin V positive cells).
[0239] The phosphorylation of downstream signaling component ERK was completely inhibited after incubation of OPM-2 cells with 0.1 pM of 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one.
Western blotting was used to show inhibition of ERK phosphorylation.
Example 3-Inhibition of C-Met by 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1- yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one
[0240] 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]-1H-quinolin-2-one inhibited c-MET with an ICsp>3 pM. The kinase activity of c-
MET was measured by providing ATP at a final concentration of 25 uM and 10 nM of the ¢-MET enzyme (Upstate#14-526) in the presence of 1 uM biotinylated substrate (KKKSPGEYVNIEFG (SEQ ID NO: 3)). Substrate bound to Streptavidin plates was detected with Europium labeled antiphosphotyrosine Antibody PT66.
Phosphorylated peptide substrate was measured with the DELPHIA time resolved fluorescence system, and the ICso was calculated employing non-linear regression using XL Fit data analysis software. C-MET was constitutively activated in
KM12L4A cells which is one of the most sensitive cell lines with respect to inhibition of proliferation by 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol- 2-yl]-1H-quinolin-2-one (ECsp20 nM). This suggests that 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-y1)-1H-benzimidazol-2-yl]-1H-quinolin-2-one either inhibits mutated c-MET or a kinase in the downstream signaling pathway of c-MET.
[0241] Each of the following compounds was synthesized and assayed using the procedures described above, or those described in U.S. Patent No. 6,605,617. which is hereby incorporated by reference in its entirety as if fully set forth herein:
Table 7. Example Compounds
Example Name LC/MS m/z
ES ES SU (10 ME 4-amino-3-{5-[(3S)-3-(dimethylamino)pyrrolidin-1- 389.4 1 lyl]-1H-benzimidazol-2-yl}quinolin-2(1H)-one 4-[(38)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 420. 2 benzimidazol-2-yl)-6-chloroquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 420 3 benzimidazol-2-yl)-6-chloroquinolin-2(1 H)-one 3-(1H-benzimidazol-2-yl)-4-[(3R)-3- 374.2 4 (dimethylamino)pyrrolidin-1-yl]quinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-6-chloro-4-[(3R)-3- 408.1 (dimethylamino)pyrrolidin-1-yllquinolin-2(1H)-one 4-amino-3-[5-(4-ethylpiperazin-1-yl)-1H- 403.2 benzimidazol-2-yI]-1-methylquinolin-2(1H)-one 4-amino-3-(6-piperazin-1-yl-1H-benzimidazol-2- 361.2 7 yDquinolin-2(1H)-one 4-amino-3-[6-(pyridin-4-ylmethyl)-1H- 368.2 benzimidazol-2-yljquinolin-2(1H)-one
4-amino-3-{5-[(3R,5S)-3,5-dimethylpiperazin-1- 389.4 y1}-1H-benzimidazol-2-yl} quinolin-2(1H)-one 4-amino-3-[5-(4-methylpiperazin-1-yl)-1H- 375.2 benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-3-(6-methyl-S-morpholin-4-yl-1H- 376 11 benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-3-{5-[(1-methylpiperidin-3-yloxy]-1H- 390.1 12 benzimidazol-2-yl}quinolin-2(1H)-one 4-amino-3-{5-[(2R,6S)-2,6-dimethylmorpholin-4- 408.2 yl]-6-fluoro-1H-benzimidazol-2-y1} quinolin-2(1 H)- 13 one 4-amino-3-{5-[(1-methylpyrrolidin-3-yl)oxy]-1H- 376.2 14 benzimidazol-2-y1}quinolin-2(1H)-one 4-amino-3-[5-(4-methyl-1,4-diazepan-1-y1)-1H- 389.2 benzimidazol-2-yl}quinolin-2(1H)-one 4-amino-3-{5-[(3R)-3-(dimethylamino)pyrrolidin- 389.2 16 1-y1]-1H-benzimidazol-2-yl} quinolin-2(1H)-one 4-amino-6-chloro-3-{5-[(3R)-3- 423 (dimethylamino)pyrrolidin-1-yl]-1H-benzimidazol- 17 2-y1}quinolin-2(1H)-one ethyl {4-[2-(4-amino-2-oxo-1,2-dihydroquinolin-3- 4472 18 y1)-1H-benzimidazol-6-yl]piperazin-1-yl} acetate 4-amino-3-{6-[methyl(1-methylpiperidin-4- 403.1 ylamino]-1H-benzimidazol-2-yl}quinolin-2(1H)- 19 one 3-[6-(4-acetylpiperazin-1-yl)-1H-benzimidazol-2- 403.3 yl]-4-aminoquinolin-2(1H)-one 4-amino-3-[6-(1,4"-bipiperidin-1'-yl)-1H- 443.3 21 benzimidazol-2-yllquinolin-2(1H)-one - 2-(4-amino-2-oxo-1,2-dihydroquinolin-3-yl)-1H- 321.2 22 benzimidazole-6-carboxylic acid 4-amino-5-(methyloxy)-3-[6-(4-methylpiperazin-1- 405.3 23 yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one : . 4-amino-3-{6-[4<(1-methylethyl)piperazin-1-yl]- 403.3 24 1H-benzimidazol-2-yl}quinolin-2(1H)-one {4-[2-(4-amino-2-0x0-1,2-dihydroquinolin-3-yI)- 419.2 1H-benzimidazol-6-yl]piperazin-1-yl}acetic acid 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H- 386.1 26 benzimidazol-2-yl)quinolin-2(1H)-one {4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H- 386.1 27 benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-3-[5-(4-ethylpiperazin-1-yl)-1H- 389.1 28 benzimidazol-2-yl]quinolin-2(1H)-one
4-amino-3-(5-{(28,5 S)-2-{(dimethylamino)methyl}- 433.3 5-methylmorpholin-4-yl}-1H-benzimidazol-2-
29 yl)quinolin-2(1H)-one 4-amino-6-chloro-3-[5-(4-methylpiperazin-1-yl)- 409.2 1H-benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-6-chloro-3-{5-[(3S)-3- 423.1 (dimethylamino)pyrrolidin-1-y1]-1H-benzimidazol- 31 2-yl}quinolin-2(1H)-one 4-amino-5,6-dichloro-3-{5-[(3S)-3- 457.2 (dimethylamino)pyrrolidin-1-yl]-1H-benzimidazol- 32 2-yl}quinolin-2(1H)-one 4-amino-5,6-dichloro-3-[5-(4-methylpiperazin-1- 443.2 33 y1)-1H-benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-y1)-6-[(pyridin-2- 384.2 34 ylmethyl)oxy]quinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-y1)-6-[(2R,6S)-2,6- 390.1 dimethylmorpholin-4-yllquinolin-2(1 H)-one 4-amino-3-(1H-benzimidazol-2-yl)-6-morpholin-4- 362.2 36 ylquinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-y1)-5-[(1- 390.2 37 methylpiperidin-3-yl)oxy]quinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-y1)-5-[(pyridin-2- 384.1 ylmethyl)oxylquinolin-2(iH)-one 4-amino-3-(5-morpholin-4-yl-1H-benzimidazol-2- 469.2 39 y1)-5-[(pyridin-4-ylmethyl)oxy]quinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-yl)-5- 307.1 (methyloxy)quinolin-2(1H)-one - 4-amino-3-(5-methyl-1H-benzimidazol-2-y1)-5- 321.1 41 (methyloxy)quinolin-2(1H)-one 4-amino-3-{5-[(2R,6S)-2,6-dimethylmorpholin-4- 420.2 yl}-1H-benzimidazol-2-y1}-5-(methyloxy)quinolin- 42 2(1H)-one . 4-amino-3-(1H-benzimidazol-2-yl)-5-morpholin-4- 362.2 43 ylquinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-y})-5-[(2R,68)-2,6- 390.2 44 dimethylmorpholin-4-yl]quinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-yl)-5-(4- 375.1 methylpiperazin-1-yl)quinolin-2(1H)-one 4-amino-5,6-dichloro-3-(5-morpholin-4-yl-1H- 430 : 46 |benzimidazol-2-yI)quinolin-2(1H)-one 3-{5-[(2-morpholin-4-ylethyl)oxy]-1H- 391.3 47 benzimidazol-2-yl}quinolin-2(1H)-one 4-amino-3-{5-[(3-pyrrolidin-1-ylpropyloxy]-1H- benzimidazol-2-yl}quinolin-2(1 H)-one - 1] 97
4-amino-3-{5-[(3-morpholin-4-ylpropyDoxy]-1H- 420.4 benzimidazol-2-yl}quinolin-2(1H)-one 4-amino-6-fluoro-3-(5-morpholin-4-yl-1H- 380. benzimidazol-2-yl)quinolin-2(1 H)-one 4-amino-3-{5-[3-(dimethylamino)pyrrolidin-1-y1]- 407
51 1H-benzimidazol-2-yl}-6-fluoroquinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-yI)-6- 295 52 fluoroquinolin-2(1H)-one 4-amino-3-(6-fluoro-5-morpholin-4-yl-1H- 380 53 benzimidazol-2-yl)quinolin-2(1H)-one : 4-amino-3-{5-[(tetrahydrofuran-2-ylmethyloxy]- 377 54 1H-benzimidazol-2-yl}quinolin-2(1H)-one 4-amino-6-fluoro-3-(6-fluoro-5-morpholin-4-yl-1H- 398 55 benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-3 ~[6-fluoro-5-(4-methylpiperazin-1-y])- 393 1H-benzimidazol-2-yljquinolin-2(1 H)-one 4-amino-3-(5-{[2-(methyloxy)ethyljoxy}-1H- 351 57 benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-3-[4,6-difluoro-5-(4-methylpiperazin-1- 411 58 yl)-1H-benzimidazol-2-yl] quinolin-2(1H)-one 4-amino-3-{5-[3-(dimethylamino)pyrrolidin-1-y1}- 407.1 59 1 H-benzimidazol-2-yl}-5-fluoroquinolin-2(1 H)-one 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yi)- 393.1 1H-benzimidazol-2-yllquinolin-2(1H)-one 4-amino-5-chloro-3-[5-(4-methylpiperazin-1-yI)- 409.1 : 61 1H-benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-3-{5-[3-(dimethylamino)pyrrolidin-1-yI}- 407.1 62 6-fluoro-1H-benzimidazol-2-y1} quinolin-2(1H)-one 4-amino-5-chloro-3-{5-3- 423.1 : (dimethylamino)pyrrolidin-1-y1}-1H-benzimidazol- 63 2-y1}quinolin-2(1H)-one 4-amino-6-chloro-3-{5-[3- 441 (dimethylamino)pyrrolidin-1-yt]-6-fluoro-1H- benzimidazol-2-yl}quinolin-2(1 H)-one 4-amino-5-[(2R,6S)-2,6-dimethylmorpholin-4-y1]- 391.2 3-(3H-imidazo[4,5-b]pyridin-2-y)quinolin-2(1H)- 65 one 4-amino-3-(6-thiomorpholin-4-y}-1H-benzimidazol- 378.4 2-yDquinolin-2(1H)-one 4-amino-3-[5 “(4-cyclohexylpiperazin-1-yl)-1H- } 4431 pu benzimidazol-2-yl]quinolin-2(1H)-one
~ |4-amino-3-{6-[3-(diethylamino)pyrrolidin-1-yl]- 417.1 6 1H-benzimidazol-2-y1}quinolin-2(1H)-one 4-amino-3-[6-(4-pyridin-2-ylpiperazin-1-yl)-1H- 438.3 benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-3-[5-(4-methylpiperazin-1-yl)-3H- 376.3
7 imidazo[4,5-b]pyridin-2-yl]quinolin-2(1H)-one 4-amino-6-chloro-3-[5-(4-methylpiperazin-1-y)- 410.2
7 1H-imidazo[4,5-b]pyridin-2-y1]quinolin-2(1H)-one 2-(4-amino-2-oxo-1,2-dihydroquinolin-3-yl)-N- 431.3 methyl-N-(1-methylpiperidin-4-yl)-1H-
72 benzimidazole-5-carboxamide 4-amino-3-(5-{[4-(1-methylethyl)piperazin-1- 431.3 yl]carbonyl}-1H-benzimidazol-2-yl)quinolin-
73 2(1H)-one : 4-amino-3-[5-(4-methylpiperazin-1-yl)-1H- 420.2
” benzimidazol-2-y1]}-6-nitroquinolin-2(1H)-one 4-amino-3-[5-(1,4'-bipiperidin-1'-ylcarbonyl)-1H- 471.1
75 benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-3-{5-[(4-methylpiperazin-1-yl)carbonyl}- 403.3
76 1H-benzimidazol-2-yl}quinolin-2(1H)-one 4-amino-3-[5-(1-oxidothiomorpholin-4-y1)-1H- - benzimidazol-2-yl]quinolin-2(1H)-one 3-{5-[(4-acetylpiperazin-1-yl)carbonyl]-1H- 431.3 18 benzimidazoi-2-yi}-4-aminoquinolin-2(1H)-oie 4-amino-3-(5-{[(3R)-3-(dimethylamino)pyrrolidin- 4174 1-yl]carbony1}-1H-benzimidazol-2-yl)quinolin- 79 2(1H)-one 4-amino-3-(5-{[(3S)-3-(dimethylamino)pyrrolidin- 4174 : 1-yl]carbonyl}-1H-benzimidazol-2-yl)quinolin- 2(1H)-one 4-amino-3-(5-{[4-(dimethylamino)piperidin-1- 431.4 yl]carbonyl}-1H-benzimidazol-2-yl)quinolin- 81 2(1H)-one methyl 2-(4-amino-5-flucro-2-0x0-1,2- 353.2 dihydroquinolin-3-yl)-1H-benzimidazole-6- 82 carboxylate 4-amino-3-[5-(1,3"-bipyrrolidin-1'-yl)-1H- 415.5 benzimidazol-2-yl]quinolin-2(1H)-one
4-amino-3 -[5-(pyridin-3-yloxy)-1H-benzimidazol- 370.2 } 84 2-yl]quinolin-2(1H)-one 4-amino-5,6-bis(methyloxy)-3-[5-(4- 435.5 methylpiperazin-1 -yl)-1H-benzimidazol-2- yllquinolin-2(1H)-one 2-(4-amino-2-oxo-1,2-dihydroquinolin-3 -yD)-N-[2- 405.3 (dimethylamino)ethyl]-N-methyl-1 H- benzimidazole-5-carboxamide 2-(4-amino-2-oxo-1 ,2-dihydroquinolin-3-yl)-N- 417.2 methyl-N-(1-methylpyrrolidin-3 -yl)-1H-
87 benzimidazole-5-carboxamide 4-amino-3-{5-[(5-methyl-2,5- 415.2 diazabicyclo[2.2. 1Jhept-2-yl)carbonyl]-1H-
88 benzimidazol-2-yl} quinolin-2(1H)-one 4-amino-3-{5-{(4-cyclohexylpiperazin-1- 471.6 yl)carbonyl]-1H-benzimidazol-2-yl} quinolin- 2(1H)-one 4-amino-3-{5-[(2-piperidin-1-ylethyl)amino]-1H- 403.2 : benzimidazol-2-yl} quinolin-2(1H)-one ethyl 4-{[2-(4-amino-2-0x0-1 ,2-dihydroquinolin-3- 4473 yl)-1H-benzimidazol-5-yl] amino }piperidine-1-
91 carboxylate
4-amino-3-[5-({(SR)-5- 405.2 [(methyloxy)methyllpyrrolidin-3 -yl}amino)-1H-
92 benzimidazo!-2-yt]quinolin-2(1H)-one 4-amino-3-{5-[(pyridin-2-ylmethyl)amino}-1H- 383.3
03 benzimidazol-2-yl}quinolin-2(1H)-one
4-amino-3-{5-(piperidin-3-ylaminc)-1H- , 375.2 ot benzimidazol-2-yljquinolin-2(1H)-one 4-amino-5-fluoro-3-{5-[(pyridin-2- 401.3 ylmethyl)amino]-1H-benzimidazol-2-yl} quinolin- 95 2(1H)-one ethyl 4-{[2-(4-amino-5-fluors-2-oxo-1,2~ 465.5 dihydroquinolin-3-yl)-1H-benzimidazol-5- yl]Jamino} piperidine-1-carboxylate 4-amino-5-fluoro-3-[5-(piperidin-3-ylamino)-1H- 393.3 97 benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-y1)-6- 3571 bromoquinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-yl)-7- 357.1 bromogquinolin-2(1H)-one
4-amino-3-(5-bromo-1H-benzimidazol-2- 357.1 yhquinolin-2(1H)-one 100 :
N,N-dimethyl-2-(2-oxo-1,2-dihydroquinolin-3-yI)- 333.1 101 1H-benzimidazole-5-carboxamide 4-amino-3-(5-thien-2-yl-1H-benzimidazol-2- 359.2
Dquinolin-2(1H)-one we )q ( 2-(4-amino-2-oxo-1,2-dihydroquinolin-3-y1)-N,N- 384.1 103 dimethyl-1H-benzimidazole-5-sulfonamide 4.amino-6-iodo-3-[5-(4-methylpiperazin-1-yl)-1H- 501.1 104 benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-3-(5-{2-[(dimethylamino)methyl]- 419.2 morpholin-4-yl} -1H-benzimidazol-2-yl)quinolin- . 105 2(1H)-one : 4{(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 547 benzimidazol-2-yI)-7-chloro-6-iodoquinolin-2(1H)- 106 one : 4-[(3R)-1 -azabicyclo[2.2.2]oct-3~ylamino]-3-(1H- 431 107 benzimidazol-2-yl)-6-nitroquinolin-2(1H)-one 4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 401 108 benzimidazol-2-y1)-6-methylquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3 -(1H- 422 109 benzimidazol-2-yl)-6,7-difluoroquinolin-2(1H)-one 4-[(3S)-1-azabicyclo [2.2.2]oct-3-ylamino]-3-(1H- 421 110 benzimidazol-2-yl)-7-chloroquinolin-2(1H)-one . 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 465 111 benzimidazoi-2-yi)-6-bromoquiiolin-2(1 H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 411 benzimidazol-2-y1)-2-0xo-1,2-dihydroquinoline-6- 112 carbonitrile 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino}-3-(1H- 404 113 benzimidazol-2-yl)-6-fluoroquinolin-2(1H)-one 4-[(38)-1-azabicyclo[2.2.2]oct-3-ylamino]-3(1H- 447 benzimidazol-2-y1)-6,7-bis(methyloxy)quinolin- 114 2(1H)-one 4-[(3R)-1-azabicyelo[2.2.2]oct-3-ylamino]}-3-(1H- 455 115 benzimidazol-2-yl)-6,7-dichloroquinolin-2(1H)-one 11-[4-[(3S)-1-azabicyclo[2.2.2]Joct-3-ylamino}-3- 531 : (1H-benzimidazol-2-y1)-6-fluoro-2-oxo-1,2- 116 dihydroquinolin-7-yl]piperidine-4-carboxamide
4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino}-3 -(1H- 478 benzimidazol-2-yl)-6-fluoro-7-{(3-
117 hydroxypropyl)amino]quinolin-2(1 H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3 -ylamino}-3-(1H- 448 benzimidazol-2-yI)-7-(dimethylamino)-6-
118 fluoroquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 404
119 benzimidazol-2-y1)-5-flucroquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 508 benzimidazol-2-y1)-6-(4-nitrophenylquinolin-
120 2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- benzimidazol-2-yl)-7-{[2- (dimethylamino)ethy!]amino}-6-fluoroquinolin-
121 2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 471 benzimidazol-2-yl)-6-fluoro-7-(1H-imidazol-1-
122 yl)quinolin-2(1H)-one
: 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3(1H- 493 benzimidazol-2-yl)-6-[4-
123 (methyloxy)phenyl]quinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H- 490 benzimidazol-2-y1)-6-fluoro-7-morpholin-4-
124 ylquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-6,7- 423 difluoro-3-(3H-imidazo[4,5-b]pyridin-2-
125 yI)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 508 benzimidazol-2-y1)-6-(3-nitrophenyl)quinolin-
x 126 |2(1H)-one 1-[4-[(38)-1-azabicyclo[2.2.2] oct-3-ylamino] -3- 531 (1H-benzimidazol-2-yI)-6-fluoro-2-0xo0-1,2-
127 |dihydroquinolin-7-yl}piperidine-3-carboxamide 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H-
128 benzimidazol-2-yI)-5-methylquinolin-2(1H)-one 6-(3-acetylphenyl)-4-[(3R)-1-azabicyclo[2.2.2]oct- 506 3-ylamino}-3-(3H-imidazo[4,5-b]pyridin-2-
129 yl)quinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 421
: 130 benzimidazol-2-yl)-5-chloroquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-6- 491 {fluoro-3-(3H-imidazo[4,5-b]pyridin-2-yl)-7-
131 morpholin-4-ylquinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 460 benzimidazol-2-yI)-7-(cyclopropylamino)-6-
132 fluoroquinolin-2(1H)-one
N-{3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3- 521 (3H-imidazo[4,5-b]pyridin-2-y1)-2-ox0-1,2-
133 dihydroquinolin-6-yI]phenyl} acetamide 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 503 benzimidazol-2-yI)-6-fluoro-7-(4-methylpiperazin-
134 1-yDquinolin-2(1H)-one
4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-6- 472 fluoro-7-(1H-imidazol-1-y1)-3-(3H-imidazo[4,5-
135 b]pyridin-2-yl)quinolin-2(1H)-one 4-[(38)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 525 benzimidazol-2-y1)-6-fluoro-7-[(2-pyridin-2-
136 ylethyl)amino]quinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3~(1H- 488 benzimidazol-2-yl)-6-fluoro-7-piperidin-1-
137 ylquinolin-2(1H)-one 6-chloro-3-(3H-imidazo[4,5-b]pyridin-2- 298
138 yl)quinolin-2(1H)-one ethyl 1-[4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]- © 560 3-(1H-benzimidazol-2-yl)-6-fluoro-2-oxo-1,2-
139 dihydroquinolin-7-yl]piperidine-4-carboxylate 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H- 519 benzimidazol-2-y1)-6-(1-benzothien-2-yl)quinolin-
. 140 2(1H)-one 4-[(3S)-1-azabicyclof2.2.2]oct-3-ylamino]-3-(1H- 474 benzimidazol-2-yl)-6-fluoro-7-pyrrolidin-1- : 141 ylquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(3H- 532 imidazo[4,5-b]pyridin-2-yI)-6-[2-
142 (trifluoromethy)phenyli]quinolin-2(1H)-one 4-[(3R)-1-azabicyclol2.2 2loct-3-ylaminel-3-(3H- 404 imidazo[4,5-b]pyridin-2-y1)-6-[2-
143 (methyloxy)phenyljquinolin-2(1H)-one ethyl 1-[4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]- 560 3-(1H-benzimidazo!-2-yI)-6-fluoro-2-oxo0-1,2-
144 dihydroquinolin-7-yl]piperidine-3-carboxylate 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 491 benzimidazol-2-yl)-6-(4-ethylphenyl)quinolin~
145 2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H- 476 benzimidazol-2-yl)-6-fluoro-7-[(2-
146 methylpropyl)amino]quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]Joct-3-ylamino}-3-(1H- 401
147 benzimidazol-2-yl)-5-methylquinolin-2(1 H)-one
4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-6-(2,4- 532 dichlorophenyl)-3-(3H-imidazo[4,5-b]pyridin-2- 148 [yDquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H- 531 benzimidazol-2-yl)-6-[3- 149 (trifluoromethyl)phenyl]quinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-4- 305 150 (dimethylamino)quinolin-2(1H)-one 4-hydroxy-3-(1H-imidazo[4,5-flquinolin-2- 329 151 yl)quinolin-2(1H)-one 4-hydroxy-3-(1H-imidazo[4,5-b]pyridin-2- 279 152 yl)quinolin-2(1H)-one 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3- 525 (1H-benzimidazol-2-yI)-5-fluoro-2-0xo0-1,2- 153 dihydroquinolin-6-yl]benzoic acid 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3 ~ylamino}-3- 524 (1H-benzimidazol-2-y1)-5-fluoro-2-oxo-1,2- 154 dihydroquinolin-6-ylJbenzamide
N-{3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3- 538 (1H-benzimidazol-2-y1)-5-fluoro-2-oxo-1,2- 155 dihydroquinolin-6-yl]phenyl} acetamide 3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3~ 525 (1H-benzimidazol-2-yl)-5-fluoro-2-0x0-1,2- 156 dihydroquinolin-6-yI]benzoic acid . 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3- 525 (1H-benzimidazol-2-yl)-7-fluoro-2-oxo-1,2- 157 dihydroquinolin-6-ylJbenzoic acid
N-{3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3- 538 (1H-benzimidazol-2-y)-7-fluoro-2-oxo-1,2- 158 dihydroquinolin-6-yijphenyi} aceiamide 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- S11 benzimidazol-2-y1)-7-chloro-6-(2- 159 methylphenyl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 411 benzimidazol-2-yI)-2-0xo-1,2-dihydroquinoline-7- 160 carbonitrile 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 417 benzimidazol-2-yl)-7-(methyloxy)quinotin-2(1H)- 161 one 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3- 506 (1H-benzimidazol-2-yl)-2-ox0-1,2-dihydroquinolin- 162 7-yl]benzamide 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 434 benzimidazol-2-y1)-6-fluoro-7- 163 (methyloxy)quinolin-2(1H)-one
4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H- 464 benzimidazol-2-yl)-6-chloro-7- :
164 (dimethylamino)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H- 555 benzimidazol-2-yl)-7-(dimethylamino)-6- a
165 iodoquinolin-2(1H)-one 3-[4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3- 573 (1H-benzimidazol-2-y1)-7-(1H-imidazol-1-y1)-2- oxo-1,2-dihydroquinolin-6-y]]benzoic acid 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3- (1H-benzimidazol-2-y1)-2-oxo-7-piperidin-1-yl-1,2-
167 dihydroquinolin-6-yl]benzoic acid 4-{(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 571 benzimidazol-2-yl)-7-(methyloxy)-6-[4-
168 (methylsulfonyl)phenyl]quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 401
169 benzimidazol-2-yl)-8-methylquinolin-2(1H)-one 4-[(38)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 422
170 benzimidazol-2-yl)-6,7-difluoroquinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-6-methyl-4-(piperidin-3- 374
171 ylamino)quinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2)oct-3-ylamino]}-3-(1H- 493 benzimidazol-2-yl)-6-[2-
172 (methyloxy)phenyl]lquinolin-2(1H)-one } 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 493 benzimidazol-2-yl)-6-[3- :
173 (methyloxy)phenyl]quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6,7-difluoro-4-(piperidin-
174 4-ylamino)quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6,7-difluoro-4- 382
175 (pyrrolidin-3-ylamino)quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-[(3- 439
176 morpholin-4-ylpropyl)amino]quinolin-2(1H)-one
} 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2- 480
177 y1)-4-(piperidin-4-ylamino)quinolin-2(1H)-one g 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2- 494 y1)-4-[(piperidin-2-ylmethyl)amino}quinolin-2(1H)-
178 one 4-[(38)-1-azabicyclo[2.2.2]oct-3-ylamino]-6-' 506 chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2-
179 |yDquinolin-2(1H)-one 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2- 480 y1)-4-(piperidin-3-ylamino)quinolin-2(1H)-one
6-chloro-4-{[2-(dimethylamino)ethyl]Jamino}-3-(5- 468 morpholin-4-yl-1 H-benzimidazol-2-yl)quinolin-
181 2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino}-6- chloro-3-(5-morpholin-4-y1-1H-benzimidazol-2-
182 yl)quinolin-2(1H)-one 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2- yl)-4-[(piperidin-3 -ylmethyl)amino}quinolin-2(1H)-
183 one 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2- 494 yI)-4-[(piperidin-4-ylmethyl)amino]quinolin-2(1 H)- 184 one 4-{ [(IR,2R)-2-aminocyclohexyl]amino} -6-chloro- 494 3-(5-morpholin-4-yl-1H-benzimidazol-2-
185 yl)quinolin-2(1H)-one 4-[(4-aminocyclohexyl)amino]-6-chloro-3-(5- 494 morpholin-4-yl-1H-benzimidazol-2-yl)quinolin- }
186 2(1H)-one : ) 4-{[(2S)-2-amino-3-methylbutyl] amino }-6-chloro- 482 3-(5-morpholin-4-yl-1H-benzimidazol-2-
187 yl)quinolin-2(1H)-one 4-({[4<(aminomethy])phenyljmethyl} amino)-6- 516 chloro-3-(5-morpholin-4-y}-1H-benzimidazol-2-
188 yl)quinolin-2(1H)-one 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2- 480 ylI)-4-[(pyrrolidin-2-ylmethyl)amino]quinolin- 2(1H)-one
: 4-{[(1R)-1-(aminomethyl)propylJamino}-6-chloro- 468
3-(5-morpholin-4-yl-1H-benzimidazol-2-
190 yl)quinolin-2(1H)-one B
4-{[(1S)-2-amino-1~(phenylmethyl)ethyl]amino}-6- 530 ) chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2-
191 yhquinolin-2(1H)-one 6-chloro-4-{[3-(4-methylpiperazin-1- 537 yDpropyl]amino}-3-(5-morpholin-4-yl-1H-
192 benzimidazol-2-yl)quinolin-2(1H)-one 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2- 570 yI)-4-{[1-(phenylmethyl)piperidin-4-
193 yl]amino}quinolin-2(1H)-one 6-chloro-3-(S-morpholin-4-yl-1H-benzimidazol-2- 524 yl)-4-[(3-morpholin-4-ylpropyl)amino]quinolin-
194 2(1H)-one 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2- yI)-4-[(2-piperidin-1-ylethyl)amino]quinolin-2(1H)-
195 one
6-chloro-3(5-morpholin-4-yl-1H-benzimidazol-2- 488 y1)-4-{(pyridin-3-ylmethyl)amino] quinolin-2(1H)-
196 one 6-chloro-4-{[3-(1 H-imidazol-1-yl)propylJamino}-3- : (5-morpholin-4-yl-1H-benzimidazo}-2-yl)quinolin-
197 2(1H)-one 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2- 488 y)-4-[(pyridin-4-ylmethyl)amino]quinolin-2(1H)-
198 one 6-chloro-4-{[2-(methylamino)ethyljamino}-3-(5- 454 morpholin-4-yl-1H-benzimidazol-2-yl)quinolin-
199 2(1H)-one 6-chloro-4-{[(2-methyl-1-piperidin-4-y1-1H- 624 benzimidazol-5-yl)methyl]amino}-3-(5-morpholin-
200 4-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2- 494 yl)-4-[(2-pyrrolidin-1 -ylethyl)amino]quinolin-
201 2(1H)-one 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2-
202 yl)-4-(pyrrolidin-3-ylamino)quinolin-2(1 H)-one 4-{[(1 R,2R)-2-aminocyclohexylJamino}-6-chloro- 507 3-[5-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-
203 yl]quinolin-2(1H)-one 4-[(4-aminocyclohexyl)amino]-6-chloro-3-[5-(4- 507 methylpiperazin-1-yl)-1H-benzimidazol-2-
204 yllquinolin-2(1H)-one 4~({[4-(aminomethyl)phenyl]methyl}amino)-6- 529 chloro-3-[5-(4-methylpiperazin-1-yl)-1H-
205 benzimidazol-2-yl]quinolin-2(1H)-one §-chloro-4-{[2-(methylamino)ethyllamino}-3-[5-(4- 467 methylpiperazin-1-y1)-1H-benzimidazol-2-
206 [yllquinolin-2(1H)-one ’ 6-chloro-3-[5~(4-methylpiperazin-1-y1)-1H- . 550 benzimidazol-2-yl]-4-{[3-(4-methylpiperazin-1-
207 yl)propyl]amino} quinolin-2(1H)-one } 6-chloro-3-[5-(4-methylpiperazin-1-yl)-1H- 583 benzimidazol-2-yl]-4-{[1-(phenylmethyl)piperidin-
208 4-ylJamino }quinolin-2(1H)-one 6-chloro-3-[5-(4-methylpiperazin-1-y})-1H- 507 benzimidazol-2-yI]-4-[(2-pyrrolidin-1-
ylethyl)amino]quinolin-2(1H)-one 6-chloro-3-[5-(4-methylpiperazin-1-yl)-1H- i 479 benzimidazol-2-yl]-4-(pyrrolidin-3-
210 |ylamino)quinolin-2(1H)-one
6-chloro-3-[5-(4-methylpiperazin-1-yl)-1H- 493 benzimidazol-2-y1}-4-(piperidin-4- 211 ylamino)quinolin-2(1H)-one 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2- y1)-4-{(2-piperidin-2-ylethyl)amino]quinolin-2(1H)- 212 one 4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-7- 506 chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2~ 213 |yDquinolin-2(1H)-one 7-chloro-3-(S-morpholin-4-yl-1H-benzimidazol-2- 480 214 y1)-4-(piperidin-3-ylamino)quinolin-2(1H)-one 6-chloro-3-[5-(4-methylpiperazin-1-y1)-1H- 507 benzimidazol-2-yi]-4-[(piperidin-2- 215 ylmethyl)amino]quinolin-2(1H)-one 6-chloro-3-[5-(4-methylpiperazin-1-y1)-1H- 493 benzimidazol-2-y1}-4-{[(2S)-pyrrolidin-2- 216 ylmethyl}amino}quinolin-2(1H)-one 6-chloro-3-[S-(4-methylpiperazin-1-yl)-1H- 493 benzimidazo!-2-yl]-4-{[(2R)-pyrrolidin-2- 217 ylmethyl]Jamino} quinolin-2(1H)-one 6-chloro-4-({[(2S)-1-ethylpyrrolidin-2- 521 yljmethyl}amino)-3-[5-(4-methylpiperazin-1-y1)- 218 1H-benzimidazol-2-yl]quinolin-2(1H)-one 6-chloro-4-({[(2R)-1-ethylpyrrolidin-2- 521 ylJmethyl}amino)-3 -[5-(4-methylpiperazin-1-yD)- 219 1H-benzimidazol-2-yl}quinolin-2(1H)-one 4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 493 : benzimidazol-2-y1)-6-[4- 220 (methyloxy)phenyl]quinolin-2(1H)-one 6-(3-aminophenyN)-4.[(38)-1-azabicyclo[2.2.2]oct- 478 3-ylamino}-3-(1H-benzimidazol-2-yl)quinolin- 221 2(1H)-one
Table 8. Additional Example Compounds
Example Name : LC/MS m/z 4-amino-3-(1H-benzimidazol-2-yl)quinolin-2(1H)-one 271.3 4-amino-3-(1H-benzimidazol-2-yl)-6,7-dimethoxyquinolin-2(1H)- 337.3 223 one 3-(1H-benzimidazol-2-y1)-4-(dimethylamino)-1 -methylquinolin- 319.4 224 2(1H)-one 3-(1H-benzimidazol-2-y1)-4-{[2-(dimethylamino)ethyl]amino}-1- 362.4 225 methylquinolin-2(1H)-one
4-amino-3-(1H-benzimidazol-2-yl)-1-methylquinolin-2(1H)-one 291.3 4-amino-3-(6-methyl- 1H-benzimidazol-2-yl)quinolin-2(1H)-one
3-(1H-benzimidazol-2-yl)-4-{[3-(1H-imidazol-1- 385.4 228 yD)propyl]amino}quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-4-[(pyridin-3-ylmethyl)amino]quinolin- 368.4 229 | 2(1H)-one 4-amino-3-(1 H-benzimidazol-2-y1)-5-fluoroquinolin-2(1H)-one 2953 3-(1H-benzimidazol-2-yl)-4-pyrrolidin-1-ylquinolin-2(1H)-one 3314 3-(1H-benzimidazol-2-yl)-4-{(pyridin-4-ylmethyl)amino]quinolin- 368.4 232 2(1H)-one 3-(1H-benzimidazol-2-yl)-4-{[2-(1-methylpyrrolidin-2- 388.5 233 yl)ethylJamino}quinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-yl)-7-methylquinolin-2(1H)-one 4-amino-3-(1 H-benzimidazol-2-yl)-7-chloroquinolin-2(1H)-one 311.7 4-amino-3-(1 H-benzimidazol-2-yl)-6-chloroquinolin-2(1H)-one 311.7 4-amino-3-[6-(3-aminopyrrolidin-1 -yb)-1H-benzimidazol-2- 3614 237 . | yllquinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-4-(diethylamino)quinolin-2(1H)-one 333.4 3-(1H-benzimidazol-2-yl)-4-(1 2-dimethylhydrazino)quinolin-2(1H)- | 3204 239 one 4-amino-3-[5-(trifluoromethy!)-1H-benzimidazol-2-yl]quinolin- 3453 240 2(1H)-one 4-amino-3-(5,6-dichloro-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4-(3-aminopyrrolidin-1 -yl)-3-(5-morpholin-4-yl-1H-benzimidazol-2- 431.5 242 yl)quinolin-2(1H)-one 4-amino-5-fluoro-3-(5-methyl-1H-benzimidazol-2-yl)quinolin-2(1H)- 309.3 243 one . 4-amino-3-(1 H-benzimidazol-2-yl)-6-nitroquinolin-2(1H)-one 322.3 4-amino-3-(4-methyl-1H-benzimidazol-2-yl)quinolin-2(1H)-one 291.3 4-amino-3-(6-ethoxy-1H-benzimidazol-2-yl)quinolin-2(1H)-one 321.4 4-amino-3-(7-hydroxy-1H-benzimidazol-2-y)quinolin-2(1H)-one 4-amino-3-(6-tert-butyl-1H-benzimidazol-2-yl)quinolin-2(1H)-one 333.4 2-(4-amino-2-0xo-1,2-dihydroquinolin-3-yl)-1H-benzimidazole-5- 302.3 249 carbonitrile : 4-amino-3-(5,6-dimethyl-1 H-benzimidazol-2-yl)quinolin-2(1H)-one | 305.4 4-amino-3-(4,5-dimethyl-1H-benzimidazol-2-yl)quinolin-2(1H)}-one | 305.4 4-amino-6-chloro-3-(5-methyl-1H-benzimidazol-2-yl)quinolin- 325.8 252 2(1H)-one 4-amino-3-(1 H-benzimidazol-2-y1)-6,8-dichloroquinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-yl)-5-chloroquiriolin-2(1H)-one 311.7
2-(4-amino-2-o0xo-1,2-dihydroquinolin-3-yl)-N,N-dimethyl-1H- 348.4 255 benzimidazole-5-carboxamide 4-amino-3-{5-[3-(dimethylamino)pyrrolidin-1-yl]-1H-benzimidazol- 389.5 256 2-yl}quinolin-2(1H)-one 4-amino-3-(6-methoxy-5-methyl-1H-benzimidazol-2-yl)quinolin- 321.4 257 2(1H)-one 2-(4-amino-2-oxo-1,2-dihydroquinolin-3-y1)-1H-benzimidazole-6- 319.3 258 carboximidamide 4-amino-7-(3-aminophenyl)-3-(1H-benzimidazol-2-yl)quinolin- 368.4 259 2(1H)-one : 4-amino-3-(1H-benzimidazol-2-yl)-7-thien-2-ylquinolin-2(1H)-one 359.4 4-amino-3-(5-thien-3-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one 359.4 4-amino-3-(1H-benzimidazol-2-yl)-7-thien-3-ylquinolin-2(1H)-one : . 4-{[(1S,2R)-2-aminocyclohexyljamino}-3-(5-morpholin-4-yl-1H- 459.6 263 benzimidazol-2-yl)quinolin-2(1H)-one 4-{[(1R,2R)-2-aminocyclohexylJamino}-3-(5-morpholin-4-yl-1H- 459.6 264 benzimidazol-2-yl)quinolin-2(1H)-one 4-{[(1 S,25)-2-aminocyclohexyl]amino}-3-(S-morpholin-4-yl-1H- 459.6 265 benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-3-{5-[(2R,6S)-2,6-dimethylmorpholin-4-y1]-1H- 390.5 266 benzimidazol-2-yl}quinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-4-morpholin-4-ylquinolin-2(1H)-one 347.4 3-(1H-benzimidazol-2-yl)-4-(piperidin-3-ylamino)quinolin-2(1H)- 360.4 268 one 4-(1-azabicyclo[2.2.2]oct-3-ylamino)-3 -(5-chloro-1H-benzimidazol- 420.9 269 2-yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-6-chloro-3-(5-methyl-1H- 434.9 270 benzimidazol2-yDquinolin-2(1H)-one 6-chloro-3-(5-methyl-1H-benzimidazol-2-y!)-4-(piperidin-3- 408.9 271 ylamino)quinolin-2(1H)-one 3«1 H-benzimidazol-2-yl)-4-[(2-hydroxyethyl)amino]quinolin-2(1H)- 321.4 272 one 3(1H-benzimidazol-2-yl)-6-chloro-4-(piperidin-3 -ylamino)quinolin- 3949 273 2(1H)-one 3-(1H-benzimidazol-2-y1)-6-chloro-4-{[(18)-1- 421.9 274 cyclohexylethyljamino} quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-[(piperidin-3- 408.9 275 ylmethyl)amino]quinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-6-chloro-4-(pyridin-4-ylamino)quinolin- 388.8 276 2(1H)-one ‘ 3-(1H-benzimidazol-2-yl)-6-chloro-4-[(piperidin-4~ 408.9 277 ylmethyl)amino]quinolin-2(1H)-one
3-(1H-benzimidazol-2-yl)-6-chloro-4-[(2-morpholin-4- 424.9 278 ylethyl)amino]quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-(cyclohexylamino)quinolin- 393.9 279 2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-{[3-(1 H-imidazol-1- C4199 280 yDpropyllamino}quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-{[2- 382.9 281 (dimethylamino)ethyl}amino} quinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-6-chloro-4- 407.9 282 [(cyclohexylmethyl)amino]quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-[(tetrahydrofuran-2- 395.9 283 ylmethyl)amino}quinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-6-chloro-4-[(pyridin-4- 402.9 284 ylmethyl)amino]quinolin-2(1H)-one } 3-(1H-benzimidazol-2-y1)-6,7-difluoro-4-(piperidin-3- 285 ylamino)quinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H-benzimidazol-2-y1)- 465.4 286 6-bromoquinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-6-fluoro-4-(piperidin-3-ylamino)quinolin- 378.4 287 2(1H)~one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)- 400.5 288 6-methylquinolin-2(1H)-one 4-[(38)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)- 289 6-fluoroquinolin-2(1F)-one 4-amino-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-y1]-1- 417.5 290 propylquinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-{[(1-ethylpyrrolidin-2- 422.9 yDmethyllamino}quinolin-2(1H)-one 3-(1H-benzimidazoi-2-yi)-6-chioro-4-{{3~(2-oxopyrroiidin-i- 435.5 292 yDpropyl]Jamino} quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-[(piperidin-2- 408.9 293 ylmethyl)amino]quinolin-2(1 H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-(4-methyl-1,4-diazepan-1- 408.9 294 yl)quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-[(pyridin-3- 402.9 295 ylmethyl)amino]quinolin-2(1H)-one 4-anilino-3-(1H-benzimidazol-2-yl)-6-chloroquinolin-2(1H)-one 387.3 3-(1H-benzimidazol-2-yl)-6-chloro-4-{[(5-methylpyrazin-2- 417.9 297 yDmethyljamino}quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-(piperidin-4-ylamino)quinolin- 402.9 298 2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-{[2-(1-methylpyrrolidin-2- 4229 299 yl)ethyl]Jamino}quinolin-2(1H)-one
3(1H-benzimidazol-2-yD-4-[(1H-benzimidazol-5-ylmethylamino}- 441.9 6-chloroquinolin-2(1H)-one 3(1H-benzimidazol-2-y1)-6-chloro-4-(piperidin-4-ylamino)quinolin- 394.9
301 2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-{(4- 409.9 302 hydroxycyclohexyl)amino]quinolin-2(1¥)-one 4-[(38)-1-azabicyclo[2.2.2]oct-3 -ylamino}-3 -(1H-benzimidazol-2-yl)- 404.5 303 5-fluoroquinolin-2(1H)-one 3-(1H-benzimidazol-2-y])-6,8-dimethyl-4-(piperidin-3- 388.5 304 ylamino)quinolin-2(1H)-one 3-(1H-benzimidazol-2-yD-5-fluoro-4-(piperidin-3-ylamino)quinolin- 3784 |: 305 2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 414.5 306 y)-6,8-dimethylquinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]act-3 -ylamino]-3-(1H-benzimidazo 1-2-yD)- | 4145 307 6,8-dimethylquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3 -(1H-benzimidazol-2- 420.9 308 y1)-7-chloroquinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-[(2-piperidin-1 - 422.9 309 ylethyl)amino]quinolin-2(1H)-one 4-({2-{(4-amino-5 -nitropyridin-2-yl)amino]ethyl}amino)-3 -(1H- 491.9 310 benzimidazol-2-y1)-6-chloroquinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-6-chloro-4-({2-[(5-nitropyridin-2- 4769 31 yDaminojethyl} amino)quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-4-[(1H-benzimidazol-2-ylmethyl)amino]- 441.9 312 6-chloroquinolin-2(1H)-one 3.(1H-benzimidazol-2-yl)-6-chloro-4-(2,5-diazabicyclo[2.2. 1 }hept-2- 3929 - 313 ylquinolin-2(1H)-one 3.(1H-benzimidazoi-2-yi)-6-chioro-4-{{2-{[>- 499.9 314 (trifluoromethyl)pyridin-2-y1] amino } ethyl)amino}quinolin-2(1H)-one 4-[(38)-1 _azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-y1)- 400.5 315 7-methylquinolin-2(1H)-one 4-[(3R)-1 “azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 400.5 316 yl)-7-methylquinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-7 _chloro-4-{[(2R)-pyrrolidin-2- 394.9 317 ylmethyljamino}quinolin-2(1H)-one 3(1H-benzimidazol-2-yl)-6-chloro-4-[(pyrrolidin-2- 394.9 318 ylmethyl)amino]quinolin-2(1H)-one 6-[(2-{[3 -(1H-benzimidazol-2-yl)-6-chloro-2-0xo0-1 2- 4749 319 dihydroquinolin-4-ylJamino}ethyl)amino]nicotinamide 3-(1H-benzimidazol-2-yl)-6-chloro-4-(pyrrolidin-3 -ylamino)quinolin- | 380.8 320 2(1H)-one 4-{[(2R)-2-aminobutyl]amino}-3 -(1H-benzimidazol-2-yl)-6- 3829 321 chloroquinolin-2(1H)-one
4-{[(2S)-2-amino-3-phenylpropyl]amino}-3-(1H-benzimidazol-2-y1)- 444.9 322 6-chloroquinolin-2(1H)-one 4-[(4-aminocyclohexyl)amino]-3(1 H-benzimidazol-2-y1)-6- 408.9 323 chloroquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 512.4 324 yI)-6-iodoquinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)- 512.4 325 6-iodoquinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6,7-dimethoxy-4-(piperidin-3- 420.5 326 ylamino)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 446.5 327 y1)-6,7-dimethoxyquinolin-2(1H)-one 4-[(35)-1 _azabicyclo[2.2 .2Joct-3-ylamino]-3 -(1H-benzimidazol-2-y1)- 431.5 328 6-nitroquinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-iodo-4-(piperidin-3-ylamino)quinolin- 486.3 329 2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 420.9 330 y1)-5-chloroquinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-{[(1-piperidin-4-yl-1H- 525.0 331 benzimidazol-6-yl)methylJamino} quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-methyl-4-[(piperidin-3- 388.5 332 ylmethyl)amino]quinolin-2(1H)-one 3(1H-benzimidazol-2-yl)-6-methyl-4-(piperidin-4-ylamino)quinolin- 374.5 333 2(1H)-one 3.(1H-benzimidazol-2-yl)-6-methyl-4-[(piperidin-4- 388.5 334 ylmethyI)amino]quinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-6-methyl-4-[(piperidin-2- 388.5 335 ylmethyI)amino]quinolin-2(1H)-one 4-{[4-{2-aminoethoxy)benzyljamino}-3-{{H-benzimidazol-2-y1)-6- | 460.9 336 chloroquinolin-2(1H)-one ) 4-{[2-(2-aminoethoxy)benzylJamino}-3-(1H-benzimidazol-2-y1)-6- 4609 337 chloroquinolin-2(1H)-one 4<(1-azabicyclo[2.2.2]oct-3-ylamino)-3-(5-hydroxy-1H- “| 4025 338 benzimidazol-2-yl)quinolin-2(1H)-one 4-[3S)-1-azabicyclo[2.2.2]oct-3-ylamino)-3-(LH-benzimidazol-2-y1)- 411.5 339 2-0x0-1,2-dihydroquinoline-6-carbonitrile 4-[(3R)-1 _azabicyclo[2.2.2]oct-3-ylamino]-3 -(1H-benzimidazol-2- 418.5 340 y1)-6,7-dihydroxyquinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)- 418.5 341 6,7-dihydroxyquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 430.5 342 yI)-2-0x0-1,2-dihydroquinoline-6-carboxylic acid 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 404.5 343 yb)-7-fluoroquinolin-2(1H)-one
Z-[(35)-1azabicyclo[2.2.2oct-3-ylamino}-3(1H-benzimidazol-2-y1)- 404.5
344 7-fluoroquinolin-2(1H)-one } 2-(4-amino-2-oxo-1-propyl-1,2-dihydroquinolin-3-y1)-1H- 344.4 benzimidazole-6-carbonitrile tert-butyl 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H- 567.7 benzimidazol-2-yl)-2-0xo0-1 ,2-dihydroquinolin-6-yl1]-3,6-
346 dihydropyridine-1(2H)-carboxylate tert-butyl 4-{4-[(3S)-1-azabicyclo[2.2.2] oct-3-ylamino}-3-(1H- 567.7 benzimidazol-2-y1)-2-0xo-1,2-dihydroquinolin-6-y1]-3,6-
347 dihydropyridine-1(2H)-carboxylate 4-[(3R)- 1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 467.6
348 y1)-6(1,2,3,6-tetrahydropyridin-4-yl)quinolin-2(1H)-one 4-[(38)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-y1)- 468.6
. 349 6-thien-2-ylquinolin-2(1H)-one 4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-y1)- 467.6 350 6-(1,2,3 ,6-tetrahydropyridin-4-yl)quinolin-2(1H)-one 4-[(38)-1-azabicyclo[2.2.2]oct-3-ylamino)-3-(1H-benzimidazol-2-y1)- 498.5 351 6-(2,4-difluorophenyl)quinolin-2(1H)-one . tert-butyl 2-[4-[(3S)-1-azabicyclo[2.2.2] oct-3 -ylamino}-3-(1H- 551.7 benzimidazol-2-yl)-2-0xo-1,2-dihydroquinolin-6-yl]-1H-pyrrole-1- 352 carboxylate 3 tert-butyl 2-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 551.7 benzimidazol-2-y1)-2-0xo-1,2-dihydroquinolin-6-y1]- 1H-pyrrole-1- 353 carboxylate 4-(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yI)- 463.6 354 6-pyridin-2-ylquinolin-2(1H)-one ’ 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 468.6 355 yl)-6-thien-2-ylquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 498.5 356 y1)-6-(2,4-difluorophenyl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 468.6 357 | yD-6-thien-3-ylquinolin-2(1H)-one 4-[4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 487.6 358 yl)-2-0x0-1,2-dihydroquinolin-6-yiJbenzonitrile 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 497.0 359 y1)-6-(2-chlorophenyl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 360 y1)-6-[2-(trifluoromethyl)phenyljquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 492.6 361 | y)-6-(3-methoxyphenyl)quinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)- | 463.6 362 6-pyridin-3-ylquinolin-2(1H)-one 4-[(3 S)-1-azabicyclo[2.2.2]oct-3-ylamino}-3(1 H-benzimidazol-2-y1)- 463.6 363 6-pyridin-4-ylquinolin-2(1H)-one
2-[(35)- 1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)- 430.5 364 2-0x0-1,2-dihydroquinoline-6-carboxylic acid 3-(5-hydroxy-1H-benzimidazol-2-yl)-4-(piperidin-3- 3764 365 | ylamino)quinolin-2(1H)-one 4-[(3 S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 -(1 H-benzimidazol-2-yl)- | 400.5 8-methylquinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2-y)- 497.0 367 6-(2-chlorophenylquinolin-2(1H)-one 4-[(38)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H-benzimidazol-2-yl)- 530.6 368 6-[2-(trifluoromethyl)phenyl] quinolin-2(1H)-one 4-[4-[(3S)-1-azabicyclo[2.2.2] oct-3-ylamino]-3-(1H-benzimidazol-2- 487.6 369 yl)-2-0x0-1 ,2-dihydroquinolin-6-yl}benzonitrile 4-[(35)-1-azabicyclo[2.2.2)oct-3-ylamino]-3-(1H-benzimidazol-2-y1)- 468.6 370 6-thien-3-ylquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3 -(1H-benzimidazol-2- 463.6 371 yl)-6-pyridin-4-ylquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 492.6 372 y1)-6-(2-methoxyphenyl)quinolin-2(1H)-one 4-{(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino}-3-(1H-benzimidazol-2- 476.6 373 y1)-6-(2-methylphenyl)quinolin-2(1H)-one 6-(3-acetylphenyl)-4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 504.6 374 benzimidazol-2-yl)quinolin-2(1H)-one 6-(4-acetylphenyl)-4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 504.6 375 benzimidazol-2-yl)quinolin-2(1H)-one 4-[4-[(3R)-1-azabicyclo[2.2.2] oct-3 -ylamino]-3-(1H-benzimidazol-2- 376 yl)-2-oxo0-1,2-dihydroquinolin-6-yl]benzoic acid
N-{3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H~ 519.6 benzimidazol-2-yl)-2-oxo-1 ,2-dihydroquinolin-6- nryey . «1h nsmnrl) mnatnmida ea JiJplviy Ij avian 4-[(3R)-1-azabicyclof2.2.2]oct-3-ylamino)-3 -(1H-benzimidazol-2- 498.5 378 y1)-6-(2,6-difluorophenyl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo [2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- . 379 yI)-6-(1,3-benzodioxol-5-yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino) -3«(1H-benzimidazol-2- 497.0 380 y1)-6-(4-chlorophenyl)quinolin-2(1H)-one 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- | 490.6 381 yl)-2-oxo-1 ,2-dihydroquinolin-6-yl]benzaldehyde 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1 H-benzimidazol-2- 508.7 yI)-6-[4-(methylthio)phenyljquinolin-2(1H)-one _ 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3«(1H-benzimidazol-2- 505.6 383 y1)-6-[4-(dimethylamino)phenyl] quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 -(1H-benzimidazol-2- 515.0 384 y1)-6-(4-chloro-2-fluorophenyl)quinolin-2(1H)-one
4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3 -(1H-benzimidazol-2- 531.5
385 yl)-6-(2,4-dichlorophenyl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 462.6
386 y1)-6-phenylquinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-[(1-ethylpiperidin-3- 422.9
387 yl)amino]quinolin-2(1H)-one [_[A-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 530.6 y1)-6-fluoro-2-0xo-1,2-dihydroquinolin-7-yljpiperidine-4-
388 carboxamide ethyl 1-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 559.7 benzimidazol-2-y!)-6-fluoro-2-oxo-1,2-dihydroquinolin-7-
389 yl]piperidine-4-carboxylate [-[4-[GR)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 530.6 y1)-6-fluoro-2-oxo-1,2-dihydroquinolin-7-ylipiperidine-3-
390 carboxamide ethyl 1[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 559.7 benzimidazol-2-yl)-6-flucro-2-oxo-1,2-dihydroquinolin-7-
391 yl]piperidine-3-carboxylate
‘ 4-[(3R)- 1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 470.5
: 392 yI)-6-fluoro-7-(1H-imidazol-1-yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 490.6
393 yD)-7-{[2-(dimethylamino)ethyl]amino}-6-fluoroquinolin-2(1 H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 1 489.6
394 yl)-6-fluoro-7-morpholin-4-ylquinolin-2(1H)-one . 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-( 1H-benzimidazol-2- 447.5
395 y)-7-(dimethylamino)-6-fluoroquinolin-2(1H)-one 4-{(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H-benzimidazol-2- 465.4
396 y1)-7-bromoquinolin-2(1H)-one
1-[4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3 (1H-benzimidazol-2- | 531.6 y1)-6-fiuoro-2-oxo-1,2-dihydroquinolin-7-yl}piperidine-4-carbuxyiic
397 acid 1-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 531.6 y1)-6-fluoro-2-oxo-1,2-dihydroquinolin-7-yl]piperidine-3-carboxylic
398 acid methyl 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 520.6
399 benzimidazol-2-yl)-2-oxo-1 ,2-dihydroquinolin-6-ylJbenzoate 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 505.6
400 y1)-7-chloro-2-0xo-1,2-dihydroquinolin-6-yljbenzamide 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 540.7
401 y1)-6-[4-(methylsulfonyl)phenyl]quinolin-2(1H)-one methyl 3-amino-4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 535.6
402 benzimidazol-2-yl)-2-oxo-1,2-dihydroquinolin-6-yl]benzoate 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3(1H-benzimidazol-2- 541.0
403 yl)-7-chloro-2-oxo-1,2-dihydroquinolin-6-yl]benzoic acid
N-{3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1B- 554.1 benzimidazol-2-y1)-7T-chloro-2-oxo0-1,2-dihydroquinolin-6- 404 yllphenyl} acetamide 6-(3-acetylphenyl)-4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 539.0 405 benzimidazol-2-yl)-7-chloroquinolin-2(1¥)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 -(1H-benzimidazol-2- 527.0 406 yI)-7-chloro-6-(2-methoxyphenyl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino)-3-(1H-benzimidazol-2- 565.9 407 yl)-7-chloro-6-(2,4-dichlorophenyl)quinolin-2(1F)-one 6-(4-acetylphenyl)-4-[(3R)-1-azabicyclo[2.2.2joct-3-ylamino]-3-(1H- 539.0 408 benzimidazol-2-yl)-7-chloroquinolin-2(1H)-one 4-[A-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- . 540.0 yl)-7=chloro-2-oxo-1,2-dihydroquinolin-6-yl]benzamide methyl 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- benzimidazol-2-yl)-7-chloro-2-oxo-1 ,2-dihydroquinolin-6- yl]benzoate 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 504.6 y1)-7-[[2-(dimethylamino)ethyl](methyl)amino]-6-fluoroquinolin- 411 2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3~( 1H-benzimidazol-2- 491.6 412 yD)-6-fluoro-7-[(3 -methoxypropyl)amino}quinolin-2(1H)-one
N-{(3R)-1-[4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino}-3-(1H- 530.6 benzimidazol-2-y1)-6-fluoro-2-oxo-1,2-dihydroquinolin-7- 413 yllpyrrolidin-3-yl} acetamide 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3~(1 H-benzimidazol-2- 544.6 y1)-6-fluoro-7-{[3-(2-oxopyrrolidin-1-yl)propyljamino}quinolin- 414 2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino)-7-azepan-1-yl-3-(1H- 501.6 415 benzimidazol-2-y1)-6-fluoroquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 469.5 416 yI)-6-fluoro-7-(1H-pyrrol-1-yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3<1 H-benzimidazol-2- 484.5 417 yI)-6-fluoro-7-(2-methyl-1H-imidazol-1-yDquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 473.6 yI)-6-fluoro-7-pyrrolidin-1-ylquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H-benzimidazol-2- 4876 419 yl)-6-fluoro-7-piperidin-1-ylquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 502.6 420 yl)-6-fluoro-7-(4-methylpiperazin-1-yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 471.6 421 yI)-6-fluoro-7-[(3-hydroxypropyl)amino]quinolin-2(1H)-one 4-[(3R)-1 -azabicyclo[2.2.2)oct-3-ylamino]-3-(1H-benzimidazol-2- 506.0 422 y1)-6-chloro-7-morpholin-4-ylquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3« 1H-benzimidazol-2~ 519.1 423 y1)-6-chloro-7-(4-methylpiperazin-1-yl)quinolin-2(1H)-one
4-[(3R)-1-azabicyclo[2 22] oct-3-ylamino}-3-(1 H-benzimidazol-2- 504.0 424 yl)-6-chloro-7-piperidin-1-ylquinolin-2(1H)-one 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 506.6 425 yl)-2-oxo-1,2-dihydroquinolin-7-yl]benzoic acid 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3 -(1H-benzimidazol-2- 531.5 426 yl)-7-(2,4-dichlorophenyl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3 -(1H-benzimidazol-2- 429.5 4217 yI)-7 ~(dimethylamino)quinolin-2(1H)-one 7-(4-acetylphenyl)-4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3{1H- 504.6 428 benzimidazol-2-yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3 -(1H-benzimidazol-2- 476.6 429 yh)-7 -(2-methylphenylquinolin-2(1H)-one 7-3 -acetylphenyl)-4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino}-3-(1H- 504.6 430 benzimidazol-2-yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino}-3-(1 H-benzimidazol-2- 492.6 431 yl)-7-(2-methoxyphenyl)quinolin-2(1 H)-one 3.(1H-benzimidazol-2-y1)-6,7-difluoro-4-{(piperidin-2- 4104 432 ylmethyl)amino}quinolin-2(1H)-one
N-[3« 1H-benzimidazol-2-y1)-6,7-difluoro-2-oxo-1,2- 371.3 433 dihydroquinolin-4-yl]glycine
N-[3<1H-benzimidazol-2-y1)-6,7-difluoro-2-0xo-1,2- 385.3 434 dihydroquinolin-4-yl)-beta-alanine 4-{(3S)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(6-fluoro-1H- 464.5 435 benzimidazol-2-y1)-6,7-dimethoxyquinolin-2(1H)-one 3-(6-fluoro-1H-benzimidazol-2-yl)-6,7-dimethoxy-4-(piperidin-3- 438.5 ylamino)quinolin-2(1H)-one 3-(6-fluoro-1H-benzimidazol-2-y1)-6,7-dimethoxy-4-(pyrrolidin-3- 424.4 437 ylamino)quinolin-2(1H)-one : 4-[(4-aminocycionexyainiio}-3-(6-fluoro-1 H-benzimidezel-2-y1)- 452.5 438 6,7-dimethoxyquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 -(6-fluoro-1H- 464.5 439 benzimidazol-2-yl)-6,7-dimethoxyquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino)-3-(1H-benzimidazol-2- 461.6 440 yI)-7-[ethy](methy)amino}-6-fluoroquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 -(1H-benzimidazol-2- 475.6 441 y1)-7-(diethylamino)-6-fluoroquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3 -(1H-benzimidazol-2- 516.6 y1)-7-[(3R)-3-(dimethylamino)pyrrolidin-1 -yl]-6-fluoroquinolin- 442 2(1H)-one i 7-(3-acetyl-1H-pyrrol-1 -y1)-4-[(3R)-1-azabicyclo[2.2.2]ect-3- 511.6 443 ylamino]-3-(1H-benzimidazol-2-yl)-6-fluoroquinolin-2(1H)-one ethyl 4-[4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 534.6 444 benzimidazol-2-yl)-2-oxo-1,2-dihydroquinolin-6-yl]benzoate methyl 3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H- 520.6 445 benzimidazol-2-y1)-2-oxo-1,2-dihydroquinolin-6-yl]benzoate 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino}-3 -(1H-benzimidazol-2- 518.6 446 yb-7- {[2-(diethylamino)ethyljamino} -6-fluoroquinolin-2(1H)-one 4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 516.6 : 447 yI)-6-fluoro-7-[(2-pyrrolidin-1-ylethyl)amino] quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3(1H-benzimidazol-2- 530.7 448 y1)-6-fluoro-7-{(2-piperidin-1-ylethylamino]quinolin-2(1F)}-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol -2- 504.6 449 y1)-7-{[3-(dimethylamino)propyl]amino}-6-fluoroquinolin-2(1H)-one
N-(2-{[4-[(3R)-1-azabicyclo[2.2.2] oct-3-ylamino]-3-(1H- 504.6 benzimidazol-2-y1)-6-fluoro-2-oxo-1,2-dihydroquinolin-7- 450 yljamino}ethyl)acetamide
N-{1-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 584.6 benzimidazol-2-y!)-6-fluoro-2-oxo-1,2-dihydroquinolin-7- 451 ylpyrrolidin-3-y1}-2,2,2-trifluoroacetamide 3-{[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3(1 H-benzimidazol- 4725 452 2-yl)-6-fluoro-2-oxo-1,2-dibydroquinolin-7-ylJamino} propanenitrile 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 463.5 453 y1)-6-fluoro-7-[(2-hydroxyethyl)amino]quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 471.6 454 y1)-6-fluoro-7-[(2-methoxyethyl)amino]quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 503.6 455 y1)-6-fluoro-7-(3-hydroxypiperidin-1-yl)quinolin-2(1H)-one 4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)- 504.6 7-[[2-(dimethylamino)ethyI](methyl)amino}-6-fluoroquinolin-2(1H)- 456 one 4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-y1)- 504.6 : 457 7-{[3-(dimethylamino)propylJamino} -6-fluoroquinolin-2(1H)-one 4-[(35).1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-y1)- 518.6 7-{[2-(diethylamino)ethy!]Jamino}-6-fluoroquinolin-2(1H)-one 4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yI)- 516.6 459 6-fluoro-7-[(2-pyrrolidin-1-ylethyl)amino]quinolin-2(1 H)-one 4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2-y1)- 530.7 460 6-fluoro-7-(3-hydroxypiperidin-1-yl)quinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-y1)- 544.6 , 6-fluoro-7-{[3-(2-oxopyrrolidin-1-yl)propyllamino} quinolin-2(1H)- 461 one
N-2-{[4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 504.6 benzimidazol-2-yl)-6-fluoro-2-oxo-1,2-dihydroquinolin-7- 462 yl]amino}ethyl)acetamide 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)- 491.6 463 6-fluoro-7-[(3-methoxypropyl)amino]quinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-y1)- 471.6 464 6-fluoro-7-[(2-methoxyethyl)amino]quinolin-2(1H)-one
4-[3S)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H-benzimidazol-2-y1)- 463.5 465 6-fluoro-7-[(2-hydroxyethyl)amino]quinolin-2(1H)-one 4-[(3S)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3~(1 H-benzimidazol-2-yl)- | 461.6 466 7-[ethyl(methyl)amino}-6-fluoroquinolin-2(1H)-one 4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino)-3-(1H-benzimidazol-2-yl)- 475.6 467 7-(diethylamino)-6-fluoroquinolin-2(1H)-one
N-{(3R)-1-[4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 530.6 . benzimidazol-2-yl)-6-fluoro-2-oxo-1,2-dihydroquinolin-7- 468 yl]pyrrolidin-3-yl}acetamide
N-{(39)-1-[4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 530.6 benzimidazol-2-y1)-6-fluoro-2-oxo-1,2-dihydroquinolin-7- 469 yl]pyrrolidin-3-yl}acetamide 4-{(38)-1-azabicyclo[2.2.2Joct-3-ylamino}-3-(1H-benzimidazol-2-y1)- 516.6 7-[(3R)-3 ~(dimethylamino)pyrrolidin-1 -yl}-6-fluoroquinolin-2(1H)- ) 470 one
N-{1-[4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 584.6 benzimidazol-2-y1)-6-fluoro-2-oxo-1 ,2-dihydroquinolin-7- “ 471 yl]pyrrolidin-3-y1}-2,2,2-trifluoroacetamide 4-[(3S)-1-azabicyclo[2.2.2]oct-3 -ylamino]-7-azepan-1-yl-3-(1H- 501.6 472 | benzimidazol-2-yl)-6-fluoroquinolin-2(1H)-one 4-[(35)-1-azabicyclo[2.2.2Joct-3-ylamino]-3-(1H-benzimidazol-2-y1)- 503.6 : 473 6-fluoro-7-(3-hydroxypiperidin-1-yl)quinolin-2(1H)-one 3-{[4-[(35)-1-azabicyclo[2.2.2}oct-3-ylamino]-3-(1H-benzimidazol- 472.5 474 2-y1)-6-fluoro-2-0x0-1,2-dihydroquinolin-7-yljamino} propanenitrile 4-[(35)-1-azabicyclo[2.2.2Joct-3-ylamino]-3-(1H-benzimidazol-2-y)- 469.5 475 6-fluoro-7-(1H-pyrrol-1-yDquinolin-2(1H)-one 7-(3-acetyl-1H-pyrrol-1-y1)-4-[(3S)-1 -azabicyclo[2.2.2]oct-3- 511.6 476 ylamino]-3-(1H-benzimidazol-2-yl)-6-fluoroquinolin-2(1 H)-one 4-1(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)- 484.5 477 6-fluoro-7-(2-methyl-1H-imidazol-1-yl)quinolin-2(1H)-one 4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yD)- 516.6 7-[(35)-3-(dimethylamino)pyrrolidin-1-yI]-6-fluoroquinolin-2(1H)- 478 one 4[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H-benzimidazol-2-y1)- 434.5 479 6-fluoro-7-methoxyquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 516.6 yI)-7-[(38)-3-(dimethylamino)pyrrolidin-1-yl}-6-fluoroquinolin- 480 2(1H)-one i
N-{(38)-1-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 530.6 benzimidazol-2-yl)-6-fluoro-2-oxo-1,2-dihydroquinolin-7- 481 yl]pyrrolidin-3-yi}acetamide 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 524.6 482 y1)-6-fluoro-7-[(2-pyridin-2-ylethyl)amino]quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2] oct-3-ylamino]-3-(1H-benzimidazol-2- 475.6 483 y1)-6-fluoro-7-(isobutylamino)quinolin-2(1H)-one :
methyl 3-amino-4-[4-[(3R)-1-azabicyclo[2.2.2] oct-3-ylamino]}-3-(1H- 570.1 benzimidazol-2-y1)-7-chloro-2-oxo-1,2-dihydroquinolin-6-
484 yllbenzoate 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H-benzimidazol-2- 575.1 485 y1)-7=chloro-6-[4-(methylsulfonyl)pheny!]quinolin-2(1H)-one methyl 3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino}]-3-(1H- 555.0 benzimidazol-2-yl)-7-chloro-2-0xo-1 ,2-dihydroquinolin-6~ 486 yl]benzoate 1-[4-[(3S)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3 -(1H-benzimidazol-2- 531.6 yl)-6-fluoro-2-oxo-1,2-dihydroquinolin-7-yllpiperidine-4-carboxylic 487 acid 1-[4-[(3S)-1-azabicyclo[2.2.2] oct-3-ylamino}-3-(1H-benzimidazol-2- 531.6 yI)-6-fluoro-2-oxo0-1,2-dihydroquinolin-7 cyl]piperidine-3-carboxylic 4388 acid 4-[(4-aminobenzyl)amino]-3-(1H-benzimidazol-2-y1)-6,7- 442.5 489 dimethoxyquinolin-2(1H)-one 4-(2-{[3-(1H-benzimidazol-2-y1)-6,7-dimethoxy-2-oxo-1,2- 520.6 490 dihydroquinolin-4-yl]amino}ethyl)benzenesulfonamide 4-[(3-aminopropyl)amino]-3-(1H-benzimidazol-2-y1)-6,7- 394.4 491 dimethoxyquinolin-2(1H)-one 4-[(2-aminoethyl)amino]-3-(1 H-benzimidazol-2-y1)-6,7- 380.4 492 dimethoxyquinolin-2(1H)-one : 3.(1H-benzimidazol-2-y1)-4-{{2~(1H-imidazol-5-yl)ethyl]amino}- 431.5 493 6,7-dimethoxyquinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-4-{[2-(1H-benzimidazol-2- 481.5 494 'yDethyl]amino}-6,7-dimethoxyquinolin-2(1H)-one 4-{[(4-amino-2-methylpyrimidin-5-yl)methy!]amino}-3-(1H- 458.5 495 benzimidazol-2-yl)-6,7-dimethoxyquinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-4-{[2-(5-fluoro-1H-indol-3- 498.5 496 yDethyl]amino}-6,7-dimethoxyquinolin-2(1H)-one 4-{[2-(4-aminophenyl)ethylJamino}-3-(1H-benzimidazol-2-y1)-6,7- 456.5 497 dimethoxyquinolin-2(1H)-one . 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3+(1H-benzimidazol-2- 471.6 498 yl)-7-morpholin-4-ylquinolin-2(1 H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3(5,6-difluoro-1H- 430.5 499 benzimidazol-2-y1)-6,7-dimethoxyquinolin-2(1H)-one methyl 3-amino-4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 535.6 500 benzimidazol-2-y1)-2-0xo-1,2-dihydroquinolin-7-yl]benzoate 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 540.7 501 y1)-7-[4-(methylsulfony)phenyl]quinolin-2(1H)-one ] methyl 4-[4-[(3R)-1-azabicyelo[2.2.2]oct-3-ylamino]-3-(1H- 520.6 502 benzimidazol-2-yl)-2-0xo-1,2-dihydroquinolin-7-yl]benzoate methyl 3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 520.6 benzimidazol-2-yl)-2-oxo-1,2-dihydroquinolin-7-yl]benzoate
N- {3-[4-[(3R)-1-azabicyclo[2.2.2Joct-3-ylamino]-3-(1H- 519.6 benzimidazol-2-yl)-2-oxo-1,2-dihydroguinolin-7- : 504 yl}phenyl}acetamide 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(5 ,6-difluoro-1H- 482.5 505 benzimidazol-2-y1)-6,7-dimethoxyquinolin-2(1H)-one 3-(5,6-difluoro-1H-benzimidazol-2-y1)-6,7-dimethoxy-4-(piperidin-3- 456.5 506 ylamino)quinolin-2(1H)-one 4-[(4-aminocyclohexyl)amino]-3-(5,6-difluoro-1H-benzimidazol-2- 470.5 507 y1)-6,7-dimethoxyquinolin-2(1H)-one 34(5,6-difluoro-1H-benzimidazol-2-y1)-6,7-dimethoxy-4-(pyrrolidin- 442.4 3-ylamino)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2 2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 487.0 yl)-6-chloro-7-(1H-imidazol-1 -yDquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 1H-benzimidazol-2- 459.6 y1)-7-[(3-hydroxypropyl)amino]quinolin-2(1H)-one 4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3 -(1H-benzimidazol-2- 526.7 511 y1)-7-{[3«(2-oxopyrrolidin-1 -yDpropyljamino}quinolin-2(1H)-one : 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 484.6 512 y1)-7-(4-methylpiperazin-1-y))quinolin-2(1H)-one } 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino) -3-(1 H-benzimidazol-2- 487.6 513 yl)-2-0x0-1 ,2-dihydroquinolin-7-yl}benzonitrile 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 530.6 514 yl)-7-[2~(trifluoromethyl)phenyl] quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 -(1H-benzimidazol-2- 506.6 515 y1)-7-(1,3-benzodioxol-5-yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H-benzimidazol-2- 499.6 516 yl)-7-(morpholin-4-ylcarbonyl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 451.5 517 yi-N,N-dimethyl-2-cxo-1 ,2-dihvdroguinoline-7-carboxamide 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 429.5 518 yl)-2-0x0-1,2-dihydrogquinoline-7-carboxamide 3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H-benzimidazol -2- 506.6 519 yI)-2-0x0-1,2-dihydroquinolin-7-yl] benzoic acid 4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-y1)- 465.4 520 7-bromoquinolin-2(1H)-one 4-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 661.8 yI)-7-[4~(ethoxycarbonyl)piperidin-1-y1]-2-oxo-1,2-dihydroquinolin- 521 6-yl}benzoic acid 4-[7-(3-acetyl-1H-pyrrol-1-yl)-4-[(3R)-1-azabicyclo[2.2.2]oct-3- 613.7 ylamino}-3-(1H-benzimidazol-2-yl)-2-oxo-1,2-dihydroquinolin-6- 522 yl]benzoic acid 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamina]-3-(1H-benzimidazol-2- 549.6 523 yl)-7-(dimethylamino)-2-oxo-1 ,2-dihydroquinolin-6-yl]benzoic acid
4-[+-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 572.6 y1)-7-(1 H-imidazol-1-y1)-2-oxo-1,2-dihydroquinolin-6-yllbenzoic 524 acid 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 530.4 525 yl)-7-fluoro-6-iodoquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 526 y1)-7-flucro-6-[4-(methylsulfonyl)phenyl]quinolin-2(1H)-one 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 523.6 527 yl)-7-fluoro-2-oxo-1,2-dihydroquinolin-6-yl]benzamide 6-(4-acetylpheny])-4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 522.6 528 benzimidazol-2-yl)-7-fluoroquinolin-2(1H)-one methyl 4-[4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino}-3-(1H- 538.6 benzimidazol-2-yl1)-7-fluoro-2-oxo-1,2-dihydroquinolin-6- 529 yl]benzoate methyl 3-amino-4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 553.6 benzimidazol-2-yl)-7-fluoro-2-oxo-1,2-dihydroquinolin-6- 530 yljbenzoate 6-(3-acetylphenyl)-4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 522.6 531 benzimidazol-2-y1)-7-fluoroquinolin-2(1H)-one methyl 3-[4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 538.6 benzimidazol-2-yl)-7-fluoro-2-oxo-1,2-dihydroquinolin-6- 532 yl]benzoate 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 4946 |. 533 yI)-7-fluoro-6-(2-methylphenyl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3 -(1H-benzimidazol-2- 510.6 534 yl)-7-fluoro-6-(2-methoxyphenyl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 549.4 535 y1)-6-(2,4-dichlorophenyl)-7-fluoroquinolin-2(1H)-one ethyl 1-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 667.6 benzimidazol-2-yl)-6-iodo-2-0x0-1,2-dihydroquinolin-7- 536 yl]piperidine-4-carboxylate : 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 578.4 537 y1)-7-(1H-imidazol-1-yI)-6-iodoquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino)-3-(1H-benzimidazol-2- 556.7 538 yI)-6-(2-ethylpheny)-7-(1 H-imidazol-1-yl)quinolin-2(1H)-one , 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 571.7 y1)-7-(1H-imidazol-1-y1)-2-oxo-1,2-dihydroquinolin-6-yl]benzamide 6-(4-acetylphenyl)-4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3(1H- 570.7 540 benzimidazol-2-y1)-7-(1H-imidazol-1-yl)quinolin-2(1 H)-one 6-(3-acetylphenyl)-4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 587.7 541 benzimidazol-2-yl)-7-(1H-imidazol-1-yl)quinolin-2(1 H)-one
N-{3-[4-[(3R)-1-azabicyclo[2.2.2Joct-3-ylamino]-3-(1H- 585.7 benzimidazol-2-yl)-7-(1H-imidazol-1-y1)-2-oxo-1,2-dihydroquinolin- 542 6-yllphenyl}acetamide
6-(3-acetylphenyl)-4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 570.7
543 benzimidazol-2-y1)-7-(1H-imidazol-1 -yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino}-3 -(1H-benzimidazol-2- 542.7
544 yI)-7-(1H-imidazol-1 -y1)-6-(2-methylphenyl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylaminoj-3 -(1H-benzimidazol-2- 558.7
545 yl)-7-(1H-imidazol-1 -y1)-6-(2-methoxyphenyl)quinolin-2(1 H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino}-3 -(1H-benzimidazol-2- 597.5
546 yl)-6-(2,4-dichloropheny!)-7-(1H-imidazol-1 -yDquinolin-2(1H)-one 4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino}-3 -(1H-benzimidazol-2- 490.6
547 y1)-6-(2-ethylphenyl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1 H-benzimidazol-2- 508.6
548 y1)-6-(2-ethylphenyl)-7-fluoroquinolin-2(1H)-one 3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2-
549 yl)-2-0xo-1,2-dihydroquinolin-6-yl]benzoic acid 3-amino-4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino}-3-(1H- 556.0 benzimidazol-2-yl)-7-chloro-2-oxo0-1 ,2-dihydroquinolin-6-yl]benzoic
550 acid 3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino] -3{(1H-benzimidazol-2- | 541.0
551 yl)-7-chloro-2-oxo-1 ,2-dihydroquinolin-6-yi]benzoic acid 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 510.6
552 y1)-6-fluoro-7-[(pyridin-2-ylmethyl)amino]quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 527.6
553 y)-6-fluoro-7-[(3-pyrrolidin-1 -ylpropyl)amino]quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 -(1H-benzimidazol-2- 510.6 554 yl)-6-fluoro-7-[(pyridin-3 -ylmethyl)amino]quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 <(1H-benzimidazol-2- 530.7 555 yl)-6-fluoro-7-[(3 -pyrrolidin-1-ylpropyl)amino]quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 ~ylamino]-3-(1H-benzimidazol-2- 489.6 556 yi)-6-Sluoro-7-[(3R)-3-hydroxypyrrolidin-1-yllquinolin-2(1 H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 -(1H-benzimidazol-2- 530.7 yl)-6-fluoro-7- {[2-(1-methylpyrrolidin-2-ylethyl]Jamino} quinolin- 557 2(1H)-one 4-{(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-31 H-benzimidazol-2- 510.6 558 yl)-6-fluoro-7-{(pyridin-4-ylmethyl)amino] quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino}-3(1H-benzimidazol-2- 551.7 559 yI)-6-fluoro-7-{3-(methylsulfonyl)pyrrolidin-1-yl] quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 550.7 560 y1)-6~fluoro-7-(3-pyridin-4-ylpyrrolidin-1 -yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3(1 H-benzimidazol-2- 532.6 561 yb-6=fluoro-7-[(2-morpholin-4-ylethyl)amino]quinolin-2(1 H)-one 4-[(3R)-1-azabicyclof2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 579.7 y1)-6-fluoro-7-[4-(pyridin-4-ylmethyl)piperazin-1-yl]quinolin-2(1H)- 562 one
2-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino] -3-(1H-benzimidazol-2- [5055 563 yl)-7-(benzylamino)-6-fluoroquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 550.7 564 y1)-6-fluoro-7-(2-pyridin-3-ylpyrrolidin-1-yDquinolin-2(1)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 524.6 565 y1)-6-fluoro-7-[(2-pyridin-4-ylethylamino]quinolin-2(1 F)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H-benzimidazol-2- 546.7 y1)-6-fluoro-7-[(3-morpholin-4-ylpropyl)aminolquinolin-2(1¥)-one 4-[(3R)-1-azabicyclo[2.2.2}oct-3-ylamino]-3-(1H-benzimidazol-2- 524.6 567 y1)-6-fluoro-7-[(4-hydroxycyclohexyl)amino]quinolin-2(1F)-one 7-{[2-(4-aminophenyDetbylJamino}-4-[(3R)-1-azabicyclo[2.2.2]oct- 538.6 3-ylamino]-3 -(1H-benzimidazol-2-yl)-6-fluoroquinolin-2(1H)-one 4-[(3R)-1 -azabicyclo[2.2.2]oct-3 -ylamino]-3 -(1H-benzimidazol-2- 517.6
569 y1)-6-fluoro-7-[(4-hydroxycyclohexyl)amino]quinolin-2(1H)-one 4-(1-azabicyclo[2.2.2]oct-3-ylamino)-3-(1H-benzimidazol-2-yI)-6- 516.6
570 fluoro-7-[(piperidin-3-ylmethyl)amino]quinolin-2(1 H)-one 4-(1-azabicyclo[2.2.2]oct-3-ylamino)-3-(1B-benzimidazol-2-yl)-6- 488.6
571 fluoro-7-(pyrrolidin-3-ylamino)quinolin-2(1H)-one
4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 -(1H-benzimidazol-2- 586.7 y1)-7-(2-methyl-1H-imidazol-1-yl)-2-oxo-1,2-dihydroquinolin-6-
572 yl]benzoic acid 1-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 547.1 yl)-6-chloro-2-oxo-1,2-dihydroquinolin-7-yl]piperidine-4-
573 carboxamide ethyl 1-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 576.1 benzimidazol-2-y1)-6-chloro-2-0xo-1,2-dihydroquinolin-7- :
574 yl}piperidine-4-carboxylate 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 452.5
575 vI)-7« 1H-imidazol-1-yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 466.6
576 y1)-7-(2-methyl-1H-imidazol-1-yl)quinolin-2(1H)-one ethyl 1-[4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H- 541.7 benzimidazol-2-y1)-2-0xo-1,2-dihydroquinolin-7-yl]piperidine-4- 577 carboxylate 1-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 512.6 578 yl)-2-oxo0-1,2-dihydroquinolin-7-yl]piperidine-4-carboxamide 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 479.6 579 y1)-6-fluoro-7-[(2-mercaptoethyl)amino]quinolin-2(1 H)-one 4-[(3R)-1-azabicyclo[2.2.2] oct-3-ylamino]-3-(1H-benzimidazol-2- 579.7 yl)-6-fluora-7-[4-(pyridin-3-ylmethyl)piperazin-1-yl] quinolin-2(1H)- 580 one 3-(1H-benzimidazol-2-y1)-4-{(2-hy droxyethyl)amino]-6,7- 381.4 581 dimethoxyquinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-4-[(3-hydroxypropyl)amino]-6,7- 395.4 582 dimethoxyquinolin-2(1H)-one
4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 531.6 y1)-6-fluoro-7-{[(1-hydroxycyclohexymethyllamino} quinolin-
583 2(1H)-one 3-(1H-benzimidazol-2-y1)-6,7-dimethoxy-4-[(3-pyrrolidin-1- 448.5 584 ylpropyl)amino]quinolin-2(1H)-one 4-{(38)-1-azabicyclo[2.2.2]oct-3 -ylamino}-3 -(1H-benzimidazol-2-yl)- | 411.5 585 2-ox0-1,2-dihydroquinoline-7-carbonitrile 3-(1H-benzimidazol-2-yl)- 6-chloro-4-(pyridin-3-ylamino) quinolin- 388.8 2(1H)-one 3-(1H-benzimidazol-2-y1)-4-[(1-benzylpiperidin-4-yl)amino}-6- 485.0 587 chloroquinolin-2(1H)-one 4-[(35)-1-azabicyclo[2.2 2]oct-3-ylemino]-3-(1H-benzimidazol-2-yl)- 416.5 588 7-methoxyquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3 -(1H-benzimidazol-2- 4954 589 y1)-6-bromo-7-methoxyquinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-6,7-dimethoxy-4-{[(5-methylpyrazin-2- 443.5 590 yl)methylJamino} quinolin-2(1H)-one 4-[(3-amino-2-hydroxypropyl)amino]-3-(1H-benzimidazol-2-y1)-6,7- 4104 591 dimethoxyquinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-6,7-dimethoxy-4-[(2- 395.4 methoxyethyl)amino]quinolin-2(1H)-one {[3-(1H-benzimidazol-2-y1)-6,7-dimethoxy-2-o0xo-1,2- 376.4 593 dihydroquinolin-4-ylJamino}acetonitrile 3-(1H-benzimidazol-2-yl)-4-{[2-(2-hydroxyethoxy)ethyl]amino}-6,7- 425.5 594 dimethoxyquinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-4-[(3R)-3-hydroxypyrrolidin-1-y1]-6,7- 407.4 dimethoxyquinolin-2(1H)-one 4-[4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 487.6 556 yi)-2-ono-1,2-dlhydroguinolin-7-y!lbenzonitrile 4-[4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 506.6 597 yI)-2-ox0-1,2-dihydroquinolin-7-yl]benzoic acid 4-[4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 505.6 yI)-2-ox0-1,2-dihydroquinolin-7-yi]benzamide methyl 3-[4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 520.6 599 benzimidazol-2-yI)-2-oxo-1,2-dihydroquinolin-7-yl]benzoate 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2-y1)-4-({[6- 587.1 (piperidin-3-yloxy)pyridin-3-yl]methyl} amino)quinolin-2(1H)-one 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2-yl)-4- {[3-(2- 488.0 oxopyrrolidin-1-yl)propyl]amino}quinolin-2(1H)-one _ 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2-y1)-4-{(2-pyridin- 502.0 602 2-ylethyl)amino]quinolin-2(1H)-one 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2-yl)-4-{[3-(2- 522.0 603 oxopyrrolidin-1-yl)propylJamino}quinolin-2(1H)-one
6-chloro-4-[(6-methoxypyridin-3-yl)amino}-3 -(5-morpholin-4-yl-1H- | 504.0 604 benzimidazol-2-yl)quinolin-2(1H)-one 6-chloro-3-(5 -morpholin-4-yl-1H-benzimidazol-2-yl)-4-[(3 -pyridin- 516.0 2-ylpropyl)amino]quinolin-2(1H)-one 6-chloro-3-(5 -morpholin-4-yl-1H-benzimidazol-2-yl)-4-(pyridin-4- 473.9 ylamino)quinolin-2(1H)-one 6-chloro-3-(5 -morpholin-4-yl-1H-benzimidazol-2-y1)-4-({ [6- 601.1 (piperidin-3 -ylmethoxy)pyridin-3-yljmethyl} amino)quinolin-2(1H)- 607 one 6-chloro-3-(5 -morpholin-4-yl-1H-benzimidazol-2-yl)-4-(pyridin-2- 473.9 608 ylamino)quinolin-2(1H)-one 1-{4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 548.1 : yl)-6-chloro-2-oxo-1 ,2~dihydroquinolin-7 -yl]piperidine-4-carboxylic acid : 1-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 513.6 610 yl)-2-0x0-1,2-dihydroquinolin-7-yl]piperidine-4-carboxylic acid 3-[4-[(38)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 506.6 611 yl)-2-0xo0-1,2-dihydroquinolin-7 -yl]benzoic acid 6-chloro-3-(5 -morpholin-4-yl-1H-benzimidazol-2-yD)-4-({{2- 430.5 612 (piperidin-4-yloxy)pyridin-3-yl]methyl} amino)quinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2 2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)- 455.4 613 6,7-dichloroquinolin-2(1H)-one 6-chloro-3(5-morpholin-4-yl-1H-benzimidazol-2-yl)-4-({ [2- 587.1 614 (piperidin-4-yloxy)pyridin-3-yl]methyl} amino)quinolin-2(1H)-one 6-chloro-3 -(5-morpholin-4-yl-1H-benzimidazol-2-yl)-4-(pyrazin-2- 474.9 615 ylamino)quinolin-2(1H)-one 4-amino-3-(6-thiomorpholin-4-yl-1 H-benzimidazol-2-yl)quinolin- 378.5 616 2(1H)-one . 4.[0R}-1-azabicyclo{2.2.2]oct-3-ylamine]-3-(1 H-benzimidazol-2- 550.7
617 yl)-6-fluoro-7-(3 -pyridin-3-ylpyrrolidin-1-y)quinolin-2(1 H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 -(1H-benzimidazol-2- 558.6
618 yl)-5-fluoro-6-[4-(methylsulfonyl)phenyl] quinolin-2(1H)-one 6-(4-acetylphenyl)-4-[(3R)-1-azabicyclo[2.2.2] oct-3-ylamino]-3-(1H- | 522.6 benzimidazol-2-yl)-5-fluoroquinolin-2(1H)-one methyl 4-[4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3«(1H- 538.6 benzimidazol-2-yl)-5-fluoro-2-oxo-1,2-dihydroquinolin-6- yllbenzoate : methyl 3-amino-4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino}-3-(1H- | 553.6 benzimidazol-2-y1)-5-fluoro-2-oxo-1,2-dihydroquinolin-6-
621 yl]benzoate methyl 3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3 _ylamino]-3-(1H- 538.6 benzimidazol-2-yl)-5-fluoro-2-0xo-1,2-dihydroquinolin-6-
622 yl]benzoate 4-{(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3 -(1H-benzimidazol-2- 494.6
623 yI)-5-fluoro-6-(2-methylphenyl)quinolin-2(1H)-one
4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino}-3-(1H-benzimidazol-2- 508.6 624 yl)-6-(2-ethylphenyl)-5-fluoroquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino)-3-(1H-benzimidazol-2- 510.6 625 y1)-5-fluoro-6-(2-methoxyphenyl)quinolin-2(1H)-one 4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 549.4 626 y1)-6-(2,4-dichlorophenyl)-5-fluoroquinolin-2(1H)-one 4-[4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 524.6 627 yl)-7-fluoro-2-oxo-1,2-dihydroquinolin-6-ylJbenzoic acid 4-[4-{(3S)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 523.6 628 yI)-7-fluoro-2-oxo-1,2-dihydroquinolin-6-yljbenzamide
N-{3-[4-[(3 S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H- 537.6 benzimidazol-2-yl)-7-fluoro-2-0xo-1,2-dihydroquinolin-6- 629 yl]phenyl}acetamide 3-[4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 524.6 630 y1)-7-fluoro-2-oxo-1,2-dihydroquinolin-6-ylJbenzoic acid 4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H-benzimidazol-2-yl)- 494.6 © 631 7-fluoro-6-(2-methylphenyl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2] oct-3-ylamino]-3-(1H-benzimidazol-2- 620.7 yl)-7-(2-methyl-1H-imidazol-1-y1)-6-[4- 632 (methylsulfonyl)phenyl]quinolin-2(1H)-one
N-{3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H- 599.7 benzimidazol-2-yl)-7-(2-methyl-1H-imidazol-1-y1)-2-0xo-1,2- 633 dihydroquinolin-6-yl]phenyl}acetamide
N-{3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 602.8 benzimidazol-2-yl)-2-oxo-7-piperidin-1-yl-1,2-dihydroquinolin-6- 634 yllphenyl}acetamide
N-{3-[7-(3-acetyl-1H-pyrrol-1-yl)-4-[(3R)-1-azabicyclo[2.2.2]oct-3- 626.7 ylamino]-3-(1H-benzimidazol-2-yl)-2-0xo-1,2-dihydroquinolin-6- 635 yllphenyl}acetamide
N-{3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 562.7 benzimidazol-2-yl)-7-(dimethylamino)-2-oxo-1,2-dihydroquinolin-6- 636 yl]phenyl}acetamide
N-{3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 613.7 benzimidazol-2-y1)-7-(2-ethyl-1H-imidazol-1-yl)-2-0xo0-1,2- 637 dihydroquinolin-6-yl]phenyl} acetamide 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 498.6 638 yl)-7-(2-ethyl-1H-imidazol-1-yl)-6-fluoroquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 -(1H-benzimidazol-2- 512.6 yI)-6-fluoro-7-(2-isopropy!-1H-imidazol-1-yl)quinolin-2(1H)-one 1-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- | 513.5 y1)-6-fluoro-2-oxo-1,2-dihydroquinolin-7-yl]-1H-pyrrole-3- 640 carboxylic acid } 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)- 546.8 641 7-chloro-6-iodoquinolin-2(1H)-one
4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 530.4 642 y1)-5-fluoro-6-iodoquinolin-2(1H)-one 4-[(3)-1-azabicyclo[2.2.2]oct-3-ylamino]-3(1 H-benzimidazol-2-y1)- 530.4 643 7-fluoro-6-iodoquinolin-2(1H)-one 6-chloro-3(5-morpholin-4-yl-1H-benzimidazol-2-yl)-4-{(2-pyridin- 502.0 644 3-ylethyl)amino]quinolin-2(1H)-one 4~{[4{(aminomethyl)benzy!]amino}-3-(1H-benzimidazol-2-y1)-7- 4309 _chloroquinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-7-chloro-4-{[2- 382.9 646 (dimethylamino)ethyl]lamino} quinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-4-(1,4'-bipiperidin-1'-y1)-7-chioroquinolin- 463.0 647 2(1H)-one ) 3-(1H-benzimidazol-2-yl)-7-chloro-4-{[3-(4-methylpiperazin-1- 452.0 648 . | yDpropyllamino}quinolin-2(1H)-one 31 H-benzimidazol-2-yl)-7-chloro-4-[(2-piperidin-1- 422.9 649 ylethyl)amino]quinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-7-chloro-4-{[3 -(1H-imidazol-1- 419.9 yl)propyl]amino} quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-7-chloro-4-(pyridin-3-ylamino)quinolin- 388.8 651 2(1H)-one 3-(1H-benzimidazol-2-yl)-7-chloro-4-(pyridin-4-ylaminc)quinolin- 388.8 : 652 2(1H)-one 3-(1H-benzimidazol-2-y1)-7-chloro-4-({[6-(piperidin-3- 502.0 653 yloxy)pyridin-3-yl]methyl}amino)quinolin-2(1H)-one } 3-(1H-benzimidazol-2-yl)-7-chloro-4-{[3-(2-oxopyrrolidin-1- 436.9 654 yDpropyl]amino} quinolin-2(1H)-one 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 536.6 655 yI)-7-methoxy-2-oxo-1,2-dihydroquinolin-6-yljbenzoic acid 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazoi-2- 535.6 656 y1)-7-methoxy-2-oxo-1,2-dihydroquinolin-6-yljbenzamide 6-(4-acetylphenyl)-4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 534.6 657 benzimidazol-2-yl)-7-methoxyquinolin-2(1H)-one : methyl 4-[4-[(3R)-1-azabicyclo[2.2.2] oct-3-ylamino}-3-(1H- benzimidazol-2-yl)-7-methoxy-2-oxo-1,2-dihydroquinolin-6- ylJbenzoate methyl 3-amino-4-[4-[(3R)-1-azabicyclof2.2.2]oct-3-ylamino]-3-(1 H- benzimidazol-2-yl)-7-methoxy-2-oxo-1,2-dihydroquinolin-6- 659 yllbenzoate
N-{3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 549.6 benzimidazol-2-yl)-7-methoxy-2-0x0-1,2-dihydroquinolin-6- 660 yl]phenyl}acetamide 6-(3-acetylphenyl)-4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H- 534.6 661 benzimidazol-2-yl)-7-methoxyquinolin-2(1H)-one methyl 3-[4-[(3R)-1 -azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H- 550.6 benzimidazol-2-y1)-7-methoxy-2-oxo-1,2-dihydroquinolin-6-
662 yl]benzoate 3-[4-[3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2- 536.6 : 663 y1)-7-methoxy-2-oxo-1,2-dihydroquinolin-6-yllbenzoic acid 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 506.6 664 y1)-7-methoxy-6-(2-methylphenyDquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 520.6 665 yl)-6-(2-ethylphenyl)-7 -methoxyquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 -(1H-benzimidazol-2- 522.6 yI)-7-methoxy-6-(2-methoxyphenyl)quinolin-2(1H)-one 4-[(3R)-1 ~azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- | 561.5 . 667 y1)-6-(2,4-dichlorophenyl)-7-methoxyquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-3 -(1H-benzimidazol-2- 491.6 668 y1)-7-[2-(dimethylamino)ethoxy]-6-fluoroquinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 503.6 y1)-6-fluoro-7-{(28)-pyrrolidin-2-ylmethoxy]quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 531.6 670 yI)-6-fluoro-7-[2-(2-oxopyrrolidin-1-yDethoxy]quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamine]-3-(1H-benzimidazol-2- 624.7 yl)-6-fluoro-7-{[(2S)-1-(4-nitrophenyl)pyrrolidin-2- : 671 yllmethoxy} quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 531.6 672 y1)-6-fluoro-7-[(1-methylpiperidin-2-ymethoxylquinolin-2(1 H)-one 3-(1H-benzimidazol-2-y1)-6,7-dimethoxy-4-{[2-(1-methylpyrrolidin- 448.5 673 2-yDethyl]amino}quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6,7-dimethoxy-4-{[2- 443.5 674 (methylsulfonyl)ethyl]amino}quinolin-2(1 H)-one 3-(1H-benzimidazol-2-y1)-6,7-dimethoxy-4-[(2-morpholin-4-yl-2- 527.6 675 pyridin-3-ylethyl)amino]quinolin-2(1 H)-one . 7-[(2-aminoethyl)amino]-4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]- 462.5 676 3-(1H-benzimidazol-2-yl)-6-fluoroquinolin-2(1H)-one 4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 581.7 6717 yD)-6-fluoro-7-(3 -phenylthiomorpholin-4-yl)quinolin-2(1H)-one 4-[(3R)-1-azzbicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 581.7 678 yI)-6-fluoro-7-(2-phenylthiomorpholin-4-ylquinolin-2(1 H)-one 4-[(3R)-1-azabicyclo[2.2.2] oct-3-ylamino]-3-(1H-benzimidazol-2- 587.7 679 yl)-6-fluoro-7-{[2-(phenylsulfonyl)ethylJamino} quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 525.6 680 y1)-6-fluoro-7- {[2-(methylsulfonylethyl]amino} quinolin-2(1H)-one 7-{[(2R)-2-aminopropyl]amino}-4-{(3R)-1-azabicyclo[2.2.2]oct-3- 476.6 681 ylamino]-3-(1H-benzimidazol-2-yl)-6-fluoroquinolin-2(1H)-one
4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 609.7 yl)-6-fluoro-7 -[(2-morpholin-4-yl-2-pyridin-3- 682 ylethyl)amino]quinolin-2(1H)-one 3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 524.6 683 y1)-7-fluoro-2-oxo-1,2-dihydroquinolin-6-ylJbenzoic acid 4-[4-[(3S)-1-azabicyclo[2.2.2]oct-3 -ylamino}-3-(1H-benzimidazol-2- 572.6 yI)-7-(1 H-imidazol-1-y1)-2-oxo-1 ,2-dihydroquinolin-6-yl]benzoic 684 acid 4-[A-[(3 S)-1-azabicyclo[2.2.2)oct-3-ylamino}-3-(1H-benzimidazol-2- 586.7 yl)-7-(2-methyl-1H-imidazol-1 -yl)-2-0x0-1,2-dihydroquinolin-6- yllbenzoic acid 4-[4-[(3 S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 589.7 686 yI)-2-0x0-7-piperidin-1-yl-1,2-dihydroquinolin-6-yllbenzoic acid 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 600.7 yb)-7 -(2-ethy]-1 H-imidazol-1-yl)-2-0x0-1,2-dihydroquinolin-6- 687 yl]benzoic acid 3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 586.7 y1)-7-(2-methyl-1H-imidazol-1-y1)-2-oxo-1,2-dihydroquinolin-6- 688 . | yl]benzoic acid 3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 589.7 689 yl)-2-0xo-7-piperidin-1-yl-1 ,2-dihydroquinolin-6-yljbenzoic acid 6-chloro-3-[5-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-y1]-4- 507.1 [(piperidin-3 -ylmethyl)amino]quinolin-2(1H)-one 3-[4-(3S)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(1H-benzimidazol-2- 572.6 y1)-7-(1H-imidazol-1 -yl)-2-oxo0-1,2-dihydroquino lin-6-yI]benzoic acid . 6-chloro-3-[5(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-4- 507.1 692 [(piperidin-4-ylmethyl)amino]quinolin-2(1H)-one 3-[4-[(38)-1-azabicyclo[2.2.2]oct-3 -ylamino]-3-(1H-benzimidazol-2- 586.7 yi)-T-(2-methyi-1 H-imidazoi-1-yl)-2-oxc-1,2-dibydroguinelin-6- 693 yl]benzoic acid : 6-chloro-3-[ 5-(4-methylpiperazin-1 _yI)-1H-benzimidazol-2-yl]-4- 493.0 694 [(pyrrolidin-2-ylmethyl)amino]quinolin-2(1H)-one 3-[4-[(35)-1-azabicyclo[2.2.2] oct-3-ylamino]-3-(1H-benzimidazol-2- 589.7 695 yl)-2-oxo-7-piperidin-1-yl-1 ,2-dihydroquinolin-6-yl]benzoic acid 4-{[(2R)-2-aminobutylJamino}-6-chloro-3-[5 -(4-methylpiperazin-1- 481.0 yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one 4-{[(2S)-2-amino-3-methylbutyl]amino}-6-chloro-3-[5-(4- 495.0 697 methylpiperazin-1-yl)-1H-benzimidazol-2-yllquinolin-2(1H)-one 4-{[(1S)-2-amino-1-benzylethyl]amino}-6-chloro-3 -[5-(4- 543.1 698 methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-6-chloro-3-[5-(4- 519.1 methylpiperazin-1-y1)-1H-benzimidazol-2-yl]quinolin-2(1H)-one 6-chloro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl}-4- 700 (piperidin-3-ylamino)quinolin-2(1H)-one
6-chloro-4-{[2-(dimethylamino)ethyJamino}-3-[5-(4- 481.0 701 methylpiperazin-1 -yl)-1H-benzimidazol-2-yl] quinolin-2(1H)-one 7-chloro-3-(5-morpholin-4-yl- 1H-benzimidazol-2-y1)-4-(piperidin-4- 480.0 702 ylamino)quinolin-2(1H)-one 4-{[(1R,2R)-2-aminocyclohexyl]amino} -3-(1H-benzimidazol-2-yl)- 408.9 703 7-chloroquinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-7-chloro-4-[(3 -morpholin-4- 438.9 704 ylpropyl)amino]quinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-7-chloro-4-{(pyridin-3 - Co 402.9 705 ylmethyl)amino]quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-7-chloro-4-{(2-pyridin-3- 416.9 706 ylethyl)amino]quinolin-2(1H)-one 4-{ [(IR,2R)-2-aminocyclohexyljamino}-7-chloro-3 -(5-morpholin-4- 494.0 707 yl- 1 H-benzimidazol-2-yl)quinolin-2(1H)-one 4-[(4-aminocyclohexyl)amino}-7 —chloro-3-(5-morpholin-4-yl-1H- 494.0 708 benzimidazol-2-yl)quinolin-2(1H)-one 7-chloro-4-{[2-(methylamino)ethyl]amino}-3 -(5-morpholin-4-yl-1H- 453.9 709 benzimidazol-2-yl)quinolin-2(1H)-one 7-chloro-3 ~(5-morpholin-4-yl-1H-benzimidazol-2-yl)-4-[(pyrrolidin- 480.0 710 2-ylmethyl)amino]quinolin-2(1H)-one 4-{[(1S)-2-amino-1-benzylethyl] amino }-7-chloro-3-(5-morpholin-4- 530.0 711 yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one 7-chloro-3 -(S-morpholin-4-yl-1H-benzimidazol-2-yl)-4-(pyrrolidin-3 -] 466.0 712 ylamino)quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-7-chloro-4-[(2-pyrrolidin-1 - 408.9 713 ylethyl)amino]quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-7-chloro-4-[(2-piperidin-2- 422.9 714 ylethyl)amino]quinolin-2(1H)-one 3-(1H-benzimidazoi-2-yi)-7-chioro-4-[{pipsridia-3- 408.9 715 ylmethyl)amino]quinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-7-chloro-4-[ (piperidin-4- 408.9 716 ylmethyl)amino]quinolin-2(1H)-one 3-(1H-benzimidazol-2-yI)-7-chloro-4-{[(2-methyl-1 -piperidin-4-yl- 539.1 717 1H-benzimidazol-5-yl)methyl]amino} quinolin-2(1H)-one 4-[(4-aminocyclohexyl)amino]-3-(1H-benzimidazol-2-y1)-7- 408.9 718 chloroquinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-7-chloro-4-(pyrrolidin-3 -ylamino)quinolin- | 380.8 719 2(1H)-one 4-](3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 -(1H-benzimidazol-2-yl)- | 530.6 720 6-[4-(trifluoromethyl)phenyljquinolin-2(1H)-one : 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino)-3 -(1H-benzimidazol-2-yl)- 721 6-[3-(trifluoromethyl)phenyl]quinolin-2(1H)-one 4-amino-5-fluoro-3-[6-(4-isopropylpiperazin-1-yl)-1H-benzimidazol- | 421.5 722 2-yllquinolin-2(1 H)-one
7-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2-yD)-4-{[(28)- 480.0 723 pyrrolidin-2-ylmethyllamino} quinolin-2(1H)-one 7-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2-yl)-4-{[(2R)- 480.0 724 pyrrolidin-2-ylmethyljamino} quinolin-2(1H)-one 7-chloro-4-({[(28)-1 -ethylpyrrolidin-2-yljmethyl} amino)-3-(5- 508.0 725 morpholin-4-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one 7-chloro-4-({[(2R)-1-ethylpyrrolidin-2-yljmethyl} amino)-3-(5- 508.0 726 morpholin-4-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-7-chloro-3 -(5-morpholin- 727 4-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one 7-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2-yl)-4-[(piperidin-3- 494.0 728 ylmethyl)amino]quinolin-2(1H)-one 7-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2-yl)-4-[(piperidin-4- 494.0 729 ylmethyl)amino]quinolin-2(1H)-one 4-{[(2S)-2-amino-3-methylbutyl] amino}-7-chloro-3-(5-morpholin-4- | 482.0 730 yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4-{[4-(aminomethyT)benzyl]amino}-7-chloro-3~5-morpholin-4-yl- 731 1H-benzimidazol-2-yl)quinolin-2(1H)-one . 4-{[(1R)-1-(aminomethyl)propylJamino}-7-chloro-3-(5-morpholin-4- 468.0 732 yl-1H-benzimidazo!-2-yl)quinolin-2(1H)-one 7-chloro-4-{[3-(4-methylpiperazin-1-yI)propyl]amino}-3-(5- 537.1 733 morpholin-4-yl-1 H-benzimidazol-2-yl)quinolin-2(1H)-one 7-chloro-4-{[3-(1H-imidazol-1-yl)propyljamino}-3-(5S-morpholin-4- 505.0 734 yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one 7-chloro-3-(5-morpholin-4-y1-1H-benzimidazol-2-yl)-4-[(2- 494.0 735 pyrrolidin-1-ylethyl)amino}quinolin-2(1 H)-one 7-chloro-3-(5-morpholin-4-y1-1H-benzimidazol-2-yl)-4-[(piperidin-2- | 494.0 736 ylmethyl)amino]quinolin-2(1H)-one 7-chloro-4-{[2<(dimethylamino)ethyijamino}-3-(5-morphoiin-4-yi- 468.0 737 1H-benzimidazol-2-y)quinolin-2(1H)-one 7-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2-yl)-4-[(3S)- 466.0 738 pyrrolidin-3-ylamino]quinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)- 478.6 739 6-(4-hydroxyphenyl)quinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H-benzimidazol-2-y])- | 478.6 740 6-(3-hydroxyphenyl)quinolin-2(1H)-one 4-[(38)-1-azabicyclo[2.2.2)oct-3-ylamino]-3-(1H-benzimidazol-2-yl)- 478.6 741 6-(2-hydroxyphenyl)quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-7-chloro-4-{[(28)-pyrrolidin-2- 394.9 742 ylmethyl]amino} quinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-7-chloro-4-({[(2S)-1-ethylpyrrolidin-2- 422.9 743 y1]Jmethyl}amino)quinolin-2(1H)-one . 3-(1H-benzimidazol-2-yl)-7-chloro-4-({[(2R)-1-ethylpyrrolidin-2- 422.9 744 yl]methyl}amino)quinolin-2(1H)-one
3-(1H-benzimidazol-2-yl)-7-chloro-4-[(38)-pyrrolidin-3- 380.8 745 ylamino]quinolin-2(1H)-one : 3-(1H-benzimidazol-2-yl)-6-chloro-4-{[(2S)-pyrrolidin-2- 746 yimethyljamino} quinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-6-chloro-4-{[(2R)-pyrrolidin-2- 394.9 747 yimethyljamino}quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-({[(28)-1-ethylpyrrolidin-2- 4229 748 yl]methyl} amino)quinolin-2(1H)-one \ 3-(1H-benzimidazol-2-y1)-6-chloro-4-({[(2R)-1-ethylpyrrolidin-2- 422.9 749 yljmethy1}amino)quinolin-2(1H)-one 4-amino-3-[5-(1,4-bipiperidin-1'-ylcarbonyl)-1H-benzimidazol-2- 380.8 750 yl]quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino)-7-bromo-3-(5-morpholin- 550.5 751 4-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclof2.2.2]oct-3 -ylamino]-7-bromo-3-(6-methoxy- 495.4 752 1H-benzimidazol-2-yl)quinolin-2(1H)-one 3-{[3-(1H-benzimidazol-2-y1)-6,7-dimethoxy-2-oxo-1,2- 474.5 753 dihydroquinolin-4-ylJamino}bicyclo[2.2. 1]heptane-2-carboxamide 4-[(3-amino-2,2-dimethylpropyl)amino]-3-(1 H-benzimidazol-2-yl)- 422.5 754 6,7-dimethoxyquinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-4-{[3 -(dimethylamino)-2,2- 450.6 755 dimethylpropyl]amino}-6,7-dimethoxyquinolin-2(1H)-one 3.(1H-benzimidazol-2-yl)-7-chloro-4-[(pyridin-2- 402.9 756 ylmethyl)amino]quinolin-2(1H)-one : 3(1 H-benzimidazol-2-yl)-7-chloro-4-{(2-pyridin-2- 416.9 757 ylethyl)amino]quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-7-chloro-4-{[2- 368.8 758 (methylamino)ethyljamino} quinolin-2(1H)-one 3-(1H-benzimidazoi-2-yi)-7-chioro-4-{(piperidin-2- 408.9 759 ylmethyl)amino]quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-7-chloro-4-(piperidin-4-ylamino)quinolin- 394.9 760 2(1H)-one 4-amino-3-[5-(1,4'-bipiperidin-1 "-ylcarbonyl)-1H-benzimidazol-2- 471.6 761 yl]quinolin-2(1H)-one 4-amino-3-{5-[(3S)-3-(dimethylnitroryl)pyrrolidin-1-y1]-1H- 405.5 762 benzimidazol-2-yl}quinolin-2(1H)-one 4-amino-3(5-{2-[(dimethylamino)methyljmorpholin-4-yl}-1H- 419.5 763 benzimidazol-2-yl)quinolin-2(1H)-one methyl 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 H- 534.6 benzimidazol-2-y1)-5-methyl-2-oxo-1,2-dihydroquinolin-6- 764 yljbenzoate 3-[4-[(3R)-1-azabicyclo[2.2.2)oct-3-ylamino]-3-(1H-benzimidazol-2- | 520.6 765 yI)-5-methyl-2-oxo-1,2-dihydroquinolin-6-yl]benzoic acid
4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino] -3-(1H-benzimidazol-2- 519.6 766 yl)-5-methyl-2-o0xo-1,2-dihydroquinolin-6-yl]benzamide 4-[4-[(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2- 520.6 767 yl)-5-methyl-2-oxo-1,2-dihydroquinolin-6-ylJbenzoic acid 4-amino-3-{5-[(28)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1 -yl]-1H- 429.5 768 benzimidazol-2-y1} quinolin-2(1H)-one 2-(4-amino-5-fluoro-2-oxo-1,2-dihydroquinolin-3-yl)-N-methyl-N- 449.5 769 (1-methylpiperidin-4-yl)-1H-benzimidazole-6-carboxamide 4-amino-3-(1 H-benzimidazol-2-yl)-5-[(1-methylpiperidin-4- 390.5 770 yloxy]quinolin-2(1H)-one 4-amino-5-(1-azabicyclof2.2.2]oct-3-yloxy)-3-(1H-benzimidazol-2- 402.5
IN yDquinolin-2(1H)-one : 4-amino-5-fluoro-3-{6-[(2-piperidin-1-ylethyl)amino]-1H- 421.5 772 benzimidazol-2-yl} quinolin-2(1H)-one 4 6-diamino-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- 390.5 773 yllquinolin-2(1H)-one 2-(4-amino-5-fluoro-2-oxo-1,2-dihydroquinolins3-y1)-1H- 339.3 774 benzimidazole-5-carboxylic acid 2-(4-amino-2-oxo-1,2-dihydroquinolin-3-y)-N-pyridin-3-yl-1H- 397.4 775 benzimidazole-5-carboxamide 4-amino-3-5-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}-1H- 390.4 776 benzimidazol-2-ylquinolin-2(1H)-one
N-{4-amino-3-[6-(4-methylpiperazin-1 -yD)-1H-benzimidazol-2-yl]-2- | 432.5 771 oxo-1,2-dihydroquinolin-6-yl} acetamide 4-amino-5-fluoro-3-(6-morpholin-4-yl-1H-benzimidazol-2- 380.4 778 yDquinolin-2(1H)-one 3-(5-chloro-1H-benzimidazol-2-yl)-4-{[2- 396.9 779 (dimethylamino)ethy!Jamino}-6-methylquinolin-2(1H)-one 4-{[({iR,2R)-Z-aminocyciohexyljamino}-3-(5-chlors-1H- 4239 780 benzimidazol-2-yl)-6-methylquinolin-2(1H)-one 3-(5-chloro-1H-benzimidazol-2-yl)-6-methyl-4-[(piperidin-3- 422.9 781 ylmethyl)amino}quinolin-2(1H)-one 3«(5-chloro-1H-benzimidazol-2-yl)-6-methyl-4-[(piperidin-4- 422.9 782 ylmethyl)amino]quinolin-2(1H)-one 4-[(4-aminocyclohexyl)amino]-3-(5-chloro-1H-benzimidazol-2-yl)-6- 422.9 783 methylquinolin-2(1H)-one 3-(5-chloro-1H-benzimidazol-2-yl)-6-methyl-4-{[2- 382.9 784 (methylamino)ethyl]amino} quinolin-2(1H)-one 3-(5-chloro-1H-benzimidazol-2-yl)-6-methyl-4-(pyrrolidin-3- 3949 785 | ylamino)quinolin-2(1H)-one 3-(5-chloro-1H-benzimidazol-2-yl)-6-methyl-4-[(piperidin-2- 4229 786 ylmethyl)amino]quinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino}-3-(5-chloro-1H- 4349 787 benzimidazol-2-y1)-6-methylquinolin-2(1H)-one
4-[(3R)-1-azabicyclof2.2.2]oct-3 -ylamino}-3-(5-chloro-1H- 434.9 788 benzimidazol-2-yl)-6-methylquinolin-2(1H)-one 4-amino-3(6-{(2R,5R)-2-[(dimethylamino)methy1]-5- 433.5 789 methylmorpholin-4-y1}-1 H-benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-3-(5-{[(3R)-3-hydroxypiperidin-1 -yl]carbonyl}-1H- 404.4 790 benzimidazol-2-yl)quinolin-2(1H)-one 2-(4-amino-2-oxo-1 2-dihydroquinolin-3-yl)-N-(2-piperidin-1- 431.5 791 ylethyl)-1H-benzimidazole-5-carboxamide 4-amino-3-[5-(piperazin-1 -ylcarbonyl)-1H-benzimidazol-2- 389.4 792 yljquinolin-2(1H)-one
N-{4-amino-3-[6-(4-methylpiperazin-1-y [)-1H-benzimidazol-2-yl}-2- | 474.6 793 o0xo-1,2-dihydroquinolin-6-yl} -2,2-dimethylpropanamide
N-{4-amino-3-[6-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yl]-2- 522.6 794 oxo-1,2-dihydroquinolin-6-y1}-3 -phenylpropanamide
N-{4-amino-3-[6-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yl]-2- 538.6 795 oxo-1,2-dihydroquinolin-6-y1} -2-(benzyloxy)acetamide
N-{4-amino-3-{6-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yl]-2- | 3 14.6 796 oxo-1,2-dihydroquinolin-6-y1} -2-thien-2-ylacetamide
N-{4-amino-3-[6-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yI}-2- 484.5 797 oxo-1,2-dihydroquinolin-6-y1}-2-furamide 2-(4-amino-2-oxo-1,2-dihydroquinolin-3 -yI)-N-(2-pyrrolidin-1- 417.5 798 ylethyl)-1H-benzimidazole-5-carboxamide ethyl (4-{[2-(4-amino-2-oxo-1 ,2-dihydroquinolin-3-yI)-1H- 475.5 799 benzimidazol-5-yl]carbonyl} piperazin-1-yl)acetate
N-{4-amino-3-[6-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yl]-2- | 509.6 800 oxo-1,2-dihydroquinolin-6-y1}-N'-phenylurea
N-{4-amino-3-[6-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yl]-2- | 523.6 oxo-1,2-dihydroquinolin-6-y1}-N'-benzylurea
N-{4-amino-3-{6-(4-meihyipiperazii-1 -yi)-1H-benzimidazol-2-y1}-2- 537.6 802 oxo-1,2-dihydroquinolin-6-y1}-N'-(2-phenylethyl)urea
N-{4-amino-3-[6-(4-methylpiperazin-1-yI)-1 H-benzimidazol-2-yl]-2- | 494.6 803 oxo-1,2-dihydroquinolin-6-y1} benzamide 2-(4-amino-2-ox0-1 ,2-dihydroquinolin-3-yI)-N-piperidin-3-yl-1H- 403.5 804 benzimidazole-5-carboxamide 2-(4-amino-2-o0xo-1 ,2-dihydroquinolin-3-y}-N-[(3R)-1- 429.5 azabicyclo[2.2.2}oct-3 -yl}-1H-benzimidazole-6-carboxamide 2-(4-amino-2-0x0-1 ,2-dihydroquinolin-3-yI)-N-[2- 447.6 806 (diethylamino)ethyl]-N-ethyl-1H-benzimidazole-5-carboxamide 4-amino-3-{6-(pyridin-4-yloxy)- 1H-benzimidazol-2-yl]quinolin- 370.4 807 2(1H)-one 4-amino-5-fluoro-3-{6-[(4-methylpiperazin-1-yl)carbonyl]-1H- 4214 808 benzimidazol-2-yl}quinolin-2(1H)-one 4-amino-5-fluoro-3-{6-[(4-isopropylpiperazin-1-yl)carbonyl}-1H- 449.5 809 benzimidazol-2-y1} quinolin-2(1H)-one
- y WO 2005/046589 PCT/US2004/036941 4-amino-3-{6-[(4-cyclohexylpiperazin-1-yl)carbonyl]- 1H- 489.6 810 benzimidazol-2-y1}-5-fluoroquinolin-2(1H)-one 4-amino-6-(isobutylamino)-3 -[6-(4-methylpiperazin-1-y)-1H- 446.6 811 benzimidazol-2-yi]quinolin-2(1H)-one 2-(4-amino-5-fluoro-2-oxo-1,2-dihydroquinolin-3 -y1)-N-methyl-N- 488.6 812 (1-methylpyrrolidin-3 -yl)-1H-benzimidazole-6-carboxamide 4-amino-6-[(2-methylbutyl)amino]-3 -[6-(4-methylpiperazin-1 -yl)- 460.6 813 1H-benzimidazol-2-yllquinolin-2(1H)-one 4-amino-6-[(cyclohexylmethyl)amino]-3-[6-(4-methylpiperazin-1- 486.6 814 yl)-1H-benzimidazol-2-yliquinolin-2(1H)-one 4-amino-3-(6-{[(38)-3-methylpiperazin-1 -yljcarbonyl}-1H- 403.5 815 benzimidazol-2-yl)quinolin-2(1H)-one 2-(4-amino-2-oxo-1,2-dihydroquinolin-3 -yl)-N-{(38S)-1- 429.5 816 azabicyclof2.2.2]oct-3-y1]- 1H-benzimidazole-6-carboxamide 4amino-3-[6-(1,4-bipiperidin-1'-ylcarbonyl)-1H-benzimidazol-2-y1]- 489.6 817 5-fluoroquinolin-2(1H)-one 2-(4-amino-5-fluoro-2-0xo-1 2-dihydroquinolin-3-yl)-N-methyl-N- 435.5 818 (1-methylpyrrolidin-3-y1)-1 H-benzimidazole-6-carboxamide 4-amino-3-(1H-benzimidazol-2-yl)-5-[(4- 415.5 819 methoxyphenyl)thio}quinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-yl)-5-[(4- 447.5 820 methoxyphenyl)sulfonyljquinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-y1)-5-[(2- 4155 821 methoxyphenyl)thio]quinolin-2(1H)-one
N-(4-{[2-(4-amino-2-oxo-1,2-dihydroquinolin-3-yl)- 1 H- 426.4 822 benzimidazol-5-yl]oxy}phenyl)acetamide 4-amino-6-(benzylamino)-3 -[6-(4-methylpiperazin-1-yI)-1H- 480.6 823 benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-3-[6-(4-methylpiperazin-1-y)-1H-benzimidazel-2-y1}-6- 578.7 824 { [(3-phenoxythien-2-y)methyl]amino}quinolin-2(1H)-one 4-amino-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-y1]-6- 500.6 825 {[(3-methylthien-2-y)methyl]amino}quinolin-2(1H)-one 4-amino-3 -[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-y1]-6- 487.6 826 [(1,3-thiazol-2-ylmethyl)amino]quinolin-2(1H)-one 4-amino-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-y1]-6- 482.6 827 [(pyrazin-2-ylmethyl)amino]quinolin-2(1H)-one 4-amino-3 -(5-{2-[(dimethylamino)methyl]-1,4-0xazepan-4-yl}-1H- 433.5 828 benzimidazol-2-yl)-5-fluoroquinolin-2(1H)-one - 4-amino-3-(5-{2-[(dimethylamino)methyl]-1,4-oxazepan-4-yl}-1 H- 451.5 829 benzimidazol-2-y1)-5-fluoroquinolin-2(1H)-one 6-chloro-4-{ [2-(dimethylamino)-2-pyridin-3 -ylethyl]amino}-3-(5- 545.1 830 morpholin-4-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one ’ 6-amino-4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H- 831 benzimidazol-2-yl)quinolin-2(1H)-one
6-ohloro-3-(5-chloro-1H-benzimidazol-2-y)-4-{[2- 4173 832 (dimethylamino)ethyl] amino} quinolin-2(1H)-one 4-{[(1R.2R)-2-aminocyclohexyl}amino}-6-chloro-3-(5-chloro-1H- 443.3 833 benzimidazol-2-yl)quinolin-2(1H)-one 6-chloro-3-(5 _chloro-1H-benzimidazol-2-yl)-4-[(piperidin-3- 443.3 834 ylmethyl)amino]quinolin-2(1H)-one 6-chloro-3-(5 _chloro-1H-benzimidazol-2-yl)-4-{(piperidin-4- 4433 835 yimethyl)amino]quinolin-2(1H)-one 4-[(4-aminocyclohexylamino]-6-chloro-3-(5-chloro-1H- 443.3 836 benzimidazol-2-yl)quinolin-2(1H)-one : 6-chloro-3-(5-chloro-1H-benzimidazol-2-yD)-4-{[2- 403.3 837 (methylamino)ethyljamino} quinolin-2(1H)-one 6-chloro-3 ~(5-chloro-1H-benzimidazol-2-yl)-4-(pyrrolidin-3- 4153 838 ylamino)quinolin-2(1H)-one 6-chloro-3-(5 _chloro-1H-benzimidazol-2-yl)-4-{(piperidin-2- 443.3 ylmethyl)amino]quinolin-2(1H)-one 4-[(38)-1 -azabicyclo[2.2.2]oct-3-ylamino]-6-chloro-3 -(5-chloro-1H- 455.4 840 benzimidazol-2-yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-6-chloro-3 -(5-chloro-1H- 455.4 841 benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-3 _[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-y1]-6- 473.6 842 {[(2S)-pyrrolidin-2-ylmethyl]amino} quinolin-2(1H)-one 4-amino-6- {[(5-methylisoxazol-3 -yDmethylJamino} -3-[6-(4- 485.6 843 methylpiperazin-1-yl)-1H-benzimidazol-2-yi] quinolin-2(1H)-one 4-amino-3-(5-{(2S,5R)-2-[(dimethylamino)methyI]-5- 433.5 844 methylmorpho lin-4-y1}-1H-benzimidazol-2-yl)quinolin-2(1H)-one 3-(5-chloro-1H-benzimidazol-2-yl)-4-{[2- 418.8 845 (dimethylamino)ethylJamino}-6,7-difluoroquinolin-2(1H)-one 4-{[(1R,2R)-2-aminocyciohexyijamino}-3-(5 -cliioio-1H- 444.0 : 846 benzimidazol-2-y1)-6,7-difluoroquinolin-2(1H)-one 3-(5-chloro-1H-benzimidazol-2-y1)-6,7-difluoro-4-{(piperidin-3- 4449 847 ylmethyl)amino]quinolin-2(1H)-one . 3-(5-chloro-1H-benzimidazol-2-y1)-6,7-difluoro-4-[(piperidin-4- 444.9 848 ylmethyl)aminojquinolin-2(1H)-one 4-[(4-aminocyclohexyl)amino]-3{5-chloro-1H-benzimidazol-2-yl)- 4449 849 6,7-difluoroquinolin-2(1H)-one 3-(5-chloro-1H-benzimidazol-2-y)-6,7 -difluoro-4-{[2- 404.8 (methylamino)ethyl]amino} quinolin-2(1H)-one 3-(5-chloro-1H-benzimidazo}-2-yl)-6,7-difluoro-4-(pyrrolidin-3- 416.8 851 ylamino)quinolin-2(1H)-one 3-(5-chloro-1H-benzimidazol-2-yl)-6,7 -difluoro-4-[(piperidin-2- 444.9 852 ylmethyl)amino]quinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 -(5-chloro-1H- 456.9 853 benzimidazol-2-yl)-6,7-difluoroquinolin-2(1 H)-one
4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(5-chloro-1 H- 456.9 854 benzimidazol-2-y1)-6,7-difluoroquinolin-2(1 H)-one 4-amino-3-(6-{[(3R)-3-methylpiperazin-1-yl] carbonyl}-1H- 403.5 benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-3-(5-{[(3S)-3-hydroxypyrrolidin-1 -yl]carbonyl}-1H- 390.4 benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-3-(5-{[4-(2-hydroxyethyl)piperazin-1-yI] carbonyl}-1H- 433.5 857 benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-3-[6-(4-isopropylpiperazin-1 -yl)-1H-benzimidazol-2-y1]-5- 433.5 858 methoxyquinolin-2(1H)-one 4-amino-3 ~(5-{3-[(dimethylamino)methyl]pyrrolidin-1 -yl}-1H- benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-3-(5-{3-[(dimethylamino)methy!]pyrrolidin-1-y1}-1H- 421.5 860 benzimidazol-2-yl)-5-fluoroquinolin-2(1H)-one . 4-amino-3-(6-{(2R,58)-2-[(dimethylamino)methyl]-5- 433.5 methylmorpholin-4-y1}-1H-benzimidazol-2-yl)quinolin-2( 1H)-one 4-amino-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-yl]-6- 473.6 862 (piperidin-4-ylamino)quinolin-2(1H)-one 6-chloro-3-[5-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yl]-4- 479.0 [(3S)-pyrrolidin-3-ylamino]quinolin-2(1H)-one 4-amino-3-{5-[(3R)-3-(dimethylamino)pyrrolidin-1-yI}-1H- 407.5 864 benzimidazol-2-yl}-5-fluoroquinolin-2(1H)-one 4-amino-3-{5-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-1H- 407.5 benzimidazol-2-y1}-5-fluoroquinolin-2(1H)-one 4-amino-3-[6-(2,6-dimethylmorpholin-4-yl)-1H-benzimidazol-2-yl}- 408.4 866 5-fluoroquinolin-2(1 H)-one : 4-amino-3-{6-[(3-aminopyrrolidin-1 -yDcarbonyl]-1H-benzimidazol- 389.4 867 2-yl}quinolin-2(1H)-one ethyl (38,4K)-4-({[2~(4-amino-2-0x0-1,2-dihiydroguinolin-3-yI)-1H- S08. benzimidazol-6-yl]carbonyl} amino)-3-methoxypiperidine-1- 868 carboxylate 6-amino-3-(1H-benzimidazol-2-yI)-4-[(3S)-pyrrolidin-3- 361.4 869 ylamino]quinolin-2(1H)-one 4-amino-3-(6-{(2R,58S)-2-[(dimethylamino)methyl]-5- 451.5 methylmorpholin-4-y1}-1H-benzimidazol-2-y1)-5 -fluoroquinolin- 870 2(1H)-one
N-{(3S)-1-[2-(4-amino-2-0x0-1,2-dihydroquinolin-3-y])-1H- 417.5 871 benzimidazol-6-yl]pyrrolidin-3-y1}-N-methylacetamide 2-(4-amino-2-oxo-1,2-dihydroquinolin-3-y1)-N-piperidin-4-yl-1H- 403.5 : 872 benzimidazole-6-carboxamide 2-(4-amino-2-o0xo-1,2-dihydroquinolin-3-yl)-N-[2-(1- 431.5 873 methylpyrrolidin-2-yl)ethyl]-1H-benzimidazole-6-carboxamide
N-{4-amino-3-[6-(4-methylpiperazin-1 -yD)-1H-benzimidazol-2-yl]-2- | 475.6 874 oxo-1,2-dihydroquinolin-6-y1}-N'-isopropylurea
N-{4-amino-3-[644-methylpiperazin-1-y})-1H-benzimidazol-2-yl]-2- 537.6 875 oxo-1,2-dihydroquinolin-6-y1}-N'=(3,5-dimethylphenylurea
N-allyl-N'-{4-amino-3-[6-(4-methylpiperazin-1-y)-1H- 473.6 876 benzimidazol-2-y1}-2-oxo-1,2-dihydroquinolin-6-yl}urea
N-{4-amino-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yI}-2- 489.6 877 oxo-1,2-dihydroquinolin-6-y1}-N'-(tert-butylurea
N_{-amino-3-[6-(4-methylpiperazin-1-y))-1H-benzimidazol-2-y1]-2- 555.7 878 oxo-1,2-dihydroquinolin-6-yl} N'-[2-(methylthio)phenyl]urea
N-{4-amino-3-[6-(4-methylpiperazin-1-y)-1H-benzimidazol-2-yI]-2- 879 oxo-1,2-dihydroquinolin-6-y1} heptanamide
A-amino-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yI]-6- 460.6 880 (ncopentylamino)quinolin-2(1H)-one
N-{4-amino-3-[6-(4-methylpiperazin-1-y)-1H-benzimidazol-2-yl}-2- 578.5 881 oxo-1,2-dihydroquinolin-6-y1} -N'-(3,4-dichlorophenyljurea
N-{4-amino-3-[6-(4-méthylpiperazin-1-yD)-1H-benzimidazol-2-y1}-2- 571.6 882 oxo-1,2-dihydroquinolin-6-y1}-N'-[3-(trifluoromethyl)phenyljurea
N-{4-amino-3 -[6~(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yl} 2-1] 5317 883 oxo-1,2-dihydroquinolin-6-y1} -N'-heptylurea
N-{4-amino-3-[6-(4-methylpiperazin-1-y})-1 H-benzimidazol-2-yl}-2- 553.6 884 ox0-1,2-dihydroquinolin-6-y1}-N'-(2-ethoxyphenylurea
N-{4-amino-3-[6-(4-methylpiperazin-1-y))-1H-benzimidazol-2-yl]-2- 460.6 885 oxo-1,2-dihydroquinolin-6-y1}-2-methylpropanamide
N-{4-amino-3-[6-(4-methylpiperazin-1-y)-1H-benzimidazol-2-yl}-2- 522.6 886 oxo-1,2-dihydroquinolin-6-y1} -4-ethylbenzamide
N-{4-amino-3-[6-(4-methylpiperazin-1-y!)-1H-benzimidazol-2-y1]-2- 519.6 887 oxo-1,2-dihydroquinolin-6-y1}-4-cyanobenzamide
N-{4-amino-3-[6-(4-methylpiperazin-1-y)-1H-benzimidazol-2-y1]-2- 888 . oxo-1,2-dihydroquinolin-6-yl} cyclohexanecarboxamide
N-{4-amino-3-[6-(4-methyipiperazin-1-yl)-1H-benzimidazol-2-y1}-2- 496.5 889 oxo-1,2-dihydroquinolin-6-yl} pyrazine-2-carboxamide
N-{4-amino-3-[6-(4-methylpiperazinyl)benzimidazol-2-yI]-2-0xo(6- 537.6 890 hydroquinolyl)}-2-[benzylamino]acetamide 4-amino-6-[methyl(1-methylpiperidin-4-yl)amino]-3-[6-(4- 501.6 891 methylpiperazin-1-y])-1H-benzimidazol-2-yl]quinolin-2(1H)-one : 4-amino-6-[({5-[(dimethylamino)methy]-2-furyl} methylamino}-3- 527.6 [6-(4-methylpiperazin-1-y1)-1 H-benzimidazol-2-yljquinolin-2(1H)- 892 one 4-amino-6-{[(2-ethyl-5-methyl-4H-imidazol-4-ylmethyl]amino}-3- 512.6 [6-(4-methylpiperazin-1-y)-1H-benzimidazol-2-yllquinolin-2(1H)- 893 lone \
N-{4-amino-3-[6-(4-methylpiperazin-1-yl)-1 H-benzimidazol-2-y1]-2- 460.6 894 oxo-1,2-dihydroquinolin-6-yl} butanamide 4-amino-3-(5-{[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1- 457.5 yljcarbonyl}-1H-benzimidazol-2-yl)quinolin-2(1H)-one
4-amino-3-[5<{(2R,5R)-2-[(dimethylamino)methyl]-5- 461.5 methylmorpholin-4-y1} carbonyl)-1H-benzimidazol-2-y{jquinolin-
896 2(1H)-one . 4-amino-3-[5-({(2S,5R)-2-{(dimethylamino)methyl]-5- 461.5 methylmorpholin-4-y1} carbonyl)-1H-benzimidazol-2-yllquinolin-
897 2(1H)-one 4-amino-5-fluoro-3-(6-{[(3S)-3-methylpiperazin-1-yljcarbonyl}-1H-
: 898 benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-5-fluoro-3 (6-{[3R)-3 -methylpiperazin-1-yljcarbonyl}-1H- 421.4
899 benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-5-fluoro-3-(5-{[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1- 475.5 yl]carbonyl}-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-6-(dimethylamino)-3-[5 -(4-methylpiperazin-1-yl)-1H- 418.5 901 benzimidazol-2-yllquinolin-2(1H)-one 4-amino-6-(methylamino)-3-[5-(4-methylpiperazin-1-yl)-1H- 404.5
902 benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-5-fluoro-3-[5-fluoro-6-(4-methylpiperazin-1-yl)-1H- 411.4
903 benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-3-[6-({(2R,55)-2-[(dimethylamino)methyl]-5- 461.5 methylmorpholin-4-yl}carbonyI)-1H-benzimidazol-2-yl]quinolin-
904 2(1H)-one 4-amino-3-[6-({(28,5S)-2-[(dimethylamino)methyl]-5- . 461.5 methylmorpholin-4-yl}carbonyl)-1H-benzimidazol-2-yl]quinolin-
905 2(1H)-one 4-amino-3-{6-[(3,5-dimethylpiperazin-1-yl)carbonyl}-1H- 417.5 benzimidazol-2-yl} quinolin-2(1H)-one 4-amino-3-[5-(4-ethylpiperazin-1-yl)-1H-benzimidazol-2-y1]-5- 407.5
907 fluoroquinolin-2(1H)-one 4-amino-3-[6-({(2R,58)-2-[(dimethylamino)methy1}-5- 479.5 methylmorpholin-4-y1}carbonyl)-1H-benzimidazol-2-y1}-5-
908 fluoroquinolin-2(1H)-one 4-amino-3-[6-({(28,5S)-2-[(dimethylamino)methyl]-5- 479.5 methylmorpholin-4-yl}carbonyl)-1H-benzimidazol-2-yl}-5- fluoroquinolin-2(1H)-one 4-amino-3-[5({(2R,5R)-2-[(dimethylamino)methyl]-5- k 479.5 methylmorpholin-4-yl}carbonyl)-1H-benzimidazol-2-yl]-5- fluoroquinolin-2(1H)-one 4-amino-3-[5-({(2S,5R)-2-{(dimethylamino)methyl}-5- 479.5 methylmorpholin-4-y1}carbonyl)-1H-benzimidazol-2-yl]-5-
911 fluoroquinolin-2(1H)-one
: | N-[3-({4-amino-3-[6-(4-methylpiperazin-1-yl}-1H-benzimidazol-2- | 3524.6
. 912 y1]-2-0x0-1,2-dihydroquinolin-5-y1} oxy)phenyljacetamide
4-amino-3-{6-[(4-ethylpiperazin-1-yl)carbonyl]-1H-benzimidazol-2- 417.5 913 yl}quinolin-2(1H)-one
2-(4-amino-2-oxo-1 2-dinydroquinolin-3-yl)-N,N'-dimethyl- 1 H- 363.4 914 benzimidazole-6-carbohydrazide 2-(4-amino-2-0x0-1 ,2-dihydroquinolin-3 -y1)-N-(tetrahydrofuran-2- 404.4 915 ylmethy!)-1H-benzimidazole-6-carboxamide 4-amino-5-[3 -(dimethylamino)phenoxy] -3-[6-(4-methylpiperazin-1- 510.6 916 yl)-1H-benzimidazol-2-yl] quinolin-2( 1H)-one 4-amino-5-(4-aminophenoxy)-3-[6-(4-methylpiperazin-1 -yl)-1H- 482.6 917 benzimidazol-2-yllquinolin-2(1H)-one 6-chloro-4-{[2-(dimethylamino)ethyl]amino}-3 -(6-fluoro-1H- 400.9 918 benzimidazol-2-yl)quinolin-2(1H)-one 4-{[(1R,2R)-2-aminocyclohexylJamino} -6-chloro-3-(6-fluoro-1H- 426.9 benzimidazol-2-yl)quinolin-2(1H)-one 6-chloro-3 —(6-fluoro-1H-benzimidazol-2-y})-4-[(piperidin-3- 920 ylmethyl)amino]quinolin-2(1H)-one 6-chloro-3 ~(6-fluoro-1H-benzimidazol-2-yl)-4-[(piperidin-4- 426.9 921 ylmethyl)amino] quinolin-2(1H)-one 4-[(4-aminocyclohexyl)amino}-6-chloro-3 -(6-fluoro-1H- 426.9 922 benzimidazol-2-yl)quinolin-2(1H)-one 6-chloro-3-(6-fluoro-1H-benzimidazol-2-y)-4-{[2- 386.8 923 (methylamino)ethyl]amino} quinolin-2(1H)-one 6-chloro-3-(6-fluoro-1H-benzimidazol-2-yl)-4-[(3 S)-pyrrolidin-3- 398.8 ’ 924 ylamino]quinolin-2(1H)-one 6-chloro-3 -(6-fluoro-1H-benzimidazol-2-yl)-4-{(3R)-pyrrolidin-3- 398.8 925 ylamino]quinolin-2(1H)-one 6-chloro-3-(6-fluoro-1H-benzimidazol-2-yl)-4-[(piperidin-2- 4269 926 yimethyl)amino]quinolin-2(1H)-one : 4-[(35)-1 _azabicyclo[2.2.2]oct-3 -ylamino]-6-chloro-3-(6~fluoro-1H- 4389 927 benzimidazol-2-yl)quinolin-2(1H)-one 6-bromo-4-{[2-(dimethyiamino)ethyijamino}-3 -{6-fluoro-1H- 445.3 928 benzimidazol-2-yl)quinolin-2(1H)-one 4-{[(1R,2R)-2-aminocyclohexyl]amino}-6-bromo-3 -(6-fluoro-1H- 471.3 benzimidazol-2-yl)quinolin-2(1H)-one 6-bromo-3 ~(6-fluoro-1H-benzimidazol-2-yI)-4-[(piperidin-3- 471.3 930 ylmethyl)amino]quinolin-2(1H)-one 6-bromo-3-(6-fluoro-1H-benzimidazol-2-yl)-4-[(piperidin-4- 471.3 931 ylmethyl)amino]quinolin-2(1H)-one 4-[(4-aminocyclohexyl)amino]-6-bromo-3 -(6-fluoro-1H- 471.3 932 benzimidazol-2-yl)quinolin-2(1H)-one 6-bromo-3-(6-fluoro-1 H-benzimidazo 1-2-yD)-4-{[2- 431.3 933 (methylamino)ethyljamino} quinolin-2(1H)-one 6-bromo-3-(6-fluoro-1H-benzimidazol-2-y1)-4-[(3 S)-pyrrolidin-3- 443.3 934 ylamino]quinolin-2(1H)-one 6-bromo-3-(6-fluoro- 1H-benzimidazol-2-yI)-4-[(piperidin-2- 471.3 935 ylmethyl)amino]quinolin-2(1H)-one 142 oo fig
4-[(38)-1-azabicyclo[2.2.2]oct-3-ylamino]-6-bromo-3 -(6-fluoro-1H- 483.4 936 benzimidazol-2-yl)quinolin-2(1 H)-one 6-bromo-3-(6-fluoro-1H-benzimidazol-2-y1)-4-[(3R)-pyrrolidin-3- 4433 937 ylamino]quinolin-2(1H)-one
N-[4-({4-amino-3 -[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- 524.6 938 yl]-2-0x0-1,2-dibydroquinolin-5-yl}oxy)phenyl]acetamide 4-amino-3-{6-[(4-cthylpiperazin-1-ylcarbonyl]-1H-benzimidazol-2- 435.5 . yl}-5-fluoroquinolin-2(1H)-one ethyl (38 AR)-4-({[2-(#-amino-5-fluoro-2-oxo-1,2-dihydroquinolin-3- 523.5 yl)-1H-benzimidazol-6-yl]carbonyl} amino)-3-methoxypiperidine-1- 940 carboxylate 2-(4-amino-5-fluoro-2-oxo-1 ,2-dihydroquinolin-3 -yD)-N-[(3R)-1- 447.5 941 azabicyclo[2.2.2)oct-3-y1]-1H-benzimidazole-6-carboxamide 2-(4-amino-5-fluoro-2-oxo-1,2-dihydroguinolin-3-yI)-N-{(3 S)-1- 447.5 942 azabicyclo[2.2.2]oct-3-y1}- 1 H-benzimidazole-6-carboxamide 4-amino-5-fluoro-3-{ 5-[(5-methy]-2,5-diazabicyclo [2.2.1Thept-2- 433.5 943 yl)carbonyl}-1H-benzimidazol-2-yl} quinolin-2(1H)-one 4-amino-3-[5-(1 _#-bipiperidin-1'-yl)-1H-benzimidazol-2-yl]-5- 461.6 944 fluoroquinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3 -ylamino]-6-chloro-3 -(7-morpholin- 945 4-y}-1H-benzimidazol-2-yl)quinolin-2(1H)-one : 6-chloro-3-(7-morpholin-4-yl-1H-benzimidazol-2-yl)-4-(piperidin-4- 480.0 946 ylamino)quinolin-2(1H)-one 6-chloro-3-(7-morpholin-4-yl-1H-benzimidazol-2-y1)-4-[(3 S)- 466.0 947 pyrrolidin-3-ylamino}quinolin-2(1H)-one 4-amino-7-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- 393.4 948 yllquinolin-2(1H)-one ) 4-amino-3-{6-[(2,6-dimethylpiperazin-1-yl)carbonyl]-1H- 417.5 - 949 benzimidazoi-2-yl}quinolin-2{1i)-one 4-amino-3~(5-{(2S,5R)-2-[(dimethylamino)methyl]-5- 451.5 methylmorpholin-4-y1}-1H-benzimidazol-2-y1)-5-fluoroquinolin- 950 2(1H)-one 6-chloro-3-(5-morpholin-4-yl-1H-benzimidazol-2-y1)-4-[(3 S)- 466.0 951 pyrrolidin-3-ylamino]quinolin-2(1H)-one 4-amino-3-(5-{(28,5 S)-2-[(dimethylamino)methyl]-5- 451.5 methylmorpholin-4-y1}-1H-benzimidazol-2-yl)-5-fluoroquinolin- 952 2(1H)-one 4-amino-3-(1H-benzimidazol-2-yl)-6-[methyl(1-methylpiperidin-4- ylamino]quinolin-2(1H)-one 4-amino-6-[isobutyl(methylamino]-3-[6-(4-methylpiperazin-1-yD)- 460.6 954 1H-benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-6-[(cyclohexylmethyl)(methyl)amino]-3-[6-(4- 500.7 - 955 methylpiperazin-1-yl)-1H-benzimidazol-2-yljquinolin-2(1 H)-one ess | 2.6-diamino-3-(6,7-dimethyl-1H-benzimidazol-2-yDquinolin-2(LH)- 320.4 one 4-amino-3-(6,7-dimethyl-1H-benzimidazol-2-y1)-6- 334.4 957 (methylamino)quinolin-2(1H)-one 4-amino-3-(5,6-dimethyl-1H-benzimidazol-2-y1)-6- 3344 958 (methylamino)quinolin-2(1H)-one 4.6-diamino-3-(1H-benzimidazol-2-yl)quinolin-2(1H)-one 2923 4-amino-3-(6,7-dimethyl-1H-benzimidazol-2-yl)-6- 376.5 (isobutylamino)quinolin-2(1H)-one 4-amino-3-(5,6-dimethyl-1H-benzimidazol-2-y)-6- 376.5 961 (isobutylamino)quinolin-2(1H)-one . N-(3-{[2-(4-amino-2-oxo-1,2-dihydroquinolin-3-yl)-1H- 426.4 962 benzimidazol-6-yljoxy} phenyl)acetamide 4-amino-3-[6-(3,4-dimethylpiperazin-1-y1)-1H-benzimidazol-2- 389.5 yllquinolin-2(1H)-one
N-[3-({4-amino-3-[6-(4-methylpiperazin-1-y1)-1 H-benzimidazol-2- 524.6 964 yl}-2-oxo-1 ,2-dihydroquinolin-6-yl}oxy)phenyl] acetamide 4-amino-3-(6-{(2R,5R)-2-[(dimethylamino)methyl]-5- 451.5. methylmorpholin-4-y1}-1H-benzimidazol-2-yl)-5-fluoroquinolin- 2(1H)-one 4-{[(1R,2R)-2-aminocyclohexyl]amino}-6-bromo-3-(6-chloro-5- 505.8 fluoro-1H-benzimidazol-2-yl)quinolin-2(1H)-one 6-bromo-3-(6-chloro-5-fluoro-1H-benzimidazol-2-y1)-4-[(piperidin- 505.8 967 4-ylmethyl)amino]quinolin-2(1H)-one 4-[(4-aminocyclohexyl)amino]-6-bromo-3-(6-chloro-5-fluoro-1H- 505.8 968 benzimidazol-2-yl)quinolin-2(1H)-one 6-bromo-3-(6-chloro-5-fluoro-1H-benzimidazol-2-yl)-4-{[2- 465.7 (methylamino)ethyllamino} quinolin-2(1H)-one : . 6-bromo-3-(6-chioro-3-fiuoro-1H-benzimidazol-2-yi)-4-{pyrolidin- A707 970 3-ylamino)quinolin-2(1H)-one 6-bromo-3-(6-chloro-5-fluoro-1H-benzimidazol-2-y})-4-[(3R)- 471.7 971 pyrrolidin-3-ylamino}quinolin-2(1H)-one 6-bromo-3-(6-chloro-5-fluoro-1H-benzimidazol-2-y1)-4-[(piperidin- 505.8 972 2-ylmethyl)amino}quinolin-2(1H)-one 4-[(35)-1-azabicyclo[2.2.2]oct-3 -ylamino]-6-bromo-3-(6-chloro-5- 517.8 973 fluoro-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-6-bromo-3-(6-chloro-5- 517.8 974 fluoro-1H-benzimidazol-2-yl)quinolin-2(1H)-one ) 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-6-bromo-3-(6-fluoro-1H- 483.4 975 | benzimidazol-2-yl)quinolin-2(1H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino}-6-chloro-3-(6-fluoro-1H- 438.9 976 benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-6-[bis(cyclohexylmethyl)amino]-3-(6,7-dimethyl-1H- 512.7 977 benzimidazol-2-yl)quinolin-2(1H)-one
4-amino-6-[bis(cyclohexylmethyl)amino)-3-(5,6-dimethyl-1H- 512.7 978 benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-5-(methylamino)-3-[6-(4-methylpiperazin-1-yl)-1H- 404.5 979 benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-6-[(cyclohexylmethyl)amino}-3-(6,7-dimethyl-1H- 416.5 980 benzimidazol-2-y)quinolin-2(1H)-one 4-amino-6-[(cyclohexylmethyl)amino}-3-(5,6-dimethyl-1H- 416.5 981 benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-6,7-difluoro-3-[5 -(4-methylpiperazin-1-yl)-1H- 411.4 982 benzimidazol-2-yllquinolin-2(1H)-one 4-amino-5-fluoro-3-[6-(2-methylpiperazin-1 -yI)-1H-benzimidazol-2- 393.4 983 yl]quinolin-2(1H)-one 4-amino-7-fluoro-3-{6-[(4-isopropylpiperazin-1-yl)carbonyl]-1H- 449.5 984 benzimidazol-2-yl}quinolin-2(1H)-one 4amino-3-[6-(2,A-dimethylpiperazin-1-yl)-1H-benzimidazol-2-yl}-5- 407.5 fluoroquinolin-2(1H)-one 2-(4-amino-7-fluoro-2-oxo-1,2-dihydroquinolin-3-yl)-N-methy}-N- 449.5 986 (1-methylpiperidin-4-yl)-1H-benzimidazole-5-carboxamide 6-chloro-3-(5-chloro-1H-benzimidazol-2-y1)-4-[(3 S)-pyrrolidin-3- 415.3 987 ylamino]quinolin-2(1H)-one 4-amino-7-fluoro-3-(5-{[(2R)-2-(pyrrolidin-1 -ylmethyl)pyrrolidin-1- 475.5 988 yljcarbonyl}-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-3-{6-[4-(2-methoxyethyl)piperazin-1-yl}-1H-benzimidazol- 419.5 989 2-yl}quinolin-2(1H)-one 0 | 4-amino-3-[5{(methylamino)-1 H-benzimidazol-2-yllquinolin-2(1H)- | 306.3 one 6-chloro-3-[5-(4-methylpiperazin-1-yl)-1 H-benzimidazol-2-y1}-4- 493.0 991 {[(3S)-1-methylpyrrolidin-3-yI]amino} quinolin-2(1H)-one 6-chloro-3-(5-chloro-1H-benzimidazoi-2-yi)-4-{{{35)-i- 4293 992 methylpyrrolidin-3-ylJamino} quinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-6-chloro-4-{[(38)-1-methylpyrrolidin-3- 394.9 yllamino}quinolin-2(1H)-one 3(1H-benzimidazol-2-yl)-6-chloro-4-[(1-methylpiperidin-4- 408.9 994 yDamino]quinolin-2(1H)-one : 6-chloro-3-(5-chloro-1H-benzimidazol-2-yl)-4-[(1-methylpiperidin-4- 4433 995 yl)amino]quinolin-2(1H)-one ’ 6-chloro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl}-4-[(1- 507.1 methylpiperidin-4-yl)amino]quinolin-2(1H)-one 6-chloro-3 -[5-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-yI]-4- 521.1 997 {[(1-methylpiperidin-2-yl)methylJamino} quinolin-2(1H)-one 4-{(3S)-1-azabicyclo[2.2.2]oct-3 -ylamino]-6-chloro-3- {5-[methyl(1- 547.1 methylpiperidin-4-yl)amino]-1H-benzimidazol-2-yl} quinolin-2(1H)- 998 one
6-chloro-3-{5-[methyl(1-methylpiperidin-4-yl)amino]-1H- 521.1 benzimidazol-2-y1}-4-(piperidin-4-ylamino)quinolin-2(1H)-one 6-chloro-3-{5-[methyl(1 -methylpiperidin-4-yl)amino]-1H- 507.1 1000 benzimidazol-2-y1}-4-[(3 S)-pyrrolidin-3-ylamino]quinolin-2(1H)-one 4-{[(2R)-2-aminobutyljamino} -6-chloro-3-{5-[methyl(1- 509.1 methylpiperidin-4-yl)amino]-1H-benzimidazol-2-y1} quinolin-2(1H)-
1001 one 4-amino-3-{6-[(35)-3,4-dimethylpiperazin-1-yl]-1 H-benzimidazol-2- | 389.5
1002 yl} quinolin-2(1H)-one 4-amino-3-[5-(4-methylpiperazin-1-yl)-1 H-benzimidazol-2-yl]-2-
1003 oxo-1,2-dihydroquinoline-6-carbonitrile : 4-amino-3-[5-(4-methylpiperazin-1 -yI)-1H-benzimidazol-2-y1]-2- 419.5
1004 oxo-1 ,2-dihydroquinoline-6-carboxylic acid 4-amino-5-fluoro-3-{5-[(8aS)-hexahydropyrrolo[ 1 ,2-a]pyrazin- 419.5 1005 2(1H)-yl]-1H-benzimidazol-2-yl} quinolin-2(1H)-one 4-amino-3-{6-[(38)-3,4-dimethylpiperazin-1 -yl}-1H-benzimidazol-2- | 407.5 1006 yl}-5-fluoroquinolin-2(1H)-one 4-[(3S)-1-azabicyclo[2.2.2]oct-3 -ylamino]-6-chloro-3-{6-[(3R)-3- 533.1 (dimethylamino)pyrrolidin-1 -yl]-1H-benzimidazol-2-y1} quinolin- 1007 2(1H)-one 6-chloro-3-{6-[(3R)-3 ~(dimethylamino)pyrrolidin-1 yI]-1B- 507.1 1008 benzimidazol-2-yl} -4-(piperidin-4-ylamino)quinolin-2(1 H)-one 6-chloro-3-{6-[(3 R)-3-(dimethylamino)pyrrolidin-1-yI}-1 H- 493.0 1009 benzimidazol-2-y1}-4-[(3S)-pyrrolidin-3-ylamino] quinolin-2(1H)-one 4-{[(2R)-2-aminobutyl]amino}-6-chloro-3 -{6-[(3R)-3- 495.0 (dimethylamino)pyrrolidin-1-yIJ-1 H-benzimidazol-2-yl}quinolin- 1010 2(1H)-one 6-chloro-3-{6-[(3R)-3 ~(dimethylamino)pyrrolidin-1-yl]-1H- 507.1 benzimidazol-2-y1}-4-{[(3S)-1-methylpyrrolidin-3- - 1011 yl]amino}quinolin-2(1H)-one 6-chloro-3- {6-[(3R)-3-(dimethylamino)pyrrolidin-1-y1]-1 H-- 521.1 benzimidazol-2-yl} -4-[(1-methylpiperidin-4-yl)amino]quinolin- 1012 2(1H)-one 4-amino-7-(methylamino)-3-[6-(4-methylpiperazin-1 -yl)-1H- 404.5 1013 benzimidazol-2-yl]quinolin-2(1H)-one 3(1H-benzimidazol-2-yl)-6-chloro-4-[(2-morpholin-4-y1-2-pyridin- 502.0 1014 3-ylethyl)amino]quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4- {[2-(dimethylamino)-2-pyridin- 460.0 1015 3-ylethyl]amino}quinolin-2(1H)-one : : 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino}-6-chloro-3-(6-{3- 547.1 [(dimethylamino)methyl]pyrrolidin-1-y1}- 1H-benzimidazol-2- 1016 yl)quinolin-2(1H)-one 6-chloro-3-(6-{3-[(dimethylamino)methyl]pyrrolidin-1 -yl}-1H- 521.1 1017 benzimidazol-2-yl)-4-(piperidin-4-ylamino)quinolin-2(1H)-one
6-chloro-3-(6-{3-[(dimethylamino)methy]pyrrolidin-1-yl}-1H- 1 507.1 1018 benzimidazol-2-y1)-4-[(3S)-pyrrolidin-3-ylaminolquinolin-2(1H}-one . 4-{[(2R)-2-aminobutyl}amino}-6-chloro-3-(6-{3- 509.1 [(dimethylamino)methyl]pyrrolidin-1-yl}-1H-benzimidazol-2- 1019 yDquinolin-2(1H)-one 6-chloro-3~(6-{3-[(dimethylamino)methyl]pyrrolidin-1-y1}-1H- 521.1 benzimidazol-2-yI)-4-{[(3S)-1-methylpyrrolidin-3- 1020 ylJamino}quinolin-2(1H)-one 6-chloro-3-(6-{3-[(dimethylamino)methyl]pyrrolidin-1-yl}-1H- 535.1 benzimidazol-2-y!)-4-[(1-methylpiperidin-4-yl)amino]quinolin- 1021 | 2(1H)-one 3-(1H-benzimidazol-2-y1)-6-chloro-4-{[(3S)-piperidin-3- 408.9 1022 ylmethyljamino}quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-{[(3R)-piperidin-3- 408.9 1023 ylmethyljamino}quinolin-2(1H)-one
N-(3-{[4-amino-3-(1H-benzimidazo}-2-yl)-2-0x0-1,2- 426.4 1024 dihydroquinolin-5-ylJoxy} phenyl)acetamide 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-6-chloro-3- {6-[3- 533.1 (dimethylamino)pyrrolidin-1-yl]-1H-benzimidazol-2-y1}quinolin- 1025 2(1H)-one 6-chloro-3-{6-[3-(dimethylamino)pyrrolidin-1 -yl]-1H-benzimidazol- 507.1 1026 2-yl}-4-(piperidin-4-ylamino)quinolin-2(1H)-one 4-{[(2R)-2-aminobutyl]amino}-6-chloro-3-{6-[3- 495.0 (dimethylamino)pyrrolidin-1-ylIj-1H-benzimidazol-2-yl} quinolin- 1027 2(1H)-one 6-chloro-3-{6-[3-(dimethylamino)pyrrolidin-1-yl]-1H-benzimidazol- 521.1 1028 2-yl}-4-[(1-methylpiperidin-4-yl)amino]quinolin-2(1H)-one 4-amino-7-[[2-(dimethylamino)ethyl}(methyl)amino}-3-[6-(4- 475.6 1029 methylpiperazin-1-yI)-1H-benzimidazol-2-ylJquinolin-2(1 H)-one 4-amino-5-fluoro-3-[6-(1,4-oxazepan-4-ylcarbonyl)-1H- . 422.4 1030 benzimidazol-2-yl]quinolin-2(1H)-one ) methyl 4-amino-3-[5~(4-methylpiperazin-1-yl)-1H-benzimidazol-2- 433.5 1031 yl]-2-0x0-1,2-dihydroquinoline-6-carboxylate 4-amino-N-benzyl-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol- 508.6 1032 2-yl]-2~0x0-1,2-dihydroquinoline-6-carboxamide 4-amino-3- {6-[4-(2-morpholin-4-ylethyl)piperazin-1 -yl}-1H- 474.6 1033 benzimidazol-2-y1}quinolin-2(1H)-one 4-amino-7-fluoro-3-[6-(4-isopropylpiperazin-1-yl)-1H-benzimidazol- | 421.5 1034 2-yllquinolin-2(1H)-one 4-amino-3-[5<(4-ethylpiperazin-1-yl)-1H-benzimidazol-2-yl]-7- 407.5 1035 fluoroquinolin-2(1H)-one 4-amino-3-{6-[(2-aminoethyl)(methyl)amino]-1H-benzimidazol-2- 349.4 1036 yl}quinolin-2(1H)-one 4-amino-3-{6-[[(2-ethyl-4-methyl-1H-imidazol-5- 428.5 1037 yl)methyl](methyl)amino]-1H-benzimidazol-2-y1} quinolin-2(1H)-one
2-amino-3-[6-(hydroxymethyl)-1 H-benzimidazol-2-yl]quinolin- 307.3 1038 2(1H)-one 4-amino-3-(6-{methyl[(2R)-pyrrolidin-2-ylmethyl]amino}-1H- 389.5 1039 benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-3-{6-[(1 H-imidazol-2-ylmethyl)(methyl)amino}-1H- 386.4 1040 benzimidazol-2-yl}quinolin-2(1H)-one 4-amino-3-{6-[(2-furylmethyl)(methyl)amino}-1H-benzimidazol-2- 386.4 1041 yl}quinolin-2(1 H)-one 4-amino-3-{6-[methyl(piperidin-4-ylmethyl)amino}-1H- 403.5 1042 benzimidazol-2-yl} quinolin-2(1H)-one 4-amino-3-{6-[methyl(piperidin-3-ylmethyDamino]-1H- 403.5 1043 benzimidazol-2-y1} quinolin-2(1H)-one 4-amino-3-(6-{methy1[2-(methylamino)ethylJamino}-1H- 363.4 1044 benzimidazol-2-yl)quinolin-2(1H)-one 6-acetyl-4-amino-3-[6-(4-methylpiperazin-1-y)-1H-benzimidazol-2- 417.5 : yllquinolin-2(1H)-one 4-amino-5-[2-(methylamino)phenoxy]-3-[6-(4-methylpiperazin-1-y1)- 496.6 1046 1H-benzimidazol-2-yl]quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-chloro-4-{[(2S)-piperidin-2- 408.9 . 1047 ylmethyl]amino} quinolin-2(1H)-one 4-amino-3-[6-(1,4-oxazepan-4-yl)-1H-benzimidazol-2-yl]quinolin- 3764 11048 | 2(1H)-one 4-amino-3-[5-(4-cthylpiperazin-1-yl)-1H-benzimidazol-2-yl]-6- 407.5 1049 fluoroquinolin-2(1H)-one 6-chloro-3-(5-chloro-1H-benzimidazol-2-yl)-4-[(3R)-pyrrolidin-3- 415.3 ylamino}quinolin-2(1H)-one } 4-amino-6-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- 478.5 1051 yl]-7-morpholin-4-ylquinolin-2(1H)-one 4-amino-6-fluoro-3-[5-(4-methyipiperazin-i-yl)-1 H-benzimidazol-2- 462.5 1052 yl}-7-pyrrolidin-1-ylquinolin-2(1H)-one 4-amino-7-(dimethylamino)-6-fluoro-3-[5-(4-methylpiperazin-1-yl)- 436.5 1053 1H-benzimidazol-2-y1]quinolin-2(1H)-one 4-amino-6-fluoro-7-(4-methylpiperazin-1-y1)-3-[5-(4- 491.6 1054 methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-6-fluoro-7-[(4-methoxybenzyl)amino]-3-{5-(4- 528.6 1055 methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-6-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- 1 499.6 yI]-7-{(pyridin-4-ylmethyl)amino]quinolin-2(1H)-one 4-amino-7-[[2-(dimethylamino)ethyl](methyl) amino]-6-fluoro-3-[5- 493.6 1057 (4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-3-[6-(4-cyclopentylpiperazin-1-yl)-1H-benzimidazol-2-yI]- 447.5 5-fluoroquinolin-2(1H)-one 4-amino-6-[1-(methylamino)ethyl]-3-[6-(4-methylpiperazin-1-yl)- 432.5 1H-benzimidazol-2-yl]quinolin-2(1H)-one
4-amino-5-fluoro-3-[6-(1,4-oxazepan-4-y1)-1H-benzimidazol-2- 394.4 1060 yllquinolin-2(1H)-one . 4-amino-3-{6-[methyl(pyridin-3-ylmethyl)amino]-1H-benzimidazol- 397.5 1061 2-y1} quinolin-2(1H)-one 4-amino-3-{6-[({5-[(dimethylamino)methyl]-2- 443.5 furyl}methyl)(methyl)amino]-1H-benzimidazol-2-y1} quinolin-2(1H)~ 1062 one 4-amino-3-[6-(4-oxopiperidin-1-y1)-1 H-benzimidazol-2-yl]quinolin- 374.4 1063 2(1H)-one 4-amino-3-{6-[4-(4-methylpiperazin-1-yl)piperidin-1-yI]-1H- 458.6 1064 benzimidazol-2-yl} quinolin-2(1H)-one 4-amino-3-[6-(4-{[(4-benzylmorpholin-2-yl)methylJamino} piperidin- 564.7 1065 1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-bromo-4-{[2- 427.3 1066 (dimethylamino)ethylJamino} quinolin-2(1H)-one 4-{[(1R,2R)-2-aminocyclohexyl]lamino}-3-(1 H-benzimidazol-2-yl)- 453.4 1067 6-bromoquinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-bromo-4-[(piperidin-4- 453.4 1068 'ylmethyl)amino]quinolin-2(1H)-one 4-[(4-aminocyclohexyl)amino]-3<(1H-benzimidazol-2-yl)-6- 453.4 1069 bromoquinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-bromo-4-{[2- 413.3 ~ 1070 (methylamino)ethyl]amino} quinolin-2(1H)-one 3-(1H-benzimidazol-2-y1)-6-bromo-4-[(3 S)-pyrrolidin-3- 4253 1071 ylamino]quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-bromo-4-[(3R)-pyrrolidin-3- 425.3 1072 ylamino}quinolin-2(1H)-one . 3-(1H-benzimidazol-2-yl)-6-bromo-4-[(piperidin-2- 453.4 1072 yimethyheminglguinolin-2(1H)-one 4-amino-N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-3-[5-(4- 527.6 methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-2-oxo-1,2- 1074 dihydroquinoline-6-carboxamide 4-amino-N-methyl-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol- 529.7 2-yl]-N-(1-methylpiperidin-4-y1)-2-oxo-1,2-dihydroquinoline-6- 1075 carboxamide
4-amino-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-2- 502.6 oxo-N-(tetrahydrofuran-2-ylmethyl)-1,2-dihydroquinoline-6- 1076 carboxamide
3-(1H-benzimidazol-2-y1)-6-chloro-4-[(3R)-pyrrolidin-3- 380.8 1077 | ylamino]quinolin-2(1H)-one oo i
3-(1H-benzimidazol-2-yl)-6-chloro-4-{[(2R)-piperidin-2- 408.9 1078 yimethyl]amino}quinolin-2(1H)-one
4-amino-3-{6-[(3R)-3,4-dimethylpiperazin-1-yl]-1H-benzimidazol-2- | 407.5 1079 yl}-5-fluoroquinolin-2(1H)-one
6-chloro-3-(6-chloro-5-fluoro-1H-benzimidazol-2-yl)-4-{[2- 4353 1080 (dimethylamino)ethyljamino} quinolin-2(1H)-one 4-{[(1 R2R)-2-aminocyclohexyl]amino}-6-chloro-3-(6-chloro-3- 461.3 1081 fluoro-1H-benzimidazol-2-yl)quinolin-2(1H)-one 6-chloro-3-(6-chloro-5-fluoro-1H-benzimidazol-2-y1)-4-[(piperidin-4- 461.3 1082 ylmethyl)amino]quinolin-2(1H)-one 4-[(4-aminocyclohexyl)amino]-6-chloro-3-(6-chloro-5 -fluoro-1H- 461.3 1083 benzimidazol-2-yl)quinolin-2(1H)-one 6-chloro-3-(6-chloro-5-fluoro-1 H-benzimidazol-2-y1)-4-{[2- 421.3 1084 (methylamino)ethyl]amino} quinolin-2(1H)-one 6-chloro-3-(6-chloro-5-fluoro-1H-benzimidazol-2-y)-4-[(3 S)- 433.3 1085 pyrrolidin-3-ylamino}quinolin-2(1H)-one 6-chloro-3-(6-chloro-5-fluoro-1H-benzimidazol-2-yD)-4-[(3R)- 433.3 1086 pyrrolidin-3-ylamino]quinolin-2(1H)-one 6-chloro-3-(6-chloro-5-fluoro-1H-benzimidazol-2-yl)-4-[(piperidin-2- 461.3 1087 ylmethyl)amino]quinolin-2(1H)-one 4-3 S)-1-azabicyclo[2.2.2]oct-3-ylamino]-6-chloro-3-(6-chloro-5- 4733 1088 fluoro-1H-benzimidazol-2-yl)quinolin-2(1 H)-one 4-[(3R)-1-azabicyclo[2.2.2]oct-3 -ylamino]-6-chloro-3-(6-chloro-5- 473.3 1089 fluoro-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-6-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- 393.4 1090 yllquinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-yl)-5-(methylamino)quinolin-2(1H)- 306.3 1091 one 4-amino-3-{6-[(25)-2,4-dimethylpiperazin-1-y1]-1H-benzimidazol-2- 407.5 1092 y1}-5-flucroquinolin-2(1H)-one 4-amino-5-fluoro-3-{6-[(2S)-2-methylpiperazin-1-yl]-1H- 393.4 1093 benzimidazol-2-yl} quinolin-2(1H)-one 4-amino-3-{6-[(2S)-4-isopropyl-2-methylpiperazin-1-yij-1¥i- 417.5 1094 benzimidazol-2-yl}quinolin-2(1H)-one 4-amino-5,7-difluoro-3-[5-(4-methylpiperazin-1 -y)-1H- 411.4 1095 benzimidazol-2-yl]quinolin-2(1H)-one 3-(1H-benzimidazol-2-yl)-6-bromo-4-{[(2S)-piperidin-2- 453.4 1096 ylmethyl]amino}quinolin-2(1H)-one 3.(1H-benzimidazol-2-yl)-6-bromo-4-{[(2R)-piperidin-2- 453.4 1097 ylmethyl]amino}quinolin-2(1H)-one 4-amino-3-{6-{methyl(1,3-thiazol-2-ylmethyl)amino]-1H- 403.5 1098 benzimidazol-2-yl}quinolin-2(1H)-one 4-amino-3-{6-[(1-ethylpiperidin-4-yI)(methyDamino]-1H- 417.5 1099 benzimidazol-2-yl}quinolin-2(1H)-one 4-amino-3-[6-(4-morpholin-4-ylpiperidin-1-y1)-1H-benzimidazol-2- 445.5 1100 yllquinolin-2(1 H)-one 4-amino-3-[6-(4-isopropylpiperazin-1-yl)-1H-benzimidazol-2-yI]-5- 432.5 i 1101 (methylamino)quinolin-2(1H)-one
4-amino-3- {6-[methyl(pyridin-2-ylmethyl)amino]-1H-benzimidazol- 397.5 1102 2-y1}quinolin-2(1H)-one 4-amino-3-{6-[(2S)-2,4-dimethylpiperazin-1-y1}-1H-benzimidazol-2- 389.5 1103 yl}quinolin-2(1H)-one : 4-amino-3-{6-[(2S)-2-methylpiperazin-1-yl}-1H-benzimidazol-2- 3754 1104 y1}quinolin-2(1H)-one
N-[2-(4-amino-2-oxo-1 ,2-dihydroquinolin-3-y1)-1 H-benzimidazol-6- 348.4 1105 yl}-N-methylacetamide 4-amino-5-fluoro-3-{6-[(2S)-4-isopropyl-2-methylpiperazin-1-yIl- 435.5 1106 1H-benzimidazol-2-yl} quinolin-2(1H)-one 4-amino-3-{6-[(3R)-3,4-dimethylpiperazin-1 -yl]-1H-benzimidazol-2- | 389.5 1107 yl} quinolin-2(1H)-one 4-[(35)-1-azabicyclo[2.2.2]oct-3-ylamino]-3 -(1H-benzimidazol-2-yl)- | 429.5 1108 6-(dimethylamino)quinolin-2(1H)-one 4-amino-3-{6-[(2S)-4-cyclobutyl-2-methylpiperazin-1 -yl}-1H- 429.5 1109 benzimidazol-2-yl} quinolin-2(1H)-one 4-amino-5-fluoro-3-[6-(methylamino)-1H-benzimidazol-2- 324.3 1110 yllquinolin-2(1 H)-one 4-amino-3-( 1H-benzimidazol-2-yl)-5-(dimethylamino)quinolin- 320.4 1111 2(1H)-one 4-amino-3-(1H-benzimidazol-2-yl)-5-{[2- 363.4 1112 (dimethylamino)ethyl]amino}quinolin-2(1H)-one 4-amino-5-fluoro-3-(5-piperazin-1-yl-1H-benzimidazol-2- 379.4 1113 yDquinolin-2(1H)-one 4-amino-3-{5-[[2-(dimethylamino)ethyl](methyl)amino]-1H- 395.5 1114 benzimidazol-2-y1}-5-fluoroquinolin-2(1H)-one 4-amino-5-fluoro-3-{5-[methyl(piperidin-3-ylmethyl)amino]}-1H- 421.5 1115 benzimidazol-2-y1}quinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-yI)-5-[[2- 377.5 1116 (dimethylamino)ethyl](methyl)amino]quinolin-2(1H)-one 4-amino-5-fluoro-3-{5-[(2R)-4-isopropyl-2-methylpiperazin-1-yl]- 435.5 1117 1H-benzimidazol-2-y1}quinolin-2(1H)-one 4-amino-3-{5-[(2S)-4-ethyl-2-methylpiperazin-1-yl]-1H- 421.5 1118 benzimidazol-2-y1}-5-fluoroquinolin-2(1H)-one 4-amino-3-(5-{[(1-ethylpyrrolidin-2-yl)methyl]amino}-1H- 421.5 1119 benzimidazol-2-yl)-5-fluoroquinolin-2(1H)-one 4-amino-3-(5-{[2-(dimethylamino)-1-methylethyl]amino}-1H- 395.5 1120 benzimidazol-2-yI)-5-fluoroquinolin-2(1H)-one 4-amino-3-{5-[[2-(dimethylamino)-1-methylethylj(methyl)amino]- 409.5 1121 1H-benzimidazol-2-yl}-5-fluoroquinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-yl)-5-(1,2- 335.4 1122 dimethylhydrazino)quinolin-2(1H)-one 4-amino-5-fluoro-3-{6-[4-(2-methoxyethyl)piperazin-1-yl]-1H- 437.5 1123 benzimidazol-2-y1} quinolin-2(1H)-one
4-amino-5-fluoro-3-{6-[methyl(1-methylpiperidin-4-yl)amino]-1H- 421.5 1124 benzimidazol-2-y1} quinolin-2(1H)-one 4-amino-5-fluoro-3-(6-{[3 -(4-methylpiperazin-1-yl)propyl]amino}- 450.5 1125 1H-benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-5-flucro-3~(6-{methy1[3-(4-methylpiperazin-1- 464.6 1126 yl)propylJamino} -1H-benzimidazol-2-yl)quinolin-2(1H)-one
N-[2-(4-amino-5-fluoro-2-0xo-1 ,2-dihydroquinolin-3-y1)-1H- 366.4 1127 benzimidazol-6-y1]-N-methylacetamide 4-amino-6-fluoro-3-(5-{[(2R)-2-(pyrrolidin-1 -ylmethyl)pyrrolidin-1- 475.5 1128 vil carbonyl} -1H-benzimidazol-2-yl)quinolin-2(1H)-one 4-amino-3-(1H-benzimidazol-2-yl)-5 (ethylamino)quinolin-2(1H)- 3204 1129 one 4-amino-3-{5-[(2R)-2,4-dimethylpiperazin-1-yl]-1H-benzimidazol-2- 407.5 1130 yl}-5-fluoroquinolin-2(1H)-one 4-amino-5-fluoro-3-{5-[(2R)-2-methylpiperazin-1-y1]-1H- 3934 1131 benzimidazol-2-y1}quinolin-2(1H)-one 4-amino-3-{5-[(2R)-4-cyclobutyl-2-methylpiperazin-1-yl}-1H- 447.5 1132 benzimidazol-2-y1}-5-fluoroquinolin-2(1H)-one 4-amino-5-(dimethylamino)-3-[6-(4-isopropylpiperazin-1 -yl)-1H- 446.6 benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-5-{[2-(dimethylamino)ethyljamino}-3-[6-(4- 489.6 1134 isopropylpiperazin-1 -yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-5-[[2-(dimethylamino)ethyl](methyl)amino}-3-[6-(4- 503.7 1135 isopropylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-5-(ethylamino)-3-[6-(4-isopropylpiperazin-1-yl)-1H- 446.6 1136 benzimidazol-2-ylJquinolin-2(1H)-one
N-[2-(4-amino-2-0x0(3 -hydroquinolyl))benzimidazol-6-y1]-2- 391.4 1137 (dimethylamino)-N-methylacetamide 4-amino-5-fluoro-3-[6-(9-isopropyi-i-oxa-4,9-diazaspirof 5.5 jundsc- 451.6 1138 4-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-7-fluoro-3-[6-fluoro-5-(4-methylpiperazin-1-yl)-1H- 4114 1139 benzimidazol-2-yl]quinolin-2(1H)-one 4-amino-3+(5-{(2S,58)-2-[(dimethylamino)methy]}-5- methylmorpholin-4-y1}-6-fluoro-1H-benzimidazol-2-yI)-5 - 1140 fluoroquinolin-2(1H)-one 4-amino-3-(5-{(2S,5S)-2-[(dimethylamino)methyl]-5- 451.5 methylmorpholin-4-y1}-6-flucro-1H-benzimidazol-2-yl)quinolin- 1141 2(1H)-one 4-amino-5-methyl-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- | 389.5 1142 ylquinolin-2(1H)-one 4-amino-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl}-5- 443.4 1143 (trifluoromethyl)quinolin-2(1H)-one 4-amino-5-fluoro-3-[6-(2-isopropyl-5-oxa-2,8-diazaspiro[3.5]non-8- 463.5 1144 yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one
4-amino-6-fluoro-3-[5-(4-isopropylpiperazin-1 -yl)-1H-benzimidazol- | 421.5 1145 2-yllquinolin-2(1H)-one
N-[2-(4-amino-5-fluoro-2-oxo-1,2-dihydroquinolin-3-yl)-1H- 464.5 1146 benzimidazol-6-y1}-N-methyl-2-(4-methylpiperazin-1-yl)acetamide
N-[2-(4-amino-5-fluoro-2-oxo-1 ,2-dihydroquinolin-3-yl)-1H- 451.5 1147 benzimidazol-6-y1]-N-methyl-2-morpholin-4-ylacetamide
N-[2-(4-amino-5-flucro-2-oxo(3-hydroquinolyl))benzimidazol-6-y1]- 492.6 1148 N-methyl-2-morpholin-4-ylacetamide 4-amino-5-fluoro-36-methyl-1H-benzimidazol-2-yl)quinolin-2(1H)- 309.3 1149 one 4-amino-3-[5-(4-ethylpiperazin-1-yl)-1H-benzimidazol-2-y1}-5- 1 403.5 1150 methylquinolin-2(1H)-one 4-amino-3-{6-[(4-methylpiperazin-1-yl)methyl}-1 H-benzimidazol-2- 389.5 1151 yl}quinolin-2(1H)-one 4-amino-3-[6-(1,4-diazepan-1-yl)-1H-benzimidazol-2-yI}-5- 393.4 1152 fluoroquinolin-2(1H)-one 4-amino-5-fluoro-3-[6-(4-methyl-1,4-diazepan-1-yI)-1H- 407.5 1153 benzimigdazol-2-yllquinolin-2(1H)-one 3-[6-(4-acetylpiperazin-1-yl)-1 H-benzimidazol-2-yl]-4-amino-3- 421.4 1154 fluoroquinolin-2(1H)-one 4-amino-3-[6-(4-ethyl-1,4-diazepan-1-yl)-1H-benzimidazol-2-y1]-5- 421.5 1155 fluoroquinolin-2(1H)-one 4-amino-5-fluoro-3-[6-(4-isopropyl-1,4-diazepan-1-y1)-1H- | 435.5 1156 benzimidazol-2-yl]quinolin-2(1H)-one
[0242] Many of the above Examples (1-1156) displayed an ICso value of less than 10 uM with respect to Flt-1, KDR, PDGF, ¢-KIT, FLT-3, VEGFR1, VEGFR2, c-
Met, CSF-1, FGFR3 and/or bFGFR. Additionally, many of the above Examples : displayed an ICs value of less than 10 pM with respect to PDGFR.
In Vitro Activity of 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yljquinolin-2(1H)-one Against Various RTKs
[0243] 4-Amino substituted quinolinone benzimidazolyl compounds such as 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-yl]quinolin- 2(1H)-one and tautomers and salts thereof are potent inhibitors of various kinases such as VEGFR2 (KDR, Flk-1), FGFR1 and PDGFR with ICsos ranging from 10-27 nM. See U.S. Patent No. 6,605,617, U.S. Patent Application No. 10/644,055, and
U.S. Patent Application No. 10/706,328, each of which is hereby incorporated by reference in its entirety and for all purposes as if fully set forth herein, for a list of various tyrosine and serine/threonine kinases for which 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-y1)-1H-benzimidazol-2-yl]quinolin-2(1H)-one bas shown activity and for assay procedures. These RTKs are important for the initiation and maintenance of new blood vessel growth as well as tumor proliferation. Systematic profiling against class III-IV RTKs as well as a subset of RTKs from other classes shows potent inhibition of CSF-R1/c-fns, c-kit, flt3 and FGFR3. FGFR3 is ; abnormally expressed and in some cases constitutively activated in a subset of multiple myeloma patients as a consequence of the t(4;14) translocation (about 15- 20%).
[0244] The effects of 4-amino substituted quinolinone benzimidazolyl compounds such as 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one on multiple myeloma cell lines with the t(4;14) translocation were investigated with respect to effects on proliferation, cell cycle, © apoptosis, and FGFR3 and ERK (extracellular regulated kinase) phosphorylation.
Multiple myeloma presents with detrimental bone loss mainly mediated by the large increase in IL6 production and concomitant activation of osteoclasts responsible for bone resorption. M-CSF has a role in recruitment of osteoclast precursors and may promote their survival. Blocking signaling through the CSF-1R may thus provide additional benefit to multiple myeloma patients. Inhibition of M-CSF mediated proliferation of the murine myeloid cell line M-NFS-60 correlated with inhibition of in vitro kinase activity against c-fms/CSF-1R.
[0245] 4-Amino substituted quinolinone benzimidazolyl compounds such as 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin- 2(1H)-one and tautomers and salts thereof act as potent inhibitors of Class m-v
RTKs. ICs values of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H- benzimidazol-2-yl]quinolin-2(1H)-one are presented in the following table.
Table 9. Activity of 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yllquinolin-2(1H)-one Against Various RTKs
Tom om
CO ori [oo
EC CT
VeGRRIFR [00]
EC CC
Varo [00m
EX e214 (HERZ [>10
[0246] The in vitro RTK assays used to prepare the above table were run in the presence of an ATP concentration that was within three-fold or at Ky, of enzymes used (for enzymes where the Kn, was available). Phosphorylated peptide substrate was detected with a Europium labeled anti-phospho-tyrosine Antibody (PT66). The
Europium was then detected using time resolved fluorescence. For some assays, y-P**
ATP was incubated with the enzyme and the radioactivity of phosphorylated peptide substrate was quantified in the presence of various concentration of 4-amino-5-fluoro- 3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl] quinolin-2(1H)-one and used to calculate the ICs.
[0247] FIG. 1 shows that 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yD)-1H- benzimidazol-2-yl]quinolin-2(1H)-one inhibits proliferation of multiple myeloma cell lines. KMS11, OPM-2, and H929 are multiple myeloma cell lines that were incubated with serial dilutions of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-
benzimidazol-2-yl]quinolin-2(1H)-one. After 72 hours, the number of viable cells left was determined using the CellTiter-Glo™ Assay (Promega). KMS11 and OPM-2 have activating mutations in the FGFR3 receptor, and H929 expresses WT FGFR3. 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin- 2(1H)-one inhibited FGFR3 receptor kinase (ICso = 9 nM, Table 9) and blocked proliferation of two cell lines with activating FGFR3 mutations: KMS11 (Y 3730) and OPM-2 (K650E) cells with ECsgs of 60 nM and 87 nM, respectively (see FIG. 1).
H929 cells express WT FGFR3 and mutant N-ras (13G>D), and proliferation was inhibited, but less potently, by 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one in this cell line (ECsp = 2.6 pM, ECsp in serum : reduced growth media = 0.6 uM).
[0248] FGFR3 tyrosine phosphorylation was inhibited by 4-amino-5-fluoro-3- [6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-yllquinolin-2(1H)-one at 0.5 uM in
KMS11 cells (see FIG. 2). KMSI11 cells were starved for two hours in growth media containing 1% FBS. The cells were then incubated with different concentrations of 4- amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl] quinolin-2(1H)- one for two hours in growth media without FBS, washed and lysed for immunoprecipitation with FGFR3 Ab (sc123 Santa Cruz Biotech). Lysates were analyzed by western blotting and probed with anti-phosphotyrosine Antibody 4G10 (Upstate Biotech). The lower panel showed total FGFR3 after stripping the western blot and reprobing with FGFR3 Ab (See FIG. 2).
[0249] 4-Amino-5-flucro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one was found to inhibit ERK phosphorylation at 0.5 uM in
KMS11 cells. KMS11 cells were starved for two hours in growth media containing 1% FBS. The cells were then incubated with different concentrations of 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-yl]quinolin-2(1H)-one for two hours in growth media without FBS, washed, lysed, and analyzed by western blotting and probed with anti phospho-ERK Antibody (Cell Signaling). The lower panel of FIG. 3A shows cyclophilin protein (Upstate Biotech) as a loading control. 4-
Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H).- one also inhibited ERK phosphorylation at 0.1 uM in OPM-2 cells. OPM-2 cells were incubated with different concentration of 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yllquinolin-2(1H)-one for one hour in growth media with 1% FBS, washed, lysed, and analyzed by western blotting and probed with anti phospho-ERK Antibody (Cell Signaling). The lower panel of FIG. 3B shows 14-3-3 protein (Santa Cruz Biotech) as a loading control. ERK in the
MAPK pathway is a downstream FGFR3 signaling component and phosphorylation of ERK was inhibited in both OPM-2 and KMS11 cells at 0.5 pM 4-amino-5-fluoro- 3-[6-(4-methylpiperazin-1-yl)-1 H-benzimidazol-2-yl}quinolin-2(1H)-one (See FIGS. 3A and 3B). In contrast, the compound had no effect on phospho-ERK levels up to 5 pM in H929 cells. H929 cells were starved for two days in growth media without
FBS. The cells were then incubated with different concentrations of 4-amino-35- . fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one for one hour in growth media without FBS, washed, stimulated for 5 minutes with 50 ng/mL aFGF and 10 pg/mL Heparin, lysed, and analyzed by western blotting and probed with anti phospho-ERK Ab (Cell Signaling). Only a minor change in phospho-ERK in response to stimulation with aFGF after two days of serum starvation indicated that the pathway is constitutively activated due to the Ras mutation (See FIG. 3C).
[0250] KMS11 cells were incubated with 4-amino-5 -fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one at various concentrations for 96 hours. The incubated KMS11 cells were washed and stained with AnnexinVPE and 7AAD according to the Nexin assay protocol (Guava
Technologies). Samples were run on Guava PCA™ instrument and percentage of cells in each category were analyzed with the Guava Nexin™ software. OPM-2 cells were incubated with 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one at various concentrations for 72 hours. The incubated OPM-2 cells were washed and stained with AnnexinVPE and 7AAD according to the Nexin assay protocol (Guava Technologies). Samples were run on
Guava PCA™ instrument and percentage of cells in each category were analyzed with the Guava Nexin™ software. Results of the above experiments show that 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one induced apoptosis as measured by AnnexinVPE staining in KMS11 and OPM-2 cells starting at concentrations of 0.1 uM and 0.5 pM respectively (FIGS. 4 and 6).
[0251] The experimental data regarding induction of apoptosis by 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-ylJquinolin-2(1H)-one in
KMS11 and OPM-2 cells was confirmed by significant increases in the sub G1 population of cells in a cell cycle analysis observed at concentrations of 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yllquinolin-2(1H)-one of 0.1 pM and higher (FIG. 5). KMS11 cells were incubated with 4-amino-5-fluoro-3- [6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-yllquinolin-2(1H)-one at concentrations of 0.001 uM, 0.01 pM, 0.1 pM, and 1 uM for 72 hours. Cells were then fixed and stained with propidium iodide before analyzing the samples by FACS (See FIG. 5). These results showed that the compound has minor effects on the cell cycle, but induced apoptosis in KMS11 cells at 0.1 pM. OPM-2 cells were also incubated with 4-amino-5 -fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one at concentrations of 0.001 pM, 0.01 pM, 0.1 pM, and 1 pM for, 72 hours. Cells were similarly fixed and stained with propidium iodide before analyzing the samples by FACS (See FIG. 7). These results showed that the compound has minor effects on the cell cycle, but induced apoptosis in OPM.-2 cells at 0.5 pM. Other effects on the cell cycle by the compound were minor e.g., there was no significant G1 arrest. Increases in the sub G1 population were less significant in the OPM-2 cell line compared to the KMS11 cells and started at 0.5 uM (FIG. 7).
[0252] H929 cells were incubated with 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one at concentrations of 0.01 uM, 0.1 uM, 0.5 uM, and 1 pM for 72 hours. Cells were then fixed and stained i with propidium iodide before analyzing the samples by FACS (See FIG. 8). 4-
Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)- one had no effects on the cell cycle in H929 cells with concentrations up to 1 uM confirming that the FGFR3 expressing N-ras mutant cell line is less sensitive to 4- amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)- one (FIG. 8) than are the KMS11 and OPM-2 cells.
[0253] Osteolytic bone loss is one of the major complications in multiple myeloma disease. The major cytokines involved in bone resorption are IL1f and IL6.
In addition, increased serum concentrations of M-CSF have been detected in patients. 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yllquinolin- 2(1H)-one inhibits CSF-1R activity, the only known receptor for M-CSF with an ICso of 36 nM (See Table 9). M-CSF mediated proliferation of a mouse myeloblastic cell line M-NFS-60 was inhibited with an ECso of 220 nM (FIG. 9). Murine M-NFS-60 cells were incubated with serial dilutions of 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one in assay media with ng/mL M-CSF and without GM-CSF. Cells in control wells were incubated with assay media only. ‘After 72 hours incubation time, the number of viable cells left was determined using the CellTiter-Glo™ Assay (Promega). ECsp values were determined using nonlinear regression (FIG. 9).
[0254] 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one has significant antiproliferative activity and inhibits FGFR3 receptor phosphorylation and ERK phosphorylation in multiple myeloma cell lines with activating FGFR3 mutations. Therefore, the invention provides a method for inhibiting FGFR3 receptor phosphorylation and ERK phosphorylation in multiple myeloma cell lines with activating FGFR3 mutations which includes administering an effective amount of a 4-amino substituted quinolinone benzimidazolyl compound, a tautomer thereof, a salt of the 4-amino substituted quinolinone benzimidazolyl compound, a salt of the tautomer, a combination thereof, or a pharmaceutical formulation comprising the 4-amino substituted quinolinone benzimidazolyl : compound, the tautomer thereof, the salt of the 4-amino substituted quinolinone benzimidazolyl compound, the salt of the tautomer, or the combination thereof to a subject with a multiple myeloma cell line with activating FGFR3 mutations, wherein inhibition of FGFR3 receptor phosphorylation and/or ERK phosphorylation is inhibited after administration of the compound or the pharmaceutical formulation. In some embodiments, the 4-amino substituted quinolinone benzimidazolyl compound is 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin- 2(1H)-one. In some embodiments, the subject is a mammal such as a rodent or primate. In some such embodiments, the subject is a mouse, whereas in other embodiments the subject is a human, The invention further provides the use of a 4- amino substituted quinolinone benzimidazolyl compound, a tautomer thereof, a salt of the 4-amino substituted quinolinone benzimidazolyl compound, a salt of the tautomer, or a combination thereof, in the preparation of a medicament for inhibiting the FGFR3 receptor phosphorylation and/or ERK phosphorylation. In some such embodiments, the 4-amino substituted quinolinone benzimidazolyl compound is 4-amino-5-fluoro-3- [6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl|quinolin-2(1H)-one.
[0255] 4- Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one caused apoptosis, but had minor effects on the cell cycle in
FGFR3 mutant cell lines at concentrations of <0.5 uM. Therefore, the invention provides a method of inducing apoptosis in FGFR3 mutant cell lines which, in some embodiments, is not accompanied by a large effect on the cell cycle. The method includes administering an effective amount of an effective amount of a 4-amino substituted quinolinone benzimidazolyl compound, a tautomer thereof, a salt of the 4- amino substituted quinolinone benzimidazolyl compound, a salt of the tautomer, a combination thereof, or a pharmaceutical formulation comprising the 4-amino substituted quinolinone benzimidazolyl compound, the tautomer thereof, the salt of the 4-amino substituted quinolinone benzimidazolyl compound, the salt of the tautomer, or the combination thereof to a subject with a multiple myeloma cell line with activating FGFR3 mutations, wherein apoptosis in FGFR3 mutant cell lines is induced following administration. In some embodiments, the 4-amino substituted quinolinone benzimidazolyl compound is 4-amino-5-fluoro-3-[6-(4-methylpiperazin- 1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one. In some embodiments, the subject is a mammal such as a rodent or primate. In some such embodiments, the subject is a mouse, whereas in other embodiments the subject is a human, The invention further provides the use of a 4-amino substituted quinolinone benzimidazolyl compound, a tautomer thereof, a salt of the 4-amino substituted quinolinone benzimidazolyl compound, a salt of the tautomer, or a combination thereof, in the preparation of a medicament for inducing apoptosis in FGFR3 mutant cell lines, which in some : embodiments, is not accompanied by a large effect on the cell cycle when incubated for the indicated times.
In some such embodiments, the 4-amino substituted quinolinone benzimidazolyl compound is 4-gmino-5-fluoro-3-[6-(4-methylpiperazin- 1-y1)-1H-benzimidazol-2-yl]quinolin-2(1H)-one. 1025 6] Inhibition of M-CSF mediated proliferation of the murine myeloid cell line M-NFS-60 correlated with inhibition of the in vitro kinase activity of CSF-1R by 4-amino-S-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yljquinolin- 2(1H)-one.
Potent activity of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one against t(4:14) multiple myeloma cell lines especially those with activating FGFR3 were observed.
Furthermore, this compound and salts and tautomers thereof may be used to protect patients with multiple myeloma from osteolytic bone loss and lesions.
Therefore, in some embodiments, the invention provides a method of inhibiting M-CSF mediated proliferation of myeloid cell lines and inhibiting CSF-1R activity.
The method comprises administering an effective amount of an effective amount of a 4-amino substituted quinolinone benzimidazolyl compound, a tautomer thereof, a salt of the 4-amino substituted quinolinone benzimidazolyl compound, a salt of the tautomer, a combination thereof, or a pharmaceutical formulation comprising the 4-amino substituted quinolinone benzimidazolyl compound, the tautomer thereof, the salt of the 4-amino substituted quinolinone benzimidazolyl compound, the salt of the tautomer, or the combination thereof to a subject with a myeloid cell line, wherein M-CSF mediated proliferation of myeloid cell lines and/or CSF-1R activity is inhibited.
In some embodiments, the 4- amino substituted quinolinone benzimidazolyl compound is 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one.
The invention further provides the use of a 4-amino substituted quinolinone benzimidazolyl compound, a tautomer thereof, a salt of the 4-amino substituted quinolinone benzimidazolyl compound, a salt of the tautomer, or a combination thereof, in the preparation of a medicament for inhibiting M-CSF mediated proliferation of myeloid cell lines and/or CSF-1R activity.
In some such embodiments, the 4-amino substituted quinolinone benzimidazolyl compound is 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-y1)-1H-benzimidazol-2-yl]quinolin-2(1H)-one.
The invention also provides a method of reducing osteolytic bone loss or lesions in subjects with multiple myeloma, the method comprising administering effective amount of an effective , amount of a 4-amino substituted quinolinone benzimidazolyl compound, a tautomer thereof, a salt of the 4-amino substituted quinolinone benzimidazolyl compound, a salt of the tautomer, a combination thereof, or a pharmaceutical formulation comprising the 4-amino substituted guinolinone benzimidazolyl compound, the tautomer thereof, the salt of the 4-amino substituted quinolinone benzimidazolyl compound, the salt of the tautomer, or the combination thereof to a subject with multiple myeloma, wherein a reduction in osteolytic bone loss or lesions is observed in the subject after administration. In some embodiments, the 4-amino substituted quinolinone benzimidazolyl compound is 4-amino-5-fluoro-3-[6-(4-methylpiperazin- 1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one. In some embodiments, the subject is a mammal such as a rodent or primate. In some such embodiments, the subject isa mouse, whereas in other embodiments the subject is a human. The invention further provides the use of a 4-amino substituted quinolinone benzimidazolyl compound, a tautomer thereof, a salt of the 4-amino substituted quinolinone benzimidazolyl compound, a salt of the tautomer, or a combination thereof, in the preparation of a medicament for reducing osteolytic bone loss or lesions in subjects with multiple myeloma. In some such embodiments, the 4-amino substituted quinolinone benzimidazolyl compound is 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H- benzimidazol-2-yl]quinolin-2(1H)-one.
TREATMENT OF MULTIPLE MYELOMA
[0257] "The t(4:14) translocation that occurs uniquely in a subset (20%) of multiple myeloma (MM) patients results in the ectopic expression of the receptor tyrosine kinase (RTK), fibroblast growth factor receptor 3 (FGFR3). Inhibition of activated FGFR3 in MM cells induces apoptosis, validating FGFR3 as a therapeutic target in t(4;14) MM and encouraging the clinical development of FGFR3 inhibitors for the treatment of these poor-prognosis patients. 4-Amino substituted quinolinone benzimidazolyl compounds such as 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yi)- 1H-benzimidazol-2-yl]quinolin-2(1H)-one, act as inhibitors of FGFR3. 4-Amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one potently inhibits FGFR3 with ICs of 5 nM in in vitro kinase assays and selectively inhibited the growth of B9 cells and human myeloma cell lines expressing wild-type (WT) or activated mutant FGFR3. In responsive cell lines, 4-amino-5-fluoro-3-{6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one induced cytostatic and eytotoxic effects.
Importantly, addition of interleukin-6 (IL-6), insulin growth factor 1 (IGF-1) or co-culture on stroma did not confer resistance to 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yljquinolin-2(1H)-one.
In primary myeloma cells from t(4;14) patients, 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one inhibited downstream ERK 1/2 phosphorylation with an associated cytotoxic response.
Finally, therapeutic efficacy of 4-Amino substituted quinolinone benzimidazolyl compounds such as 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one was demonstrated in a xenograft mouse model of FGFR3 MM. © 4-Amino substituted quinolinone benzimidazolyl compounds such as 4-amino-5- fluoro-3-[6-(4-methylpiperazin- 1-y1)-1H-benzimidazol-2-yl]quinolin-2(1H)-one are potent inhibitors of FGFR3-transformed hematopoietic cell lines and human multiple myeloma cell lines expressing either WT or mutant FGFR3. In addition, these "compounds are potent inhibitors in a mouse model of FGFR3-mediated MM and are cytotoxic to primary myeloma cells from t(4;14) patients.
Taken together, these data indicate that 4-amino substituted quinolinone benzimidazolyl compounds such as 4- amino-5-fluoro-3-[6-(4-methylpiperazin-1 -y)-1H-benzimidazol-2-yl]quinolin-2(1H)- one have significant potential in treating MM associated with FGFR3 expression.
METHODS
Chemical Compounds and Biological Reagents
[0258] 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one was dissolved in DMSO at a stock concentration of 20 mM.
For animal experiments, 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one was formulated in 5 mM citrate buffer. Acidic
FGF (aFGF) and heparin were purchased from R&D Systems (Minneapolis, MN) and
Sigma (Ontario, Canada), respectively. FGFR3 antibodies (C15, H100 and BY) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA), and 4G10 from Upstate
Biotechnology (Lake Placid, NY).
In Vitro Kinase Assays :
[0259] The ICso values for the inhibition of RTKs by 4-amino-5-fluoro-3-[6- (4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one were determined in a time resolved fluorescence (TRF) or radioactive format, measuring the inhibition by 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin- 2(1H)-one of phosphate transfer to a substrate by the respective enzyme. Briefly, the respective RTK domain was expressed or purchased as recombinant protein and incubated with serial dilutions of 4-amino-S-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one in the presence of substrate and ATP concentrations within 2-3 times the Kp, of the enzyme. ICs; values were calculated using non-linear regression and represent the average of at least 2 experiments. :
FGFR3 Expression Vectors and BY Cell Transfectants
[0260] BO cells expressing WT FGFR3 (B9-WT), FGFR3-K650E (B9-
K650E) and empty retrovirus (B9-MINV) have been described previously. Plowright,
E.E. et al., Blood, 2000; 95:992-998. Full-length FGFR3 cDNAs, containing F384L,
Y373C, or J807C (gift of Marta Chesi, Weill Medical College of Cornel}, New York,
NY) were cloned into an MSCV-based retroviral vector containing a green fluorescent protein (GFP) cassette. A construct carrying the G384D mutation was created from the FGFR3-WT by replacing the PmiI-BglIl fragment between amino acid 290 and 413 with the same fragment obtained from the KMS18 as previously described. Ronchetti, D. et al., Oncogene, 2001; 20:3553-3562. The constructed retroviral vectors were transfected into GP-E ecotropic packaging cells. The resulting retroviruses were used to introduce FGFR3 into the IL-6 dependent murine myeloma cell line, BY. A limiting cell dilution was further performed to generate single cell clones. A high-expressing clone for each construct (B9-F384L, B9-Y373C, BY-
G384D and B9-J807C) was cryopreserved.
Cell Lines and Tissue Culture
[0261] All human MM cell lines and BO cells were maintained in Iscove’s
Modified Dulbecco’s Medium (IMDM) supplemented with 5% FCS, 100 pg/ml penicillin and 100 pg/m! streptomycin (Gibco, Invitrogen Canada, Ontario) and 1%
IL-6 conditioned medium (BY cells only). BM stroma cells (BMSCs) were derived from BM specimens obtained from MM patients. Mononuclear cells separated by
Ficoll-Hipaque density sedimentation were used to establish long-term cultures, as described previously. Hideshima, T. et al., Blood, 2000; 96:2943-2950. For the purposes of viability assays BMSCs were irradiated with 20 Gy after plating on 96 well plates.
Viability Assay
[0262] Cell viability was assessed by 3-(4,5-dimethylthiazol)-2,5-diphenyl tetrazolium (MTT) dye absorbance. Cells were seeded in 96-well plates at a density of 5,000 (BY ceils) or 20,000 (MM cell lines) cells per well in IMDM with 3% FCS,
Cells were incubated with 30 ng/ml aFGF and 100 pg/ml heparin or 1% IL-6 where indicated and increasing concentrations of 4-amino-5-fluoro-3-[6-(4-methylpiperazin- 1-y1)-1H-benzimidazol-2-yl1quinolin-2(1H)-one. For each concentration of 4-amino- 5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, 10 pl aliquots of drug or DMSO diluted in culture medium was added. For drug combination studies, cells were incubated with 0.5 pM dexamethasone, 100 nM 4- : amino-5-fluoro-3-[6-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yl]quinolin-2(1H)- one or both simultaneously where indicated. To evaluate the effect of 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one on growth of MM cells adherent to BMSCs, 10,000 KMS11 cells were cultured on
BMSC-coated 96-well plates, in the presence or absence of 4-amino-5-fluoro-3-[6-(4-
methylpiperazin-1-y1)-1H-benzimidazol-2-yllquinolin-2(1H)-one. Plates were incubated for 48 to 96 hours at 37°C, 5% CO. The MTT assay was performed according to the manufacturer’s instruction (Boehringer Mannheim, Mannheim,
Germany). For assessment of macrophage-colony stimulating factor (M-CSF) mediated growth, 5000 M-NFS-60 cells per well were incubated with serial dilutions of 4-amino-S-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-ylJquinolio- 2(1H)-one in media with 10 ng/ml M-CSF and without granulocytemacrophage- colony stimulating factor (GM-CSF). After 72 hours, cell viability was determined using Cell Titer-Glo™ Assay (Promega, Madison, WI). ECsp values were determined using non-linear regression. Each experimental condition was performed in triplicate.
Intracellular Phospho-Protein Staining
[0263] Determination of ERK 1/2 phosphorylation by flow cytometry has been described previously. Chow, S. et al., Cytomeiry, 2001; 46:72-78; and Irish, J. M. ef al., Cell, 2004; 118:217-228Briefly, cells were serum starved overnight and then stimulated with 30 ng/ml aFGF and 10 pg/ml heparin for 10 minutes at 37°C. The cells were immediately fixed by adding 10% formaldehyde directly into the culture medium to obtain a final concentration of 2%. Cells were incubated in fixative for 10 minutes at 37°C then on ice for an additional 2 minutes. The cells were permeabilized by adding ice-cold methanol (final concentration of 90%) and incubated on ice for 30 minutes. Cells were stained with anti-ERK1/2 (Cell Signaling Technology, Beverly,
MA) for 15 minutes and labeled with FITC-conjugated goat anti-rabbit and anti-
CD138-PE (PharMinogen, San Diego, CA) where indicated. Malignant cells were identified as cells that express high levels of CD138. Flow cytometry was performed on a FACS Caliber flow cytometer (BD Biosciences, San Jose, CA) and analyzed using Cellquest software (Becton Dickinson).
Apoptosis Analysis
[0264] For studies of apoptosis, cells were seeded at an initial density of 2 x 10°/m] medium supplemented with DMSO, 100 nM or 500 nM 4-amino-5-fluoro-3- [6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-yl] quinolin-2(1H)-one and cultured for up to 6 days. The medium and drug were replenished every 3 days, and the cell density was adjusted to 2 x 10%/ml. Apoptosis was determined by Annexin V staining (Boehringer Mannheim, Indianapolis, IN) and analyzed by flow cytometry.
Primary Patient Samples
[0265] Patients identified for the study were determined to possess a t(4;14) translocation by fluorescence in situ hybridization (FISH). Expression of FGFR3 was confirmed by flow cytometry as described previously. Chesi, M. et al., Blood, 2001; 97:729-736. Briefly, erythrocytes were lysed and BM mononuclear cells were incubated on ice for 30 minutes with rabbit anti-FGFR3 (H100) or rabbit preimmune serum. The cells were stained with FITC-conjugated goat antirabbit IgG and mouse anti-CD138-PE to identify MM cells. The samples were then analyzed by flow cytometry.
[0266] All t(4;14) positive samples were further analyzed for the presence of
FGFR3 or Ras mutations. Four pairs of primers were designed to amplify the regions of FGFR3-containing codons of the extracellular (EC) domain, transmembrane (™) domain tyrosine kinase (TK) domain and stop codon (SC), known hot spots for activating mutations. Two pairs of primers were designed to amplify regions of codons 12, 13, and 61 of N-ras and K-ras. Chesi, M. et al., Blood, 2001; 97:729-736.
A first PCR reaction was performed on genomic DNA extracted from CD1 38 purified myeloma cells and amplicons were used for DHPLC analysis. Results were confirmed by sequence analysis of ihe PCR products.
[0267] For cell death analysis, mononuclear cells were separated by Ficoll-
Hipaque gradient sedimentation and plated at a cell density of 5 x 10° cells/ml in
IMDM supplemented with 20% FCS and 30 ng/ml aFGF and 10 pg/ml heparin. Cells were cultured in the presence of DMSO or 500 nM 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-y1)-1H-benzimidazol-2-yl]quinolin-2(1H)-one for up to 12 days.
The medium, aFGF/heparin and drug were replenished every 3 days. After 3, 7 and 12 days, cells were triple stained with anti-CD38-PE, antj-CD45-CyChrome (PharMinogen) and FITC-conjugated Annexin V as previously described. LeBlanc,
R. et al., Cancer Res., 2002; 62:4996-5000. Controls included unstained cells, isotype control stained cells, and single-stained cells. Malignant cells plasma cells were defined as cells that express high levels of CD38 and no or low levels of CD45 (CD38"/CD45"). Samples were analyzed by FACScan analysis using Cellquest software. BM aspirates were obtained by consent under an IRB-approved protocol.
Xenograft Mouse Model
[0268] The xenograft mouse model was prepared as previously described.
Mohammadi, M. et a.,l Embo. J., 1998; 17:5896-5904. Briefly, six to eight week old female BNX mice obtained from Frederick Cancer Research and Development Centre (Frederick, MD) were inoculated s.c. into the right flank with 3 x 10” KMS11 cells in 150 pl of IMDM, together with 150 pl of matrigel basement membrane matrix (Becton Dickinson, Bedford, MA). Treatment was initiated when tumors reached volumes of approximately 200 mm? at which time mice were randomized to receive "10, 30 or 60 mg/kg 4-amino-5-fluoro-3 -[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one or 5 mM citrate buffer. Dosing was performed daily by gavage and continued for 21 days. Eight to 10 mice were included in each treatment group. Calliper measurements were performed twice weekly to estimate tumor volume, using the formula: 4n/3 x (width/2)? x (length/2). One way analysis of variance was used to compare differences between vehicle and 4-amino-5-fluoro-3- [6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl] quinolin-2(1H)-one treated groups.
Immunoprecipitation and Iimmunobiviting
[0269] Immunoprecipitation and immunoblotting were performed as described ’ previously. LeBlanc, R. et al., Cancer Res., 2002; 62:4996-5000. Briefly, tumors from sacrificed mice were immediately homogenized on ice and lysed in detergent buffer. Clarified cell extracts (1 mg/sample) were incubated for 6 hours with C15
FGFR3 antibody, then protein A/G agarose (Santa Cruz) was added for an additional 2 hours. Immunoblotting was performed with anti-phosphotyrosine antibody, 4G10 to assess phosphorylated FGFR3, or with anti-FGFR3 (B9) to measure total FGFR3.
Histopathology and Immunohistochemical Analysis : [0270] Tissue samples were fixed in 10% formalin and embedded in paraffin, from which 5 pm histologic sections were cut and stained with hematoxylin and eosin. Immunohistochemistry (IHC) studies were performed by indirect immunoperoxidase staining of paraffin tissue sections using a TechMate500™
BioTek automated immunostainer (Ventana Medical Systems, Inc., Tucson, AZ) and antibodies recognizing FGFR3 (C15), Ki-67 (Zymed, San Francisco, CA), and cleaved caspase 3 (Signaling Cell Technology) as previously described.
RESULTS OF MULTIPLE MYELOMA STUDIES
Selective Kinase Inhibition of 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)- 1H-benzimidazol-2-yl]quinolin-2(1H)-one
[0271] The ability of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H- benzimidazol-2-yl]quinolin-2(1H)-one to inhibit exogenous substrate phosphorylation was tested against a wide range of kinases. The concentration of 4-amino-5-fluoro-3- [6-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yl] quinolin-2(1H)-one resulting ina : 50% reduction in the activity of receptor tyrosine kinases (ICso) is reported in Table 9. 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-yl]quinolin- 2(1H)-one inhibited members of the class III RTKs including FLT3, ¢-Kit, CSF-R1 and PDGFRo/Bwith ICs; values of 0.001-0.21 mM as assessed by in vitro kinase assays. In addition, 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one potently inhibited class IV (FGFR1 and 3) and class V (VEGFR1-4) RTKs with ICsp values of 0.008-0.013 mM. When similar kinase assays for InsR, EGFR, ¢-MET, EphA2, TIE2, IGFR1 and HERZ were performed, significant inhibition was observed only at >10-fold higher concentrations.
These studies demonstrated that 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one is a selective but multi-targeted inhibitor of class III, IV and V RTKs with high potency against FGFRs. 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin- 2(1H)-one Inhibits the Growth of WT and Mutant FGFR3 Transformed Cells 10272] The ability of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one to inhibit constitutively activated FGFR3 mutants identified in MM patients (Y373C, G384D, K650E, J807C) was also tested.
Chesi, M. et al., Blood, 2001; 97:729-736; and Ely, S. A. et al., Cancer, 2000;
89:445-452. Stable expression of these cDNAs conferred IL-6 independent growth to
B9 cells, demonstrating that these mutants retain biologic activity and providing a platform for testing potential FGFR3 inhibitors against various classes of FGFR3 mutations. To determine the effect of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1- y1)-1H-benzimidazol-2-yl]quinolin-2(1H)-one on FGFR3-mediated cell growth, B9 cells expressing FGFR3-WT, FGFR3-F384L (a non-transforming polymorphism) and the FGFR3-activated mutants were grown in increasing concentrations of inhibitor for 48 hours exposure following which viability was determined by MTT assay (FIG. 10).
As expected, 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one potently inhibited the FGF-stimulated growth of WT and
F384L-FGFR3 expressing B9 cells with ICso values of 25 nM. In addition, 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl] quinolin-2(1H)-one inhibited proliferation of BY cells expressing each of the various activated mutants of
FGFR3. Interestingly, there were minimal observed differences in the sensitivity of the different FGFR3 mutations to 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)- oo 1H-benzimidazol-2-yl]quinolin-2(1H)-one, with the ICs ranging from 70-90 nM for each of the various mutations. IL-6 dependent B9 cells 11 containing vector only (BS-
MINV) were used to detect non-specific toxicity. B9-MINV cells were resistant to the inhibitory activity of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one at concentrations up to 1 pM. These data further confirm the in viiro kinase daia demonstrating inhibition of FGFR3 by 4- amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)- one and indicate that nonspecific cytotoxic effects are not observed within the effective range of drug concentration. These results also indicate that 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one has potent activity against a variety of activated mutants of FGFR3 described in MM. 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin- 2(1H)-one is Cytotoxic to FGFR3-Expressing Myeloma Cells
[0273] To assess the potential of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1- yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one as a therapeutic agent in MM, the effect of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-
yl]quinolin-2(1H)-one on the growth and survival of human myeloma cell lines was also investigated. FGFR3 positive cell lines (KMS11, KMS18, OPM2, H929) and the
FGFR3 negative cell lines, U266 and 8226 were incubated with increasing concentrations of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol- 2-yl]quinolin-2(1H)-one and cell viability was monitored (Table 10). 4-Amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-ylJquinolin-2(1H)-one inhibited cell proliferation of KMS11 (FGFR3-Y373C) and OPM2 (FGFR3-K650E), and KMS18 (FGFR3-G384D) cells with ICso of values of 90 nM (KMS11 and
QPM2) and 550 nM respectively. FGFR3 negative cell lines and H929 (F GFR3-WT), : a cell line that harbors a downstream activating mutation of N-Ras (Chesi, M. et al.,
Blood, 2001; 97:729-736), were resistant, requiring greater than 5-fold higher _ concentrations to inhibit cell growth. Inhibition of cellular growth was associated . with disappearance of downstream ERK 1/2 phosphorylation as determined by flow cytometry. The 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one sensitive cell lines (KMS11, KMS18, OPM?2) all demonstrated loss of ERK 1/2 phosphorylation in the presence of effective doses of 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yljquinolin-2(1H)-one. In contrast, H929 cells, which displayed minimal cytostatic response to 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl}quinolin-2(1H)-one, demonstrated high basal levels of MAP kinase activation as a result of constitutive "Ras activation and showed no change in ERK 1/2 phosphorylation, indicating that 4- amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)- one is acting upstream of Ras.
Table 10. ICs values (in nM) of 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)- 1H-benzimidazol-2-yl]quinolin-2(1H)-one Against Human Myeloma Cell Lines. ee BE | ee ___gemotype —%sii + | vanc | 90 —Msis | + | GasaD [550 —opMz___ | + | Resee | 90 — woe | + | wr | >3500 — sme | - [ND | >2500 ues | - | ND | _ >2500
Listed are MIM cell lines and the presence (+) or absence (-) of the t(4;14) translocation and the FGFR3 mutations. WT denotes the wild-type genotype and N'D means not determined. The concentration of 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1 -y1)-1H-benzimidazol-2-yl]quinolin-2(1H)-one that inhibits 50% viability (ICs0) as compared to DMSO control (MTT assay or Cell titer Glo) after 72 hours incubation with 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one was determined.
[0274] 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yllquinolin-2(1H)-one also induced apoptosis in responsive FGFR3 expressing cell lines. Treatment of KMS11, OPM2, and KMS18 cells with 500 nM 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one for 96 hours resulted in a significant increase in the percentage of annexin-V binding cells when compared to DMSO controls (FIG. 11). The delayed induction of apoptosis observed in some myeloma cell lines is similar to that previously reported with the more selective FGFR3 inhibitor, PD173074. Trudel S. of al, Rlood, 2004; 103:3521-3528. Treatment of FGFR3-negative cells (U266 not shown) had no effect on annexin V-binding suggesting that class IIT and V RTKs that can potentially be inhibited by 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one are not expressed or are not essential for survival of these myeloma cells,
[0275] The cytotoxic potential of 4-amino-5-fluoro-3-[6-(4-methylpiperazin- 1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one was assessed against primary human myeloma cells, Freshly isolated BM mononuclear cells were obtained from patients previously identified by FISH as t(4;14) positive or negative. Chang, H. ef al., Br. J.
Haematol., 2004; 125:64-68. The presence or absence of FGFR3 expression was confirmed by flow cytometry (FIG. 12A). Of the five t(4;14) positive samples, all but one demonstrated high level expression of FGFR3 on CD138 positive myeloma cells (Table 10). In addition, these samples were screened by DHPLC for FGFR3 mutations and downstream mutations of N and K-Ras. Results were confirmed by sequence analysis. No mutations were identified. FGF stimulation of primary cells in culture resulted in upregulation of ERK 1/2 phosphorylation in CD138 positive myeloma cells demonstrating biological activity of FGFR3 in these cells (FIG. 12B). : 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin- 2(1H)-one at 500 nM fully inhibited ERK 1/2 phosphorylation in all samples. In addition, mononuclear cells were cultured with 500 nM 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1 -y1)-1H-benzimidazol-2-yl] quinolin-2(1H)-one or DMSO vehicle and apoptosis was determined by annexin V staining. Four of five t(4;14) myeloma samples demonstrated a cytotoxic response to 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one when compared to vehicle control whereas none of the other myeloma samples were affected (FIGS. 12C and 12D and Table 11). Interestingly, the t(4;14) positive sample that demonstrated low level FGFR3 expression was 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)- 1H-benzimidazol-2-yl]quinolin-2(1H)-one resistant implying that only high level of
WT FGFR3 expression can confer dependence. Support for this hypothesis is provided by studies of ¢-KIT (Rubin, B. P. ef al., Cancer Res., 2001; 61:8118-8121) in gastrointestinal tumors and FLT3 (Armstrong, S. A. et al. Cancer Cell, 2003; 3:173-183) in AML where high level expression of the WT receptor, as well as receptor mutation, lead to constitutive activity and inhibitor sensitivity, Furthermore, sensitivity to Herceptin in breast cancer correlates with the level of HER2/neu expression. Vogel, C. L. et al., J. Clin. Oncol., 2002; 20:719-726. Alternatively, MM cells from this patient may have activation of additional pathways, that circumvent dependency on FGFR3 signaling.
Table 11. Summary of Expression of FGFR3 on Primary MM Cells in Relation to Sensitivity to 4-Amino-5-fluore-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yllquinolin-2(1H)-one (Compound).
Patient | FGFR3 FGFR3 | N&K- % % Annexin % (flow genotype Ras Annexin Vv Increase cytometry) genotype A Compound | Annexin pi | DMSO | (500aM) _V_ —TT Wb | WI | Wi | 90 | 218 | 209 — 1 + [wr | Wr _| 104 | 86 | 18 —5— 1 = [wr | wr _| 08 | 41 [| 323 —4 | = | wr | wr | 68 | 257 | 189 += | Wr | wr | doi | 245 | 144 —% | - | ND | Nb | 88 | 102 | 14 — _- [Np | ND | 153 | 160 | 07 —s | _- | Wp | ND | 200 | 207 | 02 — | - | Nb | ND | 128 | 134 | 06 —10 | - | ND | ND | 150 | 171 [ 21
FGFR3 expression on CD138 primary MM cells was analyzed by flow cytometry and the fluorescence was expressed as follows: +, weak; ++ intermediate; +++ strong; -, absent. CD138 selected cells were screened for the FGFR3 and N and K-Ras mutations. WT denotes wild-type status and N/D indicates not determined.
Effect of IL-6, IGF-1 and Stroma on Response of MM cells to 4-Amino-5-fluoro- 3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yljquinolin-2(1H)-one
[0276] Given the known role of IL-6 (Klein, B. et al., Blood, 1995; 85:863- 872; and Anderson, K. C. et al., Semin. Hematol., 1999; 36:14-20) and more recently,
IGF-1 (Ogawa, M. et al., Cancer Res., 2000; 60:4262-4269; and Mitsiades, C. S. al., Cancer Cell, 2004; 5:221-230) in tumor cell proliferation, survival and drug resistance in MM, experiments were performed to determine whether exogenous IL-6 and IGF-1 could overcome the growth inhibitory effects produced by 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one.
Inhibition with 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one was still observed when KMS11 cells were grown in the presence of 50 ng/ml IL-6 or 50 ng/ml IGF-1 and was comparable to that of cells cultured in the presence of aFGF (FIG. 13A). These studies highlight the critical role of FGFR3 function in the hierarchy of growth factor. receptors in these cells.
[0277] Because the BM microenvironment has been shown to confer drug resistance in MM cells (Dalton, W. S. et al., Semin Hematol., 2004; 41:1-5; and
Hideshima, T. et al., Semin. Oncol., 2001; 28:607-612), the effect of 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)- 1H-benzimidazol-2-yl]Jquinolin-2(1H)-one on
MM cell growth was investigated in the BM milieu. The direct toxicity of 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)- 1H-benzimidazol-2-yl]quinolin-2(1H)-one on
BMSCs was determined using the MTT assay, and no significant difference in cell viability of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one treated cells compared to DMSO controls (FIG. 13B) was observed. KMS11 cells were then cultured with or without BMSCs in the presence or absence of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)- 1H-benzimidazol-2- yl]quinolin-2(1H)-one. BMSCs did confer a modest degree of resistance with 44.6% growth inhibition for cells treated with 500 nM 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl] quinolin-2(1H)-one and cultured on stroma compared to with 71.6% growth inhibition for cells grown without BMSCs.
However, cell growth was still significantly inhibited by the 4-amino-5-fluoro-3-[6- (4-methylpiperazin-1-yl)-1H-benzimidazol-2~yl]quinolin-2(1H)-one despite the presence of stroma. 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl] quinolin- 2(1H)-one Augments Dexamethasone Cytotoxicity in Multiple Myeloma
[0278] FGFR3 expression results in increased STAT3 phosphorylation and higher levels of Bel-xt. expression than that observed in parental B9 cells after IL-6 withdrawas. Plowright, E. E. ef al., Blood, 2000; 95:992-998; and Pollett, J. B. et al.,
Blood, 2002; 100:3819-3821. These findings were associated with inhibition of dexamethasone-induced apoptosis, a phenomenon that was reversed by Bel-xi anti- sense oligonucleotide. Treatment of FGFR3 expressing MM cells may, thus overcome resistance to dexamethasone. As shown in Table 12, KMS11 cells are relatively resistant to dexamethasone; however, when combined with 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, synergistic inhibitory effects were observed. These data indicates the usefulness of combining dexamethasone with 4-gmino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one as a therapeutic strategy.
Table 12. Effect of 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-y})-1H- benzimidazol-2-yljquinolin-2(1H)-one (Compound) and/or Dexamethasone on
KSM11 Viability. : oMso iow nM 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl] quinolin- 2(1H)-one Inhibits M-CSF Mediated Cell Growth
[0279] Osteolytic bone loss is one of the major complications in MM. The major osteoclast activating factors involved in bone resorption are IL-1B, IL-6,
RANK-L and M-CSF. Croucher, P. 1. ef al., Br. J. Haemaatol., 1998; 103:902-910.
MM cells, osteoblasts and stromal cells in the BM express M-CSF which together with RANK-L is essential for osteoclast formation. Quinn, J. M. et al.,
Endocrinology, 1998; 139:4424-4427. Increased serum concentrations of MCSF have been detected in MM patients. Janowska-Wieczorek, A. et al., Blood, 1991; 77:1796- 1803. In vitro kinase assays demonstrate potent activity of 4-amino-5-fluoro-3-[6-(4~ methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one against CSF-1R, the only known receptor for M-CSF with an ICs of 36 nM (Table 9). 4-Amino-5-fluoro- 3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one inhibited proliferation of M-NFS-60, a M-CSF growth driven mouse myeloblastic cell line with an ECsp of 220 nM (FIG. 14). It would appear, therefore, that in addition to inhibiting
MM cell growth, 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol- 2-yl]quinolin-2(1H)-one has the advantage of potentially inhibiting tumor-associated osteolysis.
Evaluation of 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol- 2-yllquinolin-2(1H)-one in vivo in a Xenograft Mouse Model
[0280] The efficacy of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one was tested in a murine model in which KMS11 cells are injected subcutaneously into BNX mice. Grad, J. M. et al., Blood, 2001; 805-813; and Lentzsch, S. et al., Leukemia, 2003; 17:41-44. A similar plasmacytoma xenograft mouse model has been used in pre-clinical studies of Bortezomib and
IMiDs in MM. Each of 36 BNX mice were injected in the flank with 3 x 10” KMS11 cells together with matrigel by s.c. injection. ‘When the tumors reached approximately 200 mm?, mice were randomized (n=8-10) to receive vehicle or 4-amino-5-fluoro-3- [6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yllquinolin-2(1H)-one at 10 mg/kg, 30 mg/kg and 60 mg/kg, administered by oral gavage once daily for 21 days. When compared to vehicle controls, a significant (p<0.001) anti-tumor effect was observed in all three 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one dose groups with a minimum effective dose of 10 mg/kg/d (FIG. 15). Specifically, 48%, 78.5% and 94% growth inhibition was calculated in the mg/kg, 30 mg/kg and 60 mg/kg treatment arms, respectively, compared to the placebo treated mice. On the last day of dosing, 7 of 10 mice in the highest treatment group had achieved and maintained a partial remission with > 50% reduction in tumor volumes compared to day 1 of drug administration. Weight loss, as a marker of significant toxicity, was not observed in any of the treatment groups.
[0281] To demonstrate that the observed responses correlated with FGFR3 inhibition, mice were sacrificed 4 hours after receiving the last dose of 4-amino-3- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one and tumors were harvested for analysis of in vivo inhibition of FGFR3 phosphorylation.
FGFR3 was immunoprecipitated from tumor cell lysates and the level of expression and phosphorylation was determined on immunoblots. In vivo inhibition of FGFR3 was observed, with complete inhibition of FGFR3 occurring at the 60 mg/kg dose.
Inhibition of FGFR3 phosphorylation was dose dependent and correlated with the anti-tumor response.
[0282] Histopathologic examination of the tumors from representative animals further supported the interpretation of tumor reduction in the drug-treated mice compared to the placebo controls. Tumors from the drug-treated mice showed large areas of tumor necrosis. Immunohistochemistry for expression of the proliferative antigen, Ki-67, and for cleaved caspase 3, demonstrated that 4-amino-5-fluoro-3-[6- (4-methylpiperazin-1-y1)-1H-benzimidazol-2-yllquinolin-2(1H)-one inhibited cell growth and induced apoptosis. These findings suggest that 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one induces both cytostatic and cytotoxic responses in vivo resulting in regression of FGFR3 expressing tumors.
DISCUSSION
[0283] The identification of recurrent cytogenetic abnormalities in MM and characterization of the translocation partners has identified novel molecular targets and presents the potential for molecular targeted therapy for this universally fatal disease. Kuehl, W. M. et al., Nat Rev Cancer, 2002; 2:175-187; and Chesi, M. et al.,
Nat. Genet., 1997; 16:260-265. Nearly 20% of newly diagnosed cases of MM harbor the t(4;14) translocation as detected by the presence of IgH-MMSET hybrid transcript (Santra, M. et al., Blood, 2003; 101 12374-2376), the presence of which has generally been reported to be associated with a poor-prognosis. Fonseca, R. et al., Blood, 2003; 101:4569-4575; Keats, J. J. et al., Blood, 2003; 101: 1520-1529; Moreau, P. et al.,
Blood, 2002; 100:1579-1583.; and Chang, H. et al., Br. J. Haematol., 2004; 125:64- 68. FGFR3 is expressed in approximately 70% (Keats, J. J. et al, Blood, 2003; 101:1520-1529; and Quinn, J. M. et al., Endocrinology, 1998; 139:4424-4427) of these cases and 10% (Intini, D. ef al., Br. J. Haematol., 2001; 114:362-364) of patients will acquire an activating mutation of FGFR3 with disease progression.
[0284] An understanding of the genetic defects that are causally implicated in oncogenesis has led to targeted therapy for the treatment of a number of cancers.
Druker, B. J. etal., N. Engl. J. Med., 2001; 344: 1031-1037; Demetri, G. D. ef al., N.
Engl. J. Med., 2002; 347:472-480; Slamon, D. J. etal, N. Engl. J. Med. 2001; 344:783-792; and Smith, B. D. et al., Blood, 2004; 103:3669-3676. Most notably, the inhibition of BCR-ABL kinase activity by STI571 has produced major cytogenetic remissions in chronic myelogenous leukemia (CML). Druker, B. J. et al.,N. Engl. J.
Med., 2001; 344:1031-1037. Inhibition of activated c-Kit in gastrointestinal stromal tumors by STI571 has also been effective against this chemoresistant tumor. Demetri,
G.D. etal, N. Engl. J. Med., 2002; 347:472-480. In addition, Herceptin, a monoclonal antibody targeting HER2/neu, has resulted in improved chemotherapy responses and prolonged survival of breast cancer patients. Slamon, D. J. et al, N.
Engl. J. Med. 2001; 344:783-792. A similar kinase inhibitor strategy targeting FLT3 in acute myeloid leukemia (AML) is also showing promising results in Phase IT clinical trial. Smith, B. D. et al., Blood, 2004; 103:3669-3676. Pre-clinical studies of
FGFR3 inhibition in t(4;14) myeloma have likewise identified this RTK as a plausible candidate for targeted therapy. Two antagonists of FGFR3, PD173074 and SU5402 inhibited the growth and induced apoptosis of MM cells expressing mutant FGFR3.
Trudel, S. et al., Blood, 2004; 103:3521-3528; Paterson, J. L. et al., Br. J. Haematol., 2004; 124:595-603; and Grand .E. K. ef al., Leukemia, 2004; 18:962-966. Together these studies support the clinical development of FGFR3 inhibitors for these patients.
Unfortunately, PD173074 is not a candidate compound for the clinic and the ICsp of
SU5402, required to inhibit FGFR3 is not likely to the achieved in vivo.
[0285] - 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one is a potent inhibitor of FGFR3 and class III, IV and V RTKs including, FLT3, c-Kit, c-Fms, PDGFR and VEGFR. In this study, 4-amino-5-fluoro- 3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one was demonstrated to be a highly active inhibitor of both WT and mutant FGFR3 17 tyrosine kinases. The activity of this inhibitor against a broad spectrum of RTKs implies that 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one requires less stringent conformation requirements for binding to the kinase domain and is consistent with the retained activity of 4-amino-5-fluoro- 3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl] quinolin-2(1H)-one against many FGFR3 mutants. 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yljquinolin-2(1H)-one treatment selectively induced apoptotic cell death of MM cell lines and primary patient samples that harbor FGFR3. The potential clinical application of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one for the treatment of MM was further validated using a xenograft mouse model in which 4-amino-5-fluoro-3-[6-(4-methylpiperazin- 1-y1)-1H-benzimidazol-2-yl]quinolin-2(1H)-one treatment inhibited FGFR3 activity in vivo and produced tumor regression and significantly decrease disease progression.
[0286] Although the data suggests that FGFR3 is the primary target of 4- amino-5 _fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)- one in MM cells, it is important to note that OPM2 cells responded to this broadly active RTK inhibitor when they did not respond to the more selective FGFR3 inhibitor PD173074. Trudel, S. et al., Blood, 2004; 103:3521-3528; and Paterson, J.
L.etal, Br. J. Haematol., 2004; 124:595-603. This cell line is characterized by high basal levels of AKT phosphorylation (data not shown) and biallelic PTEN deletion.
Consistent with our results, Grand et al. demonstrated that the multi-targeted RTK inhibitor, SU5402 induced cytotoxic responses in OPM2 cells whereas PD173074 failed to induce apoptosis. Grand ,E.K. et al., Leukemia, 2004; 18:962-966. These findings also raise the possibility that 4-amino-5-fluoro-3-[6~(4-methylpiperazin-1- yl)-1H-benzimidazol-2-yllquinolin-2(1H)-one is targeting other, as yet to be defined, targets important for myeloma cell viability, a fact that is of further relevance given the demonstration that FGFR3 is sometimes lost during disease progression and may, therefore, be supplanted by other downstream signaling mediators.
[0287] With the latter point in mind, it is important to note that the clinical _ relevance of FGFR3 in t(4;14) myeloma has been questioned by observations that the der(14) chromosome is lost in some myeloma patients suggesting that FGFR3 is dispensible and that MMSET is the true causal target of t(4;14) in MM. Keats, J. J. et al., Blood, 2003; 101:1520-1529; and Intini, D. et al., Br. J. Haematol., 2001; 114:362-364. Moreover, studies in model systems indicate that WT FGFR3 is not dominantly transforming, requiring additional cooperating oncogenic events to complement transformation. Chesi, M. et al., Blood, 2001; 97:729-736; and Li, Z. et al., Blood, 2001; 97:2413-2419. The data presented above, however, indicates that primary MM cells that definitively express FGFR3 remain dependent on this pathway for survival despite the presence of additional genetic events. It is likely, therefore,
that FGFR3 acts in concert with TACC3 and MMSET providing survival signals through the stimulation by FGF ligands expressed in the BM microenvironment.
Along these lines, FLT3 mutations and high level expression of FLT3 have been described in acute lymphoblastic leukemia where MLL, a gene similar to MMSET, is also expressed. Armstrong, S. A. et al,, Cancer Cell, 2003; 3:173-183. These observations suggest a possible mechanism of complementation between tyrosine kinases and trithorax genes.
[0288] Studies of FGFR3 inhibition in MM cell lines indicated that only cell lines expressing the constitutively active receptor responded to FGFR3 inhibition.
Trudel, S. ef al., Blood, 2004; 103:3521-3528; and Paterson, J. L. et al., Br. J.
Haematol, 2004; 124:595-603. This highlights the limitation of using MM cell lines that grow independently of BM microenvironment and, thus, are no longer reliant on
FGF produced by the stroma for growth and survival. Studies using primary patient material are therefore critical. The cytotoxic effect demonstrated by primary MM cells exposed to 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2- yl]quinolin-2(1H)-one indicates that this drug will be an effective therapy in patients expressing either WT or mutant FGFR3. Nevertheless, the only modest and delayed cytotoxic response to 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one observed in primary MM cells may imply that inhibition of WT FGFR3 does not itself introduce proapoptotic signal, but more likely results in the withdrawal of strong anti-apoptotic signals. One would predict, therefore, the most effective use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)- © |H-benzimidazol-2-yl]quinolin-2(1H)-one may be in combination with chemotherapeutic agents such as dexamethasone as demonstrated in KMS11 cells.
[0289] The importance of the BM microenvironment in supporting tumor growth is becoming increasingly clear. Mitsiades, C. S. ef al, Cancer Cell, 2004; 5:221-230; and Dalton, W. S. et al., Semin Hematol., 2004; 41:1-5. In particular, cytokines such as IL-6 and IGF-1 and direct interaction with BMSCs have been shown to confer drug resistance. The in vitro experiments demonstrate that these paracrine factors failed to overcome the anti-tumor effects of 4-amino-5-fluoro-3-[6- (4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one. Given its target profile, 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2- yl]quinolin-2(1H)-one may also impact host-derived tumor-associated cells within the
BM that have implications in supporting tumor growth. 4-Amino-5-fluoro-3-{6-(4- methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one exhibits potent anti- : angiogenic activity in several angiogenesis assays including endothelial cell migration ' and tube formation on fibrin gels as well as in the ex vivo rat aortic ring assay.
Wiesmann, M. et al., Proc AACR, 2003; 44:934a. In agreement, tumors from 4- amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)- one treated mice were less vascular when compared to controls (data not shown). It has been demonstrated that 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one also inhibits CSF-1R activity, the receptor for
M-CSF, an osteoclast activating factor that may contribute to pathogenesis of bone disease in MM. Taken together, the data suggests that 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-y1)-1H-benzimidazol-2-yl] quinolin-2(1H)-one can potentially target both the MM cell within the BM milieu and the BM microenvironment directly.
[0290] In summary, 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H- benzimidazol-2-yl]quinolin-2(1H)-one represents a novel and potent small molecule inhibitor of FGFR3 for the treatment of t(4;14) myeloma. The cytotoxic effects of 4- amino-5-fluoro-3-[6+(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)- one on MM cell lines and primary patient samples, and a target profile that suggests the potential to favorably modulate the BM milieu, lead to the prediction that this will be an effective therapy in this poor-prognosis group, particularly in combination therapies. The ultimate success of this therapeutic strategy now awaits the outcome of clinical trials of that are soon to be underway to evaluate the efficacy of 4-amino-5- fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one of the treatment of t(4;14) MM. To
[0291] "The preparation of numerous 4-amino substituted quinolinone benzimidazolyl compounds, pharmaceutical formulations thereof, and descriptions-of salts and tautomers thereof are set forth in the following U.S. Patent, U.S. Patent
Applications, and U.S. Provisional Applications each of which is hereby incorporated by reference in its entirety and for all purposes as if fully set forth herein: U.S. Patent
No. 6,605,617; U.S. Patent Application No. 10/644,055; U.S. Patent Application No. 10/706,328; U.S. Provisional Application No. 60/526,426; U.S. Provisional
Application No. 60/517,915, and U.S. Provisional Application No. 60/546,017.
[0292] It should be understood that the organic compounds according to the invention may exhibit the phenomenon of tautomerism. As the chemical structures within this specification can only represent one of the possible tautomeric forms ata time, it should be understood that the invention encompasses any tautomeric form of the drawn structure. For example, the compound of formula IIIB is shown below with one tautomer, Tautomer Il1Ba:
H
— oO
F NH,
H = ] y H
H N (o]
H nm
H, ! — 0
F NH, \
NN on
H
Tautomer [IIBa
[0293] Other tautomers of the compound of formula IIIB, Tautomer IINBb and Tautomer ITN Bc, are shown below:
) a
LO
F NH, HN
H N == H
Wo N )
H
¢ Tautomer IIIBb
H. — 9,
F NH; HN
P
H N OH
H
Tautomer IIIBc
[0294] All documents or references cited herein are hereby incorporated by reference in their entireties and for all purposes as if fully set forth herein.
[0295] It is understood that the invention is not limited to the embodiments set forth herein for illustration, but embraces all such forms thereof as come within the scope of the claims.
Claims (1)
- What is claimed is:1 1. A lactate salt of a compound of Formula I or a tautomer of the 2 compound, wherein the compound of Formula I has the following structure, RSRS . RZ R13 R? rR NT bes R% R® N | \ RY R3 N 0] R* ks 3 1 4 wherein, R!, R% R’, and R* may be the same or different and are independently selected 6 from the group consisting of H, CI, Br, F, I, -CN, -NO,, -OH, -OR"® groups, NR'RY 7 groups, substituted and unsubstituted amidiny] groups, substituted and unsubstituted g guanidinyl groups, substituted and unsubstituted primary, secondary, and tertiary 9 alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted alkynyl groups, substituted and 11 unsubstituted heterocyclyl groups, substituted and unsubstituted aminoalkyl groups, 12 substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted 13 dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, 14 substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylalkyl 16 groups, and -C(=0)R'® groups; 17 R®, R®, R7, and R® may be the same or different and are independently selected 18 from the group consisting of H, Cl, Br, F, I, -NO,, -OH, -OR'® groups, NRZR19 groups, -SH, -SR? groups, -S(=0)R* groups, -S(=0),R* groups, -CN, substituted and unsubstituted amidinyl groups, substituted and unsubstituted guanidinyl groups, 21 substituted and unsubstituted primary, secondary, and tertiary alkyl groups, 22 substituted and unsubstituted aryl groups, substituted and unsubstituted alkenyl 23 groups, substituted and unsubstituted alkynyl groups, substituted and unsubstituted 24 heterocyclyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted 26 arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, 27 substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and 78 unsubstituted heterocyclylalkyl groups, -C(=O)R® groups, substituted and 29 unsubstituted aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, 31 substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted 32 aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; 33 Ris H; 34 Ris selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, and substituted and 36 unsubstituted heterocyclyl groups;37 RD is selected from the group consisting of H, substituted and unsubstituted 38 alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted 39 heterocyclyl groups, -OH, alkoxy groups, aryloxy groups, -NH,, substituted and 40 unsubstituted heterocyclylalkyl groups, substituted and unsubstituted aminoalkyl 41 groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and 42 unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl 43 groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and 44 unsubstituted (alkyl)(aryl)aminoalkyl ‘groups, substituted and unsubstituted45 alkylaminc groups, substituted and unsubstituted arylamino groups, substituted and46 unsubstituted dialkylamino groups, substituted and unsubstituted diarylamino groups, 47 substituted and unsubstituted (alkyl)(aryl)amino groups, -C(=O)H, -C(=0)-alkyl 48 groups, -C(=0)-aryl groups, -C(=0)0-alkyl groups, -C(=0)0-aryl groups,49 -C(=0)NHa, -C(=O)NH(alkyl) groups, -C(=0)NH(aryl) groups, -C(=0)N(alkyl) 50 groups, ~-C(=O)N(aryl), groups, -C(=0)N(alkyD)(aryl) groups, -C(=0)-heterocyclyl 51 groups, -C(=0)-O-heterocyclyl groups, -C(=0)NH(heterocyclyl) groups, -C(=0)- 52 N(heterocyclyl), groups, ~C(=0)-N(alkyl)(heterocyclyl) groups, -C(=0)- 53 N(aryl) (heterocyclyl) groups, substituted and unsubstituted heterocyclylaminoalkyl 54 groups, substituted and unsubstituted hydroxyalkyl groups, substituted and 55 unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, 56 and substituted and unsubstituted heterocyclyloxyalkyl groups; 57 R"isH; 58 RS and RY may be the same or different and are independently selected from 59 the group consisting of substituted and unsubstituted alkyl groups, substituted and 60 unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, 61 substituted and unsubstituted heterocyclylalkyl groups, -C(=O)H, -C(=0)-alkyl 62 groups, -C(=0)-aryl groups, -C(=O)NH,, -C(=0)NH(alkyl) groups, -C(=O)NH(aryl) 63 groups, -C(=O)N(alkyl), groups, -C(=O)N(aryl). groups, —C(=0)N(alkyl)(aryl) 64 groups, substituted and unsubstituted aminoalkyl groups, substituted and 65 unsubstituted alkylaminoalkyl groups, substituted and unsubstituted 66 dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, 67 substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted 68 (alkyi){aryi)aminoalKyl groups, substituted and unsubstituted heterocyclylaminoalkyl. 69 substituted and unsubstituted diheterocyclylaminoalkyl, substituted and unsubstituted 70 (heterocyclyl)(alkyl)aminoalkyl, substituted and unsubstituted : 71 (heterocyclyl) aryl)aminoalkyl, substituted and unsubstituted alkoxyalkyl groups,: 72 substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted . 73 aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; 74 R'S and R?" may be the same or different and are independently selected from 75 the group consisting of H, substituted and unsubstituted alkyl groups, substituted and 76 unsubstituted aryl groups, and substituted and unsubstituted heterocyclyl groups;77 RY and R*! may be the same or different and are independently selected from 78 the group consisting of H, substituted and unsubstituted alkyl groups, substituted and 79 unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, - 80 C(=O)H, -C(=0)-alkyl groups, ~C(=0)-ary! groups,-C(=O)NH, -C(=0)NH(alkyl) 81 groups, -C(=O)NH(aryl) groups, -C(=0)N(alkyl), groups, -C(=0)N(aryl), groups, - 82 C(=O)N(alkyl)(aryl) groups, -C(=0)0-alkyl groups, -C(=0)0-aryl groups, substituted 83 and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted aminoalkyl 84 groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and 85 unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl 86 groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and 87 unsubstituted (alkyl)(aryl)aminoalkyl groups, -C(=0)-heterocyclyl groups, -C(=0)-0- 88 heterocyclyl groups, -C(=0)NH (heterocyclyl) groups, -C(=0)-N(heterocyclyl) 89 groups, -C(=0)-N(alkyl)(heterocyclyl) groups, -C(=0)-N(aryl)(heterocyclyl) groups, . 90 substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and 91 unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, 92 substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted 03 heterocyclyloxyalkyl groups; : 94 R!®, RB, R?, and RZ may be the same or different and are independently 95 selected from the group consisting of H, -NHa, -NH(alkyl) groups, -NH(aryl) groups, 96 -Nfalkyl), groups, -N(aryl), groups, -N(alkyl)(aryl) groups, -NH(heterocyclyl) 97 groups, -N(heterocyclyl)(alkyl) groups, “N(heterocyclyl)(aryl) groups, 98 -N(heterocyclyl), groups, substituted and unsubstituted alkyl groups, substituted and 99 unsubstituted aryl groups, -OH, substituted and unsubstituted alkoxy groups, 100 substituted and unsubstituted aryloxy groups, substituted and unsubstituted 101 heterocyclyl groups, -NHOH, -N(alkyl)OH groups, -N(ary)OH groups, -N(alkyl)O- 102 alkyl groups, -N(aryl)O-alkyl groups, -N(alkyl)O-aryl groups, and -N(aryl)O-aryl 103 groups; and 104 R2 is selected from the group consisting of substituted and unsubstituted alkyl 105 groups, substituted and unsubstituted aryl groups, and substituted and unsubstituted 106 heterocyclyl groups;107 and further wherein at least one of RS, RS, R/, or RY is selected from the group 108 consisting of substituted and unsubstituted amidinyl groups, substituted and 109 unsubstituted guanidinyl groups, substituted and unsubstituted saturated heterocyclyl 110 groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and 111 unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl112 groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and 113 unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted 114 heterocyclylalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl 115 groups, substituted and unsubstituted hydroxyalkyl groups, substituted and 116 unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, 117 and substituted and unsubstituted heterocyclyloxyalkyl groups; —-ORY groups wherein 118 RY is selected from the group consisting of substituted and unsubstituted aryl groups, 119 substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted 120 heterocyclylalkyl groups, -C(=0)H, —C(=0)-aryl groups, -C(=0)NH_, 121 -C(=O)NH(alkyl) groups, -C(=0)NH(aryl) groups, -C(=0)N(alkyl), groups, 122 -C(=O)N(aryl), groups, -C(=O)N(alkyl)(aryl) groups, substituted and unsubstituted 123 aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted 124 and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted 125 arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, 126 substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and 127 unsubstituted heterocyelylaminoalkyl groups, substituted and unsubstituted 128 diheterocyclylaminoalkyl groups, substituted and unsubstituted 129 (heterocyclyl)(alkyl)aminoalkyl groups, substituted and unsubstituted 130 (heterocyclyl)(aryl)aminoalkyl groups, substituted and unsubstituted hydroxyalkyl 131 groups, substituted and unsubstituted alkoxyalkyl groups, substituted and 132 unsubstituted aryloxyalkyl groups, and substituted and unsubstituted 133 heterocyclyloxyalkyl groups; -NR®R?! groups wherein R? is selected from the group 134 consisting of substituted and unsubstituted heterocyclyl groups; ~NR?R? groups 135 wherein R? is selected from the group consisting of substituted and unsubstituted136 heterocyclyl groups, -C(=0)H, —C(=0)-aryl groups, -C(=0)NH,, -C(=O)NH(alkyl)137 groups, -C(=O)NH(aryl) groups, -C(=0)N(alkyl), groups, -C(=0)N(aryl), groups,-189- i138 -C(=O)N(alkyl)(aryl) groups, -C(=0)0-alkyl groups, -C(=0)0-aryl groups, 139 substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted 140 alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, 141 substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted 142 diarylaminoalkyl groups, substituted and unsubstituted (alkyl) (aryl)aminoalkyl 143 groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and 144 unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, 145 substituted and unsubstituted aryloxyalkyl groups, substituted and unsubstituted 146 heterocyclylalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl 147 groups; and -C(=0)R* groups wherein R? is selected from the group consisting of H, 148 -NH,, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl) groups, -N(aryl); groups, : 149 -N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyclyl)(alkyl) groups, 150 -N(heterocyclyl)(aryl) groups, -Ni(heterocyclyl), groups, substituted and unsubstituted 151 aryl groups, substituted and unsubstituted aryloxy groups, and substituted and 152 unsubstituted heterocyclyl groups. }1 2. The lactate salt of claim 1, wherein R" and R*? are both H.1 3. The lactate salt of claim 1, wherein R! is selected from the group 2 consisting of F, Cl, substituted and unsubstituted alkoxy groups, substituted and . 3 unsubstituted heterocyclylalkoxy groups, substituted and unsubstituted heterocyclyl 4 groups, substituted and unsubstituicd alkylaminoalkoxy groups, substituted and unsubstituted arylaminoalkoxy groups, substituted and unsubstituted 6 dialkylaminoalkoxy groups, substituted and unsubstituted diarylaminoalkoxy groups, 7 and substituted and unsubstituted (alkyl)(aryDaminoalkoxy groups.1 . 4 The lactate salt of claim 1, wherein R' is selected from the group © 2 consisting of Hand F.1 5. The lactate salt of claim 1, wherein R'is F.1 6. The lactate salt of claim 1, wherein R%isH.1 7. The lactate salt of claim 1, wherein at least one of RéorR’isa 2 substituted or unsubstituted heterocyclyl group.1 8. The lactate salt of claim 1, wherein one of RS or R’ is a substituted or unsubstituted heterocyclyl group comprising at least one O or N atom.1 9. The lactate salt of claim 1, wherein one of RS or R is a substituted or 2 unsubstituted heterocyclyl group and the heterocyclyl group is selected from the 3 group consisting of morpholine, piperazine, piperidine, pyrrolidine, thiomorpholine, 4 homopiperazine, tetrahydrothiophene, tetrahydrofuran, and tetrahydropyran. 1 10. The lactate salt of claim 1, wherein one of RS or R’ is selected from the 2 group consisting of substituted and unsubstituted morpholine groups, and substituted 3 and unsubstituted piperazine groups. 1 11. The lactate salt of claim 10, wherein R'isF. 1 12. The lactate salt of claim 11, wherein R? is H. 1 13. The lactate salt of claim 12, wherein R!? and R" are both H. 1 14. The lactate salt of claim 13, wherein R® is H and R® is H. 1 15. The lactate salt of claim 14, wherein R}isHand R*is H. 1 16. The lactate salt of claim 1, wherein R® and R® are both H. 1 17. The lactate salt of claim 1, wherein at least one of RS or R is selected 2 from the group consisting of -NR”R?! groups wherein R® is selected from the group 3 consisting of substituted and unsubstituted heterocyclyl groups; and -NR*R?! groups 4 wherein R? is selected from the group consisting of substituted and unsubstituted 5 heterocyclyl groups, groups, substituted and unsubstituted aminoalkyl groups, 6 substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted 7 dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, § substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted 9 (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and 11 unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, 12 substituted and unsubstituted heterocyclylalkyl groups, and substituted and 13 unsubstituted heterocyclyloxyalkyl groups. 1 18. The lactate salt of claim 17, wherein R! is selected from the group 2 consisting of H and F. 1 19. The lactate salt of claim 18, wherein R*isH. 1 20. The lactate salt of claim 19, wherein R'2 and R" are both H. 1 21. The lactate salt of claim 20, wherein R’ is Hand R® is HL. 1 22. The lactate salt claim 21, wherein R® is Hand R* is HL.J 93. The lactate salt of claim 1, wherein the compound of Formula I is 4- 2 amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)- 1H-benzimidazol-2-ylJquinolin-2(1H)- 3 one 1 24. The lactate salt claim 23, wherein the salt comprises the mono-lactate 2 or bis-lacate salt. 1 25. The lactate salt claim 23, wherein the salt comprises the mono-lactate 2 salt 1 26. The lactate salt of claim 23, wherein the solubility of the salt in water 2 at 22°C is greater than 30 mg/mL. 1 27. The lactate salt of claim 23, wherein the solubility of the salt in water 2 at22°C is from 150 mg/mL to 250 mg/mL. 1 28. The lactate salt of claim 23, wherein the salt comprises the DL lactate 2 salt.1 59. The lactate salt of claim 23, wherein the salt comprises the D lactate 2 salt 1 30. The lactate salt of claim 23, wherein the salt comprises the L lactate 2 salt. 1 31. The lactate salt of claim 23, wherein the salt comprises the D lactate 2 salt thel lactate salt, or a mixture thereof. 1 32. The lactate salt of claim 23, wherein the salt is crystalline and 2 comprises plate-shaped crystals. 1 33. A composition comprising a tablet of the lactate salt of claim 23. 1 34. A method of preparing the lactate salt of claim 23, comprising: 2 (@ suspending the compound of Formula I or the tautomer thereof in a 3 solvent or mixture of solvents; 4 (b) contacting lactic acid with the compound of Formula I or the tautomer thereof to provide a mixture; 6 (©) heating the mixture; 7 (d cooling the mixture; and 8 (e) isolating the salt. 1 35. A method of preparing the lactate salt of claim 1, comprising: 2 (@ suspending the compound of Formula or the tautomer thereof in a 3 solvent or mixture of solvents; 4 (b) contacting lactic acid with the compound of Formula I or the tautomer 5 thereof to provide a mixture; 6 (© heating the mixtue; 7 (4) cooling the mixture; and 8 (e) isolating the salt. 1 36. The method of claim 35, wherein the solvent is a protic solvent.1 37. The method of claim 35, wherein the solvent is selected from the group 2 consisting of methanol, ethanol, water, tetrahydrofuran, and mixtures thereof.1 38. A lactate salt of a compound of Formula II or a tautomer of the 2 compound, wherein the compound of Formula II has the following structure,R¥ ) SM ) R%® NH, i (3 val xr YY NRi HA N 03 H 4 II wherein:6 L is a covalent bond, -(CHa)-, -CHR*-, or -N®*")-;7 X is CHoarN;8 Wis CH, O, or NN;9 R% is selected from the group consisting of substituted or unsubstituted alkyl groups, substituted or unsubstituted alkylamino groups, substituted or unsubstituted 11 dialkylamino, -OH, substituted or unsubstituted alkoxy groups, substituted or 12 unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl 13 groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted 14 heterocyclylalkyl groups; provided that when Wis O, RS is absent,RY is absent or selected from the group consisting of -NO,, -OH, F, CL, Br, I,16 -NH,, substituted or unsubstituted alkyl groups, substituted or unsubstituted17 akylamino groups, substituted or unsubstituted dialkylamino groups, substituted or18 unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl19 groups, and substituted or unsubstituted alkoxy groups;R28 is selected from the group consisting of F, Cl, Br, I, -OH, -NH;, and 21 substituted or unsubstituted alkyl groups; 22 R?, R%, and R*! are independently selected from the group consisting of H, F, 23 Cl, Br, I, substituted and unsubstituted alkyl groups, -OH, alkoxy groups, substituted 24 and unsubstituted aryloxy groups, -NH,, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted 26 heteroaryl groups, substituted and unsubstituted heterocyclyl groups, substituted and 27 unsubstituted alkylaminoalkyl groups, substituted and unsubstituted 28 dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, 70 substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted alkylamino groups, 31 substituted and unsubstituted dialkylamino groups, substituted and unsubstituted 32 diarylamino groups, substituted and unsubstituted (alkyl)(aryl)amino groups, 33 -C(=O)H, -C(=0)-alkyl groups, -C(=0)-aryl groups, -C(=0)0-alkyl groups, 34 -C(=0)O-aryl groups, -C(=0)NH,, -C(=0)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=0)N(alkyl), groups, -C(=0)N(aryl), groups, -C(=0)N(alkyl)(aryD 36 groups, -C(=0)-heterocyclyl groups, -C(=0)-O-heterocyclyl groups, 37 -C(=0)NH(heterocyclyl) groups, -C(=0)-Niheterocyclyl), groups, —C(=0)- 38 N(alkyl)(heterocyclyl) groups, -C(=0)-N(aryl)(heterocyclyl) groups, substituted and 30 unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted 40 hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted 41 and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted 42 heterocyclyloxyalkyl groups; 43 nis 0, 1,or2; and 44 misl,2,3,0r4 1 39. The lactate salt of claim 38, wherein the salt comprises the mono- 2 lactate or bis-lacate salt. : 1 40. The lactate salt of claim 38, wherein R®isFand R¥isH.PCT/US2004/036941 lL] 41. The lactate salt of claim 40 wherein n is 1.42. A pharmaceutical formulation, comprising the lactate salt of claim 1 and a pharmaceutically acceptable carrier.43. Use of the lactate salt of claim 1 or a pharmaceutical formulation comprising the lactate salt in the manufacture of a medicament for treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase. 44, A pharmaceutical formulation, comprising the lactate salt of claim 23 and a pharmaceutically acceptable carrier.45. Use of the lactate salt of claim 23 or a pharmaceutical formulation comprising the lactate salt in the manufacture of a medicament for treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase.46. A compound of any one of claims 1 to 32 or 38 to 41, substantially as herein described with reference to and as illustrated in any of the examples and accompanying drawings.47. A composition of claim 33, substantially as herein described with reference to and as illustrated in any of the examples and accompanying drawings.48. A method of any one of claims 34 to 37, substantially as herein described with reference to and as illustrated in any of the examples and accompanying drawings.49. A formulation of claim 42 or claim 44, substantially as herein described with reference to and as illustrated in any of the examples and accompanying drawings.50. Use of claim 43 or claim 45, substantially as herein described with reference to and as illustrated in any of the examples and accompanying drawings. - 196 - - AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51791503P | 2003-11-07 | 2003-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200603598B true ZA200603598B (en) | 2008-04-30 |
Family
ID=37510725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200603598A ZA200603598B (en) | 2003-11-07 | 2006-05-05 | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties |
Country Status (3)
Country | Link |
---|---|
CN (3) | CN101160308B (en) |
SI (1) | SI1699421T1 (en) |
ZA (1) | ZA200603598B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX365214B (en) * | 2012-03-08 | 2019-05-27 | Astellas Pharma Inc | Novel fgfr3 fusion product. |
CN103319403B (en) * | 2013-05-10 | 2016-03-30 | 重庆理工大学 | Own quinoline ketone of a kind of neonate tumour blood vessel inhibitor and its production and use |
CN104529894B (en) * | 2015-01-15 | 2017-02-22 | 成都丽凯手性技术有限公司 | Quinolinone derivative and preparation method thereof |
CN105646449A (en) * | 2016-04-07 | 2016-06-08 | 戊言医药科技(上海)有限公司 | Preparation method of dovitinib |
CN110016014B (en) * | 2018-01-08 | 2023-02-17 | 中国科学院上海药物研究所 | EZH2 inhibitor, preparation thereof and application thereof in antitumor therapy |
JP2022515622A (en) * | 2018-12-26 | 2022-02-21 | ヤンセン ファーマシューティカ エヌ.ベー. | Thienopyridinone compound |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG129306A1 (en) * | 2000-09-11 | 2007-02-26 | Chiron Corp | Quinolinone derivatives as tyrosine kinase inhibitors |
-
2004
- 2004-11-05 CN CN2004800371260A patent/CN101160308B/en not_active Expired - Fee Related
- 2004-11-05 SI SI200432176T patent/SI1699421T1/en unknown
- 2004-11-05 CN CN2004800327003A patent/CN1976706B/en not_active Expired - Fee Related
- 2004-11-05 CN CN2004800328379A patent/CN1878766B/en not_active Expired - Fee Related
-
2006
- 2006-05-05 ZA ZA200603598A patent/ZA200603598B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1878766A (en) | 2006-12-13 |
CN1878766B (en) | 2011-08-17 |
CN1976706B (en) | 2012-01-18 |
CN101160308B (en) | 2011-05-25 |
CN101160308A (en) | 2008-04-09 |
SI1699421T1 (en) | 2014-09-30 |
CN1976706A (en) | 2007-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2544492C (en) | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties | |
US7825132B2 (en) | Inhibition of FGFR3 and treatment of multiple myeloma | |
EP1650203B1 (en) | Process of preparation of benzimidazol-2-yl quinolinone derivatives | |
AU2003226275B2 (en) | Quinolinone derivatives | |
ZA200503598B (en) | Bicomponent monofilament | |
ZA200603598B (en) | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties | |
AU2004288692B2 (en) | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties | |
MXPA06004981A (en) | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties |